<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main"></title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">James</forename><forename type="middle">R</forename><surname>Marshall</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peiyuan</forename><surname>Yao</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Tianjin Institute of Industrial Biotechnology</orgName>
								<orgName type="institution" key="instit1">National Engineering Laboratory for Industrial Enzymes</orgName>
								<orgName type="institution" key="instit2">Tianjin Engineering Research Centre of Biocatalytic Technology</orgName>
								<orgName type="institution" key="instit3">Chinese Academy of Sciences</orgName>
								<address>
									<addrLine>32 Xi Qi Dao</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sarah</forename><forename type="middle">L</forename><surname>Montgomery</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">James</forename><forename type="middle">D</forename><surname>Finnigan</surname></persName>
							<affiliation key="aff1">
								<address>
									<addrLine>West End Ind. Estate</addrLine>
									<postBox>Building 4</postBox>
									<postCode>NE49 9HA</postCode>
									<settlement>Haltwhistle</settlement>
									<region>Northumberland, UK</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">W</forename><surname>Thorpe</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ryan</forename><forename type="middle">B</forename><surname>Palmer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Juan</forename><surname>Mangas-Sanchez</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><forename type="middle">A M</forename><surname>Duncan</surname></persName>
							<affiliation key="aff1">
								<address>
									<addrLine>West End Ind. Estate</addrLine>
									<postBox>Building 4</postBox>
									<postCode>NE49 9HA</postCode>
									<settlement>Haltwhistle</settlement>
									<region>Northumberland, UK</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rachel</forename><forename type="middle">S</forename><surname>Heath</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kirsty</forename><forename type="middle">M</forename><surname>Graham</surname></persName>
							<affiliation key="aff1">
								<address>
									<addrLine>West End Ind. Estate</addrLine>
									<postBox>Building 4</postBox>
									<postCode>NE49 9HA</postCode>
									<settlement>Haltwhistle</settlement>
									<region>Northumberland, UK</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Darren</forename><forename type="middle">J</forename><surname>Cook</surname></persName>
							<affiliation key="aff1">
								<address>
									<addrLine>West End Ind. Estate</addrLine>
									<postBox>Building 4</postBox>
									<postCode>NE49 9HA</postCode>
									<settlement>Haltwhistle</settlement>
									<region>Northumberland, UK</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><forename type="middle">J</forename><surname>Charnock</surname></persName>
							<affiliation key="aff1">
								<address>
									<addrLine>West End Ind. Estate</addrLine>
									<postBox>Building 4</postBox>
									<postCode>NE49 9HA</postCode>
									<settlement>Haltwhistle</settlement>
									<region>Northumberland, UK</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicholas</forename><forename type="middle">J</forename><surname>Turner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">School of Chemistry</orgName>
								<orgName type="institution" key="instit1">University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Institute of Biotechnology</orgName>
								<address>
									<addrLine>131 Princess Street</addrLine>
									<postCode>M1 7DN</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Tianjin Airport Economic Area</orgName>
								<address>
									<addrLine>53.072533 -4.06568 54.829710 -3.417950 54.967491 -2.461932 53.071498 -4.06592 54.828466 -3.419280 54.967319 -2.461117 53.071580 -4.06735 54.825994 -3.422284 54.948887 -2.682835 53.071302 -4.06776 54.801067 -3.438592 54.947777 -2.683157 53.071589 -4.06868 54.820640 -1.319655 54.946200 -2.684917 53.070948 -4.06940 54.813176 -1.314805 54.946003 -2.685217 53.072720 -4.06741 54.813992 -1.315706 54.945707 -2.685024 53.071810 -4.07300 54.860359 -1.347300 54.945547 -2.688264 53.071558 -4.07306 54.927545 -1.364084 54.944598 -2.689573 53.072160 -4.07386 54.931064 -1.364630 54.942923 -2.689606 53.071573 -4.07291 54.943684 -2.690577 54.791184 -1.311578 53.072330 -4.07427 54.942551 -2.690405 54.788808 -1.311235 53.072573 -4.07457 54.941638 -2.691071 54.787126 -1.308832 53.072435 -4.07617 54.940899 -2.689654 54.786829 -1.307630 53.073529 -4.07710 54.943241 -2.686650 53.072521 -4.07959 54.944498 -2.685556 53.070657 -4.06305 53.071014 -4.06285 53.071448 -4.05820 53.070868 -4.06034 53</addrLine>
									<postCode>300308 070387 -4.05971</postCode>
									<settlement>Tianjin</settlement>
									<country>People&apos;s Republic of China</country>
								</address>
							</affiliation>
						</author>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">AACA729B3BE2D1385BEEEEA1FC5DD083</idno>
					<idno type="DOI">10.1038/s41557-020-00606-w</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-24T12:31+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=0, consolidateHeader=0, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[0], sentenceSegmentation=false, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Sample Collection 1 Sample Collection 2 Sample Collection 3 Latitude Longitude Latitude Longitude Latitude Longitude 3</term>
					<term>2</term>
					<term>2: Non-selective isolation</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>0.25 g of samples were weighed out aseptically and then re-suspended in 10 mL of Ringer's solution (¼ strength) in 15 mL centrifuge tubes and agitated for 1 hour using a Stuart Rotator SB2. Each suspension was then serially diluted to 10 -6 in the Ringer's solution. Each diluted sample was homogenised by gentle inversion and 150 µL plated onto 1.5 % (w/v) agar plates containing either modified R2A growth media or Trypticase Peptone Agar (TPA), supplemented with 5 g / L yeast, with all plates containing nystatin (50 µg / mL). This was repeated with serial agar dilutions</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="22" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="23" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="24" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="25" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="26" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="27" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="28" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="29" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="30" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="31" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="32" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="33" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="34" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="35" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="36" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="37" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="38" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="39" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="40" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="41" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="42" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="43" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="44" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="45" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="46" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="47" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="48" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="49" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="50" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="51" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="52" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="53" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="54" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="55" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="56" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="57" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="58" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="59" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="60" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="61" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="62" ulx="0.0" uly="0.0" lrx="842.0" lry="595.0"/>
		<surface n="63" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="64" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="65" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="66" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="67" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="68" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="69" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="70" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="71" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="72" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="73" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="74" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="75" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="76" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="77" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="78" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="79" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="80" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="81" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="82" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="83" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="84" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="85" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="86" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="87" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="88" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="89" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="90" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="91" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="92" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="93" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="94" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="95" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="96" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="97" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="98" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="99" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="100" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="101" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="102" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="103" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="104" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="105" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="106" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="107" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="108" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="109" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="110" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="111" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="112" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="113" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="114" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="115" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="116" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="117" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="118" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="119" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="120" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="121" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="122" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="123" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="124" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="125" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="126" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="127" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="128" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="129" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="130" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="131" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="132" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="133" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="134" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="135" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="136" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="137" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="138" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="139" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="140" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="141" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="142" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="143" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="144" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="145" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="146" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="147" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="148" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="149" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="150" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="151" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="152" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="153" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="154" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="155" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="156" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="157" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="158" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="159" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="160" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="161" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="162" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="163" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="164" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="165" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="166" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="167" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="168" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="169" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="170" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="171" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="172" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="173" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="174" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="175" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="176" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="177" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="178" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="179" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="180" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="181" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="182" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="183" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="184" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="185" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="186" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="187" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="188" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="189" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="190" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="191" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="192" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="193" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="194" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="195" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="196" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="197" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="198" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="199" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="200" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="201" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="202" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="203" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="204" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="205" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="206" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="207" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="208" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="209" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="210" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="211" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="212" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="213" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="214" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="215" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="216" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="217" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="218" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
		<surface n="219" ulx="0.0" uly="0.0" lrx="595.0" lry="842.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Section 1: General Methods.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.1: Chemicals</head><p>Commercially available chemicals and reagents were purchased from Sigma-Aldrich (Poole, Dorset, UK), Alfa Aesar (Karlsruhe, Germany), Fluorochem (Hadfield, Derbyshire, UK) and Acros Organics (Geel, Belgium) unless stated otherwise. Isopropyl β-D-1-thiogalactopyranoside (IPTG), kanamycin, Terrific broth (TB) and LB (Luria-Bertani) Agar Miller was purchased from Formedium (Hunstanton, England). Co-factors were obtained from Prozomix Ltd (Haltwhistle, Northumberland, UK). Spectra of 1 H and <ref type="bibr">13</ref> C NMR were recorded on a Bruker Avance 400 instrument (400 MHz for 1 H and 100 MHz for <ref type="bibr">13</ref> C) or Bruker Advance 500 instrument (500 MHz for 1 H and 125 MHz for 13 C) in CD3OD using residual protic solvent as an internal standard. GC analysis was performed on an Agilent 6850 GC (Agilent, Santa Clara, CA, USA) with a flame ionization detector (FID) and autosampler. Columns used include a 25 m CP-Chirasil-DEX CB column with 0.25 mm inner diameter and 0.25 μm film thickness (Agilent, Santa Clara, CA, USA). All chemical structures and some names were generated using ChemDraw Professional 18.2. Flash Column Chromatography was performed using silica gel (Sigma-Alrich) 40-63 µm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.2: Enzymes</head><p>NAD(P)H-oxidase 001 and diaphorase 001 were supplied by Prozomix Ltd (Haltwhistle, Northumberland, UK). Glucose dehydrogenase (CDX-901) was purchased from Codexis (Redwood, California, USA). Restriction enzymes and T4 DNA ligase and polymerases were purchased from New England Biolabs (NEB) (Hitchin, Hertfordshire, UK). In this study the IREDs were termed pIR-XXX where 'p' is an abbreviation for Prozomix.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.3: Synthetic DNA</head><p>All synthetic DNA encoding the codon optimised genes for IREDs were purchased from TWIST Biosciences (San Francisco, California, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.4: Molecular Biology Kits</head><p>All kits for mini-preparation of DNA, PCR purification, and gel extraction were purchased from QIAGEN (Hilden, Germany).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Section 2: Numerical Compound Chart</head><p>In this study a combination of free amines, carbonyls, amine partners, imines and compounds containing other functional groups were all used as substrates. The following tables outline the structures of the compounds along with numbering of the compounds.</p><p>Table 2.1. Numbering of carbonyls, alcohols, imines and analogous amines used in this study. Table 2.2. Numbering of simple amines for reductive aminations used in this study. Table 2.3. Numbering of amine substrate/products used in this study. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Identification of Metagenomics IRED</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.2.1: Sampling Locations</head><p>Table <ref type="table" target="#tab_7">3</ref>.2.1 denotes all sampling locations. Approximately 1 -10 g or 1 -10 mL of sample was taken from each location. All locations are on UK territory for compliance with the Nagoya Protocol. <ref type="bibr">1</ref> containing 10 -1 and 10 -2 dilutions of both medium. The plates were subsequently incubated at 25 °C for 2-7 days and monitored daily for colony appearance / morphological changes. Following 72 hours since the appearance of colonies, individual colonies were selected and streaked onto an agar plate containing the same medium (without nystatin) to obtain pure isolates. All pure isolates with apparent differences in characteristics were taken and resuspended into 1 mL of sterile 20 % (v/v) glycerol in a 2 mL cryovial. The OD600 of each sample was then measured and recorded. 100 µL of 10.0 OD600 equivalents of each bacterial isolate was combined and homogenised by gentle inversions in sterile 50 mL centrifuge tubes. 1 mL of each homogenous solution was transferred to a 1.5 mL microcentrifuge tube. The microcentrifuge tubes were centrifuged at 15'000 x g for 5 minutes and the supernatant aspirated. All metagenomic DNA extractions were performed using an NZYtech NZY Tissue gDNA Isolation kit. The manufacturer's instructions for gDNA extraction from bacterial cells was followed with the exception of the final elution volume, where 100 µL was employed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.2.3: NU-OMICS DNA sequencing</head><p>All metagenome samples used in this study were sequenced using the NU-OMICS DNA sequencing services at Northumbria University. To summarise, a 600 cycle MiSeq Reagent Kit v3 was used with a MiSeq Sequencer (Illumina Corporation). The CLC genomics workbench (QIAGEN) was used to analyse the quality of the data output, trimming the adaptors and barcodes and to perform the 'de novo assembly' of the samples. To further strengthen the assembly, the raw sequences were mapped back onto the assembled contiguous sequences, increasing the N50 values for the assembled contigs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.2.4: Metagenome mining of novel IRED using ProzOMIGO™</head><p>ProzOMIGO™, a proprietary bioinformatics platform developed by Prozomix Limited in collaboration with Newcastle University as part of Technology Strategy Board (TSB) Innovate UK Project 132161. This software permits the rapid analysis of large metagenomic datasets. The metagenome sample's sequencing results were uploaded into ProzOMIGO™ in FASTA format and protein sequence BLAST databases created, completing a 6 frame translation and ORF prediction from all assembled contigs. Seed targets were taken from the literature and used as query sequences against the BLAST databases. The returned hits were then filtered using the software, eliminating any targets sharing &gt;80% primary sequence identity to any other IRED in the returned hits or query sequences. All selected targets were extracted in FASTA format and ordered as synthetic DNA fragments from TWIST biosciences. All genes were codon optimised for recombinant expression in an E. coli host.</p><p>Table 3.2.2. Statistical analysis of the culture enriched metagenomes generated by QUAST. Meta 1 Meta 2 Meta 3 Meta 4 Meta 5 Meta 6 Meta 7 # contigs 332458 23955 71422 90704 63943 83683 73619 # contigs (&gt;= 0 bp) 332458 23955 71422 90704 63943 83683 73619 # contigs (&gt;= 1000 bp) 82780 23955 71331 90684 63943 83683 73619 # contigs (&gt;= 5000 bp) 15409 11887 11346 14561 13034 17036 13799 # contigs (&gt;= 10000 bp) 6709 3976 4378 5187 5992 7230 5948 # contigs (&gt;= 25000 bp) 2005 723 1125 1119 2024 1933 1548 # contigs (&gt;= 50000 bp) 666 181 349 336 703 603 497 Largest contig (bp) 413325 164434 405142 458790 483366 667007 400461 Total length (bp) 489277880 178907612 276463515 341009530 331976916 394310194 326644924 Total length (&gt;= 0 bp) 489277880 178907612 276463515 341009530 331976916 394310194 326644924 Total length (&gt;= 1000 bp) 377311636 178907612 276375542 340989954 331976916 394310194 326644924 Total length (&gt;= 5000 bp) 239025342 132834426 152997668 179244237 225116053 251846414 202811706 Total length (&gt;= 10000 bp) 178854112 78595966 105227314 114895088 176668056 183973381 148279929 Total length (&gt;= 25000 bp) 107701306 31504199 56613544 54932018 116294294 104365802 81790958 Total length (&gt;= 50000 bp) 61927309 13379637 30120435 28575568 70599713 58782343 46073436 # N's 147198 4193 561 0 0 27 0 # N's per 100 kbp 30.08 2.34 0.2 0 0 0.01 0</p><p>The flow diagram (Figure <ref type="figure">3</ref>.2.1) gives an idea as to the process that was performed in collating the novel IRED sequences from collecting the query sequences to the cloning stages where the synthetic gene fragments are ordered. The phylogenetic tree (Figure <ref type="figure">3</ref>.2.2.) shows all 677 putative IRED sequences which were identified in the initial mining stages of sequences. These 677 were then trimmed down to 333 sequences based on several filters applied by ProzoMIGO ™ . These filters included:</p><p>• No two sequences &gt;90% sequences identity to each other (redundancy of genes in the dataset).</p><p>• Redundancy of genes to online open database.</p><p>• Length of the sequence.</p><p>• Specific restriction sites within the gene.</p><p>Also shown in the phylogenetic tree are the query sequences which used in the process of mining the putative IRED genes. the overall phylogenetic tree to visualise the number of targets being mined from both metagenomic and genomic databases. b-l, the phylogenetic tree of that shown in Figure <ref type="figure">3</ref>.2.2a broken down into sections so tips are legible. Red represents the 90 sequences historically from the Turner Group. Green shows metagenomic targets, and purple identifies the targets from public databases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.5.">IRED Sequences</head><p>&gt;pIR1 MSTKKVTVIGLGSLGSALAAALLRTGHDVTVWNRTPEKAEALVAQGATRADTVAEAAAAS PVVIVCVFDTEAARELLAPIQAGKAVVNLTSGSPDEARELAAWAASRGVDYLDGAVMAVP AAIGTPDAFVMYSGSREVFDAHRAALDSFGASHFLGEDAGVAEFHDLGLLYAGYATLVGF LNSVAIVGTAGVTARELLPLVTTWLTGMVAYLADVAREVDERDYTDGASSVAINQVALDK IIAASRAAGVSPDLLLPFKELLDRRAADGHARDSASSVIELLRPGIHPE &gt;pIR2 MTDTSAKLTLLGLGAMGSALATAWLAADYDITVWNRTASRAEPLRTLGAQVADTAADAVA ANDLVVACLLDDASVRSTLDGVDLTGKDLINLTTGTPGSGRELAACATARGARYVDGGIM AVPPMIGVPDSGAYVFYSGSAAAFEAHRDALAVGAGTKFVGEDPGFAALYDVALLSAMTG MFAGVSHAFALVRKENIDPREFAGLVSGWITAMSGYAHGIAEHLASGDYTTGVTSNLAMM VEGNATMLRTAHEQGVSPELLEPFMRLMRQRVDDGHGDEDTTGVIDLLLSRR &gt;pIR3 MSKHISIFGLGAMGAALAARYLEHGYKTTVWNRTTAKATPLVEQGAKLASTISEGINASD LIIICLLNNEAAEDILRDVFHSLSSKTIVNLTNGTPYQARNLADFVTSNGARYIHGGIMA VPAMIGSPHAVLLYSGGSFELFQSIESHLSLLGMSKFLGTDAGSASLHDLALLSGMYGLF SGFLHAVALIKSEQSKTATGLLPLLTPWLSAMMGYLSSIASQIDEGDYATQGSNLEMQLV GVENILKAGKEQGISSQMILPMKALIEKAVGEGHGGEDLSVLIDYFKGEKSLE &gt;pIR4 MSTITLFGLGAMGKALAAKYIEKGYTTTIWNRTPSKAAPLVEKGAKLANTVGEGLASADL IILCLLDNASVRQTLDQATAALNGKTVINLTNGTPSQARETSEWVISHGAQYIHGGIMAV PDMIGSPHAVLLYSGESAETFSRVEAHLSHLGTSKFLGTDPGSASLHDLALLSGMYGLFS GFFHATALVKSQPGTTATGFVQLLTPWLSAMTHYLGALAKQIDEGDYATQGSNMAMQVTG VQNIVRASEEAGVTADLIMPILGRMTRAAEAGYADVDVSAVIEFMKE &gt;pIR5 MADKPRVGWIGTGVMGQAMCGHILKDGYPVRVFNRTPSKAQTLIENGALMAENPKSVAEG SDVVFTIVGYPHDVSEVILGDKGVLQGLKPGGVIVDMTTSEPSLAQKIYKFAKERGCESV DAPVSGGDKGAKGGTLAIFAGGDEKVVETLKPLFDCMGKVTYMGGPGLGQCTKLGNQITI ASTMVGLVEGMVFAHKAGLDVETYIRAISSGAAGSKSLELYANRILKGDFEPGFFVNHFV KDLGISLRECQQMGLSLPGLALAQQLYVSLKAHGEGNLGTQALVLALERLNNVQLPRMQ &gt;pIR6 MPESTTPSTATPVTIIGLGAMGTALANAFLDAGHSTTVWNRTAARATALAARGAHHAETV TEAIAASPLVIACVLDYDAFHETLAPATDALAGRALVNLTNGTPKQARETASWAADHRID YLDGGIMAIPPGIATPDSFILYSGPLGTFEAHRSTLEVLGAANHVGTDHGLASLHDLALL TGMYGMFAGILQAFALIDSEGIPAGDLAPMLTNWLTGMAHSVAHYAQQIDTGDYETGVVS NLAMQSAGFANLVQAGEDQGVDVGLLRPLFELMRHQVAAGYGNGDVASVIELIRREERRQ PAKSPGADKITRARRP &gt;pIR7 MSEHGKTPVTVLGLGAMGTALVEALLAAGHPVTAWNRTASWAEAVAAQGASVASTISEAL AANTIVIACLLDYDSVHEVLDPVAAELEGRQLINLTNGTPGQAREMSAWAEGLGAAYLDG GIMAVPPMIGTPAAFIFYSGSGTVFGHARTALDTFGGVNYLGADPGLAPLHDIALLSGMY GYFVGVIQAYALVGSAGVKAREFAPLLRGWLDAMGGFLERSAEQIDDGDYVTDVVSNIGM QAAAYPNLAQAAEDQGISAELLTPLQSLMDKRVARGHGAEDLIGVIELLKK &gt;pIR8 MSEHGKTPVTVLGLGAMGTALVEALLTAGHPVTVWNRTASRTEAVAAKGASVASTVSEAL AADTNAIVLACLLDYDSVHEVLDPVAAELAGRQLINLTNGTPGQAREMNAWAEELGAAYL DGGIMAVPPMIGTPAAFIFYSGSGTVFGRARTALETFGGVNYLGADPGLAPLHDIALLSG MYGYFVGVIQAYALVGSAGVKAREFAPLLRGWLDAMGGFLERSAEQIDDGDYMTDVVSNI GMQAAAFPNLAKAAADQGISAELLTPLQPLMDKRVADGHGAEDLIGVIELLKK &gt;pIR9 MSSVSIFGLGAMGTALASRFLEEKYKVAVWNRSPEKASPLLEKGATLSHTALDGINASDL IVICLLDNAAVQATLNSALEHLRGKTIINLTNGTPDQARKLSDLIVSHGAQYVHGGIMAT PSMIGSPHALVLYSGSPDAFKTAEADLSVLAKCIFLGEDAGSASLHDLALLSGMYGLFSG FLHATALVRSSTPAVKFVDLLVPWLGAMTEYTKGMAKQIDEGNYASEGSNLGMQLVAIQN IIDASAAQQVSADFIRPMKEFMEKAVVAGHGGDDISSLIDFVKST &gt;pIR10 MPLLLRRYLSPSVVSSSFLRRSMAYSSISTDPINPSYSSISTDPINPSNTKIGWIGTGVM GRSMCGHLIRAGYSVTVFNRTISKAQTLLDMGAKLADSPSSVASQSDVVFSIVGYPSDVR NVLLDPNSGALSGLRKGGVLVDMTTSEPSLAEEIAKSASSVHCFSIDAPVSGGDLGAKNG KLSIFTGGDETTVKRLDPLFSLMGKVNFMGTSGKGQFAKLGNQITIASTMLGLVEGIIYA HKSGLDVKKFLEAISTGAAGSKSIDLYGDRIMKRDFDPGFYVNHFVKDLGICLNECQRMG LALPGLALAQQLYLSLKAHGQGDLGTQALILALERLNNVKIDFY &gt;pIR11 MPLLLRRFLSPSVVSSFFLRRSMASSSISSDPITPSNTKIGWIGTGVMGRSMCGHLIKAG YTVTVFNRTISKAQTLIDMGANLADSPNSVASQSDVVFTIVGYPSDVRHVLLDPKSGALS GLQQGGVLVDMTTSEPSLAEEIAKAASFENCFSIDAPVSGGDLGAKNGKLSIFAGGDETT VKRLDPLFSLMGKVNFMGTSGKGQFAKLANQITIASTMLGLVEGLTYAHKAGLDVKKFLE AISTGAARSKSIDLYGDRILKRDFDPGFYVNHFVKDLGICLNECQRMGLALPGLALAQQL YLSLKAHGEGGLGTQALILALERLNNVSVQPSVS &gt;pIR12 MSKISLFGLGSMGQALAHRYIDTGYTTTVWNRTPEKAQSSGLIQKGAHQALTVAEGLEAA DMVILCLLDNASVRETLSKAVTSLSGKTIVNLTNGTPTQARDLSEWAGAHGAEYIHGGIM AVPDMISSGSPHSILLYSGKSNEVFTRIEPDLAHLGAAKFLGTDPGSASLHDLALLSGMY GLFSGFFHATALVRSQSDTTSEGFLELLIPWLGAMTHYLGGLAKQIDSGDYTTQGSNIAM QVAGLENIIAASEEVGVTPAFILPIQRLMKRAADEGHGNTDISSLIQYLRTRE &gt;pIR13 MTEHGKTPVTVLGLGAMGTALVEALLAAGHPVTAWNRTASRAEGVAAKGASVASTVSEAL AANKTVIACLLDYDSVHEVLDPVASGLEGRQLINLTNGTPGQAREMSAWAEELGAEYLDG GIMAVPPMIGTPGAFIFYSGSGTVFGQARTALDTFGGVNYLGADPGLAPLHDIALLSGMY GNFIGVIQAFALVGSAGVKAREFAPLLRGWMDAMSGFLERTAELIDDGDYERGVVSNIGM QAAAFPNLAKAAEEQGISAELLAPLQPLMDKRVAAGHGAEDLVGVIELLKK &gt;pIR14 MPLLLRRFPSPSVVSSFFLRRSMASSTISSDIITPSNTKIGWIGTGVMGRSMCGHLIKAG YTVTVFNRTISKAQTLIDMGANVADSPNSVAEQSDVVFTIVGYPSDVRHVLLDPKSGALS GLRQGGVLVDMTTSEPSLAEEIAKAASFKNCFSIDAPVSGGDLGAKNGKLSIFAGGDETT VKRLDPLFSLMGKVNFMGTSGKGQFAKLANQITIASTMLGLVEGLIYAHKAGLDVKKFLE AISTGAAGSKSIDLYGDRILKRDFDPGFYVNHFVKDLGICLNECQRMGLALPGLALAQQL YLSLKAHGEGDLGTQALLLALERLNNVSVQSSDS &gt;pIR15 MTSATVIGLGPMGQAMVRVLLEHGTAVTVWNRTKSRADDVVARGAVLAGTPAEALKAAGL VILSLTDYQAMYDVLGDAGEALAGRVVVNLSSDTPQRTREAAAWLAKRGATLVAGGIMVP APLVGAEASYVFYSGPRDVFAEHEPVLRHIGRPEYLGEDHGLAQLFYQAELTVFLTSLSA YLQAFALLAAEGADPARLVPFAREVSGLAASYLDETVSQTRARAYPGDLSTATMMGATAE HILQACRDAGVDLALPEAVKSQYDRAIAAGHGGDNWTSLWEVVAKR &gt;pIR16 MSSVSIFGLGAMGKALASRFLAEKYKVAVWNRSPEKASPLLEKGATLSHTAVDGINASDL IIICLLDNAAVQATLDSALDRLHGKTIVNLTNGTPDQARKLSDLIVSHGAQYVHGGIMAT PSMIGSPHALVLYSGSPDAFNAAEADLSVLANCVFLGEDAGSASLHDLALLSGMYGLFSG FLHATALVKSSTPAVKFLDLLVPWLGAMTEYTKGMAKQIDEGQYASEGSNLAMQLVAVEN IIDASAAQQVSADFIRPMKEFMEKAVAAGHGGDDISSLIDFVKST &gt;pIR17 MANTVTAQAISVIGLGAMGAALAEALLAADHRVTVWNRTASKSAALGEVGAQVAHSAAEA IDASQVVVVCVLDYGASDSLLRTPDVAARLKGKTIIQLTTGTPEDAREASEWAREHDVAY LDGTIGCYPKDIGTSDGSILYAGSRSTFEALRPTLANLSGHALFVGERFGNAAILDGAVV GSFSLGAALGFLYGAAVCDAEGISLDTYLSLALARRPFVEDTLQTCVQMIKKGNYSGSQA TLDSWAAGIGQLVAYSQESGTDSSYPQEVLARLQQAVAKGHGQHELAAVFECFRKPLANR G &gt;pIR18 MPLLLRRPLSPSVVSSFFLRRRSMSSKSDPISPSNTRIGWIGTGVMGRSMCGHLIKAGYS VTVFNRTISKAQPLLAMGANLAASPNSLASQSDVVFSIVGYPSDVRRVLLDPTSGALSGL SPGGVLVDMTTSEPSLAEEISKSASSAGCFSVDAPVSGGDLGAKNGKLSIFAGGDEATVK RLDPLFRLMGKVNFMGASGKGQFAKLANQITIASTMVGLVEGIVYAHKAGLDVRKFLEAI STGAAGSKSIDLYGERILKRDFDPGFYVDHFVKDLGICLNECQRMGLALPGLALAQQLYL SLKAHGEGGLGTQALILALERLNNVSVQPSVS &gt;pIR19 MDLGFIGLGEMGQAIATNLLKAGHTVRVWNRSRERAEPLAALGAQIVATPADAFRGDAVF SMLADDAAARDVFDDALLAQAPRGLIHVNMATVSVALAESLAHAHASRGLDYVAAPVMGR PDVAAAARLTIMAGGPAEAIDRVQPLFDAIGQKTWRFGSLPQHANIAKIAANFTLASAIE TLGEASALLGAHGVAMRDFLDVITSSVFPGPVYAGYGGMIAERSYEPARFKARLGLKDVR LALQAGDAASVPLPVASVVRDSLLDALAHGGGDQDFAVLGEVALRRAGR &gt;pIR20 MAQNSVEKAPVTLLGLGAMGTALARTWLAGGHPLTVWNRTPARAAALSPEGARVADSAAA AVAANTLVVVCLLDDASVEEVLAGTDLADKDLVNLTTSTPAQARARAEWARERGARYLDG GIMAVPPMIGVPEIGGYVFYSGSRELFERHQQTLGVPAGTTYVGQDAGFAALHDVALLSA MYGMFAGAAHAFALIRKEDIDPASLAPLLADWLVAMAPTVHQTADQLRSGDYTKGVVSSL AMQVAGTPTFLDTAAQQGVSPELLSPYFTLMRRRLAEGSAEEDLTGVIDLLVRK &gt;pIR21 METPYPTPISPTQTRIGWIGIGVMGAAMASHLLSAGYSVTIYARNPSKAASLQSQGAHLA NSPQQLARQCDVVFTMVGNPQDVRQTVLESDGILSGLKPGAVIVDHTSSSPSLAREIYAS ARKKGCWSVDAPVSGGDIGAREGKLAIFAAGVCAVVEWLKPLFDLMGRVTYMGEAGCGQS CKIGNQIMVGANLMGLSEGLVFAEKAGLDLKKYMEAIRGGSAGSMAMELWGRRIIERDFK PGGFAEYMVKDMGMGVDVVKEEDDGKVMVLPGAALGKQMFSAMVANGDGKLGTQGLITVV ERINGK &gt;pIR22 MPPLLPLLLVLRSRTAHSYSLSVSSLVTLLLRRRSMATVASTDPVCPTNTRVGWIGTGVM GRSMCAHLLNAGYTVTVFNRTLSKAQPLLDIGAHLADSPHSLASQSDVVFSIVGYPSDVR HVLLHPSSGALSGLRPGGIIVDMTTSEPSLASELSAAASSKNCSAIDAPVSGGDRGAKTG TLAIFAGGDESVVQKLNPLFALMGKVNYMGGSGKGQFAKLANQITIASTMVGLVEGMVYA HKAGLNVELFLNAISTGAAGSKSLDLYGSRILKRDFEPGFYVNHFVKDLGICLKECQNMG LALPGVALAQQLYLSLKAHGEGNLGTQALILALERLNNVRLDNAVASKPSA &gt;pIR23 MKPGISVLGTGRMGSALVGAFLKQGYNVAVWNRTKSKCAPLAALGARVATTVRDAVADAE VVVVNVNDYVTSEALLRQDDVTKGLRGKLIVQLTSGSPRQAREMAAWARQHELQYLDGAI MGTPNFIGEPGGTILYSGPGALFEKYKPVLLVLGGNSLHVGSDVGHASALDSALLSFLWG SMFGVLQAVSVCEAEGLPLGAYMEYVQATKPMVDGAVTDFVKRIQTGRFAGDEKTLATVE AHHGALRHLIELCEEHGIHHAVPAAFGQLFQAALQAGHAQDDFAVLNKFMK &gt;pIR24 MTKTCVVGAGRMGSAFARALLAEGIETRVWNRSPEKVAPLVAAGAHAPESLAEAVAASDV VIVNVIDYAAADALLRMLAVERALAGKVVVQLTSGSPRQAREAGRWAAERDIAYLDGAIM ATPNFIGGAETTILYSGMRQAFERHRDVLRVFGGNGVFVGEDAGHASALDTGLLTQMWGK LFGTLQALAVVRAEGFGLEAYARYMRDFQLVVDAATDDLIARVGEGRWRGDAATLATIEA HYSAFHHLLAIGDEHGLDRALPAALDGLFKAALAAGHAADDFAALMRFIERGGVRHAA &gt;pIR25 MPPLLPLLLVLRSRTAHSYSLSVSSLVTLLLRRRSMATVASTDPVCPTNTRIGWIGTGVM GRSMCAHLLNAGYTVTVFNRTLSKAQPLLDIGAHLADSPHSLASQSDVVFSIVGYPSDVR HVLLHPSSGALSGLRPGGIIVDMTTSEPSLASELSAAASSKNCSAIDAPVSGGDRGAKTG TLAIFAGGDESVVQKLNPLFALMGKVNYMGGSGKGQFAKLANQITIATTMVGLVEGMVYA HKAGLNVELFLNAISTGAAGSKSLDLHGSRILKRDFEPGFFVNHFVKDLGICLKECQNMG LALPGLALAQQLYLSLKAHGEGNLGTQALILALERLNNVRLDNAVASKPSA &gt;pIR26 MPIQFSLRSLYTQSHKLTPTLSLPFLSFLRRTMSTSGDIVSPSTTRVGWIGTGVMGCSMC SHIIKAGYKLTVFNRTISKAQPLLDLGANLATSPLAVAAQSDVVFSIVGYPSDVRSVLLD PSSGALAGLRPGGVLIDMTTSEPSLASEIAASATAKGCGAIDAPVSGGDRGAKNATLAIF AGGDEDEVQRLSPLFSLLGKVNYMGESGKGQFAKLANQITIASTMVGLVEGMIYAKKAGL DVGLFLNAISTGAAGSKSLDLYGSRILKRDFEPGFFVNHFVKDLGICLKECQNMGLALPG LALAQQLYVSLKAYGEGNLGTQALILSLERLNNVSLEGSGSS &gt;pIR27 MSSITTAEPRSPSNTRLGWIGTGVMGLSMCSHLLKAGYTLTVFTRTQSKAQPLLDLGAKW AASPSSVASQSDVVFSIVGYPSDVRHVTLHPNSGALSGLNPGGILVDMTTSDPSLAVEIA DAAAAKGCFSVDAPVSGGDRGARNGSLSIFAGGDKKVIDTLSPLFNLLGKVNYMGVSGKG QFAKLGNQITIASTMVGLIEGMMFAHKAGLDLSLFINAISTGAAGSKSLELYGYRILKRD FEAGFFVNHFVKDLGICLRECQNMGIALPGLALAQQLYVSLQAHGEGDLGTQALVLALER LNNVSLQSVASSTEMA &gt;pIR28 MTTISILGLGAMGTALANALLDAGHAVTVWNRTPGKDEALVSRGARRAQTPAEAIAASEL VVICLVDYAGVETMLASAEKELSGRVVANLTTGTPKQARALAAWVEAQGAAYVDGGIMAV PPMIGTPASFIFYSGNQPAFERHKAALEAFGDAVYVGPDAGAAPLNDIALLGILDGILSG YLHAAALIRASGGTAEGFTPLARRWAESMISLFPDLAKQIDSGDYRAEGGSNLAMQAAAM DQMVEAARDEGVDPVLIEPMRALIHQRVADGFGTDDSAGVIELLFLNGRGKR &gt;pIR29 MKKDITIGWIGTGVMGTSMLGHLNKAGYECITYTRTKSKAESLLANGVKWADSPAEVAAV SDVIFTIVGFPKDVREVYFGEKGILAKAKPGAVLVDMTTTEPSLAVEIYEAAKVKGIQSV DAPVSGGDVGAKNGTLSIMAGGEKEAFDKVYPLFESMGKQIVYQGAAGSGQHTKMCNQIT IAGTMIGVCEALLYGHKAGLDLPTMLSSISGGAAGCWTLDNLAPRIVNRNFDPGFFVEHF IKDMGIALKEAEAMGLSLPGLALVKQLYLAVQAQGHGKLGTHALTLALEKLSGL &gt;pIR30 MKVGFIGIGAMGKPMAQNILRAGYSLYVNDVNEAALQELVAEGAKKAENPRELAREVDVV ITMLPNGAVVEQVLLGEQGIFAGAKPGFTVIDMSSVGPTFTQKMAKLASDRQVGYMDAPV SGGVKGAEAGTLTIMVGGEKELVQRYHSLLEVMGKKIYHVGKTGAGDAVKIVNNLLLGIN MAAAAEAFVLGTKLGLDPQVLLEIISVSSGSSYALTAKMPNFIFKGQFEAGFAIDLQYKD LELAVQTAKEAKIPMLLTNVAQQVFEQARAAGLGRDDISAVIKPLEDLMKIKVRA &gt;pIR31 MPMPSSLPLTGLLRSASPPSSSALYLLLRRAMSSAAAASDPIAPSNTRVGWIGTGVMGRS MCGHLIGAGFAVTVFNRTVSKAQPLLDMGARLADSPRSLAALSDVVFSIVGYPSDVRSVL LDPSSGALASLRPGGVLVDMTTSDPSLAEEISAAASAKGCHAVDAPVSGGDRGARNAALA IFAGGDPATVRRLEPLFSVMGKVNYMGGPGKGQFAKLGNQITIASTMVGLVEGMVYAYKA GLDVGMFVSAISTGAAGSKSLDLYGNRILQRDFEAGFYVNHFVKDLGICLKECERMGLAL PGLALAQQLYLSLKAHGEGNLGTQALILALERLNNVKLENAGSSNV &gt;pIR32 MANSPVTVFGLGAMGTALATQFLQKGHKTTVRNRTAAKAQPLIAIGASHAPTIASAAAAS SILIICQLDKTSVMQTLQQAPTAWATKTIVDLTNGTPAHARETADWALAHGAQYIHGGIM AVPSMIGQPHAMILYSGPAEVGMYGLFSGFTHAVALVQSANVPAAGFVATQLIPWLTAMT QHLNLLATQVDEKDYGDGGSSLDMQAKAAPNILEASAAQGVSVELIQPIFKLIERRVEEG GGSEGLAALVGMIMKAGTKDSV &gt;pIR33 MENSPVTVFGLGAMGTALATQFLRKHHRTTVWNRTAAKAKSLIASGASHAPTISSAASAS SLLIICQSNKDSVLQTLQQEPAAWAGKTIVDLTNGTPAHARETAEWALAHGAQYIHGGIM AVPSMIGQPHAVILYSGPGKVFEEVKETLDAVGSSTYVGEDVGLASLHDLALLSGMYGLF SGFTHAVAMVRSARVPAAGFVATQLIPWLTAMTQHLNMLAKQVDDEDFGDGGSSLEMQAH AVPNVLEASEAQGVSVELIRPIFMLIEKRVGEGGGKEGLSALVHMIMKGA &gt;pIR34 MASKSISSVPINPSNTRIGWIGTGVMGRSMCGHLIRAGYSVTVFNRTVSKAQTLIDMGAK LADSPNSLAAQSDVVFSIVGYPSDVRHVLLDPISGALSGLNPGGVLVDMTTSEPSLAEEI SKAASSANCFSIDAPVSGGDLGAKNGKLAIFAGGDETTVKRLDPLFSLMGKVNFMGTSGK GQFAKLANQITIASTMLGLVEGMIYAHKSGLDVKKFLKAISTGAAGSKSIDLYGDRILKR DFDPGFYVNHFVKDLGICLKECQRMGLALPGLAIAQQLYLSLKAHGEGDLGTQALILSLE RLNNVSVQPIM &gt;pIR35 MTSATSGITLVGLGNMGAALAHAFLKSGCLLTVWNRTSTRPTVVEAIKAGASFEPDLAKA ISANSTIVFCVLEYKNIYQGLEPLVTSGVLKGKTMVNLTNGTPRDARDADKWFKDHGVAS YFDGGIMVTPQNVGTPVSVVLISGEDESLLESRGVKDLIGAIGAPDYKGEDPGVAAGYDL ALLAGMIGMFIGSLTALAMIQKQLDRAKSTAGANGAKETATTGGLTEVVTTYFNPLLTAL IPHNELLATAIDNNDQDNNHGNPMEMMRVAMHNIIRGCEEEGVDAENLRHFAGLADQVVH LHGPDSGLAWVHSLLLK &gt;pIR36 MAISSASQQAAEREVERSVSVLGLGQMGFAVAQAFTKKGYKTTVWNRTAAKARPLVAAGA IVATSVGDCIASNQLVLSCFIETQVLIEVLKTVDPQLCRGRVLVDFASGTLRETRQFQTI ARELSFAYIRGSIASTPPYVGSSQIHAWYCGNETIFRSIQPDLAALAQPGYIDNDPGTIA LHECAGGNIFYAFAAGFVQAMAVVKASGKCHPGGAEDFVNKFMIPFLHTFPDTFRDWAHQ IDNQNYDAHGKGARLGQSAKSINLMRRFNTELGLTSVILDPVLSLIKHRIAQGGSNEELS SLVETIADSKAGI &gt;pIR37 MTTSQSLTFLGLGNMGSALVQALLKASHKVTIWNRTTARPQVRAAVEAGAILEADVQTVI SRNNIIVICLLDYSSINNVLDDIPTPAFKGKTIVNLTNGTPKQAREMANWATSHSAKQYF DGAVMVTPQMIGGPQSFFVVSGETPEAFKPIASFLEPLGRPEYLGTAIDAAARYDLAALS SMYGMFSGMFVAMALLKKGHAIADEKLEPVVSGSLNPFLGALISYNGLIARSWDDKAWDD NLGNPIGMQAQALGNILEACRDDGMDDGFLKNLTTAMERVVKDRGENGGIAVIGEYLLNG RLSNE &gt;pIR38 MRSLSYLLGSLSRYFPHSQSSSTPHLTFLLRSMATSAAAGPINPSNTRLGWIGTGVMGRS MCAHLINAGYSLTVFNRTLSKAQPLVDMGARLAQTPHDLAAQSDVVFSIVGYPSDVLQVL LDPVNGALSGLRPGGILVDMTTSEPSLAVEISTAASSKNCSSIDAPVSGGDRGAKNGTLA IFAGGDEAIVNRLNPIFTLMGKVNYMGPSGKGQFAKLANQITIASTMVGLVEGIIYAHKA GLNVASFLDAISTGAAGSKSLDLYGSRILKRDFDPGFFVNHFVKDLGICLKECQNMGLAL PGLALAQQLYLSLKAHGEGNLGTQALILALERLNNATLGS &gt;pIR39 MRVAFLGLGKMGSALVPHLLNAGCEVTVWNRSSPAAKELASKGATVALSAAEAVNSCEVV FSLLLNDAALEEVLFDGGVLDAMPKDAVHVSVGTISVALAKRLTLEHAKRGHRYVGAPVF GRPNVAAEGKLWTVVGGAKEAVQSVRSLLESYTRGMTVVSEEPWSAHAMKLAGNFSVAAM VATLSEAMMVAESMGVSPELFVEMANSATFRSPLYEVYGKTLTNPPKEVGASMELGEKDV RLFREAAAANGVKTPLAELMGKNFDAAIEAGMKDHDWATGYYELVRKRQVEEPVAL &gt;pIR40 MAAVSLRLGDLVWGKLGRYPPWPGKIVNPPKDLKKPRGKKCFFVKFFGTEDHAWIKVEQL KPYHAHKEEMIKINKGKRFQQAVDAVEEFLRRAKGKDQTSSHNSSDDKNRRNSSEERSRP NSGDEKRKLSLSEGKVKKNMGEGKKRVSSGSSERGSKSPLKRAQEQSPRKRGRPPKDEKD LTIPESSTVKGMMAGPMAAFKWQPTASEPVKDADPHFHHFLLSQTEKPAVCYQAITKKLK ICEEETGSTSIQAADSTAVNGSITPTDKKIGFLGLGLMGSGIVSNLLKMGHTVTVWNRTA EKCDLFIQEGARLGRTPAEVVSTCDITFACVSDPKAAKDLVLGPSGVLQGIRPGKCYVDM STVDADTVTELAQVIVSRGGRFLEAPVSGNQQLSNDGMLVILAAGDRGLYEDCSSCFQAM GKTSFFLGEVGNAAKMMLIVNMVQGSFMATIAEGLTLAQVTGQSQQTLLDILNQGQLASI FLDQKCQNILQGNFKPDFYLKYIQKDLRLAIALGDAVNHPTPMAAAANEVYKRAKALDQS DNDMSAVYRAYIH &gt;pIR41 MTSSPSLPTVAPGRTRVGWIGTGVMGRWMCGHLMNAGYAATVYNRTQSKARELIDRGATL ATNPREVAEASDVIFTIVGFPSDVRQVILGSDGVLAGAKPGAIVVDMTTSEPELAREIHR VAAARGVHAIDAPVSGGDLGAREARLSIMVGGDPEPVAAVQPLFQIMGKTIVHQGPPGAG QHTKMVNQILIAGNMVGVCEALLYGYKAGLDLTTVLQSVSGGAAGSWSLSNLAPRILKGD MTPGFYVEHFIKDMGIALAEARRMKLALPGLALVEQLYQALAAQGHARDGTQALTHALAR LSGFEWKAVVTTTQGQS &gt;pIR42 MTDHHPVTVIGLGAMGREIARVLLEAGHPTTVWNRNLERAVDLVSQGATRADTVVAAVGA SPLVLVCVLDYAATRELLEPIAADLAGRTVVQLTTGTPKQARELAEWAAGHGIDYVDSGM MATPPMIGRPGSTFLYSGDEAAFERYRPALDLLGTSRWFGADAGLASLYDLALLSGMYTM FAGFLHGAAMVGTAGVSAADFAESAGDWLRAMTVSLPYAATFVDSGDYTTDVQDVEFNKS ALDVIVQASIDQGVAPDLVAPIHELLARQLAEGHGKEAFDRIIESIRPAVTRPA &gt;pIR43 MILSLLRSRSHDFNTSRIHFTLPLSLFFRRSMATTTESASPSNTRVGWIGTGVMGRSMCA HLIKAGYSLTVFTRTLSKAQPLVDMGANLAQSPLAVASQSDVVFSIVGFPSDVRQVLLDS TTGALQGLRPGGILVDMTTSDPSLASEISAAASAKNCHSIDAPVSGGDRGAKNGTLAIFA GGDEAVIDRLNPLFALMGKLNYMGAPGKGQFAKLANQITIACTMVGLVEGIIYAYKAGLN VEHYLNAISTGAAGSKSLESYGARILKRDFEAGFYVNHFVKDLGICLKECQNMGLALPGL ALAQQLYLSLKAHGEGNLGTQALILALERLNNVSLENLASLQPAA &gt;pIR44 MSRLPSAVSEYSTRGGTSSYETRCTMPSDSNSRRCEASTFSVTPGSSRRSSPNRRHGCSC SAHRISTFHLPPITSIAASIPQTCPSGVPGLFSVAMPPPLRPAGSPRGKHPPESAYLITT GPWTSLIGMAHTTVDPTAKTPVTLLGLGAMGTALARTWLAAGHPVTVWNRTPSRATALAA DGASVAATAAEAVAANTLVVVCLLDDASIDQALAGTDLTGRDLVNLTTSTPEQARARAAW AHERGARYLDGGIMAVPPMIGVPQAGGYVFYSGSRELFDRHRPTLAVPVDTRWVGEDPGH AALHDVALLSAMYGMFAGAAHAFALIRKEDIDPTALAPLLADWLTAMAPAVHQTADQLRT GDYTTNVVSNLAMQVAGTPTFLATAEQQGVSPELLTPYFDLMRRRLAEGNGNEDLTGVVD LLLR &gt;pIR45 MPDLSKPAVTVLGLGDMGSALARALLKAGYPTTVWNRTPEKAKPLVEAGATHAPTVADAV TASRLVIVCLLDYKSVTDVLDTARDALTGKVLVNLTNGTPGQARELATRYDVDYLDGGIM AIPPMIGAPPAFVFYSGSRSAFDTNKQVFEAFGGTNYVSTDAGFAALYDIGLLSGMYGMF VGALHALSLVTSAGVPAQEFAPLLKQYVSAMLGSIDGMAEQIDKQDYAIDVVSNIGMQSE AYVNLTLSAEELGMSPELLAPLGPLMARRVADGHGHEDIAGVVEILKKGKK &gt;pIR46 MASSTAAEPISPSNTRLGWIGTGVMGQSMCAHLIRAGYTLTVFNRTPSKAQPLLDLGAHQ AHSPQALASQSDVVFSIVGYPSDVRSVLLDPTSGVLSGLLPGGILVDMTTSEPSLAVEIA AAAAEKNCHSVDAPVSGGDRGAKNGTLAIFAGGDKDTVHRLEPLFSLLGKVNYMGGSGKG QFAKLANQITIASTMVGLVEGMVYAHKAGLDVGLWLDAISTGAAGSKSLDLYGQRILKRD LDPGFYVNHFVKDLGICLKECQNMGIALPGLALAQQLYVSLKAHGEGNLGTQALILVLER LNNVSLAPAASSS &gt;pIR47 MRPCVGNMGTAAIQALRKASHSVTIWNRTKSRPQVQAAIDAGATFEPDLAQALSRSGVIV LCLLDYATITKIFSSIGEPGAVLKGKSVINLTNGTPKEAREMETYFTSLGTIVYLDGAIM VTPQMVGGPHAFLFLSGGQGSTETPDGATSRLVELVSPIGKPDYLGADVGAASRYDLASL APMYGMFAGGFLGMALLKRGKPNAKLVPVVQEKIVPMIAALVPYMTGIARAWDAEDWVEN DGNPVGMMAVGVQNILAAAADEGVDGTVLEEFGGLMEKVERDHGYDAGIAAVGTYLMK &gt;pIR48 MKSKVCVLGAGRMGSSIARCLVSHGYQTWVWNRTAAKCEPLAALGATVALSVEDGIRAAD VVIINVLDYAASSASLRQDSVISGLAGKTVVQLTSGSPRLAREEALWVESHGASYLDGAI MATPDFLGRPEATLLYSGPREVFEVHKGLLSTLGGGTSYVGENPGQASALDTALLTQMWG GLFGALQGMAVVEGENLNLETFRHQLTAFKPVVDAALFDLIDRTIARRFAGDETTLASLG AHYSAFQHLLEACEEQGLDASLPNAMDRFFRQALSLGGPESDFASLAPLFRANHTVAPFA ELANA &gt;pIR49 MSVSVLGLGPMGQALTRALLNANHRTTVWNRTAAKADDVVARGAVWADDPASAIAAGDLT LVNVVDQQAVDAVLTAAGDAVAGRVIIGLSAGTPDAARRTASFVTGAGGAYLDGAIMTPT DTIGTASASVLFSGPRELFDDHREVLSALGTLTWLGEDVGRAEAFDVALLDLFWTSVSGF VHALSIAKANGVSAVELLPHANGISEILPAIFTEIAERVESGRHDDASAPVSSVAASLRN LISAARSAGIDAGALETFRDYVDAAVAAGHGDAEISRITPLGIG &gt;pIR50 MATITSIGIGNMGAALATALLKSSSPPMNVTIWNRTASRPQVQSLISAGAIFEPSLAAAL ASSEVILLCLLDYPAISSVFSQVDASAKPLAGKTILNLTNGTPKQARDMEAFFKSLGAAV YFDGGVMVTPQLVGTPAAFVVLSGETEQAYNERLANAGLLSPVGAVLYIAPDPGAASLVD CAALAAMYGMFIGAFTGIGLLKRQKHERDGEAAGAKAMVDKVMVPVLTALVPYVGLLAEQ VDKEAWMDDLGNPLAMQAEGVRNIMQSCEDEGVDGTGLKFLSKLMEKGVKEGFGPGGVAV VAKYLMK &gt;pIR51 MPLSLPLRSLSSHHSSFNISSLSLRLLTHLHRSMATAAAAEPTICPSNTRVGWIGTGVMG RSMCAHLINAGYTLTVFNRTLSKAQPLLDMGAHLAHSPLAVASQSDVVFSIVGFPSDVRS VLLDPSSGTLAGLRPGGVLVDMTTSEPSLAAEISSAAASKGCSSIDAPVSGGDRGAKNGT LAIFAGGEESVIHRLNPLFSLLGKVNYMGGPGRGQFAKLANQITIASTMVGLVEGMIYAH KAGLDVAMFLDAISTGAAGSKSLDLYGARILKRDFEPGFFVNHFVKDLGICLKECQNLGL GLPGLALAQQLYLSLKAHGEGNLGTQALILALERLNNVSLESGGCSSSPAPAN &gt;pIR52 MMGGTPACPTAQLVLRVFNHGRDNGHLSQSSLITLYQVAQSPTAPLLACTPIPAIVDSRC VGLNFCTVSMAQSEAVKEIVSDQTRVGWIGTGVMGQAMCGHILAAGFQVSVYNRTASKAQ DLCSKGATMADSPLSVAQQSDVVFTIVGYPSDVREVMLGEKGILKGLRPGGIVVDMTTSQ PSLARELSLAAKERSCESIDAPVSGGDKGAKSGTLAIMVGGEKNTFELLAPLFKCMGNAT YMGPAGSGQSCKLANQVTIASTMIGLVEGMIYAQKAGLNVDTFLQAISGGAAGSKSLELY SGRIRNRDFDPGFYVNHFVKDLGIALEECRNMDLALPGLALAQQLYVSLKAHGEGALGTQ ALILALERLNNIKQ &gt;pIR53 MGAALARAYINAGHRVTVWNRSPSKAEPFQGQAKVAETAAQACSESDLTIVSVSNYQASD EVLRTPLAEQAAKGRTIVQLTSGTPGDARSGAAWAQEHGIEYLDGCILAYPSYIGGEQTT IFYSGPKALYDRHEATLRVIGGGTSHVGEPIGAAATLDCALLESYYGATLAFLHGAAICR SEKFPLDAYFAGVQAIMPLISITADMCKRMLATGDFKGTDCTLDIHAGAIQHIVRLSREN NVDRRIPELILSYFDRALKLGHGSDEMAAVINAIQEPPRG &gt;pIR54 MPLPFLRFRSLYRHSHTHLLTRHFMATSEPITPSNTRLGWIGTGVMGQSMCAHLIRSGYT LTVFNRTPSKAQPLLDIGATLATSPHAVASQSDVVFSIVGYPSDVRSVLLDPNTGALAGL KSGGILVDMTTSDPSLAVEIADAASVKSCHSIDAPVSGGDRGAKNGTLAIFAGGDESIVK KLSPLFSSLGKVNYMGTSGKGQFVKLANQITIASTMVGLVEGMVYAHKAGLDVGLYLDAI STGAAGSKSLELYGKRILKRDFEAGFYVNHFVKDLGICLKECEKMGIALPGLALAQQLYV SLKAHGEGNLGTQALILVLERLNNVSLPPSVI &gt;pIR55 MAPNTVDKTPVTLLGLGAMGTALARTWIAAGHPLTVWNRTPARAAAISDEGAGLADSAAA AVAANTLVVVCLLDDDSVGEVLAGTDLTGKDLVNLTTGTPAEARSRAEWARERGARYLDG GIMAVPPMIGLPEAGGYVFYSGSRELFERHRETLGVPAGTTYVGRDAGFAALHDVALLSA MYGMFAGAAHAFALIRKEDIDPASLAPLLADWLVTMAPAVHQTADQLRGGDYTKGVVSSL AMQVAGTPTFLSTAEQQGVSPELLSPYFELMRRRLAQGGGEEDLTGVIDLLVRGPDHVRT SARTARTSWR &gt;pIR56 MRFMRLLRLLPNHQFHCYVPQAIFTTSAGTTTHLHHTMETATTEAINPSNTRLGWIGTGV MGRSMCAHLINAGYTLTVFTRTPSKAQELISMGAHWVDSPKAVASQSDVVFSIVGYPSDV RHVILDSNSGALSGLRPGGVIIDMTTSEPSLAVEIYSAASAAGCSAVDAPVSGGDLGARN AALSIFAGGDESIILRLNPLFNLLGRVYYMGAPGKGQFTKLGNQVVIASTMVGLCEGLIY AHKAGLDLNMFLNAISTGAAGSKSLDLYGSRILSRDFEPGFYVNHFVKDLGICLRECQNM GLALPGLALAQQLYLSLKAHGEGNFGTQALILALERINNLSLASSSSVGKP &gt;pIR57 MPLLLRRSFSPSVVSSFFRRFSMASKSISSDPINPSNTRIGWIGTGVMGRSMCGHLIRAG YSVTVFNRTISKAQTLVDMGAKLAESPSSLAAQSDVVFSIVGYPSDVRHVLLDPNSGALS GLNPGGVLVDMTTSEPSLAEEISEAASSGNCFSIDAPVSGGDLGAKNGKLAIFAGGDETT VKRLDPLFSLMGKVNFMGTSGKGQFAKLANQITIASTMLGLVEGIIYAHKAGLDVRKFLE AISTGAAGSKSIDLYGDRILKRDFDPGFYVNHFVKDLGICLKECERMGLALPGLALAQQL YLSLKAHGEGDLGTQALILALERLNNVSVS &gt;pIR58 MATPQALTFLGLGNMGSALVQTLLKASHRVTIWNRTVDRPQVKAAVEAGAILEVDVQTAI SRNNIIVICLLDYSSIKTALAGISASALDGKTIVNLTNGTPKQAREMAAWTASHSAKHYF DGAVMVTPQMIGGPQSFFVVSGQTSEAFKPIASLLEPIGRPEYLGTAIDAAARYDLAALS SMFGMFSGMFVAMALLKKGHTKTDEKLEPVVSGSLNPFLGALIPYNGLLARSWDDKAWDD NLGNPIGMQVQALRNILEACRDDGMDDGFLKNLTTVMEGVVKDRGENGGIAVIGEYLLNG RLTKE &gt;pIR59 MREHNDESFEFEVSVIGLGAMGTIMAQALLGQGRRVAIWNRSPGKAAALVAAGAHLCESA EAALAASPATIFVLLDNQATHEVLGMPGVMQALANRTIVDYTTNARDEGLALQSLVNRAG GHYVKGMIVAYPRNVGRRESHSIHTGDPEAFERHRALLEGLAGHTTFLPWDEALAFATVL HAHAFAAMVAFFEAVGAGVHFGLPPSKTARLMLDTSRFFVADALEEAVRRLEAQDFAGDQ ARLDVHAQAFAHIAGALHAQGAWTPVFDALCQAVQRAAAMGYGDQDIVAVTRLFARECDT ASAAGQ &gt;pIR60 MSASLPSLAFAGLGLMGVPMCRRLLAAGYPLAVWNRSPGKRELLAAEGAKAVEVPAELAA DAEILMLCLADTAAVREVVFGAGGIVENARPGQLLVDFSSAEPAATREMAAELEARCGVR WVDAPVSGGTPGAESGSLAIMAGGRAADIERLRPVLSRLGQRLTRMGEVGAGQVTKVCNQ MIVACNALVIAEVVALAERAGVDASLVAPALAGGFADSKPLQILAPQMAESRYEPVKWHV RTLLKDLDTAVKLSREQGAATPMSGLAAQLMRLHGSQGYLERDPATLVEQYRTAVE &gt;pIR61 MSSVSILGLGAMGTALAARFLEKKYKVAVWNRSPEKASPLLDKGANIAQTAVDGINASDL IIICLLDNAAVQTTLAGALDQLQGKTIVNLTNGTPDQARKMSDLIVGHGARYVHGGIMAT PSMIGSPHALVLYSGSQQAFKASEPDMLMLAKCVFVSEDAGAASLHDLALLSGMYGLFSG FLHATALVRSSTPAVKFMDLLVPWLGAMTEYTKRMAKQIDEGNYASEGSNIAMQLVAIQN IIDTSAAQKVSADFIRPMKQFMEKAVAAGHSGDDISALIYFAKPS &gt;pIR62 MSSEQTVSVLGLGLMGSALAKALVQNGWKTTVWNRSPEKAQPLVELGASASTTAADCVRA SRVIITCVMDPAALQGILKTLTQEDCKGRILVDYTSGVPSEMRKCEDQALALSLKYFHGA ILTMPSLIGMSTSTLLHSGADEITFESINPVLKAFGQSIYLGQDASWATLQEGILGCCFY GFAGGFVQAMALLKSSSFYVPGGAQTLMSQGILPLLTEQFPHIFADLARQIDEQAYDSEG NGIRLDTLKSSLEQLIRVNSEQGLVSNAFDPMLSLLKARIAQGGAAEEMSGLVEAISNPP KQT &gt;pIR63 MSTSEPKSISILGLGQMGHAIASNFVSQGFKTFVWNRTPSKAADLVEQGAIQSPSSTECI RSSPLSILCVNTDDIVMDILAAAGDIPGHTIVNIVNGSPQQVRKTAEKSISQYMAAGYLH GSVMASPGLVRSGGAMTIFAGSSETFKKWELTLQPLGVTLWLLDDVGAAPLYDCSLLSIL SGIFSGFMQALAMIGAAGHSETEFARGFVVPLLGQMEEWLVRTAEEVQNKDYVAEKNGSP IAVQLDSTKHIFETAKELGVSSRLLQGFLDVVKEGVQRGQGREEISGLVRLLREPK &gt;pIR64 MTTTTEISIIGLGNMGTALAHTFLKANKTLTIWNRTPTAPSITALISAGATFVPSLPTAL SASPLIILCILDYPAIDSLFATLPPGILKDKIIINLTNGTPRQARHLATWMQDNGVANYL DGGIMATPDMIGTPASSLFISGADEPAFASVKEEIAILGAPRYMGTDPGAAALYDLALLA GMYGMFAGSLTAMALMRRLGGEETLEARVEGLLNPWMAALIPYQAAMAGSVDRGSFEALG NPVGMQREALKNILRACEEEGVDGGCLGYFEGLVGRVVEDKGGDGGLAGVEGLLGSKE &gt;pIR65 MTTNTSLSGQDVSVIGLGNMGVAIANCLLRAGATVTVWNRTASKAEQLIAQGALLALSPS ACISASPITIICLLSNATAEQALSDVQDLSRRTIINLTNGSPGQARQMATLLQSQKGARY IHGAIMVPPLLLGQPTSVTLCSGPSDVFHACTSVLSALGTPRHVGEDISQASLLDNALLS LMGGIFEGWVQALAIVQRGGVDEVEFATGLAGPFVKAMADWLPRIAESVRDEQYVGGSPL RMQLEALDNIAVTGEELGVGVLLGELRGVMERAVTLGKGEEGIAGLVPLLTGKK &gt;pIR66 MAAEKPRVGWIGTGVMGQAMCGHILSAGYSVTVFNRTLSKAQTLCDRGAIMVDSPKSVAA ESDIVFTIVGYPQDVREVIIGENGVLQGLKPGGTVVDMTTSEPSLAREIIDYAKQRGCES VDAPVSGGDKGAKAGALAIFAGGEETVVEGLKPLFDCMGKVTYMGGPGLGQCTKLGNQIT IASTMVGLVEGMVYAHKAGLDVEMYIKAISAGAAGSRSLDLYADRILRRDFDPGFFVNHF VKDLGISLRECQQMGLSLPGLALAQQLYVSLKAHGEGNLGTQALVLALERLNNVQLPKIG &gt;pIR67 MNSSPNEKENHENAGADSRTPVTVIGLGMMGTALAEAFLKAGHRTTVWNRSADKADALVA KGAIRAATAAEAVSASPLIVVCVLDYEAAHEILGSVGGLLTGRTLVNLTNGKPEQARKAA KWAAEQGADYLDGGIMAIPQMIAGPGALLLYSGSPGAFETYRGELDVLGASQYLGEDAGL AALYDLALLSAMYGMFGGFYHAVALVGTEKVEASAFTALVIPWLQAMMASLPLQAQAMDA NVHATDVSSLYINKIGFVNLIKASQEQGISTELVAPLQALVDRAVAEGYGADGLSRLAGL LKKPQ &gt;pIR68 MTSQILEFNSMTTIGFFGAGRMGASLVRTLAKSGHEVHVWNRTAAKAEALAPFGVQPRPT PEAAAAEAEIVFVNLLDYAASDAQLRKPEVTQALKGKLLVQLTSGSPKAARDTGAWATGH GIAYLDGAIMATPNVIGEPDTLILFAGSKSLYQKHERVFVALGGKSAFLSEDFGAASALD SALLGQMWGTLFGTLQALAINRAENIDADAYSTYLKLVQPVIDGAERDLMQRVHDGRDRG DDETFATIAAHNVALQHLRHINAERGLNPVLADAFDSLFTTAIQNGHVGDDFAILARFMR AP &gt;pIR69 MQQIYCIHRQIKLSNMNKQKVTVLGLGAMGSRMGVNLLKAGYSVTVWNRSPKPTEALAAK GAVVATTPKLAVKEADVVISMVTDSDASRAVWLDSETGALSAMRQSAIAIESSTLTVSWV KELATEFKHSGIAFLDAPVVGTRPQADSGNLIYLIGGEIETLKQAENIFLSAGGGKINHA GEIGKGMAMKLAVNAMFGIQVAAISEIIGMLIKNGFGLEKAVQYLAELPVTSPAAKNAAN LILKGNHAAMFPIDLVEKDFRYVMQTAKDVEAASPISEAIHRVYLDAVDKGYGGDNITGV AKLFV &gt;pIR70 MTTTEQVSVGYIGLGNMGAPMAKRLLDRPGGLIVCDTRPEALEPFGKAGARVTSSPREVA ENADVISVTVLNDEQVRAVVTQILDTARPGTVVAVHSTISDVTAVELADRCRAHGVDLID APVSGGAPGALEGKLAVMVGASDDAFEKVREPFGHWAELVVHAGDVGAGTRMKLARNLLH FISFTAAAEAQRLAEAAGLDITELGKVVRHTDAITGGAGAIMLRDTTDALDETDNWYPIM THVRDLGEKDLSLAIGLGERLDVALPLARLALTGLGPGLGVDSTVDKKEQP &gt;pIR71 MSSTTSHITLVGLGNMGTALAHALVKAGRRVTIWNRAGTRPSVSELVQVGAGYGPELPRA IAGSSTIIFCVLDYNSIHQVMDPVVTSQGTDAREMDRWMHKHGAARYFDGGIMVTPQLIS TSTSFILCSGENEALFNDSDVIDLIIILGRPHYVASDPGAAALYDLSLLAGMFGMFAGSM TAMALMQKQIHRDGNRPHSPSGAVKFTLEDRVSTLLNPLLNALVPYTLNIAQSITSGRMD ENFGNPMAMVSMAMQNVLRACEEEGVDGGSLKYFADLMKAVVDERGGEVGIGWVSTLLTK &gt;pIR72 MSDTVVGIAGTGRMGTAFARRLRETGTPVRVWNRSSDRTGAAVDAGAEAVALEALAEADL VLLSLTDAAAAEAVLAGMGAALAGRIVVEMSTLLPDQAEALEAQATALGAQFLHCPVGGT VAPALKGQLLGFAGGPAETLEQARPVLERLCRRVEHLGSVGAAARMKLAVNLPLALYWQT LGESLLLLRGAGIPAEQAIGLMAESSGGPAVLKNRAQVVVETLEGADQRGTFDIAGLAKD LHLALALAEREGAALPLSAAAEERYRAALEAGLGRFDGASLARRTAEG &gt;pIR73 MAQNAVEKTPLTLLGLGAMGTALARAWLAAGHQVTVWNRTPGRAAPLVAEGAVLAESAAA AVAANSLVVLCLLDEASVEEVLAGTEPAGKDLVNLTTGTPAEARARAAWASARDARCLDG GIMAVPPMIGVPASGAYVFYSGSHELFTRHRETLAVPAGTTWTGTDPGHAALHDVALLSA MYGMFAGTAHAFALIRGEDIDPVAFAPLLADWLTAMAPAVHRTAERLKSGDLTGDVVSDL AMQTAGVPTFLGTAEQQGVSPELLSPYFALMRRRLAEGGGGEDLAGLIDLLRRAPGTAA &gt;pIR74 MAGTDRTPVTVIGLGLMGQALASAFVAAGHPTTVWNRSADKAAAVVEQGTVLADTPAEAV AASELLVVCLLDNDAVHAVLDPVAGSLAGRVVANLTSGSSDQARENAAWAEEVGFRYLDA AIMTVPAAVGAPESVVFYSGPREAYDRHSDTLRLLGGGTTHLGEDHALSALYDVSLLGVM WGTLNSFLQGAALLSTAEVKAADFLPLALKWIDTVKLFATDYAAQIDQKDGAFPANDATM EVHLGAVRHLLHESEAQGVNAELPRFVHALMERTVAKGFGQNSYASMSELFRTPEK &gt;pIR75 MDSRDGLRVGPYLACAGHRLTVRNRTPSRAAALAAEGARVADSANEAVAANTLVIVSLMD DSSVDEVLAGIDLADTDLVNLTTSTPAQARARAEWANERGARYLDGGIMAVPAMIGVPEA GSYVFCSGSRELFERHQETLGIPAGTTYVGMDAGFAALHDMALLSAMYGMFAGVAHAFAL IHKEDIDPTSLAPMLADWLVAMAPAVHQTADHLRSGDYTKGVVSTLAMQVAGTPTFLSTA EQQGVSPELLSPY &gt;pIR76 MTQNAVEKESVTLLGLGAMGTALARTWLAAGHPLTVWNRTPARAASLAADGAKVADSAAA AVAANALVVVCLLDDASVEDALTGTDLAGKDLVNLTTSTPAQARARAEWARERGARYLDG GIMAVPPMIGVPESGGYIFYSGSPELFQRHRETLVVPAGTVYVGHDAGFAALYDMALLSA MYGMFAGAAHAFALIRKEDIDPASLAPLLADWLVAMAPAVHRTADQLRSGDYTQGVVSNL AMQVAGTPAFVSAAEQQGVSPELLSPYFALMRRRLAEGSGEEDLTGVIDLLVR &gt;pIR77 MTQNAVEKESVTLLGLGAMGTALARTWLAAGHPLTVWNRTPARAASLAADGAKVADSAAA AVAANALVVVCLLDDASVEDALAGTDLAGKDLVNLTTSTPAQARARAEWARERGARYLDG GIMAVPPMIGVPESGDYIFYSGSPELFQRHRETLVVPAGTVYVGHDAGFAALYDMALLSA MYGMFAGAAHAFALIRKEDIDPASLAPLLADWLVAMAPAVHRTADQLRSGDYTQGVVSNL AMQVAGTPAFVSAAEQQGVSPELLSPYFALVRRRLAEGSGEEDLTGVIDLLVR &gt;pIR78 MSSQITCIGIGNMGAALAQALLKAETPVTIWNRTVDRPQVKAVIEAGGILEPNIELAIQK SDIIVICVLNYETIFHALAPLKSSTSPLANKKIINLTNGTPRQAREAEEWMNARGASQYF DGAVMVTPSLVDSPHSFLVYSGESEDDFSSVATALKPLGQALYVAPDASAASAFDLAALA AMYGMFSGAFIGMSLLKRQFGKTVPGVDKVVLPVLTALVPYVGLIAKSVDEKSWMEDNLG NPLAMQLAGVGNILQACKDEGVHGAGLEFLAAMMERAVGEGAGDGGVAAVGDYYLVD &gt;pIR79 MTDNKVGSSHDTAGTRPLTLLGLGAMGAALGHAWLAAGYPLTVWNRTPGRAEPLAAQGAQ VAGTAAEAVAANRLVVVCLLNDDTLGETLDGVDLAGKDLVNLTTSTPGQARVRAEWARER GARFLDGGIMAVPPMIGAPGSGASVFYSGSRALFDAHAEALAVPAGTAYVGEDPGFAALH DVALLSAMYGMFAGVAHAFALIRKEEIPPKDFAPLLSGWLTAMTSSVHQAAAQLESGDYT KNVVSNLAMQVAGSETLLGTAEEQGVSAELLTPYLALMERRLAEGHGDEDTTGLIDLLVR RTGR &gt;pIR80 MVGEQETRMRCGLIGTGLLGTAIAERLLTVGQLLTVWNRTAERSQPLVALGATIAPTPAA LLADCEVCLLLLSDAEAIAATLLTEESRSQLVGKTIIQMGTISPAESRAIADQIAAAGGQ YLEAPVLGSLPEARNGTLIVMVGAEPAVFEQWRSLLCHLSPEPEWIGPIGTAATLKLALN QLIGSLTSAFGGSLALLQRSGLAVEPFMAILRQSALYAPTFDKKLSRLLSHQYDNPNFPT THLAKDLRLFRETAADLGITTDAVEGVESIVQKAIAQGWGDQDYSALYEAINPDSN &gt;pIR81 MTKTPVSVIGLGRMGATIAEIYLREGHPTTVWNRTPAKAEPLLAKGARPAATVAEAVAAS PVSVIMLADDTVVRASLESATSELDGRTIVNLTTGRPDEARELGDWLAGHGAEYLDGGVL GVPQTLATPESVIIYSGSTAANQRHGEIVAALGTARYLGADHGLASLNDMAILSGMYGLF SGYFHSVAMVDSEGFKAAEFTKDLLIPWLRSIVDVLPTLADEIDSGDYPVNFSNLDVNVA GIENIMRTSRSQGVTDAPLVPLRDALAAQQEKGHGEASFSRAVEELKSSE &gt;pIR82 MSVDDSVGNAAGNAVGQVEGNSAVNAAGNAAGAAARRNVAVLGLGDMGTALAAALLAAGH RVTVWNRTARKADGLVEQGARRAASPAEAIGASDVVIVCILDYADVAPLLSDDGADAALK GKVVVNVTNGSPAEARELAERVAGLGADYLDGGIMAVPEIIGAPQAVVLYSGAKDAFEAH REVLDAFAGSVYLGADPGLAPLNDLALLSGMYGMFGGFLHAAGLVRSAGGNVTAFTTELL IPWLRAMADSQLPAMAAQVDSGDYGATGSNLAMQVSHDAIGDVSRAQGVSTELFAPLWEL MKRRVADGHGAESVGGVVELVHPREARA &gt;pIR83 MTTNDTATRPGSTPSATTAPAPLTLLGLGAMGAALADAWLSAGHPLTVWNRTAARAEPFA AKGAITAATPAAAVAANRLVVVCLLDDESVGEALAGVDLTGKDIVDLVTGTPGTARARAA WAADRGARYLDGGIMAVPPMIGVPQAGPYVFYSGSRELFEEHREVLAVPAGTRYVGEDAG FAALHDVALLSAMYGMFAGVAHAFALVREESVDPVAFAPLLSSWLTAMTGSVATTARQLA AGDYTEGVVSDLAMQVAGVPTFLRTAEEQGVSAELLTPYFDLMKRRLVADARHGAEDLTG VVDLLRG &gt;pIR84 MSNTSPVTVLGLGDMGRALAAAFLAEERATTVWNRTAAKADELISLGAVRADSVAEAVTG SPLVVVCLLDYGVVRETLEPVAGQLRGRTVVNLTNGTPSQAAEMAAWVTGHGGDYLDGGI MAVPTTVATPEAFILYSGEQRIFDTYRGVLGELGSARYLGDDIGLASLYDLALLSGMHLM FDGFHHAVAMATSQEGGSAFGFTELLVPWLTNMARLLPAFAAEVDADLTTAAEPRLTQGL DVQVSGLANIMDAARDAGVSTTPLESSMAALEALLAHGHKVWSAPASVRQLRTAP &gt;pIR85 MRSEPAAVTVLGLGSMGTALAGALLKGGHATTVWNRSPHKAKPLAERGATVAATPEEAVA ASPLLIACVLDYAALHTVLDPVADSLAGKTLVNLTSGSPEQAAEAAAWARAHGAHYLDGA IMTTPPGVGSPEMMFLYSGERTVFDTHRPVLASLGDPLHLGTDPGLASLYDAALLGLMWA AMTGWLHGTALVGAEGTPATAFTPVAIRWLSAVTGFLTTYAPQVDAGHYPGDDATVDVQI AAIDHLIHAAAARGVDNALPELLKATMERTRAAGHGSSSYASVIETLRKAAGTR &gt;pIR86 MARIAFIGLGIMGSPMAVHFHNAGHQVVGYNRTPAKTKALVEAGGTAAASVSEAVADADV VALMVTDTPDVVEVLTGAGGVFETAKPGTLIIDFSTIRPDVTADLAAQARSRGLRMVDAP VSGGEVGAQNATLSIMVGGTEEDFAAARPFLEVVGKTIVHVGPSGSGQTVKAANQLIVAG HLAVLAEAIVFLEAYGVDVSAALDVLGGGLARSAIMEHKAELMRRRSFTPGFRLDLHHKD LGIVTTAAREAGVVIPVAAAAAQLIAAARANGDGDLDHSALFRTIARLSGRD &gt;pIR87 MRSLPFLLRTLSRHYLHSQTPSPPHLTFLHRSMATSATAEPISPSNTRLGWIGTGVMGRS MCAHLINAGYTLTVFNRTLSKAQPLVDMGARLAQTPHDLAAQSDVVFSIVGYPTDVRQVL LDPTNGALSGLSPGGVLVDMTTSEPSLAVEISAAASSKNCSSIDAPVSGGDRGAKNGTLA IFAGGDEAIVRRLNPLFTLMGKVNYMGPSGKGQFAKLANQITIASTMVGLVEGIVYAHKA GLNVASFLDAISTGAAGSKSLDLYGSRILKRDFEPGFFVNHFVKDLGICLKECQNMGLAL PGLALAQQLYLSLKAHGEGNLGTQALILALERLNNVTLDS &gt;pIR88 MNMTTSRNVTAFGVGNMGAALAHALLKADTKVTIWNRTVDRPQVQSVLKAGATLEADVKA AISGSSDILLFCLIDYDAMYKTLEPIKGTSDGLAGKTIVNVTNGTPQQALEMRDWIKARG AARYFDGAVLVTPQMVATPQSLLVYSGESQETFDNIKTILQPLGTPLYYGPQVDAAAAQD LAMLATMYGMFYGAFVGFGILKRSGQGQDVKVAPGTKQITIPVMAALTEYLGLLADVIDS EDWASNGGNPLLMQVAGVANIIQAAKDANVNASGLEVLAEAMGKAVEDGWADGNVAAAAK FI &gt;pIR89 MATITSIGIGNMGAALASALLKSVGLRQLTIWNRTADRPQVKSLVEQGAHFEPSVAAAVA RSDTILICLLDYQTVTAVFEAISPGGLAGKTVINVTNGTPRQAREAEARFKGLGAAAAYF DGGIMVTPQQIGTPEAFVILSGEDESAFRAAGGPAELLEPIGAIQYVASDAGAAALYDLA ALAAMFGMFAGAFTGIALLKKQKRQRQDGGKEEGDRDNKALAKPATDSVIVPVLNALVPY VGMIADEVDRENWMNDMGNPLKMQAIALHNILRACEEEGVDGEGLKFISRRMDRAVADGF GPGGVSAIARYMFK &gt;pIR90 MATITSIGIGNMGAALASALLKSVGLRQLTIWNRTADRPQVKSLVEQGAHFEPSVAAAVA RSDTILICLLDYQTVIAVFEAISPGGLAGKTVINVTNGTPRQAREAEARFKGLGAAAAYF DGGIMVTPQQIGTPEAFVILSGEDESAFRAAGGPAELLEPIGAIQYVASDAGAAALYDLA ALAAMFGMFAGAFTGIALLKKQKRQRQDGGKEEGDRDNKALAKPATDSVIVPVLNALVPY VGMIADEVDRENWMNDMGNPLKMQAIALHNILRACEEEGVDGEGLKFISRRMDRAVADGF GPGGVSAIARYMFK &gt;pIR91 MSEVAVIGLGRMGSALAKALITSGRSVTVWNRTPGKAEPLEHLGASRAETPAAAIAASST LIVCLSDYAATSMVLDDACATDLLQGKTVVQLTSGTPKQARQLEEWVANRGGSYLDGAIS AWPSQIGGPEASIVIAGRESVFTSLEASLRLLAPNLTHVGNDISRAKVLFNAALAYFAGH WIGFSHGAAMCAAEGMDVAEFGETIASLSPMFADDLRHVGRAIEGNRFADPQSTIRSVGV DITRLLEIADDLNINTAFPAFASDLFRNATDAGYGAEEHCAIVKVMRAR* &gt;pIR92 MARSFAFARKPVEDAVMSERRKVSFLGLGVMGSEIARHIAQAGHELTIYNRSPDRVTAWQ DAHPGLAARVATSPEDAACEADTVITCVGNDDDLADVVLGPHGVFRTIRKGATFIDHTTV SARIARQVSVEARDLQVHCIDAPMTGSQIGAERGTLTLMCGGRKDAVEQARGVMEAYSAR IVHVGKAGAGQTAKMACQICIAGNVAALAEAVRFAQASHLDMGKVYEAISGGAAQSWQMD NRWQSMNEDHFDFGFAIDWMRKDLGLALDEGRALGVSLPVAGLIDQFYADLQAMGGGRLD TSAIIKRLPRKGAK* &gt;pIR93 MAPSSPAKIVVIGNGLMGSALARAFAAAGHDVAVWNRTASKAKAVGGGTTAVEDLREAVS GRELVVVSLSNYAAWFELCSSKGVASALAGTTLVQLTSGSPSDARAGLEWAKANGADYLD AAILAYPGFVATDYATVFYAGSRPVFDRHLDTLQAIARKSIFVDEQIGSAATLDCAILEA YYGSSLAFLHAAAMCKAEGLDPKTFFAHKDSFLGLISVTADAARGMIESNDFSGDQCSLD THVAAIEHIVRLSKDARISTRFPKELLDNYKRAISAGLGSKELPAVFRTLARDDT &gt;pIR96 METKTRVTVIGLGEMGSAIAKALLDRGHSTTVWNRTASKAAPLAAMGANVAPTAGDAVSA SRLVIVCLLDSAAVDAVLATLDAAVEGKVIVNVTSGSPAHARTSAEWARTRGATYVDGGI MGDPSNVGSPSVLVSFSGDRDGFDAHRVVLEDLGTLTYYGEDAGLAAVEFLAQVAVGYEF LLGLLHTFALVQAEGADVAGFADRVAGSVGGYVPLVKAFGTAVASGEYGPDLGSLTVQAA LMDDLISHRESLGVDTLRMREVKRLMDRRIADGHGDQGFSSLFELLGRESKRMPRL* &gt;pIR100 MTKTISVIGTGLMGSGLASTLLAAGRKVTVWDGRAQAAQPLVAKGATLVPSFVDAVHASE LIIMIISSAAGGASLIESHSEALDLKGRFVANLSTSMPEDGPRYRAAVERRGGTFINAAI SSYPDLIGGPYTAIQYACAPSVWDEIAQTVTPMAPQGTIYTGEDLSVPPIVDAAMTGSFY AVGLAGFLEAAAYAKTQGVSAGQLAEFADKMLDLLRYKVQKSIKEIEADDFSTIQATVDV YLDAVLQWRDALKASGLRASHISALADDLKIAQDAGHGALGFNSQYLVAGA* &gt;pIR103 MNMNSQVTVIGLGNMGAAIAQAFLDSGYRTTVWNRTASRTEPLAAAGASVAKTVSDAVAA SPLVVICLLDSAAVDAVRENIGAAAGRVLVNVTSGSPAQARRTAEWAHEQGASYIDGGLM GDPPYVGTPKMMLSFSGDREAWEAQRSTLEALGTATYYGDDPGLAAVEFLAQVAVGYEFL IGLLHTLRLVRDEGVDVAAFAERVAGSVSGYAPLVNAFGAAVASGDYGPDLGSLDVQAAL MDDLISHRESLGVEAVRMREVKRLMDRRIADGHGDQGFSSLFELLDGDEGAE* &gt;pIR104 MTDVSLIGLGPMGIALARALRSKYTLTVWNRTAGRAEPLLNQGTVLAPNALAAVQASPVV LVCVADYAASRAILAAPGVADALRGKVLVQLSTGTPQDARDDWAALGGVAYLDGALLATP SQIGRPDTPLFISGEERALAACRPLLEAVAGNIQYMGEPIGNAAAWDLATLSCMFGAMSG FFHGVRICESEGLKVNAFSQMIGAISPVLGEMISAEGEAIHAGSYGEPESSMATCAGSGR LFVKQAREAGLDASFPDFLMALFDRSLNAGLANERLAAMIKVLRQAA* &gt;pIR107 MTDVSLIGLGPMGIALARALQASKFTLTVWNRTAERATPLLNQGTVLAPTALAAVQASPV VLVCVADYPASRAILAAPGVHDALRGKVLVQLSTGTPQDARDDWAALSGVAYLDGALLAT PGQIGRPDTPLFISGEARALAACRPLLEAIAGNIQHMGEPIGNAAAWDLATLSCMFGAMS GFFHGVRICEAEGLPVDGFAQMIGAISPVLGEMIQAEGEAIHAGRYGEPESSMATCAGSG RLFVKQAREAQLDAGFPDFLMGQFERALRAGLGNERLAAMVKVLRQPSQPA* &gt;pIR110 MKSNKISVIGLGPMGYKIAKLYTEAGYDVTVSNRTRSKAEGLKANFADSIADAIAASDTI IICVYSNEAVHAGWDTIQDKSIFKNKAIINYTGASPEEVEKMEQLISGYGANYLNGVILT SPDHLGLPGTTILYAGDKNVYNTLEDTLAVTAGNMKFLSTKASVSCTMDLAALSIFYGTY VGMIYGAALSESAGVSLDVYNDIFSAAMPGFISFLNDDLKAIRNDDFTPTQTPVSNHIDA TQRIVDALDKAGAASDFTKTIVQLIKNTDQKGYGDEELAAVIKLVRSNQK* &gt;pIR114 MTDVSLIGLGPMGLALARALQSKFTLTVWNRTAERAKPLLNQGTVLAPTALAAVQASPVV LVCVADYTAWRTILAAPGVADALRGKVLVQLSTGTPQDAREDWAALGGVAYLDGALLATP GQIGRPDTPLFISGEERALAACRPVLEAIAGNIQYMGEPIGNAAAWDLATLSCMFGAMSG FFHGVRICESEGLGVDAFSQMIGAISPVLGEMISAEGEAIHANRYGEPESSMATCAGSGR LFVKQAREAKLDASFPDFLMGLFERSLSAGFANERLAAMVKVMR* &gt;pIR115 MQPAISVLGMGRMGSALAHALLKAGHPTTVWNRTPAKAAPLAAAGAEVAASVRNAVAASD IVIVNVSDYQATQSLLRDPDVTGTLKGKLIIELTSGTPDGAREVQAWAGRHGIRYLDGAI LATPDFIGTEAGTLLISGPAAAFEESRAVLGALGGNVQHIGADPGLANALDSAVLALMWG ALFGALQSIAICRAEAIDLETLGKQWSATAPVIDGLVADLIKRSAAGRYAADDETLSSVS PHYGAFHHLVELMAARGIDRTITDGYEAIFRRAIDAGHLHDD* &gt;pIR117 MQPAISVLGTGRMGSALAYALLKAGHPTTVWNRTPAKAAPLAAAGAEVAASVRNAVAVSE VVIVNVSDYQATQSLLRDKEVAGALEGRLIIELTSGTPDGGREAHGWAQRQGARYLDGAI LATPDFIGTEAGTLLVSGPSGVFEEGRNVLGALGGNVQFIGEDPGLANALDSAVLALMWG ALFGALQSIAVCRAEAIDLGVLARQWTATAPVVEGLVSDLIKRSAAGRYDADAETLSSVS PHYSAFHHLVDLMEARGIDRTITGGYEAIFRRAIEAGHLHDDFASLSQFMGQPA* &gt;pIR118 MSKSKSKSISIIGLGAMGTALAKTLIDAGNTATVWNRTPARANALVARGARRAATVAEAI AASDVLILCLTDYAAVETTLAGVGTAIASKTVVNLTNGRPDEVRAVAARLEAYGARYLDG GIMATPPMIGTPDAFILCSGSADAFEKTREQLAAFGQSHYLGEDPVLAAVSDLALLSAMY GLFGGYLHATALAGSVGFTAKQFLPLVEPWLAAMMTALPDYAERIDSGDHGRDVMSNLSM QSVAITNIVAASRSLGIDPAFMEPIERLAKKRLAAGFGSDEASGLIEAMRGK* &gt;pIR122 METLKNQISIIGLGPMGIKIAQLYLQKGFQVTVFNRTAAKGDKLVKEGARLAKNISEAIE ASPVSVVIVHNYSVANDLFSSIETGNTLAGKLIVQLTTGTSQEARLSETWFNGKTADYLD GAIQVAPEQMAQPDTTILFSGNSRKYLEIEDTLKILGGNLKYLGENIGAAAAMDTATLSY IYGAAAGFLHGALIAESENFDVREYGNIIAEIAPGMGEFLKHEGAVISSGDFKLSQSPLA ISVEATERILATAKLSGINTEFPQFAANWLKRAKDAGYEQEEFAAVIKTLRTPQ* &gt;pIR124 MTRRVAFLGLGLMGGGMARQLLGAGFDVAVWNRSPDKAAALGEAGARIATTPADAAAGAA IVIAMLADDSVSDTVWTGAHGALAAMSPDSIAIDSSTLTDIWVTTLADLAAKYGVRFLEA PVTGSRDQAAQGALRFLVGGDPATLADARPVFEAMGSAIVHLGPVGSAATVKLANNFLCG VQAASLAEAIALLEKRGLDIEQAMAILTDGAPGSPMVKGVGRRMLDRDYAPHFLVPLMAK DLGYAAQALADVGIISAMAQAARPCFVEAAAAGEGHRDIAAIVEPLRKI* &gt;pIR127 MLGTGAMGAGVAGSLVRAGHEVTVWNRTRERAEPLASQGATVASEPAEAVEHAEVVLLTL FDTDAVVDVLEQAAGEAPEGAVWVQASTIGTDGTDTVVQLAAKYGVTLVEAMMLGTKAPA EQGKLTLLAAGPSDVLDGLGPVFDAIAVKTVRAGDQVGQGTALKLAANAWIASVTAATGQ SLAIARSLGLDPALFIEAIDGSASDSPYAHTKGESMIRGEFPAQFALDGLRKDIGLIAEA ARDAGVSTVLLDALGRVYADASAAGHGGDDIAAVGTAF* &gt;pIR128 MTDVSLIGLGPMGMALARALQSSKFTLTVWNRTAERAKPVLNPGTVLAPTALAAVQASPV VLVCVADYPASRAILTAPGVHDALRGKVLVQLSTGTPQDARDDWAALSGVAYLDGALLAT PGQIGRPDTPLFISGEARALAACRPLLEAIAGNIQHMGEPIGNAAAWDLATLSCMFGAMS GFFHGVRICESEGLGVDAFSQMIGAISPVLGEMISAEGEAIHANRYGEPESSMATCAGSG RLFVKQAREAKLDASFPDFLMGLFERSLSAGFANERLAAMVKVMR* &gt;pIR129 MTDTHVTKRPLTLLGLGGMGTALARAWLAAGHPVTVWNRTAAKAGALAPHGARVAADPAA AVAANGLVVLCLLDDASIAAVLDGVDLTGKDLVNLTTGTPAEGRARARWAEERGARFVDA GIMGTPTMIDTPGSGAYVFYSGSRALFEAHREVLEVPAAARFVGADPGHAALHDVALLSA MTGLFAGISHAYALIEGEDIAPGDLSPLLSEWLGTMGFFVGNAAERLTSRDFTTGVVSNL AMQVAASGTLLRTAADQGVSTELISPYLDLMRERLEADPARHGAEDTVGAITLLRRGAA &gt;pIR130 MKIGFIGVGSMGRAIIPLLVRAGHHVSAWNRSHAAIKDLEGISVIETPASAFQQEVVITL LADDAAVRQVLLSSAVLETADKACVHVVMSTLSPSLMLELQREHEAVGMPLIAAPVFGVP AVAAKGELNILAAGSQAAVSTVQPLFDLLGKKTWYLGDQPEQACIAKIAGNMMITQAIQS LGEASGLVQRHGLSPSIFIKLMTQTLFACPSYQRYGQNIVSSNFEPGFKLSLGLKDMNLA IDAGRLKGLELPAADAVRLKMTSAVARGDGDKDWSVFAQQTNH* &gt;pIR138 MASITDKQYDPVPAKKVAFIGLGVMGFPMAGHLARAGHDVTVYNRTGSKSADWVSEFGGK SAPTPAKAAEGAEIVFCCVGNDNDLRSVTTDADGAFHGMQQNAVFVDHTTASADVARELA AAARQGQFSFIDAPVSGGQAGAVGGVLTVMCGGEPEVFEKIKPVAGHFARAVTLLGEHGA GQLAKMVNQICIAGLVQGLSEAIAFGLRANLDMNAVLDVISKGAAQSWQMENRGKTMVQG KFDFGFAVDWMRKDLGLVLDEAKRNGALLPVTAVVDQFYAEVQQNGGKRWDTSSLITRLT PSK* &gt;pIR139 MNIGFIGLGVMGRPMAAHLIAAGHSVFLNRVKPASQHLVEQGGAPLDSAKAVAEAADVII LMLPDTPDVEAVLFGPNGVAEGLSKGKLVIDMSSISPVETQAFAARISQLGCDYVDAPVS GGELGAKNAALTIMCGGTAASFERTRPLLELMGKNITLVGHVGAGQTCKVANQIIVGLTI AAVSEAMTFAKAAGADPAKVRAALMGGFAASRVLELHGERMVNRTFDPGFRIRLHRKDLG LAVDGAKALNLALPNTAATQQLMNAAIARGDGEKDHSALILTLEALAGQTG* &gt;pIR147 MSQINPNTQLFSKENESINRQPVTVIGLGMLGSVMAKAFLNHGHPTTVWNRSANKTDVLV ARGAVQAASISEAISANPLVIVCVSDYEGVREILDAGGDALSGRVVVNISSGTPELARQM SEWVTSRGADYLDGAAMSGTRLVGQPEAVFLYSGSPASFESHRSTLASLGGATHLGTDPG LASLYDTALFSLIWGTLSGFYHAVALVGTEKVDASAFSSVATEYLPFVSGLMTNHAGQIE KGHYPGEDGTVEIHLAAMEHLLHTSQANGIRTNIPQFFKTLLEGALTAGHGENGVASVIE MIKHSASKSAQ &gt;pIR153 MNVGFIGLGIMGSPMAGHLIDAGHTLFVYDVVKIPAELTGKGATACASSAEVAQHADIII TMVPDTPHVEEVLFGKGGIAEGVSKGKIVVDMSSISPVATKEFAKKINALGVDYLDAPVS GGEVGAKAASLTIMVGGPDAAFETVKPLFEKMGKNITLVGGNGDGQTTKVANQIIVALTI EAVGEALLFASKAGANPAKVREALMGGFASSKILEIHGDRMVKRTFDPGFRIELHQKDLN LALQSAKALGVSLPNTATAQELFNACAARGGSKWDHSAMVKALELLANHEIA** &gt;pIR157 MSGQHQPNTATTATATATAPTTTVSVIGLGQMGTRLAQAFLAAGHATTVWNRTPAKADAL AAQGAVRASAVEAAVTASPLVVVCLPDYATVRGLVEPVAGALRGRVLVSLTSGTPEEAAE TARWAGEHGIGYLDGAAMSGTRLVGRPDALFVFGGRSEVFAAHREVLAALGNAVHVGDDP AHAPVYDTALFGLAWGALAGFYHSLALAGAAGVDPRTYAEVATGHMGFVTALMADHARQI EEGRYPSDDGTVEVHRAAMDHLVHTSRAAGIGTEVPELFRTLLTGAEGAGHGADGIASVV EAMRAAGAVAYGADSGATNVTEQRDV &gt;pIR161 MSSPTKTAVTILGLGNLGQALVATLLRAGHPTTVWNRSPGRAEALVAQGASEAATLAEAV AASPLVIVSVLDTAAARQVLGAATEALPGRAVVNVTSGTPEVARELAALAAEHGADYLDG AIYAVPQTIGTADSTINYSGAAAVHQKWGQQLDVLGRGTYLGADPGLASVYDLAILGGMY GMLGGFLHAAAMADAAGVRAGELTPMLVSWLIGCMPALTEFAAEIDARDYTTSMSNLDIN QAGLANIVDASAAQGVDTGILAPLRKLVDEQVAAGHGAASLARVFEVLRRQA &gt;pIR173 MTGYNRSQGRIDKLTAEGGRGASSIADAVAEADVVITMVPDSPDVEEVVGGAGGVFANAR QGALWIDASSIRPDVAARLAEEAKAAGLRPLDAPVSGGEQGAIDGALSIMVGGDAADFDA AQDVFAAVGKTIVHVGPSGSGQTVKAANQLIVAVNIGVLAEAITFLEAYGVDTAAALKVL GGGLAGSKVLDQKGQKMLDRNFDPGFRLALHHKDLGIVTSAAREAGVATPLGALAAQLVA SLVTTGDGGLDHSGLFKLINQLSGK* &gt;pIR174 MANISVLGLGAMGQALAARFLQQGHSVTLWNRTPGKAGSLVAKGARECTSAADAVASSDV TVICVLDYAASNSVLDGAASALAGRAVVNLTNGTPAQARAVAERVAGLSAAYLDGGIMAT PPMIGGDHALILYSGSKATFDAHVRTLEALGAATYLGADAGLASLHDLALLSGMYGLFAG FFHASALVDSEGIRASEFLKLLGPWMTAMMGELPGYAEKIDSGRHGVNVVSNLAMQTASL QNILTATREQGVATYLLDPMLELFRKRDGAGHGNEDISGVFELIRLKSRGG &gt;pIR177 MQIGMVGLGRMGANMVRRLLKQGHDCVVFDVNLDNVAALVKEGAVGASSPDDLVAKLSPP RAVWLMLPAAITPKIARDFAARLQAGDAIIDGGNSFYRDAIDLAAEFAPRSIDFIDTGTS GGVWGLERGYSLMIGGPLGAVQRLDPIFASLAPGAGQGIAADPVTGTAPMGYLHCGPSGA GHFVKMVHNGIEYGVMAAYAEGLNILKAANAGTQHREADAETAPLAHPQYYQFDIDLPAV TEVWRHGSVIGSWLLDLTAEALKQDPHLDQYGGRVSDSGEGRWTLQAAVETGVPAPVLAS ALFERFSSRGEAEFAGKVLSAMRNAFGGHLEKAK* &gt;pIR179 MREHNDESFEFEVSVIGLGAMGTIMAQALLRQGRRVAIWNRSPGKAAALVAAGAHLCESA EAALAASPATIFVLLDNQATHEVLGMPGVMQALANRTIVDYTTNARDEGLALQSLVNRAG GHYVKGMIVAYPRNVGRRESHSIHTGDPEAFERHRALLEGLAGHTTFLPWDEALAFATVL HAHAFAAMVAFFEAVGAGVHFGLPPSKTARLMLDTSRFFVADALEEAVRRLEAQDFAGDQ ARLDVHAQAFAHIAGALHAHGAWTPVFDALCQAVQRAAAMGYGDQDIVAVTRLFARECDT ASAAGQ &gt;pIR180 MGNKQITVLGLGSMGQTLARLFLDKGYTVTVWNRTAGKADALAARGALAAGSAAEAVRAS PVAVMCVYDYRAADAILAMEGVAAALDGRLLVQLTTGSPQDARDAEAWAHRQGASYLEGA IQAAPDQMGQPDTPILVSGAEVVFRAAEPLLGVLGGGIVYLGGKASAAAAMDLATLSTIY GTLLGFLHGARVAEHEGFDVAEYGRIVAGIMPTFAGFLQHEGGVIQSGDFAISQSPMRIS IEATQRILQTAQQAGISTEFPAFAAGLFKRADAAGLGGEEVAALIKLLRS* &gt;pIR188 MPETIGWVGLGKMGMPMAQRLLREGHPLYIWARNPEQTLGLRKQGARIATDLVELAQRSQ TLITILGDTHDVESVYKGLQPGVQPNTVFIDMTTAAPHAAPVLAEMITKKGAHFLDAPVT GGVAGAVNGTLTHFVGGNADILQRSSALLAQLGQRAVHCGPAGSGYRMKLVNQTIIAGIF LGLAEGMALARASHFDIELLTTALNKGTASGMLFNSYAERMMQGGGDITFTLGLLRKDLR LAEAEAELHQRPSQFLKFAVQCVNTACERFGAHAGIQMLSQLDS* &gt;pIR189 MTDKPVIGFIGLGFMGHGMARNLRLKGYELWVKGRANRVPVESLLAMGAREAASPKDMAQ TCDIIHICLSNSPQIEATMHGPDGILAGARPGLIVIDTSTANPGSTEALAAELAAKGGHF VDAPLGGTPVQAEAGQLSAMVGCEAAIFDRVAPVIGCWAARSTLIGPVGSGHKMKLLMNF IALSYAALYSEVVVLGVKVGISPKTVHEVISPSRMGNGFFETFMAYVVDRNRDSHKFSIA NAAKDMRYVNDMASDAKMMNIMAAAAQHYYSHAVATGREQDYVPMLSDLVGALNGVDMTD TGAKSI* &gt;pIR198 MKVGFIGLGAMGAPMARYLHAKGLLTAVGNRTQSKADALAAELNVRAARSAANFADCDVV VLCVSLDADVLENVSALAEVLKPGAIVIDHSTVAVDTARRCAAMLAPHNIGFLDAPVSGG AEGARNGKLSVMVGGEADVFESARAVIESYAARITHMGATGAGQATKAVNQVLVAGINEA VSEGLALGEKLGLDPDKLLPTLLAGAASNWFLEKRGATMLRDEFNPGFKCAHMLKDLRIV SAIARDTGVRMSTVEQALADYAELIERGQGESDTSALITLKRGG* &gt;pIR202 MSSVSIFGLGAMGTALASRFLEEKYKVAVWNRSPEKASSLLGKGATLSHTAVDGINASDL IIICLLDNAAVEATLAGALDHLHGKTIINLTNGTPDQARKLSDRFVSHGARYIHGGIMAT PSMIGSPYALVLYSGSPDAFKAAEGDLSVLAKCVFLGEDAGTASLHDLALLSGMYGLFSG FLHATALVRSSTPAVKFMDLLVPWLGAMTEYTKGMAKQIDEGKYTSEGSNLAMQLVGIQN IIDASEAQQVSAEFIRPMKEFMQKAVAAGHGGDDISSLIDFVKST &gt;pIR203 MAKIGFIGLGIMGAHMARNLIKGGHTLIVNGAYPVPEDLSKTTSVVANSTAVAQAADIVI IMVPDTPDVANVLFADDGVAAGLTQGKLVIDMSSISPLDTQEFAKKINALGADYLDAPVS GGEVGAREATLTIMVGGPEKAFALAKPLFELMGKNISLIGDNGAGQTCKVANQIIVALNI EAVAEALLFASRSGADPERVRKALMGGFASSRILEVHGERMTKRTFDPGFRIELHQKDLN LALDGARKLGIALPHTASAQQLFSVCVANGGKAWDHSAMVRALEIMANYEVAQAPGSEAK AA* &gt;pIR207 MSKHISIFGLGAMGTALAAKYIEHGYKTTVWNRTTAKATPLVEQGAKLASTISEGVNAND LIIICLLNNQVVENTLRDALHILPRKTIVNLTNGTPNQARKLADFVTSHGARYIHGGIMA VPTMIGSPHAVLLYSGESIELFQSIESHLSLLGMCKYLGTDAGSASLHDLALLSGMYGLF SGFLHAVALIKSGQNTNTTAIGLMPLLTPWLSAMTGYLSSIAKQIDEGDYATQGSNLGMQ LAGVENIIRAGEEQGVSSQMILPIKALIQQAVGEGHRDEDLSALIEYFEAGKNVD &gt;pIR208 MENPNRSPVTVIGLGPMGQALAGAFLMNGHPTTLWNRTAEKADYLISQGATLSNSVTGAV SASPLVIICVLDYNVVHEVLGPVGDSLKGRTLVNLTADSPKRAREMATWAAQHGVDYLDG AIMTPTPTIGMPAASVLYSGPESIFKVHQPTLASLGGTTSYLGADPGRAAAYDVALLDLF WTSMSGYAHALALATAENIPAKEFAVYAQGIIDILPDIMAYLASEVDSGHYPGDKSNIIS ASAGMEHIIHAAQHHGLDVSVLSAAMAVTQQAINKGYGTDGFSRLTELLKKPFA &gt;pIR210 MAHNDRSPVTVIGLGLMGSALARVLVKNGYQTTVWNRTAGKADELVSHGATRAATVREAV AASPTVIVCVTDYPAAYEVLESCGDVLSGRHLVHLSTGTPEQAREAATWAAERGAHYLDG AVMATPSGVGGSEAVLFYSGSEAVFSAEREMLDCLGGATSYLGADHGMASLYDSSLLGVE WGVLSGYFHAFSLVGTEGSKASTFLPVAIQFLRSIEMVFHEVARQVDEGKYPSDEETLDI HLNAMNRLIETSRARGIGVDVPEFFKTIITRAVALGHGADGLPSAFEAVKRPA &gt;pIR212 MKIGFIGLGIMGSRMAANLLKEDHQLIVYNRTKEKAKDLLENGAEWAQSPREVGEQADIL FTMLENPEIVEELALGADGFLKVMKKNSLWIDSSTVNPSFSEKMAKEASSQNVRFMDAPV SGSKQPAAEGALLFLVGGEPSDFEEAKPLFLKMGKDAVHIGSAGKGSAMKIMINQLLGQS ILAFSESLNLGMAMGIDKKTGLDVLLKTPVTAPILDVFRSRIENSDYEPNFPLKHLQKDL HLFTETAYELGQPSPLTNTAKEVYGMAKFKNMGDLDFTAVFKYLNEKE* &gt;pIR213 MGFGAATALLRAGFRVNGVDLRSDVLQEFAALGGTAYATAKQAGASDIVFVFVVNAAQAK EVLFGGDGALNQARQGTVFVLCVTMEPSHCIEIAAELEAAGMLVIDAPVSGGKQKAATGE LTVMGSGSQQAFDKAALALEAIAAKVFHLDDKPGTGSKVKMINQLLAGVHIAATAEALTL SARLGLDLGTVFDVIRVSAGASWMFENRGPHIVEGDYAARSAVNIFVKDMGIVAREAAAL GASTPLSETALSLFREASEAGLGLEDDAAVAKILAHKSGVMLPGMGA* &gt;pIR215 MTNIAFIGLGIMGLPMAKNLVAAGHHVSGFNRSPRRRRDLADMGGVAAQSVADAVVGAEI VITMLPDSPDVAAVVSGPDGVLEHIAPGAVIVDMSSIAPGVARELAARAEGDGIPMLDAP VSGGERGAIDGTLSIMVGGDAEVFAGVRPVLEAMGKTIELVGPAGSGQTVKVANQLMVAG NVQLVAEAVVFLRAQGVALDAALGVLGGGLAGSKVLDAKAPLMRDGSFDPGFRIELHHKD LGNYLAAARESATFTPVGALVAQLFAASVAVGDGGLDHSGVVRTVERLSADAGFSEG* &gt;pIR217 MGRALAGAFVHAGLRTTVWNRTPGRDGELLDRGASGAASAAEAVAASDATVVCVIDYDAA DAVLRQDDVAAALKGRTVVNLTADTPARARDTAAWAAEHGVRYLDGAIMTPTPTIGTPEA VFLYSGAADLYRELGPVREALGGTHTHLGEDTGRAAAYDIALLDIFWTAMAGYAHALAMA RAEGVTPTELAPFAQGIGAILPPLFAETAADAAAGAYSGEGNPLTSAVSSMSHIVHVSES HGIDAGVMRAAEGMARRAVGLGHGQDGFIRVAEVIGRR &gt;pIR219 MKIGLIGLGNMGVGIGGSLLRDGHSLTVYNRSKDKADALLAQGARWADTPRELAQGQDAV LTMVADDAALLAVTRGDNGLLAGLAAGAVHVSLSTVSPALVEQLAQEHAAQGKALIASPV FGRPDAAAAAKLFVVASGKPEHITAVRPALESIGQKLFEIGDQPQQAALVKLIGNFLISC VIEGLGEGAALAEKAGVAPEKLIEVLTGSIFAAPVYQVYGALIANAGYLNPGFALPLGQK DNRLVLQAAEGLNVPLPFASIVRDRFVRANAQGLAGADWSAIARLSRQDAGLPD* &gt;pIR220 MSNKPVAVYGLGNMGYLVAQRIAKHFPTKVADLDTAQVQRARDSFAAQPIADPKDVSDVH AIVLCLPSPAASQNVLKQIAPHLSPDTIVLETSTVNPDDIHASQKILTPFGLRIVDASIL AGVSQMEAGTATLLLGGDESDIATTQSVLNAITEKQIYFGPSGAGAAAKVINNAVAHAVM VVVAEAGALATASGVSCEKLISLLADPQMGLHRPLTHRYAERILGNNYAGGMPLDAARKD STLALELAQSLGVPMFAIQGSHTIYEIASAAGYGRDDYAAIAKVWADWGKPTVPAQ* &gt;pIR221 MAKLAFLGLGVMGGPMAGHLQKAGHDVTVYNRTTEKARQWAETYGGAMAETPREAAQGAD LVFSCVGNDDDLRSVCVGKDGAFAGMAEGTVFVDHTTVSAAVTRELYKAANDAQISFVDA PISGGQAGAENGQLSIMCGGDAGAFDRALPIMEVYSKICRRLGDSGAGQMTKMCNQIAIA GLVQGLSEALHFAQKAGLDGRDVVEVISQGAAGSWQMSNRFETMLDDKFDHGFAVDWMRK DLGICLDTADEIAASLPVTALVDQFYKDVQKLGGGRWDTSSLIKRLNAAG* &gt;pIR222 MIGLGDMGIRLAEILLSKGFQVTVWNRSAGKADALAAQGALVADSAAAAISASPVIITCV VDYNATRNILDTPEARAALKSRTQIELSTGTPQDARNAAAWAHSIGAKYLDGAILATPRQ VGHEFTPIFVSGSREVYEATEPIMKALAGGLQYMGEAVGAASTWDIGFLNTVFGAITGFF QGARLFEAEGIPVNQLGDMIGKLGSVIGEMIRFEGDVIHHKKYDEVESSVKTCYTGIGLF SRSAREAGISSEIPDFMYNIYQRAMDAGYGPKQLGAVIEVLR &gt;pIR227 MTDSRTPVTVIGLGAMGTALAEALLAGGHDVTVWNRTSAKAEPLAAKGARAAATVEEAIA ASPLVIACVLDYPALHATLDPVATALADRVLVNLTNGTPEQARATADWATEAGAQYVDGG IMAIPPMIGHPGSTLLYSGAREAFDTHRETLERFGVATYLGTDPGAAPLHDLALLCGMYG MFGGFFHAVGLVGTEGVKASEFTTTLLLPWLNAMMTAMTEFARLIDAGDFESRDSNLAMQ SAGYVNLIEASRAQGLRTELIEPMRNLIDRAVAEGKGGEDLPGLITLLSATPSS &gt;pIR232 MVNEWGFSSPIGNDSERQTKEAVSVLGLGPMGQALAGAFLKNGHPVTVWNRTPGKSDELT RQGAVLAESVTDAAAASELIIICVLDYNAVRSILSPAVEELKGRTVINLTADTPERAREM AGWASANGIDYVDGAIMTPTPTIGEATAVILYSGSEDVYLRHRQTLASLGGKASYLGSDP GRAAAYDITLLNLYWTAMNGYMHSLALARAENIAASDLAPYAHGIVAIMPAIMTQLAEEA DRGVYPGDRSNIISAAASMEHITHVAEHHGLDSSILGAGLTVANKAIQAGFGEEGFSRLV EFHKR &gt;pIR234 MNAEHSAVTVLGLGSMGSALAAALLDRGHPTTVWNRSPDKARSLAERGARLAATPQEAVA ASPLVIACVLDYEALYTVLDPVAGDLAGRTLVNLTSGSPEQAQEAVRWAHSHGVDYLDGA IMTTPPGVGDPAVMLLYSGSRQVFEAHRPTLATLGDPLHLGTDPGLASLYDAALLGLMWS TMTGWLHGTALVGTEGTPATDFTPVAIRWLDTVARLLTTYAPQVDAGHYPGDDATVDVQI AAIDHLIHAAAARGIDNALPELLRAAMEKAGAQGHGKDSYASLIEVLRPAPRD &gt;pIR235 MEVGFCGPGLMGAPMIRHLLAAGHRVSVWNRSREKAEALVKDGAQVVGTPRELAERVDTV FVCVLDGRAVGDVVFGEHGLLSGDAGARRLQRIVDHSSIPPAATRDYAARAAALGIGWVD APVSGGVPGAQAGTLAVMAGGRAADLDAVRALIDTYASRITHMGDAGAGQTAKLCNQAIV TATVTAIAEAVGLAQASGIDAARLAEALAGGWADSVLLQTFVPRMTSGGHPPIGALSTFQ KDVDTIADAARDTGAVMPVSATVQQVLRLGAAQGLAGADFAAFIDIVRPGNGRRQVS* &gt;pIR238 MRSEPAAVTVLGLGSMGTALAGALLKGGHATTVWNRSPHKAKPPAERGATVAATPEEAVA ASPLVIACVLDYAALHTVLDPVADSLAGKTLVNLTSGSPEQAAEAAAWARSHGAHYLDGA IMTTPPGVGSPEMMFLYSGERTVFDTHRPALASLGDPLHLGTDPGLASLYDAALLGLMWA AMTGWLHGTALVGAEGTPATAFTPVAIRWLSAVTGFLTTYAPQVDAGHYPGDDATVDVQI AAIDHLIHAAAARGVDNALPELLKATMERTRAAGHGSSSYASVIETLRKAAGNR &gt;pIR241 MGTERSAVTVIGLGQMGSALAATLLERGHPTTVWNRSAQKARPLVERGARPAATPEEAVA ASPLVIVCVLDHDALHATLDPAAGHLAGKVLVNLTSGSPEQAQEAEAWARAHSADYLDGA IMTTPPGVGSPEMMFLYSGSQTVFETHRPTLTALGDPLHLGAEPGLASLYDAALLGLMWS TMTGWLHGTALVGAEKTEATAFTPVAIRWLSAVTGFLATYAAQVDAGRYPGDDATVDVQI AAIDHLLHAAAARGIDNALPELLKATMERTRDLGHGSDSYASVIEVLKKGAGSA &gt;pIR246 MNSASIPASVTVIGLGHMGVALADAFLKGGHPTTVWNRSADKAKGLVEKGAVLAGSVSEA IAASSLVVVCLSTYKVMQELLAPLENELSGRVIVNLTTGTPEDARKTAKWVIEHGGQYLD GAIMAIPQMIGLPETLIFYGGSKALFEAYEPTLKLLGGNAAYLGEDYGVPLIYDLSLLTM MYGAWYGSMHAHALLSTANITGTEFLPYATNWVNHLIAPLLTDPVAARARDEGNFTTDVS NLNTNKLGLEHIIHASQEQGITVEWLMPLLTLATQKVAEGYGADSFDRVIEAIRKPRVK &gt;pIR247 MADTMHIGIVGLGKMGSNMRERMRAAGLTVTGYDPNTEVSDVAELSDLVDDLPTPRIIWV MVPSGAITDSVITDVSALLEPGDLVIDGGNTRFTDDQLHRDQLAELKISFVDVGVSGGIW GLDNGYGLMAGGDKDDIERAMPIFDALRPEGPRDEGFVHAGPVGAGHYAKMVHNGIEYAL MQAWAEGFELLDSRKDLIEDVPGTFKAWQRGTVVRSWLLELLVKALEEDPEFADIAGYVE DSGEGRWTVHEALNQAVAVPTISAAIFARFVSRQADSPSMKAVAALRNQFGGHSVRKS* &gt;pIR249 MKNITIIGLGSMGSAMASVLLDKGYQVFVWNRSFDKAEGLVQKGAQYVPTVSEAISASKT SIVCVSDYAASYEILDQLDVRSALTGRTVMQLSTGSPQQARDLEGWILAQGASYLDGAIA ASPSQIGQPEAAIFFSGAKAAYDGNTDIIESLAGYAPFLGEKVSAASTTDLAFLAYLFAA YIGFFHAARIMESDGLEVNGLGQLIASISPMIGDVMKYESEVIHNEQYDKPQTSINTCMI TIELLQQQAREAGINDDFPVFAERMFSRAIQAGYGNEEVAALVKTLR* &gt;pIR250 MANQRNVGFIGLGIMGAPMAGHLRAAGHTLFVHDVNPAPQFLVDAGVTVCTSAEEVAKRA DIVIVMVPDTPHVEAVLFGEKGVAAAFKAAGKEASYSKIVVDMSSISPIATKDFAARINK LGASYLDAPVSGGEVGAKAATLTIMVGGPAEAFDQVKPLFELMGKNITLVGGNGDGQTTK VANQIIVALNIQAVSEALLFASKAGADPAKVRQALMGGFAASRILEVHGERMVKRTFDPG FRIELHQKDLNLALQGAKALGVSLPNTSTAQELFNACAANGFGKLDHSALCRAIEIMSNH EIAKGAK* &gt;pIR253 MQDLDRTSGAVRVGMIGLGSMGMPMARNLLAAGVARQVSVFGRSPEKLTPALEAGAERCD TPGALAAQSDVLITVLPDLPQLEALIEGDDGLLAGLAGPLVLVVCSTSSPEGVRALARRL DEASQGRIRVLDAPLSGGTDGAEAGRLSIMVGGGHEDLERARPVLETMGTPVLLGPLGAG EVAKACNQMVVAATMVALSEATVMAERAGLDVEKLLGCLGGGYAGGRFLESRKQRLIDKD YTPSGIARYMIKDLGFARDEAAQQQVTTPQLSTLLTLYQDLGDRGLGELDLTVTQRYIAE LDRLPGSDGPAPSGRT* &gt;pIR257 MSSAVAVLGLGAMGSRMAARLLKAGYQVTVWNRSPEKAQALLEAGARWAASPREAASGAD VVIAMVRDDEASQQVWCDVVTGALAGMRPGAVAIESSTLSLGAVRALADAAAQAGVTLLD APVSGSRPAAEAGLLLHLVGGDAAAFQAAQPVLLAMGTAAHHVGPAGCGAAAKLVTNALL GIHVGALAELMGLLAQQGLATEPILRAVADTPVWAPVDNYLCASMMAQEFRPQFPIELMA KDFSYAVAAAGKSRLPLVSAALGAFQDALNQGLGDRNMTAVAKLYAPQTSA* &gt;pIR259 MNVTTPEPTTVAVIGLGNLGQVLARTLLDQGHKVTVWNRSQDKADDLVARGATRAATPAD AIRASDLVIICVLDYTTVRDLLTPAADALAGRVVVNVTSGIPEPARELATRVNGSGAAYV DGAVYAIPQTIGTPEAFVLYSGDEEAFARHRALLETLGTAEFVGADAGLAAVHDVALLSG MYGMFAGFFQTVAVSGSAGIEAVRVTELLVRWLKEAIAALPAFAAEIDAGDYRTQTSNLD INAVGLANILAATRAQGVGVELLAPLHALFEQQVSAGHGAESLSRTIESLR &gt;pIR274 MGHLAAKGHQVVVYNRSEAKAKAWVEKHGGSHATSPREAAAGADFVMACVGNDDDLRAIC LGEDGAFAGMAKGAIFVDHTTVSATVTRELSAIASDAGIGFVDAPVSGGQAGAENGVLSI MCGGTEADYAAAEPVMAAYARICRRLGDSGAGQLAKMMNQICIAGLVQGLSEALAFGQKA GLDGEAVVEVISQGAAGSWQMVNRHKTMLADNFDFGFAVDWMRKDLKICLETADVIGASL PVTALVDQFYKDVQRMGGNRNDTSSLIRRLK* &gt;pIR276 MINADVSIVGVGNIGAAMVSAWLDSGLKVTMWNRNINRPKIAKLVERGATFEPNINEAMR CSDKIVLCVSTYDDIDEVLSPVLPLKGTERSIMVINITTGTSKQARDMETRLKSNGIAKY FDGAIMVTPELIGTMHSSMFFSGENEAEFESISGILRPLGSSHYVAQDSGAASLWDIAAL AAMYGMYSGAIVALNVLKRQRLDDVATESPSTEVPMKKIVLPLLSTLLPHLVNLSRALDK EDWDENFGNPVSMQLKGLQTILTTLGEEKVNADGLELFYRMMQRVVRDKGENAGLAIMGT YLLE &gt;pIR278 MGSTLARALLRAGHDVTVWNRSAGRIIDLVNEGATGVEAAEVATAASPLLVMCTIDKAAT EAILRAESIGGMLLGKTVVNLSTGSCDDARRISDYVRQKGGQYIDGGIMAYPRDIGKAET TIVYSGDAEGFARHKAVLRAMAGKAEFFGDDPGTASVIYLALYAYYFGALTAFFEGAALA ERAAVSPESFRKISGIMNTMLADGLSDITRRLTGGDYSGDQATVDVHYARQLVVRDAYIS ENIGYETTKAYLSYLERAQRAGSGQKDISIMYASVKDGS &gt;pIR279 MAAFLKAGHATTVWNRSADKADGLVKDGAVLAANPADAVAASDLVVVCVSTYDVVHDVIG SLGDALRGKTVVNLTTGSSEQARQTAEWAEKNGAQYLDGAIMITPPGIGAETSVLFYAGD QAVFDAHEPVLKLLGGGTTYLGIDHGKPALFDVSLLGLMWGALNSFLHGVAIVETGGVKA QEFLPWAHMWLDAIKMFTADYAAQIDAGDERFPANDATLETHLGALKHLVEESEALGVDT ELPKYSEALMEGIIAQGHAKNSYASVVKAYRRPAE &gt;pIR285 MRSLIGVAGCGRMGGPMLAALRAADLPARGYDVVPSEMGHITDDIAVFSEDLDTLITVVR DIDQTDAVLFGDQNFTAIPSLRRIILCSTLSPRYVLGLRDQVPSHITLIDAPMSGAQIAA EQARLSFMLGGDTDDLQAAQPLFSAMGKHFHHMGAYGAGMQAKVLNNLLAASNTAMTRLV LDWADQSGLDEGKLLNLIHTSSGQNWLASGFNDIEFARDGFAPDNTIGILVKDVASALDA APTDADTALPELVKTAIKNLKPRP* &gt;pIR288 MGTALARTWLAAGHPLTVWNRTPHRAAPLAAEGAVVAATARDAVAANGLVVVCLLDDASV GETLEGVDLAGRDLVDLTTGTPGEARARAAWARARGARFLDGGIMAVPPMIGVPESGGYV LYSGSRALFDAHARTLARPAGTRYVGEDPGFAALHDVALLSAMNGMFAGMAHAFALIRRE EIAPAEFAPLLVEWVTAMAGSAYTTAERLDSGDLTSGVVSNLAMQVTGGGTLLRTADEQG VDRALMAPYLDLMRRLLAQGGRDEEDTTGVVDLLLSR &gt;pIR291 MKIGFAGLGVMGAPMARHLVGAGHEVAGFNRTHAKAQAWAKATGGRAAETVGEAADGAEL FVLCVGNDDDVREVMTQALERLRQGAVIVDHTTTSAKVAREMSEAAAAGGRTFLDAPVSG GQAGAENGQLSVMVGGDAEALARAEPALRAYAKAIQHMGPSGSGQLTKMVNQIAIASVVQ GLAEAVHFAQVAGLDTEAVYEAISKGAAQSWQMDNRWKTAAKGEFDFGFAVDWMRKDLGL VLDEARANGARLAQTALVDQFYAEVQAMGGARWDTSSLTARLNR* &gt;pIR294 MGPDSNLKVSVIGLGVMGYALAQAFAKKDLKPTVWNRCAQKALGLEPLGAVVVPSASECI KASRLIVVCLVNEAAFHNILSGVEPAICKGRIIVNATTGAPSQIKKSAELAMKLGFSTYI HGAIMTFPAYIGYPESKLWFSGSRAAYEEIEPTLRVLGSPSLVGEEITTAGFQDIVCVNM LYGFAGGFLQSLALYKTKSGWKPGDTEIFARDVLLPMFMRDGSAFLDLARQVDAGDYVSK GNGAKLGQQLFALDNIIKTNTEHGIASDFILPMRKLLMERTEAGGVDEELSAIVEVLSDP AR &gt;pIR296 MAAFLAAGHPTTVWNRSPGKADALVVRGARRAGSVAEAVAAAPLVVVCVADDEAVHQLLD PLEGALAGRTLVNLTTGTSAQARANAAWAKERGAAFLDGAIMAVPEDIATDDAVLLYSGP RDAFTPHEPALRALSPAGTTYLDSDPGLAALHDLSLLGIMWGVLNGFLHGAALLGTAGVR AETFAPLAARMTTVVAGYVTAAAPEVDAGSHPAGDATLTVHQEAMRHLAEESEALGVNAE LPRLFQLLADRAVADGHAESGYSALVEQFRKP &gt;pIR303 MNTNTMERYSYGMVGLGVMGRNLLYNIADNGFSIAGFDLDEQKIKDLEEGTTPAMKIKGI GSMEDFVSLLETPRKIILMVPAGKPVDAVLKSITPFLSKGDIVIDAGNSYFQDTNRRIAD LASKGLHFMGMGVSGGEKGARTGPSIMPGGDVEAFHLLKPMLEAISAKVDGEPCTAYMGK GSAGNYVKMVHNGIEYAIMQLISEAYDLLKRGAHLNNDQLYEVFKEWNSGEMNSFLIEIT RDIFQQKDPLTGGYLVDQILDKAGAKGTGKWTSEQAMEIGVSIPTIDVAVTSRILSAYKD ERIKASQLYPEKEITTPENIDLFIREVGDALFLATLISYAQGLALLVKASEEYDFQIPLK DVVKIWRGGCIIRSVLLEKFYAAYTKDSNLSNILLDKDIAVIVKEKISSLRKTAAFASLN GISGLGLQTALGYFDAYTTESLPINLVQAQRDYFGAHTYQRIDREGAFHTSWQTTTH* &gt;pIR304 MSEAQSAPTPVTVIGLGSMGRALAEAFLGAGHPTTVWNRTPAKAAPLVAEGAVHAGSVRA AVEASPLVVTCLTTFDDTRTALEPAGAALSGRALVTLNSGSPADARATAGWAAGHGARFL AGAVKNVPAAVGAPDTLLYYGGDKSVFDEYGTALRVLGGDTVHLGSETDLAALYEMAVGA MLLPALVGFFQGAAALQARGLDAAGMVRFAGKWLDMIKSLLPGYAEEIDSGDYTDGASSV GMFLAGAAHDKALGEETNVDTTWIDPLNDLLRRAVEAGHGSHSISALTEVLRGEASPGAR HSS &gt;pIR308 MNTTKTGWIGLGNMGIPMSQQLIKAGYPLSVYNRSKDKEEGFKAQGIGRAASPLLLIKEV DVVFIMVSDDKAISDIFYGEAGLLAANVSEKVIINMSTVSPAISREIAAACKKQGNHYLD APVSGSVKQAEDGVLVIMVGGEAEAFEKVKPILEKLGKLALLVGDAGAGNTAKLAINTLL GIVAQGFAETVTLAGKNGIQPETLTTLINNSALGSPFIKIKGDAIVNNNFNAAFALKHIT KDLRLATEIGAGTPLAQAAYQTYQNAEADLGEEDIIAVIKQFR* &gt;pIR313 MPPAIWQDGPTGVALRPKADMNMDMTDQPSPAAAPVSVSFLGLGVMGGAMARHLGEAGHN LTIYNRTPARAEGWQAANPNISVRVASSPAEAADGADVVITCVGNDDDLADVVLSPNGAF STLRRGALFIDHTTVSARIARQIAVEGRDKELLCVDAPVTGGQSGAEAGKLAVMCGGSLK AVEAARPILAAYAKRVVHVGKSGAGQTTKMANQMCIAANLAGLSEAIRFAQAAHLDLDKV FEAISGGAAQSWQMDNRFHTMARDEFDFGLAVDWMRKDLGLAMDEARNIGASVPVTALVD QFYVDIQAMGHGREDTSALIRRLPRRKAGK* &gt;pIR316 MPDTLPTLAFAGIGLMGLPMTQRLLAAGYAVSVWNRTADKCATLQTLGARVVETPAQLCG QADIVMLCLANTEVVREVVFGPGGIAETAKPGQLLVDFSSLEPAATREMAAELHARCGMH WVDAPVSGGTAGAVAGSLAIMAGGRIEDIERLRPILAHLGQRLTRMGDVGAGQVTKVCNQ MIVACNALVIAEVVALAEKAGVDASLIAPALAGGFADSKPLQILAPQMATSQFEPINWHV RTLLKDLDTAVKLSQQIGTATPLSGLAAQLMRQHGSHGNLERDPATLVDLYRESPLHESQ S* &gt;pIR319 MTTVAFIGLGAMGAPMVGHLIRAGHTVRAFVRRPEAADAARQLGAEPFFTPAEAAQGAAV VFTNVTSSEDVREVLLGRNGVVEGAAPGTICVDHSTISPIVTREIAQALAACGIEALDCP VSGGTVGAQAATLTIMVGGKAEVLEKVRPLLEQLGKTITHIGDSGAGQVAKLCNQIAQVV NIEGIAEAMRFAGAQGVDTAKVFQAMSTGMAGSRMLDMLGPKMVTRDFSAGIESRLHAKD FGLAADIATEIGLELPAMRATSAQLGELMDQGWGKDDTSSLLKVLELKG* &gt;pIR321 MAGEKHAPVTVIGLGAMGAALAEAFIRAGHPTTVWNRSPAKAARLVEKGAVHEAAVEAAV RASPLIVTCLTTYDVTRRCLGPAVEALAGRTLVTLNSGTPLGAREMADWTAERGAGFLDG AVMSVPEAVGAPDTLLLYGGDDATFGDHAAALRALGGDTVHLGAEPDSAALYDSALGGIL LPTLLGFLQGVALVTARGRPAGSLAPYAAAWLEKIGAILPALAEEVDTGEYGDPASSVGI FHDGIESLVRDSASEEGPSIDVAWLAPVQDLLRRAIADGHRDQSISVLVELLRRPGRTA &gt;pIR324 MKKGYQVTVWNRSIAKAEPLIKDGAIFATSVATAISASEVSIICVSDYEASTHILNTQEV KQALSGRVLIQLSTGSPQQARDHELWAQENQVNYLDGAIAASPLQMGNSEATIFTSGSLK AYQQSEHILKCLAGNVPYLGEQVSAASSTDLAFLSYLFGSYLGFFHAARILESDGLRVDD FGALIAQVSQVVGEVIKYESQVIQTETYDNPQSSINMCMTTVELFMVQAQEANINNEFPV FAQQLFKRVLEAGFGNEELGALIKVLR &gt;pIR327 MTEKNKVALIGAGAMGGAIGTRLIETGNQLTVFDLDAEKVAALTSLGAQSAGTAAEAASV SDVVILSLNSPKIVRIAVFGKDGVAAGAKPSTLIIDMSSIDPEATKELAADAAEKGLRWV DSPLSGGAPKALVGQLTLMAGGSEKDVADAHRVLRHVASNYTHMGPCGAGQTTKLINQVL CGLNFLAVAEATQLALDAGVNAAKIPQALKGGRADSAILQEYMPRYVAKDYRRTGRIDNM VKDLNGAQDLARRTNTAMPLTALCAEVHRMLTAAGLGGEDQAALMEFFSGAKRTFQD* &gt;pIR331 MDLGFIGLGEMGQASATNLLGAGHTVRVWNRSRERAEPLAAVGAQIVDTPADAFRGDAVF SMLADDAAARAIFDDALLAQAPRGLIHVNMATVSVALAESLAHAHASRGIHYVAAPVMGR PDVAAAARLTIMAGGPAEAIDRVQPLFDAIGQKTWRFGSLPQHANVAKIAANFTLASAIE TLGEASALLGAHGVAMRDFLDVITGSVFPGPVYEGYGSMIAERRYEPARFKARLGLKDVR LALEAGDAVSVPLPVASVVRDNLLDALAHGGGEQDFAVLGEVALRRAGR* &gt;pIR332 MSNTKLGWAGLGNMGTPMVKNLLKAGYPVTVYNRTKEKAQEAVEAGAQLADSAEALSSVS DIVLVMVSDDNAVKEIFNGNSGLLAGDVTGKLFINISTIAPATSKFIDESCKAKGAAFVD APVSGSVKPAQDGTLIFLAGGEPAAIERAQPLFDVMGKLTVNNGPAGAGSAAKLAINYFL AVSVQALAETVLFAKANGISTENMLTIVNEGAVGSAITKLKTAPILNNQFPAAFALKHIT KDLRLATEQGIASPLAGPTYSTYKAAMDSGLGEEDLMAIIKYLEK* &gt;pIR335 MDTNAPVTVIGLGKMGTAIARALIVRGHRTTVWNRTASRAAPLAELGAEVAPTAADAVAA SPLVIICLLDGTAVDAVLETVDEAVSGKVVVNVTSGSPRRARSTAEWISAHGGKYVDGGI MGDTSEVGTPNVLFSYSGDRDGFDAHRDTLEQLGTITYYGEDPGFAAVEFLAQVAIGYEF LLGLLHTLALVKAEGADVAAFSERVAGSVGGYVPLVKGFGIAVASGEYGPDLGPLSVQAA LMDDLIRHREALGVDTLRMREVKRLMDRRIADGHGDQGFSSLFELLDTQ* &gt;pIR338 MKNKKISVLGLGPMGYKIAQLCTQASHSVTVWNRTKSKAEHLQGIVFADSPRHAIATSDM IIICLHDNTIVQDILRAIENKSIFKDKIIINFTTANPADTEEVEKLVNTYHAQYINGAIL TSPDCLGNPDAGVLFSGDKDAYNYSIEVLNLFGGNGKYVGEKASKSSAMDLAFLSLAFGT YMGMMYGVALCESEGISLNEYKEVVSTTLPENVPYLLSSLETIENKSYEIVQSPIASNVT ATQRIADALEAVGARSDFYQTVSQLLKDTEQKGYGAEDLAAVIKLIRPSSY* &gt;pIR344 MKIKIGFIGLGNLGTPIAKNLIDAGYHLQIYNRTISKADELDQSSITKCSSPAEAAKFVN FIVTVLANDAVLTETVTGEEGILKTLAKDAIHISMSTIAPDTAKELAALHEQAGTHYLAS PVFGRPEAAAAKMLWSCISGDPKVKEAATPILETTSQGVVDFGNDVGNANVVKLSGNFMI QASMEMMAEAYTMAEKFGVDRSKVAEFFGNSIFNAPIFKNYGKVIAEHKYQPVGFTTELG YKDASLVFKLSQQSKTPMPFANVIHSRLLTAMAKGRTDSDWAEAFGRGVSDDAGI* &gt;pIR346 MAKVAFLGLGVMGFPMAGHLVKKGGHEVTVYNRTAAKAKEWTDKFGGKTAATPKAAAEGQ DFVMCCVGNDNDLRSVTIGADGAFAGMKKGATFVDHTTASAEVARELDAAATKAGFKFID APVSGGQAGAENGVLTVMCGGAQDVYTGAEPIITGAYARMCKLLGPAGSGQLTKMVNQIC IAGLVQGLSEGIHFAKKSGLDVAAVIETISKGAAQSWQMENRYKTMNEDKYDFGFAVEWM RKDLSIALTEARRNGANLPVTALVDQFYSEVEKMGGKRWDTSSLLARLNR* &gt;pIR349 MGLPMARRLLAAGHEVHAWNRTRAKADVLAADGAYVHDTPRQACIKADYIISMLENGSIV GEVLFGMGQDGAIHGMCQGTLVVDMASIQPREARDHAARLSERGMRHLDAPVSGGTVGAQ AGTLAIMVGGKAEDYEAARPLLAPLGRATHVGPHGAGQLAKLANQMIVGISIGAVAEALL LCAKGGADPAKVREAITGGFADSRILQLHGQRMVERDFAARGKMTVQLKDMRNALATAAE VGFDAPITQLFEQLYADGVKHGLGELDHSGLFVELASRNAMQ* &gt;pIR350 MGRALATALTTAGHDTTVWNRTPGKATGLAVTVADTAAEASAASPLVLVCVRDQSAAEAI LDADALRGRTLVNFTGNSPRQARALASWARDHDVTCLDGVIIATPDIIGTPAATLYYSGP HHAYQAHRPVLAALGENADHVGTDPGRAAALDTSLQDLLWTALSGVVHAFTLAAAEDIAP DEFAARAKNLIGILPDMIDQIAEQLDTGHFPGDDTTMDSVGAVMDHILDTVRFHDLDNGV LSAARADVRRAVDAGHGTAGYARLAAR &gt;pIR351 MRSEPAAVTVLGLGSMGTALAGALLKCGHATTVWNRSPHKTGPLAERGATVAATPEEAVA ASPLVIACVLDYAALHAVLDPVADSLAGKTLVNLTSGSPEQAAEAAAWARSHGAHYLDGA IMTTPPGVGSPEMMFLYSGERTVLDTHRPVLASLGDPLYLGTDPGLASLYDAALLGLMWA TMTGWLHGTALVGAEGTPATAFTPVAIRWLSAVTGFLTTYAPQVDAGHYPGDDATVDVQI AAIDHLIHAAAARGVDNALPGLLKAAMERTRAAGHGSSSYASVIEVLRKAADAR &gt;pIR352 MSEPRRSVTVIGLGPMGRAMVKAFLAAGVEVTVWNRSPEKADAMAESGAKRAGTVAEALD ANEVIVVSLTHYAAMYDVLEPVADRLRGKVIANLSSDSPENARKGAASVRSFGARFLSGG CMTVSDDILHPASYIFYSGPREVFDAHAELLRPLSPQEYLGADDGLSQVYYQALLTIFHS WMLALDQAFALIVNSGNEIGHFLPYALRSQTPFADFMANFAAAAEAGGWGDLANLRMMDA GAQHVIEASEDAGVDASLAHAAQALWRKAIAASETAGAPVPVFRILKGTAA &gt;pIR355 MANSPVSVFGLGAMGTALATQFLRKGHKTTVWNRTPAKAQPLIAIGASHAPTIDSAAAAS SLLIICQLDKASVMQTLQQAPTAWAAKTIVDLTNGTPAHARETADWALAHGARYIHGGIM AVPFMIGQPDAMILYSGPAAVFEGVKDTLSVLGTNTYVGEDVGLASLHDLALLSGMYGLF SGFTHAVALVQSANIPAAGFVATQLIPWLTAMTQHLNLLATQVDEKDYGDGGSSLDMQAK AAPNILEASQAQGVSVELIQPIFKLIERRVEEGKGSEGLAALVGMIMKGGTKDSV &gt;pIR356 MGTERSAVTVIGLGQMGSALAATLLERGHPTTVWNRSAQKAQPLVERGARPAATPEEAVA ASPLVIVCVLDHDALHATLDPVAGFLAGKTLVNLTSGSPEQAQEAEAWARAHSADYLDGA IMTTPPGVGSPEMMFLYSGSRTVFETHRPTLTALGDPLHLGAEPGLASLYDAALLGLMWS TMTGWLHGTALVGAEKTEATAFTPVAIRWLSAVTGFLTTYAAQVDAGRYPGDDATVDVQI AAIDHLLHAAAARGIDNALPELLKATMERTRDLGHGSDSYASVIEVLKKGAGSA &gt;pIR358 MSSKQKITVIGLGAMGATIARLYLEQGHEVTIWNRSADKAAPLVAQGAVLADSAAAAVRA SRVVLMCVYDYRAADAILGAEGVAAAMDGRLLVQLTTGSPRDARDAQAWAQRHGATFLEG AIQAAPEQMGKGDTPILMSGDEQVFRAVEPLLAVLGGGIVYLGEKISNAAAMDLATLSTI YGTMLGFLHGARVAESEGFDVAEFGRIVAGIMPTFASFLQHEGAVIQSGDFKISQSPMRI SVEATQRILQTARESGINSEFPAFAAGLFQRADAAGLGGEELAALIKLLRAPA &gt;pIR360 MHTDLQAVTVIGLGSMGSALAAALLDRGHPLTVWNRSPGKARPLVEKGARLADTPEEAIA ASPVTLTCVFDYDVLRTLLGPATGALAGRDLINLTSGSAEQARELDSWLRLHGAGHLDGG IMTTPPGVGDPAMMFLYSGSPSVLDSHRQVLEALGDPVYLGNDPGLASLYDAALLGLMWS TLTGWLHGAALVGADGVEAGAFTPIAVRWLTAVSGFVTTYSAQVDAAEYPGDDATVDVQI ATIDHLIHAAQARGIDTGLVALLKATMQRAKAAGHGSDSYASVIEVLRKPSDHA &gt;pIR361 MSDPNADRPPVTVVGLGLMGQALAAAFLKGGHPTTVWNRSPEKAERLVADGAVLADTLES AVTASPLVIVCVSDYDAVHELIRPVESALAGRVLVNLTTATSTQARETAEWAAQRNIPYL DGAIMAIPPVIGTDGAVLLYSGHKSAFEAHESTLKAIAPAATTYLEEDHGLSSLYDMALL GIMWGILNGFLHGAALLGTAKVKAETFAPLANTMISAITEYVTAYAPQVDEGRYEATDAT MTVHQAAMEHLAEESEHLGIHSELPRFFKTLADRAVADGHAENSYAAMIELFRKPTA &gt;pIR364 MNSPATVSMLGLGEMGRALAAALLRSDTRVTVWNRTPGRAGALVDAGAVEVSAVGAAVEA AELIVVCLFDHASVHQTLDPVAERLRGRTLINLTTTSPEEARELDRWAAAHGIACVDGGI MAVPSMIAGPGSEILYSGDATAFHRYRQILDVWGTSTYLGSDPGLASLYDLALLSAMYVM FAGYVQGAALVRTAGVTATDFADRAAAWISAMTGGLADFGRVIDGGDYTVAGQQSLDFSD LSTILAAANDAGVGSGPIAMVQQLIDVQRAAGHGSDGFARIFESVARPVPAGRS &gt;pIR367 MAAPLAAAGAEVAASVRNAVAASEVVIVNVSDYQATQSLLRDKEVAGALEGRLIIELTSG TPDGGREAHGWAQRQGARYLDGAILATPDFIGTEAGTLLVSGPSAVFEEGRNVLGALGGN VQFIGEDPGLANALDSAVLALMWGALFGALQSIAVCRAEAIDLGVLARQWTATAPVVEGL VSDLIKRSAAGRYDADAETLSSVSPHYSAFHHLVDLMEARGIDRTITGGYEAIFRRAIEA GHLHDDFASLSQFMGQPA &gt;pIR369 MSVLGLGRMGSALAKALVGQGYEVTVWNRTPKELPNTRSAATPEEAFKSDVVVTCLSTYD VQQPLLTNDIKTLVNLTSGTPDQARATARWAKDNGIEYVDGVIMAVPQQIGTPQAKIFFS GGENHHVLHAFGEPVYVGEDAGLAALYDLALLGIMWATFGGYLQAVALMGTEGIEPARFT PMVADWLNELGHMLPEMGEQTQTRQYETDVSALDINVSGLRLLTEANREQGLDTTIPQAL HGLFERAQRNGHGAHSIASVIEEIRK &gt;pIR372 MANLLKAGHAVTVWNRSPDKAAKLVDAGAILAQTPADAAQGEVVMTMLADDRAVEAVVYG EGGIRAAPALHVSHSTIGIALADRLAADALHGFVSAPVFGRPVAAEAAKLFVIAAGAPAD LDTCDPLFDAIGQRTFRIGDTPSAANLVKLSGNFMIMAAVEAMAEAMTLAEKGGVDRRTL LDVLTGTLFGAPIYQTYGDILVEDRFHPAGFAAPLGLKDMTLADTAATTLRAPMPILGIV RDHLRSAIASEGEDVDWAGVALAVRRGAGIV* &gt;pIR374 MSSVSIFGLGAMGTAMAARFLEKNFKVTVWNRTPEKANKLLDKGASVSNTVLDGINASDL IIVCLLDNAAVQTTFDQALEHVRGKTVINLTNGTPKQARKLSELFVSHGSQYVHGGIMAT PSMIGSPHALILYSGSKDAYNTTESTLSLLAKGWFLGDDAGVASLHDLALLSGMYGLFSG FFHATALVQSSTPATKFLDLLLPWLGAMTEYLKAMAQQVDDGKYSSEGSNMAMQLVAIQN IADASADQGVSADFIHPMRDFVQRAVDAGHGSDDISALISFMKS &gt;pIR376 MIGLGPMGQAMTRVLLTAGHPVTVWNRTAGRADGVVADGAALATTPGEAVGASDLVLLSL TDYRAMYDVLGGATASLAGRTLVNLSSDTPDRTREAAAWAAGHGAAFLSGGVMVPPPMVG TEAARVYYSGRSEVMERHLAALTPLGTPEYLGEDPGLAQLMYQAQLTVFLTTLSGLMHAT AMLGTAGTKAGEALPVLLSFTDTIGGILRAGEDSPGTALDTGEHPGDLSTVTMMGATADH IVETSTSLGLDLALPLAVRSHYGRAIGNGHGGDSWTRIIDSIRAPR &gt;pIR382 MLKAGHPTTIWNRSPGKGEDLVARGATRAATPAEAVRAGEVVVVCVVDYEASQSILEPIA ADLAGRVLVNVTSDAPERAREAGEWAAEHDIAYLDGAVMIPTVMIGTPDALLFYSGDKAA YDKHEGLLKSLGGQSAYVGADHGLAAVYDLSMLDFFWTSMSGLVHGYALAAKDGVPAASI APFLKSHISLLSLLVEETAKNLDEGAYPGAEANLAMEVEGIEHILHAAERRGLDVSVLRG VRDVAQRAVDLGHGADSWSATVEGARNPA &gt;pIR383 MKIGFAGLGVMGGPMARHLVEAGHDVAGFNRSPDKARAWAEATGGRFAATVEEAAAGAEL FILCVGNDHDVREVVAAALPAMGEGAVLVDHTTTSARVAREMSALAAEQGAFFIDAPVSG GQAGAENGQLSVMAGGDAAALARAEPILMHYAKAVKHMGPSGSGQLTKMVNQIAIAGVVQ GLAEAVHFAQTAGLDTDAVYDAISKGAAQSWQMDNRWKTAAAGQFDFGFAVDWMRKDLGL VLDEARANGAHLALTALVDQFYSEVQAMGGSRWDTSSLTARLQARTRQV* &gt;pIR384 MTSPHSNPVTVIGLGPMGTALAEALLKQGHPLTVWNRTPGRAEDLVTKGASLAATVADAV SASPVTIICLKDYETTFGIFDSAGDALKGRVLVNLNSGTPTEARGALDWAAERGAEYLDG AIMVPPPLVGHPESVFLYSGSRDVFDKAGVALASMGDPRFLGSDPGLAVLYNAALLDMMY ATMNGFLHATALVGSANVSAVEFAELALGWFMPSVVDSTLAEQAPDLDKGNYPGDLGTME MNLNALEHITRACVEQGVHSDQPRLMKEIAERAIAEGYSGKNYLAVFEIFKKATQAS 3.2.6. Phylogenetic Analysis of IREDs co-workers. However, we have broadened significantly the sequence space of IREDs with 2 distinct clades shown in by the IREDs in green, with activity distributed across both clades. IREDs in this new sequence space include enzymes such as pIR-111 and (see Table 5.4.1). Represented by box B in Figure Table 3.2.4: UniProt numbers and corresponding enzyme family of NADPH-dependent oxidoreductases used to construct the SSN in </p><formula xml:id="formula_0">P04964 Meso-diaminopimelate D-dehydrogenase G1UII1 Meso-diaminopimelate D-dehydrogenase Q890V3 Meso-diaminopimelate D-dehydrogenase B1HPA8 Meso-diaminopimelate D-dehydrogenase R0C360 Meso-diaminopimelate D-dehydrogenase Q67PI3 Meso-diaminopimelate D-dehydrogenase Q7MW40 Meso-diaminopimelate D-dehydrogenase A0A1H2SCH2 Meso-diaminopimelate D-dehydrogenase A0A2U2AH54 Meso-diaminopimelate D-dehydrogenase I4ZC80 Meso-diaminopimelate D-dehydrogenase A0A3E2SP85 Meso-diaminopimelate D-dehydrogenase A0A0X1KQT3 Meso-diaminopimelate D-dehydrogenase A0A1M7SY12 Meso-diaminopimelate D-dehydrogenase L0EAH3 Meso-diaminopimelate D-</formula><p>dehydrogenase A0A0D6I8P6 Dihydrodipicolinate reductase K0UKT5 Dihydrodipicolinate reductase A0A101AWU7 Dihydrodipicolinate reductase C3UMY1 Dihydrodipicolinate reductase E3CZE3 Dihydrodipicolinate reductase A6LLG5 Dihydrodipicolinate reductase A7HNJ8 Dihydrodipicolinate reductase A9BHL2 Dihydrodipicolinate reductase E3PY99 Dihydrodipicolinate reductase B8D005 Dihydrodipicolinate reductase D2Z5Z0 Dihydrodipicolinate reductase D7DCF5 Dihydrodipicolinate reductase D9RY14 Dihydrodipicolinate reductase W8CV45 Tryptophan dehydrogenase Accession Number Enzyme Family A0A346ILS5 Leucine dehydrogenase F5L9G2 Phenylalanine dehydrogenase Q7SIB4 Leucine dehydrogenase A0A0W7YIH9 Leucine dehydrogenase Q56304 Glutamate dehydrogenase Q59224 Phenylalanine dehydrogenase Q59771 Phenylalanine dehydrogenase Q9AJC6 Lysine dehydrogenase A0A2H6A190 Lysine dehydrogenase A0A162MCQ0 Lysine dehydrogenase I0I6W8 Lysine dehydrogenase A0A212QWI6 Lysine dehydrogenase ** ADH sequences were obtained from Prozomix's metagenomic collection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.7.">Detailed Phylogenetic Tree in Figure 2b (Main Text)</head><p>Following the characterisation of the enzymes towards the reduction of 2-phenylpipeirdine (4) and the reductive amination of cyclohexanone (2) with cyclopropylamine (b) was mapped phylogenetically.</p><p>An enlarged phylogenetically of that shown in Figure <ref type="figure">2b</ref> in the main manuscript expanded below so tip labels are legible for the reader. (4) with grey representing % ee (S)-3 and light purple denoting % ee (R)-3 and the overall height of the bar chart representing % conversion. Expression of all enzymes represented by outer blue gradient, where low expression given in light blue and good expression shown in dark blue . Parental organism of each IRED (if known) is highlighted through tip labels, clades and branches. Green highlights plantae IREDs , yellow fungal IREDs , human in dark purple , cyan highlights cyanobacteria , black and deep-blue bacterial</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Cloning, Expression and Purification of Metagenomic IREDs</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.1.">Cloning of Metagenomic IREDs</head><p>All metagenomic IREDs were cloned into pET28a(+). Successful cloning was confirmed by sequencing at LGC Genomics (Hoddeston, Hertfordshire, UK). Table <ref type="table" target="#tab_7">3</ref>.3.1 lists the E.coli strains used for the cloning of genetic material and the expression of protein material. All vectors containing the relevant codon optimised genes were transformed into chemically competent E. coli cells. Transformations were carried out aseptically by adding 2 μL into 100 μL of E. coli chemically competent cells and incubated for 30 minutes on ice. The cells were then heat-shocked for 2 minutes at 42°C. The cells were then transferred back on ice for 5 minutes before the addition of 250 μL of sterile LBp media. The cells were then incubated for 1 hour at 37°C. 100 μL of recovered cells was plated onto 2% (w/v) LB agar plate (Sarstedt), containing kanamycin (35 μg / mL). The plates were incubated overnight at 37°C.</p><p>Table 3.3.1. E. coli strains used in this study E. coli strain Relevant features, genotype Application of strain E. coli TOP10 mcrA, Δ(mrr-hsdRMS-mcrBC), Phi80lacZ(del)M15, ΔlacX74, deoR, recA1, araD139, Δ(araleu)7697, galU, galK, rpsL(SmR), endA1, nupG Cloning host E. coli BL21 E. coli B dcm ompT hsdS(rB - Prior to the inoculation of the of a 500 mL baffled 2 L flask, a small 10 mL LBp culture was inoculated with the construct of interest and was grown overnight at 37°C at140 rpm. This 10 mL culture was then used to inoculate the 0.5 L TBp medium in a 2 L baffled flask. The flasks were placed onto an Innova 5000 environmental shaker for 24 hours at 23-26℃. Protein expression was monitored via 12 % SDS-PAGE gels.</p><p>The cultures were then transferred into 500 mL centrifuge pots (Nalgene®) and centrifuged at 6000 g / 4°C in a SLA3000 rotor in a Thermo Scientific Sorvall Evolution RC centrifuge. All bacterial pellets and samples are kept on ice throughout. The bacterial pellet was then resuspended within the pot in sodium phosphate buffer (pH 7.5), to 5x pellet weight (w/v). The bacterial suspension was then transferred into a 100 mL glass beaker for sonication.</p><p>A MSE Soniprep 150 sonicator was prepared with a 9.5mm sonication probe and pre-cooled.</p><p>Samples were sonicated for 8 minutes in 2 minute intervals at 16 microns. The samples were transferred into fresh, sterile 50 mL (Nalgene®) centrifuge pots. The samples were then centrifuged at 13000 x g in a Fiberlite™ F13-1 X60cy rotor for 45 minutes. Following centrifugation the supernatants were carefully poured off and decanted into 2 mL aliquots into 5 mL tubes, ready for lyophilisation.</p><p>All 2 mL aliquots of supernatants were subjected to lyophilisation by freeze drying (Edwards SuperModulo). All samples were freeze dried at a pressure of 10</p><p>-1 mbar. The time period in the freeze dryer is dependent on the volume of samples being freeze dried. All samples were stored at -20°C following lyophilisation. All cell-free extract samples were analysed by SDS-PAGE. Samples were prepped by the addition of 10 mg/mL lyophilised cell free extract, 2x Sample Buffer of Laemmli 2× Concentrate (Sigma-Aldrich) in deionised H2O. Samples were heated at 100 °C for 10 minutes. 3μL of Colour Prestained Protein Standard, Broad Range (11-245 kDa) (New England BioLabs) was used. All samples were ran on 4-30 MINI-PROTEAN TGX (BIO-RAD) Gels at 200 V for 45 minutes. Gels were subsequently visualized with InstantBlue Protein Stain (Expedeon). SDS-PAGE analysis was performed on all 384 wild-type IREDs. See below images (Figure 3.3.1) of protein expression with corresponding Table 3.3.2 identifying which lane contains each IRED.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.1.">Spectrophotometric Activity Assay of IREDs</head><p>To determine melting temperature of pIR-09 relative to activity, initial rates of NADPHdependent activities were monitored for the reductive amination cyclohexanone (2) and cyclopropylamine (b). pIR-09 was incubated for 15 minutes in a Mastercycler Gradient (Eppendorf) across a range of temperatures. Following incubation spectrophotometric characterisation was carried out in a 96-well plate (Corning ™ Costar ™ , Thermofisher). The total reaction volume was 200 μL in 0.1 M Sodium Phosphate pH 7.0, 10 mM ketone and 11 mM amine, with an NADPH concentration on 0.5 mM and with 75 μg/mL of pIR-09. NADPH consumption was monitored at 340 nm.</p><p>Circular dichroism (CD) spectroscopy on pIR-09 was performed using a Chirascan CD spectrometer (Applied Photophysics, UK) using a 0.1 mm path length cuvette in a thermoelectrically controlled cell holder. The unfolding of the secondary structure of pIR-09 was monitored across the UV spectra of 190 nm -260 nm across temperatures 30-80 °C analysed by the Pro-Data Chirascan software. Sample preparation of pIR-09 was 5-10 mM in 100 mM Sodium Phosphate pH 7.0. Molar ellipticity (θ) was determined using the mw of pIR-09 (32.149 kDa).</p><p>Thermal melt curves were fitted using the Boltzman sigmoidal fit function of Origin 6.0.</p><p>Section 4. IREDy-to-go Principle, Proof-of-Concept and Optimisation</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">Proof-of-Concept and Optimisation</head><p>The principle of the colorimetric screen that we envisaged is shown in  HCl (100 mM, pH 7.0), 30ºC, 24 h, 250 rpm. Reaction parameters reductive amination: ketone (10 mM), amine (100 mM), IREDs (4 mg mL -1 lyophilized powder of supernatant of lysate), NADP + (0.5 mM), GDH (10 U mL -1 ), d-glucose (50 mM), TRIS HCl (100 mM, pH 8.0), 30ºC, 24 h, 250 rpm. Reaction parameters oxidative deamination: amine (10 mM), IREDs (4 mg mL -1 lyophilized powder of supernatant of lysate), NADP + (0.5 mM), PRO-NOX-001 (2% v/v), 0.1 Gly-NaOH (100 mM, pH 10.0), 30ºC, 24 h, 250 rpm.</p><p>A proof-of-concept screen was initially performed with a select number of enzymes in the form of cell-free extract pIR-23 (CfIRED), <ref type="bibr">3</ref> pIR-49 (IR-22), pIR-63 (PcIRED), <ref type="bibr">3</ref> pIR-64, pIR-65, pIR-68, AdRedAm, 4 AspRedAm 4 ). The RedAms AdRedAm and AspRedAm were included as positive controls since their activity has previously been determined <ref type="bibr">3,</ref><ref type="bibr">4</ref> A negative control of -pET28a (the expression vector) was also employed to observe any possible background reactions. Since the screen is in the oxidative direction, commercially available free amines 1 and 2a were chosen for initial studies as they had previously been shown to be products of imine reduction, <ref type="bibr" target="#b111">5</ref>  INT showed no obvious interference from side reactions in the initial screens of IREDs, and was subsequently taken forward as the substrate for the diaphorase. The pH optimum of assay was determined to be pH 9.0. INT concentration was reduced from 0.25 mg/mL to 0.125 mg/mL whilst still maintaining assay sensitivity, and the assay's stability was also monitored over 96 hours (Figure <ref type="figure">4</ref>.1.2). Figure 4.1.2 outlines the concentration of components for the assay, this was based off biotransformations see sections 5.1 and 5.2. It is envisaged however that various assay components such substrate concentrations, pH of buffer, and conditions such as temperature can be amended based on the end user's requirements. mg/ml, NADP+ 0.5 mM, PRO-DIA-001 1/100. IRED 1mg/ml. 0.1M TRIS-HCl pH 8.0-9.0 and 0.1M Glycine/NaOH pH 10.0. c) Diaphorase and INT stability over 48 hours tested with the -ve control and AdRedAm. At set time points over 96 hours (0, 1, 2, 4,24, 48) substrate was added to the solution containing salsolidine 1, INT, NADP+, IRED, PRO-DIA-001 in 0.1TRIS-HCl p 9.0. Image was taken 1hr after substrate addition Well: 1 -ve control 0hr pH 9.0. Well 2: -ve control 0hr pH 10.0. Well 3: AdRedAm 0hr pH 9.0. Well 4: AdRedAm 0 hr pH 10.0. Well 5: -ve control 4hr pH 9.0. Well 6: -ve control 4hr pH 10.0. Well 7: AdRedAm 4 hr pH 9.0. Well 8: AdRedAm 4hr pH 10.0. Well 9: -ve control 48hr pH 9.0. Well 10: -ve control 48hr pH 10.0. Well 11: AdRedAm 48 hr pH 9.0. Well 12: AdRedAm 48 hr pH 10.0. d)-IREDy-to-go following reduction diaphorase concentration from 2% to 0.02%. A01: -ve control. B01: pIR-23. C01: pIR-49. D01: pIR-63. E01: pIR-064. F01: pIR-65. G01: pIR-068. H01: pIR-102. A02: pIR-110. B02: AdRedAm. C02: AspRedAm Table 4.1.1. Final component concentrations of the IREDy-to-go ™ screen Component Concentration Substrate 10mM INT 0.25 mg/ml NADP + 0.5 mM Diaphorase 0.02 % (v/v) IRED (Lysate) 1 mg/ml Further optimisation was carried out on the 384-scale to determine the optimum temperature for assay incubation with substrate α-methylbenzylamine (13k) (Figure 4.1.3). Both 2b (data not shown) and 13k were used in the temperature optimisation. 13k was postulated to be a synthetically challenging substrate for IREDs. Data is shown for the temperatures of ambient, 30 °C, and 37 °C with both assay and blank plates (data not shown). The optimum temperature for the assay was determined to be 30 °C to ensure rapid development of the colorimetric without suffering from uneven heat transfer around the periphery of the plate (section 4.4.2) (demonstrated at 37 °C).</p><p>Ambient, 0hr. Ambient, 24hr. &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.31 0.32 0.33 0.29 0.34 0.33 0.32 0.37 0.35 0.38 0.38 0.38 0.34 0.37 0.40 0.46 0.44 0.41 0.50 0.44 0.49 0.48 0.49 0.48 B 0.30 0.42 0.35 0.33 0.34 0.32 0.35 0.35 0.34 0.36 0.38 0.36 0.38 0.37 0.39 0.42 0.41 0.41 0.42 0.48 0.48 0.49 0.55 0.53 C 0.34 0.39 0.31 0.32 0.34 0.32 0.32 0.34 0.32 0.34 0.38 0.38 0.40 0.39 0.38 0.38 0.41 0.42 0.44 0.44 0.42 0.49 0.52 0.52 D 0.37 0.31 0.34 0.32 0.32 0.32 0.34 0.43 0.34 0.37 0.35 0.33 0.35 0.41 0.28 0.39 0.40 0.42 0.42 0.41 0.41 0.42 0.49 0.50 E 0.30 0.33 0.29 0.30 0.30 0.31 0.36 0.34 0.33 0.32 0.36 0.32 0.38 0.21 0.26 0.37 0.38 0.40 0.39 0.40 0.43 0.45 0.47 0.46 F 0.33 0.33 0.27 0.29 0.31 0.31 0.33 0.32 0.36 0.32 0.32 0.36 0.31 0.31 0.42 0.35 0.38 0.44 0.44 0.45 0.46 0.47 0.41 0.51 G 0.31 0.28 0.29 0.26 0.28 0.30 0.36 0.30 0.35 0.22 0.33 0.29 0.26 0.32 0.38 0.33 0.38 0.35 0.43 0.38 0.43 0.44 0.56 0.47 H 0.32 0.28 0.31 0.23 0.25 0.28 0.25 0.27 0.30 0.34 0.30 0.24 0.20 0.36 0.34 0.37 0.33 0.32 0.41 0.58 0.88 0.47 0.48 0.50 I 0.36 0.43 0.28 0.27 0.28 0.33 0.56 0.29 0.25 0.34 0.34 0.25 0.37 0.35 0.28 0.32 0.36 0.32 0.46 0.42 0.47 0.50 0.50 0.52 J 0.30 0.28 0.43 0.38 0.28 0.26 0.30 0.31 0.32 0.29 0.30 0.28 0.38 0.32 0.37 0.26 0.36 0.37 0.46 0.43 0.45 0.52 0.53 0.57 K 0.34 0.30 0.28 0.26 0.31 0.27 0.31 0.31 0.25 0.35 0.36 0.32 0.34 0.30 0.37 0.54 0.37 0.40 0.41 0.46 0.47 0.50 0.54 0.55 L 0.32 0.31 0.30 0.28 0.30 0.29 0.30 0.30 0.34 0.30 0.35 0.28 0.35 0.35 0.36 0.40 0.42 0.42 0.38 0.46 0.48 0.50 0.52 0.55 M 0.31 0.31 0.33 0.31 0.26 0.29 0.38 0.33 0.33 0.36 0.37 0.35 0.40 0.41 0.39 0.42 0.41 0.41 0.49 0.45 0.51 0.48 0.53 0.54 N 0.31 0.33 0.31 0.32 0.31 0.33 0.38 0.35 0.36 0.34 0.37 0.36 0.40 0.42 0.43 0.45 0.42 0.44 0.46 0.47 0.49 0.46 0.52 0.56 O 0.72 0.29 0.31 0.31 0.30 0.33 0.43 0.77 0.42 0.37 0.37 0.38 0.41 0.40 0.42 0.42 0.41 0.41 0.50 0.48 0.50 0.50 0.57 0.53 P 0.34 0.32 0.31 0.31 0.34 0.35 0.38 0.42 0.41 0.41 0.41 0.41 0.55 0.44 0.45 0.45 0.83 0.45 0.60 0.51 0.50 0.54 0.55 0.46 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.43 0.50 0.45 0.42 0.51 0.79 0.46 0.64 0.69 0.51 0.49 0.61 0.63 0.49 0.53 0.74 0.60 0.51 0.60 0.54 0.60 0.58 0.67 0.60 B 0.38 0.74 0.53 0.50 0.51 0.43 0.53 0.45 0.48 0.46 0.50 0.45 0.52 0.44 0.49 0.54 0.58 0.52 0.53 0.66 0.64 0.67 0.72 0.69 C 0.65 0.88 0.43 0.46 0.46 0.44 0.45 0.44 0.50 0.70 0.51 0.51 0.59 0.54 0.49 0.58 0.56 0.61 0.58 0.55 0.50 0.62 0.68 0.65 D 0.09 0.47 0.11 0.43 0.45 0.48 0.49 1.60 0.47 0.52 0.57 0.44 0.45 0.60 0.31 0.57 0.64 0.70 0.54 0.54 0.53 0.52 0.60 0.63 E 0.56 0.51 0.42 0.42 0.40 0.42 0.46 0.61 0.45 0.43 0.62 0.44 0.54 0.33 0.44 0.58 0.48 0.73 0.46 0.49 0.82 0.53 0.61 0.65 F 0.90 0.48 0.38 0.40 0.45 0.43 0.44 0.54 0.49 0.41 0.49 0.52 0.37 0.43 0.55 0.42 0.52 0.63 0.62 0.64 0.60 0.59 0.53 0.69 G 0.45 0.44 0.39 0.40 0.36 0.38 0.53 0.43 0.52 0.34 0.46 0.37 0.39 0.42 0.50 0.46 0.49 0.44 0.50 0.49 0.49 0.54 0.65 0.59 H 0.54 0.46 0.46 0.38 0.33 0.38 0.35 0.35 0.44 0.45 0.45 0.31 0.32 0.46 0.64 0.47 0.40 0.47 0.46 0.77 2.13 0.60 0.61 0.65 I 0.54 0.68 0.42 0.41 0.44 0.69 1.04 0.43 0.36 0.93 0.47 0.33 0.52 0.60 0.42 0.44 0.50 0.42 0.61 0.54 0.65 0.68 0.66 0.65 J 0.46 0.41 0.71 0.60 0.42 0.36 0.46 0.49 0.50 0.40 0.42 0.48 0.52 0.46 0.54 0.33 0.49 0.55 0.63 0.56 0.56 0.66 0.70 0.74 K 0.61 0.46 0.48 0.39 0.45 0.46 0.43 0.49 0.39 0.52 0.55 0.49 0.49 0.34 0.51 0.78 0.49 0.57 0.50 0.61 0.65 0.67 0.68 0.70 L 0.48 0.46 0.45 0.45 0.48 0.45 0.42 0.42 0.48 0.41 0.52 0.43 0.49 0.45 0.53 0.56 0.57 0.58 0.48 0.58 0.62 0.66 0.64 0.71 M 0.53 0.43 0.59 0.42 0.38 0.41 0.54 0.47 0.48 0.50 0.50 0.51 0.59 0.60 0.57 0.55 0.55 0.55 0.72 0.61 0.67 0.63 0.64 0.72 N 0.41 0.53 0.46 0.49 0.51 0.52 0.61 0.49 0.52 0.52 0.57 0.50 0.57 0.62 0.63 0.68 0.60 0.56 0.60 0.64 0.67 0.57 0.65 0.72 O 1.74 0.46 0.43 0.44 0.44 0.49 0.58 1.35 0.58 0.51 0.52 0.54 0.59 0.54 0.61 0.57 0.56 0.55 0.77 0.67 0.82 0.68 0.76 0.70 P 0.57 0.49 0.55 0.50 0.49 0.51 0.57 0.59 0.58 0.59 0.63 0.58 0.69 0.63 0.57 0.60 2.48 0.61 0.72 0.70 0.69 0.70 0.76 0.57 a b c 30 °C, 0hr. 30 °C, 24hr. 37 °C, 0hr. 37 °C, 24hr. &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.47 0.46 0.49 0.46 0.48 0.45 0.41 0.42 0.43 0.40 0.39 0.39 0.44 0.40 0.43 0.40 0.43 0.40 0.57 0.45 0.47 0.50 0.50 0.46 B 0.45 0.51 0.49 0.45 0.44 0.40 0.44 0.42 0.45 0.41 0.43 0.42 0.42 0.42 0.40 0.43 0.44 0.41 0.47 0.45 0.46 0.46 0.46 0.46 C 0.48 0.49 0.47 0.45 0.46 0.42 0.45 0.41 0.42 0.43 0.44 0.42 0.43 0.40 0.42 0.42 0.41 0.37 0.47 0.46 0.44 0.47 0.45 0.46 D 0.46 0.44 0.44 0.45 0.43 0.43 0.44 0.46 0.43 0.43 0.43 0.41 0.42 0.41 0.39 0.39 0.38 0.38 0.44 0.44 0.45 0.45 0.47 0.46 E 0.44 0.44 0.44 0.44 0.42 0.42 0.44 0.38 0.40 0.38 0.39 0.37 0.40 0.37 0.40 0.39 0.39 0.36 0.47 0.45 0.45 0.45 0.46 0.47 F 0.44 0.45 0.42 0.41 0.41 0.36 0.38 0.34 0.38 0.35 0.35 0.33 0.38 0.33 0.33 0.33 0.37 0.33 0.47 0.43 0.44 0.47 0.46 0.48 G 0.43 0.42 0.41 0.41 0.38 0.39 0.41 0.39 0.38 0.35 0.37 0.38 0.39 0.37 0.39 0.37 0.37 0.31 0.44 0.38 0.43 0.45 0.54 0.44 H 0.42 0.40 0.42 0.39 0.39 0.36 0.44 0.36 0.38 0.35 0.38 0.35 0.40 0.34 0.37 0.36 0.36 0.33 0.43 0.44 0.65 0.43 0.44 0.41 I 0.45 0.48 0.39 0.35 0.38 0.35 0.44 0.32 0.34 0.33 0.35 0.34 0.38 0.34 0.35 0.31 0.35 0.31 0.41 0.43 0.43 0.42 0.42 0.39 J 0.47 0.44 0.50 0.42 0.39 0.32 0.37 0.32 0.34 0.31 0.35 0.30 0.38 0.31 0.32 0.31 0.33 0.34 0.40 0.38 0.40 0.41 0.42 0.42 K 0.46 0.43 0.42 0.40 0.40 0.38 0.37 0.36 0.33 0.34 0.34 0.34 0.34 0.31 0.32 0.43 0.35 0.35 0.40 0.43 0.40 0.43 0.43 0.39 L 0.45 0.42 0.43 0.41 0.44 0.38 0.39 0.36 0.43 0.35 0.43 0.35 0.42 0.35 0.39 0.37 0.38 0.34 0.44 0.40 0.46 0.42 0.42 0.41 M 0.45 0.42 0.45 0.44 0.40 0.37 0.39 0.42 0.40 0.38 0.38 0.35 0.38 0.41 0.35 0.39 0.38 0.38 0.42 0.44 0.40 0.42 0.43 0.41 N 0.46 0.40 0.42 0.40 0.39 0.38 0.37 0.35 0.38 0.39 0.39 0.36 0.38 0.38 0.37 0.40 0.40 0.36 0.44 0.40 0.39 0.42 0.43 0.40 O 0.54 0.38 0.42 0.38 0.41 0.35 0.42 0.43 0.46 0.39 0.42 0.37 0.40 0.35 0.42 0.37 0.39 0.33 0.43 0.39 0.41 0.39 0.43 0.39 P 0.42 0.41 0.43 0.38 0.41 0.38 0.41 0.40 0.40 0.41 0.40 0.42 0.57 0.43 0.36 0.39 0.55 0.38 0.44 0.40 0.41 0.42 0.40 0.45 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.92 1.05 0.82 0.87 0.86 1.28 0.89 0.79 1.20 0.67 0.66 0.97 0.88 0.62 0.65 1.09 0.83 0.55 0.70 0.78 0.69 0.60 0.83 0.79 B 0.73 0.87 0.88 0.84 0.81 0.72 0.85 0.63 0.77 0.78 0.75 0.71 0.72 0.63 0.75 0.71 0.75 0.66 0.73 0.70 0.80 0.76 0.80 0.81 C 0.99 1.31 0.76 0.72 0.63 0.57 0.58 0.53 0.53 0.85 0.60 0.61 0.70 0.63 0.59 0.65 0.62 0.60 0.61 0.60 0.52 0.71 0.73 0.78 D 0.91 0.77 0.69 0.64 0.65 0.65 0.69 1.49 0.66 0.65 0.58 0.62 0.53 0.76 0.61 0.72 0.71 0.55 0.67 0.73 0.71 0.68 0.64 0.74 E 0.94 0.81 0.66 0.67 0.72 0.75 0.71 0.84 0.65 0.63 0.80 0.65 0.68 0.60 0.74 0.96 0.65 0.90 0.69 0.69 0.98 0.57 0.76 0.92 F 0.98 0.85 0.65 0.67 0.69 0.64 0.62 0.74 0.66 0.61 0.81 0.75 0.60 0.60 0.62 0.58 0.67 0.76 0.87 0.81 0.69 0.66 0.86 0.76 G 0.90 0.80 0.59 0.84 0.70 0.58 0.78 0.62 0.78 0.65 0.58 0.57 0.77 0.63 0.55 0.66 0.62 0.56 0.64 0.76 0.63 0.61 0.78 0.79 H 0.98 0.88 0.72 0.91 0.64 0.60 0.75 0.68 0.76 0.59 0.73 0.69 0.73 0.58 0.94 0.61 0.58 0.85 0.71 0.92 2.08 0.74 0.76 0.76 I 0.89 1.06 0.69 0.80 0.77 0.68 1.14 0.64 0.73 1.12 0.75 0.70 0.66 0.84 0.66 0.62 0.70 0.67 0.84 0.73 0.86 0.74 0.70 0.62 J 0.91 0.87 1.29 0.85 0.68 0.57 0.67 0.68 0.77 0.64 0.62 0.71 0.74 0.60 0.63 0.69 0.55 0.68 0.80 0.72 0.67 0.70 0.82 0.76 K 1.01 0.85 0.68 0.72 0.72 0.92 0.68 0.71 0.66 0.66 0.74 0.64 0.68 0.49 0.76 0.89 0.64 0.71 0.77 0.74 0.83 0.69 0.73 0.74 L 0.91 0.84 0.72 0.76 0.73 0.72 0.81 0.63 0.78 0.53 0.62 0.54 0.73 0.54 0.73 0.67 0.71 0.69 0.76 0.69 0.68 0.67 0.61 0.73 M 0.98 0.72 0.77 0.64 0.75 0.59 0.71 0.71 0.65 0.67 0.61 0.73 0.80 0.80 0.76 0.74 0.70 0.79 0.91 0.81 0.77 0.68 0.57 0.80 N 0.80 0.90 0.70 0.72 0.77 0.68 0.74 0.58 0.80 0.79 0.76 0.66 0.75 0.80 0.76 0.84 0.80 0.68 0.72 0.81 0.80 0.66 0.72 0.82 O 1.49 0.82 0.82 0.72 0.71 0.66 0.77 1.26 0.82 0.63 0.70 0.65 0.69 0.61 0.82 0.63 0.70 0.62 0.86 0.69 0.90 0.69 0.72 0.68 P 1.15 0.94 0.92 0.93 0.79 0.73 0.80 0.77 0.73 0.75 0.80 0.77 0.91 0.76 0.68 0.71 1.83 0.71 0.74 0.74 0.80 0.76 0.82 0.90 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.27 0.30 0.31 0.28 0.31 0.32 0.32 0.37 0.37 0.44 0.36 0.35 0.35 0.41 0.39 0.39 0.38 0.38 0.44 0.37 0.39 0.37 0.41 0.38 B 0.30 0.36 0.33 0.31 0.32 0.29 0.33 0.35 0.33 0.33 0.34 0.34 0.36 0.37 0.32 0.42 0.36 0.36 0.39 0.39 0.35 0.40 0.41 0.40 C 0.30 0.35 0.30 0.30 0.28 0.30 0.28 0.29 0.31 0.31 0.35 0.37 0.34 0.33 0.33 0.34 0.34 0.33 0.35 0.35 0.34 0.34 0.38 0.37 D 0.29 0.33 0.29 0.30 0.28 0.28 0.33 0.33 0.34 0.32 0.36 0.31 0.32 0.33 0.33 0.32 0.33 0.33 0.37 0.34 0.34 0.32 0.37 0.39 E 0.29 0.29 0.29 0.27 0.27 0.26 0.33 0.29 0.31 0.30 0.33 0.30 0.33 0.31 0.34 0.31 0.34 0.34 0.36 0.36 0.35 0.35 0.38 0.39 F 0.30 0.30 0.29 0.27 0.26 0.29 0.30 0.33 0.33 0.35 0.30 0.34 0.38 0.39 0.39 0.35 0.34 0.36 0.41 0.39 0.41 0.41 0.37 0.39 G 0.30 0.31 0.26 0.24 0.25 0.26 0.34 0.30 0.33 0.28 0.34 0.30 0.31 0.31 0.36 0.35 0.35 0.34 0.39 0.34 0.36 0.35 0.37 0.40 H 0.30 0.28 0.28 0.26 0.26 0.25 0.34 0.29 0.35 0.31 0.29 0.29 0.33 0.32 0.31 0.33 0.34 0.32 0.37 0.42 0.58 0.33 0.35 0.40 I 0.31 0.32 0.27 0.27 0.27 0.27 0.36 0.30 0.30 0.31 0.33 0.29 0.33 0.31 0.34 0.32 0.35 0.32 0.39 0.36 0.44 0.37 0.39 0.41 J 0.30 0.31 0.37 0.30 0.28 0.27 0.36 0.33 0.34 0.31 0.35 0.34 0.37 0.34 0.36 0.36 0.33 0.33 0.42 0.38 0.37 0.38 0.39 0.42 K 0.32 0.29 0.26 0.26 0.27 0.26 0.34 0.34 0.34 0.36 0.37 0.36 0.33 0.35 0.35 0.41 0.34 0.37 0.25 0.36 0.22 0.38 0.32 0.41 L 0.31 0.32 0.29 0.28 0.29 0.30 0.31 0.32 0.35 0.37 0.38 0.36 0.36 0.33 0.36 0.31 0.36 0.37 0.35 0.35 0.40 0.37 0.43 0.42 M 0.30 0.33 0.28 0.28 0.27 0.30 0.34 0.33 0.35 0.32 0.37 0.33 0.39 0.36 0.33 0.33 0.37 0.38 0.37 0.36 0.40 0.38 0.43 0.42 N 0.31 0.31 0.33 0.30 0.29 0.30 0.32 0.34 0.35 0.35 0.32 0.34 0.36 0.38 0.36 0.40 0.39 0.38 0.39 0.40 0.38 0.38 0.43 0.44 O 0.34 0.30 0.31 0.30 0.32 0.31 0.40 0.37 0.39 0.37 0.37 0.39 0.36 0.38 0.37 0.40 0.35 0.36 0.44 0.43 0.43 0.43 0.45 0.45 P 0.33 0.33 0.34 0.33 0.34 0.33 0.37 0.37 0.40 0.37 0.40 0.37 0.54 0.42 0.42 0.40 0.59 0.41 0.51 0.42 0.43 0.42 0.45 0.44 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.82 0.96 0.83 0.96 0.86 1.49 0.95 0.90 1.49 0.82 0.74 0.98 1.03 0.81 0.84 1.34 0.92 0.61 0.77 0.85 0.87 0.71 1.17 0.83 B 0.69 0.86 0.89 0.86 0.85 0.74 0.88 0.73 0.79 0.67 0.66 0.66 0.70 0.69 0.67 0.80 0.78 0.78 0.71 0.79 0.78 0.89 0.85 0.98 C 1.00 1.47 0.77 0.75 0.62 0.67 0.59 0.53 0.58 0.85 0.59 0.70 0.76 0.59 0.55 0.58 0.51 0.65 0.57 0.57 0.43 0.60 0.65 0.89 D 0.83 0.84 0.70 0.65 0.54 0.56 0.63 1.21 0.61 0.53 0.43 0.50 0.39 0.60 0.51 0.61 0.56 0.56 0.60 0.53 0.57 0.57 0.51 0.84 E 0.91 0.84 0.63 0.58 0.48 0.65 0.75 0.79 0.61 0.51 0.71 0.53 0.58 0.49 0.64 1.20 0.51 0.86 0.54 0.51 0.62 0.51 0.77 0.97 F 0.85 0.80 0.69 0.52 0.49 0.62 0.61 0.66 0.64 0.56 0.64 0.66 1.17 0.61 0.64 0.47 0.52 0.77 0.76 0.65 0.61 0.58 0.70 0.87 G 0.93 0.81 0.64 0.62 0.48 0.49 0.77 0.58 0.75 0.52 0.44 0.43 0.60 0.48 0.45 0.59 0.50 0.54 0.54 0.59 0.47 0.53 0.61 0.88 H 1.02 1.00 0.79 0.62 0.47 0.50 0.68 0.64 0.77 0.49 0.58 0.54 0.66 0.49 0.79 0.51 0.49 0.86 0.64 0.72 2.08 0.63 0.70 1.05 I 0.92 0.99 0.74 0.60 0.59 0.48 1.14 0.65 0.70 0.95 0.64 0.57 0.60 0.71 0.56 0.51 0.62 0.67 0.75 0.55 0.86 0.66 0.70 0.86 J 0.88 0.81 2.16 0.72 0.55 0.52 0.68 0.71 0.76 0.60 0.55 0.61 0.59 0.49 0.50 0.60 0.46 0.61 0.80 0.59 0.55 0.63 0.95 0.99 K 1.03 0.93 0.70 0.49 0.55 0.76 0.65 0.70 0.71 0.64 0.62 0.62 0.57 0.60 0.63 0.69 0.53 0.74 0.11 0.60 0.15 0.72 0.26 0.88 L 0.95 0.88 0.74 0.61 0.47 0.68 0.74 0.60 0.76 0.55 0.54 0.54 0.59 0.50 0.64 0.56 0.59 0.68 0.64 0.61 0.59 0.76 0.87 0.90 M 0.98 0.81 0.84 0.55 0.60 0.62 0.72 0.75 0.67 0.62 0.68 0.79 0.67 0.67 0.65 0.64 0.60 0.72 0.82 0.79 0.74 0.97 0.90 0.92 N 0.86 0.98 0.92 0.77 0.88 0.86 0.94 0.92 1.00 0.84 0.90 0.80 0.85 0.82 0.75 0.91 0.78 0.84 0.83 0.95 1.00 0.84 1.04 0.97 O 1.78 0.81 0.84 0.78 0.89 0.96 0.94 1.71 1.02 0.96 0.81 0.93 0.89 0.80 1.05 0.99 0.88 0.91 1.31 1.12 1.43 0.98 1.06 0.96 P 1.10 1.03 0.90 1.09 0.87 0.90 0.98 0.97 0.96 0.90 1.07 0.92 1.06 1.06 0.94 0.86 2.11 0.96 0.93 0.93 0.96 0.86 1.05 0.90 d e Assay Plate Average Absorbance Blank Plate Average Absorbance Ambient 0hr 0.38 Ambient, 0hr 0.38 Ambient 24hr 0.55 Ambient 24hr 0.40 30 °C 0hr 0.41 30 °C 0hr 0.38 30 °C 24hr 0.75 30 °C 24hr 0.50 37 °C 0hr 0.34 37 °C 0hr 0.30 37 °C 24hr 0.76 37 °C 24hr 0.50 </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">Protocol for IREDy-to-go ™</head><p>The assay is based on the principle of running the reaction in the reverse direction as outlined in Scheme 1.0 using an amine of interest as the substrate which is oxidised to the corresponding imine (and subsequently hydrolysed to the corresponding carbonyl and amine). Brief Protocol:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blank plate</head><p>Master mix reagent: 25 mL of 0.125 mg.ml -1 INT in 100 mM Tris HCl adjusted to pH 9.0.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assay plate</head><p>Master mix reagent: 25 mL of 0.125 mg.ml -1 INT, and 10 mM amine substrate in 100 mM Tris HCl adjusted to pH 9.0.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Method:</head><p>1. Add 50 µL of the desired master mix reagent to each well of the IREDy-to-go ™ plate.</p><p>2. Spin down plate at 1,500 rpm for 1 minute.</p><p>3. Incubate in the dark and monitor for colour change for up to 24 hours at 30 °C.</p><p>4. Expect false positives in wells: B02, D08, F12, H21, I02, I07, K16, O01, O08 and P17.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>More detailed protocol:</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blank plate</head><p>• Each well contains lyophilised IRED lysate, and lyophilised IREDy-to-go ™ components including the co-enzyme NADP + .</p><p>• Components which require addition to the plate are INT, and 0.1 M Tris-HCl buffer pH 9.0.</p><p>Method:</p><p>1. To generate the blank master mix reagent: 25 mL of 0.125 mg.ml -1 INT in 100 mM</p><p>Tris HCl adjusted to pH 9.0 2. Using the microplate sealing film cross-hairs as a guide, dispense 50 µL of the master mix reagent to each well of the plate and aspirate carefully to reconstitute the freeze dried enzymes. Change tips between additions to avoid enzyme cross-contamination.</p><p>3. Upon addition of the master mix, spin the plate down at 1,500 rpm for 1 minute.</p><p>4. Optional: Following addition of master mix push down on the plate whilst rapidly removing red cross-hair pierce-able film to aid in visualisation of the plate. If available seal with an optically clear film to avoid potential evaporation.</p><p>5. Incubate in the dark at ambient temperature or 30 °C for up to 24 hours. A low background of red will be observed over 24 hours. Wells B02, D08, F12, H21, I02, I07, K16, O01, O08 and P17 should form an intense red colour quickly.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assay plate</head><p>• Each well contains lyophilised IRED lysate, and lyophilised IREDy-to-go components including the co-enzyme NADP + .</p><p>• Components which require addition to the plate are INT, amine substrate, and 0.1 M Tris-HCl buffer pH 9.0.</p><p>Method:</p><p>1. To generate assay master mix reagent: 25 mL of 0.125 mg.ml -1 INT, and 10 mM amine substrate in 100 mM Tris HCl adjusted to pH 9.0.</p><p>2. Using the microplate sealing film cross-hairs as a guide, carefully add 50 µL of the master mix reagent to each well and mix carefully to reconstitute the freeze-dried enzymes.</p><p>Change tips between additions, to avoid enzyme cross contamination.</p><p>3. Upon addition of the master mix reservoir, spin the plate down at 1,500 rpm for 1 minute.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4.</head><p>Optional: Following addition of master mix push down on the plate whilst rapidly removing red cross-hair pierce-able film to aid in visualisation of the plate. If available seal with an optically clear film to avoid potential evaporation.</p><p>5. Incubate the plate in the dark at ambient temperature or 30 °C for up to 24 hours.</p><p>Although a red colorimetric change can be observed within 10 minutes upon substrate addition. Wells B02, D08, F12, H21, I02, I07, K16, O01, O08 and P17 can be regarded as false positives.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Notes (i)</head><p>Prior to opening the bags in which the plates are contained it is recommended they are equilibrated to room temperature.</p><p>(ii) A single blank plate is required in the case of carrying out multiple assay plates.</p><p>A multi-channel pipette (or robot) is recommended for addition of the master-mix plate. However, if unavailable then a single channel pipette is usable.</p><p>(iii) When running multiple assays, stack plates together to ensure all reactions are carried out at the same temperature.</p><p>(iv)</p><p>The assay can be performed across a range of temperatures, but most hits are observed at ambient or 30°C.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(v)</head><p>Results can be gathered visually by placing the plates against a white background and observed by eye. Alternatively they may be analysed using a microplate reader at 490 nm. If this method is used optimum results can be obtained by first agitating the plates on a plate shaker and pulse centrifuging prior to removing the cross-hair films.</p><p>(vi) It is recommended results are confirmed by repeating reactions to ensure no sporadic contamination occurred in the first instance. It is also advised that any results from the assay place are confirmed on the analytical scale using instruments such as High-Performance Liquid Chromatography (HPLC) or Gas Chromatography (GC).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(vii)</head><p>The screen is not compatible with substrates containing an aniline moiety.</p><p>(viii) In some instances peripheral plate background reduction is stronger. This is possibly due to uneven heat transfer.</p><p>Exemplar IREDy-to-go assay: Scheme 4.2.2. Oxidation and hydrolysis of N-cyclopropylcyclohexylamine (2b) as performed in the colorimetric assay.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.">Generation of 384-well plates.</head><p>The 384-well IREDy-to-go and 0.5 mg cell-free extract plates (CFE) were generated using a Thermo Scientific Matrix Plate Mate Plus (PMP) robot. The robot was configured to dispense at both 96 and 384 formats. In this case allowing the translation from larger 96-well deep-well "master" blocks into the smaller, intermediate 384-well deep-well blocks in the generation of both types of IRED plates. These pipetting actions greatly reduce the number of pipette actions performed by human scientists, and therefore reduce human-error, and increases overall efficiency.</p><p>The first product was created by simply dispensing reconstituted CFE enzyme powder across each of the 384 wells, producing plates containing a whole panel of enzymes in each, with each well holding 0.5 mg of each of the enzyme powders (after lyophilisation). The second product was produced by dispensing a mixture consisting of the reconstituted CFE enzyme powders and a solution of assay component master-mix, producing a plate containing a pre-prepared, colorimetric assay in each well for the each of the 384 enzymes.</p><p>Over 500 of each plate type was produced. To produce this number of plates 330 mg of each of the previously prepared lyophilised CFE powders were weighed out for all 384 enzymes, dissolved and made up to a volume of 6.6 mL in 0.1 M TRIS / HCl buffer (pH 9.0) before being dispensed into master blocks. Each enzyme resuspension was split between three sets of master blocks at 2.2 mL per well, with each set consisting of four 96-well deep-well blocks containing one quarter of the 384 enzyme resuspensions each. Due to the translation between the 96 and 384 format, the 96-well master blocks were set up with a jump in numbering off-set by one both in row and column for each block in the set, so that once the enzymes were dispensed into 384 format the enzymes followed in numerical order (  The 3 sets of the 4 different (red, green, yellow, purple) 96-well master blocks were translated into 30 384-well master blocks. The PMP has a moving stage which can automatically retrieve</p><p>and deliver plates to and from easy to fill and assemblages on its sides allowing for batches to be completed without human input (Figure <ref type="figure">4</ref>.3.2). Using this function all 30 384-well master blocks were filled from the 3 blocks containing the first quarter of the enzymes, then the tips were changed and the assemblage restacked, and the same 30 plates were filled from the 3 blocks containing the second quarter of the enzymes, with the PMP off-setting the tips in order to hit the empty wells. This was repeated with the 96-well master blocks containing the other two quarters until all the wells on all 30 plates were filled with numerically sequential enzymes at 220 μL per well (Figure <ref type="figure">4</ref>.3.3). This step using the 96-well blocks was necessary as no larger volume 384well blocks were available, and hand-filling would be too labour intensive and prone to error at this scale.  Once all 384-well deep-well blocks were created they were stored in the fridge while the PMP was reconfigured to dispense at 384 format. This was done by simply changing the piston head and tips. As the PMP has two sets of assemblages for plate retrieval and delivery, it is able to use one side of its stage to move the 384-well deep-well blocks as they are emptied, while using the other side of its stage to move the 384-well plates as they are filled. This was used to dispense 10 μL of CFE per well from 24 blocks into 528 plates automatically (Figure <ref type="figure">4</ref>.3.4). The 528 plates produced in this way were frozen to be lyophilised later in an Edwards Super Modulo freeze drying system. Once lyophilised each well consistently contains 0.5 mg of CFE powder, allowing end-users to add dH2O to each well and have a known concentration of CFE to work with.</p><p>To make the IRED assay plates (IREDy-to-go) 30 384-well blocks were filled with assay component master-mix by using the PMP to add 200 μL per well from a reservoir block. As the reservoir block had a max volume of approximately 200 mL and each plate depleted the volume by 76.8 mL per plate it was re-filled after every 2 plates by hand during a programmed pause.</p><p>Next, 3 of the remaining 6 CFE blocks from the 30 were loaded into the PMP along with the master-mix blocks and 20 μL of the CFE was added to each well of the master-mix blocks producing 30 blocks assay enzyme / assay solution mixture. These blocks were then loaded back into the PMP to be used to aliquot into plates in the same way as the 0.5 mg CFE plates, however each time the PMP retrieved a plate from the stack of blocks it was programmed to aspirate 100 μL 10 times in order to ensure the CFE was fully mixed throughout the assay solution. Once again 10 μL of mixture was dispensed from 30 blocks into 660 plates automatically by the PMP.</p><p>These plates were also frozen to be later lyophilised later in the Edwards Super Modulo freeze drying system. Once lyophilised each well contains all the components with which to perform a simple colorimetric assay on 384 diverse IREDs at room temperature in a single plate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.">Further IREDy-to-go Development</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.1.">Screening of Prozomix Diaphorase Panel</head><p>Enzymes were selected from EC. 1.6.99.1, several enzymes were observed to comprise one domain from PF00724 (Oxidored_FMN). 100 proteins were mined evenly throughout the phylogenetic space containing this Pfam, enzymes were then cloned into pET28a. Enzymes were then expressed recombinantly in E coli of which 40 were subsequently found to be expressed in soluble form (see Figure <ref type="figure">4</ref> factor specificity makes these diaphorases particularly suitable for characterisation of novel IREDs of initially unknown cofactor preference. DIA-001 and DIA-006 were subsequently characterised further using the same assay but with immobilised metal affinity chromatography (IMAC) purified enzyme, and as no significant difference was observed between them (data not shown), DIA(001) was selected for all subsequent work by default. Table 4.4.1. Relative activities and cofactor specificities of the 40 expressed and soluble putative diaphorase enzymes. Expressed and soluble EREDs NADH NADPH Expressed and soluble EREDs NADH NADPH DIA(001) + + + + + + + + + + DIA(021) + + + + + + DIA(002) + + + + + + + + DIA(022) + + + + + + DIA(003) + + + + + DIA(023) + + + + + + DIA(004) + + + + + + + + DIA(024) + + + + + + + DIA(005) + + DIA(025) + + + + + + + + + DIA(006) + + + + + + + + + + DIA(026) + + + + + + DIA(007) + + + + + DIA(027) + + + + + + + DIA(008) + + + + + + + + + DIA(028) + + + + + + + DIA(009) + + + + + + + + DIA(029) + + + + + + + + DIA(010) + + + DIA(030) + + + + + + DIA(011) + + + + + + + + DIA(031) + + + + + + DIA(012) + + + + + + + + + DIA(032) + + + + + + + DIA(013) --DIA(033) + + + + + + + + + DIA(014) + + + + + + DIA(034) + + + + + + + DIA(015) + + + + DIA(035) + + + + + + + DIA(016) --DIA(036) + + + + + + + DIA(017) + + + DIA(037) + + + + + + + + DIA(018) --DIA(038) + + + + + + DIA(019) --DIA(039) + + + + + + + + + DIA(020) + + + + + + + DIA(040) + + + + + + + + + Activity score: [-], not detectable after 20 min; [+], pale pink after 20 min; [+ +], pink after 20 min; [+ + +], strong pink after 20 min; [+ + + +], red after 20 min; [+ + + + +], red instantaneously after mixing. The assays for all enzymes that scored [+ + + + +] were repeated for confirmation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.2.">PRO-Diaphoase-001 kinetics</head><p>Further characterisation was undertaken to determine Michaelis-Menten kinetics of PRO-DIA-001.</p><p>Kinetic parameters were determined by following formation of INT-formazan production at λ= 490 nm.</p><p>A stock solution of INT was made up in buffer to 1 mg/ml, and diluted to a final concentration of 0.25 mg/ml. 8 different concentrations of NADPH were examined from 0.1 mM, 0.2 mM, 0.5 mM, 1 mM, 2 mM, 5 mM, 10 mM, 20 mM. Diaphorase concentration was diluted to 0.1 mg/ml. Assays were performed in 96-well microtitre plate (path length 0.61cm). Assay was commenced by adding 20 µL of diaphorase. Absorbance was followed at 490 nm over time using a TECAN Infinite M200 spectrophotometer at 30 °C and was used to calculate initial rates. Rate of absorbance was plotted against NADPH concentrations and Michaelis-Menten model was applied to extract Km and Vmax using Graphpad Prism 7.0. Errors on the Km and Kcat values represent a 95% confidence interval based on the standard error from the regression. The KM was calculated to be 3.17 mM ± 0.5186 and the Kcat was calculated to be 0.1498 min -1 ± 0.008107. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.3.">INT-formazan inhibition studies</head><p>In an effort to determine whether the presence of INT-formazan (6) was a factor influencing why certain IREDs failed to perform the oxidative direction in the colorimetric screen (Figure <ref type="figure">2a</ref>). We chose to examine a range of different wells, those which failed to produce a colorimetric change in the oxidative direction wells M16 (pIR-304) and N13 (pIR-325). We also chose an IRED which produces a lower intensity colorimetric change well C15 (pIR-63), and a well A09 (pIR-09) which produced an intense colorimetric change when presented with amine 2b. The negative control (+/-)-pET28a (pIR-375) was also screened. The enzymes were screened under 3 different conditions and the results are highlighted in Table <ref type="table">4</ref>. Table 4.4.2. Results of analytical scale biotransformations to observe if presence INT-formazan affected the overall reaction in both the reductive and oxidative directions. Analytics were determined by GC-FID.</p><p>From conducting these studies it would appear that INT-formazan has little to no-influence on both the rate of amine oxidation and reductive amination. Following 24 hours after the biotransformations in the presence of INT-formazan the red insoluble formazan still remained highlighting the IREDs were unable to oxidise the INT back to the colourless solution.</p><p>Enzyme Condition A. Conv. (%) Condition B Conv. (%) Condition C Conv. (%) Condition D Conv. (%) pIR-09 23% 4% &gt;99% &gt;99% pIR-63 &lt;1% &lt;1% 70% 99% pIR-304 12% 5% 94% &gt;99% pIR-325 3% 2% 77% 98% pIR-375 0% 0% 0% 0%</p><p>In some of IREDy-to-go screens strong reduction was encountered around the periphery of the plate. In the screening of pramipexole and columns 1/24, and rows A/P have a higher average compared to the central portion of the plate. The average of column 1 was 0.3527625, whereas column 14 had an average of 0.255393749. The source of the problem is likely due to unequal heat transfer; however the same issue was not encountered in other screens incubated at the same temperature. Additionally, following optimisation on 384-scale we proposed the optimal temperature for the assay was 30°C see section 4.1, for a maximum period of 24 hours. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.5.">Investigation into members of panel which produce 'false-positives' from the IREDy-to-go screen.</head><p>When carrying out initial 384 colorimetric screens it was noticeable that 9 wells (B2, D8, H21, I2, I7, K16 O1, O8, P17) from the blank consistently turned pink when no amine was present, this was determined following several blank screens . It was suspected that these enzymes could be reducing INT to INT-formazan, but it was unclear what compound was being oxidised. Following purification of these 9 enzymes initial colorimetric screens were repeated (data not shown). A colorimetric change was still observed even when no amine substrate was present and in the presence of NADP + . As the enzymes were purified in TRIS, the most likely source of substrate to be oxidised was the TRIS.</p><p>Expanding on the idea that these enzymes could be performing TRIS oxidation whilst simultaneously reducing INT, IR-189 and IR-377 were purified in a TRIS-free system. IR-189 and 377 out of the 9 had the most rapid colorimetric change. Performing further colorimetric screens as well analytical analysis gained further insight into the reaction. Various controls in the colorimetric screening were</p><p>&lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.2263 0.2412 0.2249 0.2186 0.2115 0.203 0.1815 0.1975 0.1925 0.1926 0.2287 0.171 0.1845 0.1866 0.1976 0.1856 0.1899 0.1949 0.2962 0.231 0.251 0.2502 0.2366 0.2594 B 0.2311 0.2355 0.1655 0.2249 0.2349 0.2261 0.1845 0.2013 0.2007 0.1916 0.1877 0.1885 0.1948 0.1924 0.1947 0.1937 0.1957 0.1899 0.2486 0.2401 0.2465 0.2411 0.2476 0.2462 C 0.2333 0.2338 0.2349 0.232 0.2216 0.2247 0.1904 0.198 0.1977 0.1959 0.195 0.1953 0.1928 0.1872 0.1924 0.192 0.2005 0.1924 0.2357 0.2195 0.2283 0.2284 0.2395 0.2498 D 0.2334 0.2299 0.2261 0.2188 0.2138 0.2232 0.2114 0.2169 0.2058 0.194 0.1706 0.1803 0.1675 0.2027 0.1916 0.1871 0.1912 0.1879 0.2331 0.2248 0.2178 0.2387 0.2415 0.2448 E 0.2084 0.2148 0.2251 0.2157 0.223 0.2153 0.1956 0.2049 0.2066 0.1869 0.1928 0.1696 0.1728 0.1501 0.1699 0.1937 0.199 0.1822 0.2241 0.2136 0.2234 0.2333 0.2371 0.235 F 0.2168 0.2316 0.2075 0.2208 0.2111 0.208 0.1646 0.1957 0.1846 0.1615 0.1506 0.1735 0.1496 0.1808 0.1841 0.1877 0.1784 0.2067 0.2403 0.2413 0.2276 0.2459 0.2392 0.2462 G 0.2126 0.2157 0.2202 0.2195 0.2257 0.2173 0.1873 0.1848 0.1768 0.1695 0.1786 0.1766 0.1874 0.1795 0.1988 0.1874 0.2051 0.1812 0.2332 0.2174 0.2188 0.24 0.2713 0.2248 H 0.2048 0.2107 0.2099 0.218 0.2243 0.2331 0.1893 0.1634 0.1868 0.2196 0.1798 0.1885 0.1872 0.1476 0.1854 0.1816 0.184 0.1554 0.2345 0.2539 0.3714 0.2233 0.2397 0.2276 I 0.1978 0.2137 0.2142 0.2098 0.2048 0.2011 0.1965 0.1759 0.1757 0.171 0.1683 0.1768 0.1728 0.163 0.1764 0.1861 0.1928 0.1868 0.2252 0.222 0.2142 0.2262 0.2352 0.2263 J 0.2017 0.2073 0.1961 0.2391 0.2018 0.2093 0.173 0.1814 0.1728 0.179 0.1765 0.2 0.1978 0.1714 0.2037 0.1953 0.1911 0.1865 0.2308 0.2193 0.2034 0.2248 0.2312 0.2324 K 0.2078 0.1996 0.2101 0.1997 0.2153 0.1859 0.1785 0.1704 0.1888 0.1665 0.1821 0.1792 0.1736 0.1754 0.1865 0.2072 0.1894 0.1735 0.226 0.1933 0.2189 0.2212 0.2353 0.2348 L 0.2017 0.212 0.2051 0.2046 0.2164 0.1956 0.1799 0.1572 0.1811 0.1686 0.1829 0.1859 0.1901 0.1782 0.1821 0.1821 0.1882 0.1736 0.2081 0.2061 0.2239 0.24 0.2281 0.2363 M 0.2008 0.2082 0.2096 0.2124 0.2197 0.2126 0.1679 0.1884 0.1781 0.1798 0.1804 0.1736 0.2127 0.1859 0.1747 0.1885 0.1966 0.1888 0.2229 0.2195 0.2259 0.2224 0.2255 0.2403 N 0.2067 0.2107 0.2059 0.2173 0.2 0.2066 0.1695 0.1633 0.1774 0.1745 0.1671 0.1593 0.1689 0.1704 0.1788 0.1951 0.192 0.1921 0.2321 0.2235 0.2142 0.2119 0.2267 0.2299 O 0.2447 0.19 0.2091 0.1882 0.19 0.1741 0.1813 0.1853 0.1777 0.1608 0.168 0.1635 0.1787 0.1452 0.1807 0.1913 0.1786 0.1583 0.2209 0.2114 0.2099 0.2134 0.2305 0.2327 P 0.1899 0.1887 0.1799 0.1731 0.1943 0.1877 0.1666 0.1657 0.1787 0.1668 0.1696 0.1697 0.2307 0.184 0.1695 0.1823 0.284 0.1874 0.2439 0.2084 0.2215 0.2267 0.233 0.2439 implemented and the results of this clearly suggested that these enzymes are capable of oxidising TRIS and reducing INT (Figure 4.4.3). Comparing condition C with condition B the results clearly suggest that the enzyme is capable of performing both reactions, as condition B lacks any substrate to be oxidised. Condition A would indicate that the biocatalyst is capable of reducing the INT to INTformazan when the reduced co-factor is present however is unable to do so in condition B. The purified </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.">Definition and Criteria of IREDy-to-go hits</head><p>In this study to clearly assign a hit from the screening data which is displayed in Figure <ref type="figure">2a</ref> 3 (main text)</p><p>for the oxidation of compound 2, we used the following formula based on the absorbance data at 490 nm taken from the assay plate at 24 hours (X) and blank plate at 24 hours (Y). Using Formula A then followed by Formula B (also given as COUNTIFS function) to determine the number of hits from the screen. Both the assay plate and the blank were run under the exact same conditions (see SIsection).</p><p>Formula A:</p><p>(+/-)'()*+(,-./(') = 12,3/ 4 -12,3/ (5)</p><p>Formula B (COUNTIFS): c) The generation of the normalised absorbance minus the absorbance from the blank following Formula A presented in 384-well format. d)</p><p>Generation of the number of hits using Formula B using the absorbance from Formula A.</p><p>&lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.56 2.14 2.23 2.16 0.56 2.17 1.26 2.30 2.19 0.58 0.42 2.12 2.17 0.65 0.53 2.32 1.38 0.53 0.66 2.42 0.45 0.51 2.07 0.56 B 0.52 0.61 0.66 0.43 0.65 0.39 2.15 0.42 2.08 0.41 0.38 0.40 0.49 0.43 0.53 0.49 0.62 0.42 0.46 2.19 1.98 0.59 0.48 0.94 C 0.87 1.90 0.56 0.55 0.48 0.46 2.00 0.42 2.27 2.12 0.59 0.39 0.52 1.18 0.47 0.55 0.63 0.52 0.57 0.79 0.47 0.45 0.51 0.61 D 1.98 1.65 0.47 0.45 0.47 0.86 2.14 0.68 0.40 0.87 0.66 0.45 2.37 0.64 0.52 2.18 2.06 1.56 0.46 0.49 0.42 0.63 0.61 0.50 E 2.04 0.39 0.46 0.48 0.38 0.52 0.46 2.19 0.66 0.71 0.95 0.53 0.71 0.71 0.42 2.19 0.42 2.29 0.46 0.42 2.36 0.43 0.12 0.62 F 2.07 0.91 0.37 0.43 0.91 0.43 0.45 2.26 1.32 0.48 0.35 0.36 0.41 0.48 0.44 0.38 0.44 0.62 0.47 0.47 0.49 0.47 0.89 0.62 G 0.43 2.11 0.47 2.24 0.50 0.39 0.74 0.43 0.33 0.44 0.51 0.36 0.40 0.40 0.46 0.67 0.41 0.34 0.42 0.52 0.40 0.43 0.58 0.49 H 0.63 0.43 0.57 0.88 0.44 0.86 0.48 0.36 0.38 0.43 0.42 0.40 0.63 0.36 0.74 0.46 0.45 2.26 0.45 0.73 1.01 0.41 0.52 0.53 I 0.52 0.52 0.40 0.45 0.42 0.61 0.57 0.40 1.69 2.28 0.36 0.36 0.44 2.08 2.23 0.47 0.45 0.39 0.43 0.47 0.47 0.50 0.54 0.57 J 0.50 0.45 0.45 0.54 0.55 0.42 2.28 0.57 0.59 0.39 0.38 0.85 0.44 0.39 0.47 0.41 0.45 1.94 0.46 0.48 0.43 1.47 0.69 0.55 K 2.08 0.52 0.51 0.44 0.53 2.21 0.40 0.51 0.44 0.41 0.42 0.40 0.45 0.35 0.41 0.53 0.44 2.34 0.39 0.45 0.53 0.50 0.50 0.55 L 0.61 0.47 0.47 0.47 0.49 0.41 0.47 0.41 0.47 0.39 0.44 0.47 0.42 0.41 0.46 0.50 0.51 0.47 0.40 0.44 0.50 0.55 0.50 0.66 M 0.55 0.50 0.57 0.47 0.60 0.43 0.85 0.46 0.41 0.42 0.44 0.44 0.43 0.43 0.42 0.44 0.47 0.44 0.63 0.55 0.47 2.16 0.52 0.57 N 0.51 0.61 0.55 0.48 0.43 0.45 0.47 0.51 0.41 0.45 0.46 0.45 0.43 0.50 0.52 0.60 0.48 0.46 0.46 0.47 0.50 0.49 0.47 0.55 O 1.04 0.47 0.57 0.53 0.47 0.40 0.49 0.64 0.49 0.53 0.44 0.48 0.45 0.42 1.96 0.46 0.44 0.41 1.83 1.85 0.56 1.20 0.55 1.56 P 1.65 0.49 0.66 0.45 0.43 0.44 0.51 0.44 0.47 0.50 0.53 0.48 0.59 1.22 0.50 0.48 1.70 0.47 0.57 0.45 0.50 0.45 0.60 0.49 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.37 0.38 0.38 0.36 0.43 0.36 0.39 0.47 0.43 0.42 0.40 0.39 0.42 0.39 0.48 0.42 0.44 0.42 0.46 0.38 0.43 0.42 0.42 0.44 B 0.37 0.53 0.40 0.35 0.42 0.38 0.39 0.39 0.37 0.39 0.40 0.40 0.41 0.41 0.40 0.41 0.45 0.43 0.42 0.40 0.42 0.43 0.44 0.41 C 0.39 0.38 0.35 0.39 0.40 0.41 0.39 0.41 0.37 0.42 0.42 0.43 0.47 0.41 0.41 0.43 0.44 0.42 0.40 0.40 0.41 0.45 0.44 0.42 D 0.36 0.37 0.34 0.38 0.36 0.39 0.38 0.46 0.36 0.43 0.36 0.38 0.43 0.44 0.38 0.40 0.43 0.44 0.41 0.38 0.40 0.42 0.43 0.41 E 0.37 0.35 0.35 0.37 0.34 0.38 0.38 0.38 0.39 0.36 0.42 0.39 0.42 0.36 0.42 0.39 0.39 0.41 0.40 0.40 0.41 0.41 0.43 0.40 F 0.34 0.35 0.30 0.35 0.34 0.36 0.38 0.37 0.29 0.41 0.36 0.49 0.28 0.41 0.45 0.41 0.44 0.31 0.44 0.45 0.44 0.44 0.41 0.48 G 0.35 0.34 0.33 0.36 0.36 0.35 0.33 0.41 0.38 0.35 0.35 0.38 0.35 0.39 0.43 0.42 0.41 0.39 0.39 0.36 0.43 0.42 0.42 0.40 H 0.36 0.32 0.34 0.32 0.31 0.37 0.32 0.36 0.34 0.38 0.35 0.38 0.45 0.40 0.37 0.41 0.40 0.38 0.43 0.53 1.29 0.40 0.42 0.39 I 0.41 0.54 0.37 0.36 0.35 0.48 0.62 0.41 0.33 0.37 0.37 0.35 0.39 0.38 0.39 0.40 0.43 0.38 0.43 0.41 0.40 0.44 0.41 0.41 J 0.38 0.35 0.46 0.44 0.36 0.35 0.37 0.38 0.39 0.37 0.37 0.36 0.46 0.35 0.40 0.37 0.41 0.41 0.42 0.39 0.36 0.40 0.44 0.41 K 0.40 0.35 0.36 0.37 0.42 0.34 0.41 0.38 0.39 0.42 0.43 0.41 0.43 0.33 0.37 0.58 0.45 0.42 0.42 0.41 0.40 0.40 0.42 0.38 L 0.39 0.39 0.37 0.37 0.38 0.35 0.33 0.35 0.37 0.36 0.44 0.44 0.43 0.40 0.40 0.46 0.47 0.44 0.36 0.42 0.45 0.42 0.43 0.41 M 0.39 0.38 0.40 0.37 0.37 0.36 0.41 0.40 0.43 0.38 0.40 0.41 0.41 0.39 0.40 0.41 0.45 0.39 0.44 0.43 0.43 0.39 0.39 0.42 N 0.38 0.38 0.38 0.40 0.38 0.38 0.45 0.40 0.38 0.36 0.41 0.39 0.42 0.42 0.43 0.49 0.46 0.40 0.41 0.41 0.40 0.41 0.40 0.41 O 0.75 0.33 0.38 0.36 0.36 0.36 0.46 0.56 0.43 0.35 0.39 0.40 0.39 0.37 0.42 0.41 0.39 0.36 0.40 0.40 0.41 0.38 0.42 0.43 P 0.37 0.38 0.37 0.34 0.37 0.35 0.39 0.38 0.37 0.38 0.39 0.37 0.51 0.40 0.39 0.41 1.41 0.40 0.48 0.41 0.41 0.42 0.41 0.40 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.19 1.76 1.86 1.80 0.13 1.81 0.87 1.83 1.76 0.16 0.02 1.73 1.75 0.26 0.05 1.90 0.94 0.12 0.20 2.05 0.02 0.08 1.65 0.11 B 0.14 0.08 0.26 0.08 0.23 0.00 1.76 0.03 1.71 0.02 -0.02 0.00 0.08 0.02 0.13 0.07 0.17 0.00 0.04 1.79 1.55 0.16 0.03 0.52 C 0.48 1.52 0.21 0.16 0.08 0.06 1.61 0.01 1.90 1.70 0.17 -0.05 0.04 0.77 0.05 0.13 0.19 0.11 0.17 0.39 0.06 0.01 0.08 0.19 D 1.62 1.27 0.13 0.07 0.10 0.47 1.76 0.22 0.04 0.44 0.30 0.07 1.94 0.20 0.14 1.77 1.63 1.12 0.05 0.11 0.02 0.21 0.18 0.09 E 1.68 0.04 0.11 0.11 0.04 0.13 0.08 1.81 0.28 0.35 0.53 0.14 0.29 0.35 -0.01 1.81 0.03 1.88 0.07 0.01 1.95 0.03 -0.32 0.22 F 1.73 0.56 0.07 0.08 0.57 0.07 0.07 1.89 1.03 0.07 -0.01 -0.13 0.13 0.06 -0.01 -0.03 0.01 0.31 0.03 0.03 0.05 0.03 0.48 0.15 G 0.08 1.77 0.15 1.88 0.14 0.05 0.40 0.03 -0.06 0.09 0.16 -0.02 0.05 0.01 0.02 0.25 0.01 -0.05 0.03 0.16 -0.02 0.01 0.16 0.10 H 0.27 0.11 0.23 0.56 0.12 0.49 0.16 0.00 0.04 0.05 0.07 0.02 0.18 -0.03 0.37 0.04 0.05 1.89 0.02 0.20 -0.28 0.01 0.10 0.14 I 0.10 -0.02 0.04 0.09 0.07 0.13 -0.04 -0.01 1.35 1.91 -0.01 0.01 0.05 1.71 1.83 0.07 0.02 0.01 0.00 0.06 0.07 0.06 0.12 0.16 J 0.12 0.10 0.00 0.09 0.18 0.07 1.91 0.18 0.20 0.01 0.01 0.49 -0.02 0.04 0.07 0.04 0.03 1.54 0.04 0.09 0.07 1.07 0.26 0.14 K 1.68 0.17 0.15 0.07 0.11 1.87 -0.01 0.14 0.05 -0.01 -0.01 -0.01 0.02 0.02 0.04 -0.06 -0.01 1.92 -0.02 0.04 0.14 0.10 0.08 0.17 L 0.22 0.08 0.10 0.11 0.11 0.05 0.15 0.06 0.11 0.03 0.01 0.03 -0.01 0.00 0.07 0.03 0.04 0.03 0.04 0.02 0.06 0.13 0.07 0.25 M 0.16 0.12 0.17 0.10 0.23 0.07 0.44 0.06 -0.02 0.04 0.04 0.03 0.02 0.04 0.02 0.03 0.02 0.04 0.19 0.12 0.04 1.77 0.12 0.15 N 0.13 0.23 0.16 0.08 0.05 0.08 0.02 0.11 0.03 0.09 0.05 0.06 0.01 0.08 0.09 0.12 0.02 0.06 0.05 0.05 0.11 0.08 0.06 0.15 O 0.30 0.15 0.19 0.16 0.10 0.04 0.03 0.08 0.06 0.18 0.05 0.08 0.06 0.05 1.54 0.05 0.06 0.05 1.43 1.45 0.15 0.82 0.12 1.13 P 1.28 0.11 0.29 0.11 0.07 0.09 0.13 0.06 0.09 0.13 0.14 0.12 0.08 0.82 0.10 0.07 0.29 0.08 0.08 0.05 0.08 0.03 0.19 0.09 4.6. Examples of IREDy-to-go screening data. Several examples of 0hr and 24 hr time point of IREDy-to-go assays are given as a reference across a variety of substrates. IREDy-to-go of N,N-Dimethylcyclohexylamine (2f) 0hr 24hr &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.31 0.30 0.31 0.27 0.29 0.28 0.25 0.27 0.27 0.25 0.24 0.25 0.27 0.23 0.29 0.25 0.27 0.24 0.41 0.31 0.32 0.34 0.35 0.33 B 0.26 0.32 0.30 0.26 0.27 0.24 0.25 0.24 0.26 0.24 0.23 0.24 0.27 0.23 0.26 0.26 0.26 0.24 0.29 0.31 0.31 0.33 0.34 0.34 C 0.31 0.29 0.25 0.26 0.25 0.24 0.25 0.23 0.22 0.25 0.24 0.24 0.24 0.17 0.25 0.25 0.24 0.24 0.30 0.31 0.29 0.34 0.34 0.36 D 0.29 0.26 0.29 0.27 0.25 0.26 0.27 0.26 0.25 0.24 0.23 0.24 0.23 0.25 0.25 0.27 0.26 0.25 0.30 0.31 0.31 0.34 0.35 0.34 E 0.26 0.27 0.25 0.28 0.23 0.26 0.21 0.19 0.23 0.24 0.22 0.20 0.21 0.24 0.20 0.26 0.24 0.27 0.28 0.27 0.28 0.27 0.33 0.34 F 0.27 0.28 0.24 0.24 0.24 0.25 0.24 0.25 0.23 0.22 0.19 0.25 0.27 0.21 0.24 0.24 0.24 0.24 0.32 0.30 0.30 0.31 0.33 0.38 G 0.24 0.24 0.25 0.23 0.29 0.22 0.23 0.22 0.27 0.20 0.18 0.20 0.25 0.21 0.26 0.21 0.23 0.20 0.25 0.27 0.29 0.32 0.40 0.35 H 0.25 0.24 0.26 0.23 0.23 0.22 0.24 0.22 0.22 0.21 0.21 0.21 0.23 0.22 0.22 0.22 0.21 0.20 0.25 0.31 0.77 0.30 0.35 0.31 I 0.25 0.28 0.23 0.26 0.23 0.22 0.33 0.22 0.21 0.21 0.20 0.21 0.21 0.22 0.20 0.20 0.22 0.21 0.25 0.26 0.28 0.33 0.31 0.35 J 0.26 0.25 0.25 0.26 0.24 0.23 0.24 0.22 0.22 0.21 0.22 0.23 0.23 0.23 0.23 0.23 0.23 0.24 0.26 0.26 0.27 0.30 0.35 0.33 K 0.21 0.24 0.24 0.23 0.24 0.23 0.21 0.22 0.21 0.22 0.22 0.21 0.22 0.17 0.21 0.23 0.21 0.24 0.25 0.26 0.26 0.31 0.31 0.33 L 0.28 0.23 0.22 0.23 0.23 0.21 0.24 0.21 0.23 0.22 0.23 0.22 0.24 0.22 0.25 0.23 0.24 0.23 0.28 0.26 0.30 0.32 0.29 0.31 M 0.26 0.29 0.25 0.24 0.22 0.21 0.22 0.24 0.22 0.22 0.22 0.24 0.22 0.22 0.21 0.23 0.25 0.23 0.28 0.27 0.30 0.28 0.31 0.31 N 0.26 0.24 0.25 0.23 0.23 0.23 0.23 0.23 0.23 0.22 0.24 0.22 0.22 0.23 0.24 0.24 0.27 0.23 0.28 0.30 0.30 0.31 0.34 0.33 O 0.61 0.24 0.23 0.24 0.23 0.23 0.26 0.34 0.24 0.25 0.24 0.26 0.24 0.24 0.24 0.24 0.24 0.24 0.27 0.30 0.28 0.31 0.33 0.32 P 0.25 0.22 0.28 0.22 0.23 0.22 0.25 0.25 0.25 0.25 0.26 0.26 0.31 0.27 0.28 0.26 0.64 0.26 0.32 0.29 0.32 0.33 0.33 0.36 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.73 0.72 0.57 0.62 0.68 0.68 0.65 0.64 0.75 0.55 0.50 0.55 0.64 0.46 0.51 0.69 0.58 0.39 0.57 0.49 0.58 0.55 1.25 0.65 B 0.49 0.63 0.64 0.57 0.54 0.52 0.51 0.46 0.51 0.56 0.52 0.51 0.52 0.41 0.49 0.46 0.53 0.46 0.43 0.53 0.52 0.67 0.66 0.74 C 0.70 0.60 0.46 0.48 0.43 0.36 0.38 0.36 0.35 0.48 0.44 0.50 0.56 0.46 0.43 0.55 0.47 0.55 0.45 0.48 0.36 0.57 0.64 0.74 D 0.65 0.52 0.48 0.47 0.46 0.45 0.52 1.64 0.45 0.50 0.40 0.42 0.36 0.60 0.41 0.45 0.47 0.60 0.43 0.95 0.48 0.53 0.47 0.66 E 0.66 0.58 0.43 0.48 0.42 0.51 0.44 0.50 0.39 0.46 0.56 0.42 0.38 0.46 0.53 0.51 0.43 0.69 0.40 0.49 1.04 0.43 0.59 0.90 F 0.82 0.58 0.45 0.44 0.41 0.44 0.42 0.51 0.45 0.44 0.57 0.62 0.42 0.46 0.49 0.42 0.46 0.67 0.62 0.64 0.50 0.50 0.72 0.75 G 0.57 0.52 0.40 0.58 0.51 0.33 0.55 0.38 0.55 0.50 0.34 0.39 0.54 0.36 0.32 0.46 0.39 0.44 0.33 0.50 0.41 0.46 0.55 0.63 H 0.66 0.50 0.50 0.47 0.44 0.39 0.51 0.43 0.49 0.38 0.51 0.44 0.60 0.42 0.57 0.39 0.47 0.42 0.53 0.73 2.74 0.55 0.65 0.68 I 0.68 0.79 0.53 0.51 0.54 0.45 1.08 0.50 0.57 0.56 0.47 0.53 0.45 0.61 0.46 0.44 0.52 0.47 0.61 0.47 0.60 0.55 0.63 0.62 J 0.58 0.60 0.58 0.63 0.47 0.39 0.47 0.54 0.57 0.45 0.46 0.55 0.48 0.47 0.43 0.58 0.35 0.49 0.58 0.51 0.46 0.71 0.79 0.72 K 0.15 0.60 0.49 0.44 0.47 0.58 0.46 0.47 0.48 0.44 0.55 0.48 0.49 0.31 0.58 0.56 0.39 0.68 0.51 0.50 0.65 0.51 0.63 0.67 L 0.61 0.57 0.45 0.50 0.43 0.42 0.69 0.42 0.59 0.34 0.42 0.38 0.60 0.36 0.47 0.48 0.52 0.51 0.58 0.52 0.42 0.53 0.53 0.63 M 0.69 0.54 0.59 0.43 0.47 0.34 0.52 0.52 0.45 0.44 0.42 0.61 0.59 0.52 0.58 0.60 0.48 0.58 0.60 0.60 0.57 0.51 0.55 0.64 N 0.59 0.63 0.48 0.53 0.60 0.49 0.60 0.49 0.64 0.55 0.57 0.47 0.54 0.64 0.59 0.72 0.57 0.51 0.50 0.61 0.62 0.51 0.62 0.73 O 2.57 0.55 0.47 0.40 0.47 0.52 0.50 1.51 0.59 0.44 0.46 0.50 0.50 0.47 0.69 0.48 0.53 0.50 0.50 0.54 0.54 0.53 0.66 0.70 P 0.94 0.62 0.58 0.50 0.46 0.42 0.51 0.54 0.46 0.49 0.55 0.52 0.55 0.60 0.46 0.48 3.12 0.49 0.53 0.57 0.59 0.57 0.70 0.75 IREDy-to-go of 2-phenylpiperidine (3). 0hr 24hr &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.39 0.38 0.36 0.29 0.37 0.34 0.32 0.42 0.36 0.39 0.29 0.29 0.79 0.30 0.40 0.33 0.41 0.31 0.73 0.35 0.35 0.31 0.99 0.37 B 0.34 0.45 0.35 0.33 0.36 0.33 0.39 0.30 0.35 0.29 0.30 0.29 0.37 0.31 0.34 0.36 0.35 0.33 0.33 0.38 0.49 0.37 0.42 0.45 C 0.41 0.58 0.31 0.35 0.41 0.31 0.44 0.29 0.31 0.42 0.40 0.34 0.38 0.31 0.42 0.33 0.42 0.32 0.38 0.41 0.36 0.39 0.45 0.41 D 0.44 0.39 0.39 0.34 0.39 0.38 0.36 0.40 0.27 0.34 0.35 0.30 0.34 0.34 0.39 0.42 0.42 0.37 0.37 0.59 0.34 0.41 0.40 0.38 E 0.81 0.36 0.35 0.61 0.33 0.65 0.32 0.56 0.31 0.38 0.50 0.47 0.43 0.51 0.38 0.69 0.33 0.77 0.37 0.32 0.70 0.33 0.40 0.42 F 0.53 0.42 0.29 0.37 0.52 0.37 0.31 0.65 0.43 0.36 0.26 0.38 0.54 0.33 0.41 0.31 0.34 0.37 0.35 0.35 0.43 0.39 0.39 0.49 G 0.34 0.36 0.34 0.75 0.52 0.33 0.34 0.34 0.28 0.32 0.30 0.28 0.37 0.28 0.37 0.36 0.35 0.28 0.38 0.35 0.37 0.39 0.38 0.38 H 0.36 0.31 0.35 0.31 0.33 0.28 0.33 0.31 0.32 0.38 0.35 0.30 0.39 0.35 0.37 0.39 0.32 0.34 0.36 0.46 0.86 0.35 0.32 0.39 I 0.37 0.57 0.30 0.36 0.30 0.33 0.46 0.29 0.41 0.29 0.28 0.30 0.30 0.31 0.30 0.39 0.36 0.39 0.35 0.37 0.36 0.40 0.45 0.37 J 0.35 0.40 0.84 0.39 0.35 0.31 0.29 0.32 0.32 0.29 0.34 0.31 0.36 0.32 0.38 0.32 0.37 0.45 0.37 0.33 0.32 0.41 0.41 0.39 K 0.39 0.35 0.34 0.31 0.37 0.33 0.32 0.33 0.38 0.34 0.34 0.34 0.41 0.29 0.35 0.48 0.37 0.79 0.38 0.39 0.31 0.38 0.41 0.44 L 0.40 0.39 0.35 0.33 0.35 0.30 0.30 0.34 0.32 0.32 0.34 0.35 0.40 0.34 0.40 0.41 0.41 0.40 0.29 0.37 0.42 0.44 0.39 0.42 M 0.39 0.35 0.38 0.34 0.49 0.33 0.37 0.33 0.33 0.32 0.34 0.37 0.35 0.35 0.33 0.31 0.42 0.32 0.41 0.43 0.42 0.38 0.41 0.40 N 0.36 0.36 0.35 0.35 0.40 0.35 0.37 0.37 0.33 0.37 0.34 0.34 0.33 0.37 0.43 0.37 0.38 0.33 0.36 0.36 0.42 0.37 0.38 0.43 O 1.21 0.41 0.41 0.34 0.42 0.34 0.63 0.81 0.56 0.36 0.36 0.41 0.39 0.34 0.37 0.36 0.38 0.32 0.37 0.37 0.38 0.41 0.41 0.37 P 0.65 0.37 0.35 0.37 0.35 0.34 0.40 0.36 0.37 0.38 0.42 0.38 0.60 0.38 0.36 0.38 0.91 0.36 0.48 0.40 0.43 0.43 0.41 0.41 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.65 0.63 0.59 0.34 0.45 0.62 0.39 1.23 1.16 0.62 0.56 0.36 1.72 0.51 0.77 0.40 1.76 0.58 0.52 0.71 0.50 0.46 2.47 0.99 B 0.44 1.16 0.66 0.54 0.49 0.45 2.18 0.36 1.37 0.38 0.41 0.40 0.74 0.51 0.47 0.59 0.52 0.42 0.46 0.64 1.04 0.51 0.69 1.85 C 1.76 1.99 0.64 0.62 0.62 0.50 0.42 0.37 2.22 2.03 0.64 0.44 0.76 1.14 2.18 0.98 1.89 0.67 0.55 2.21 0.52 0.60 0.77 0.83 D 0.80 0.77 0.59 0.49 0.58 1.71 0.84 2.24 0.35 1.27 0.76 0.49 0.91 0.53 0.68 2.20 1.96 2.29 0.51 2.22 0.37 0.74 0.89 0.57 E 2.03 0.64 1.15 1.59 0.86 2.16 0.65 2.09 0.51 2.22 2.20 2.18 1.99 2.14 0.73 2.30 0.38 2.18 0.49 0.75 2.12 0.44 0.60 1.76 F 2.09 1.10 0.83 1.36 2.25 1.78 0.45 2.23 0.62 0.55 0.37 0.56 0.65 2.26 0.60 0.35 0.48 0.57 0.57 0.53 0.57 0.50 0.55 1.00 G 0.53 1.02 0.82 1.80 0.82 2.16 1.18 0.45 0.45 1.56 0.34 0.34 0.45 0.42 0.66 0.46 0.38 0.30 0.40 0.37 0.44 0.51 0.49 0.57 H 0.64 0.47 0.47 1.61 0.90 0.35 0.40 0.36 0.35 0.47 1.73 0.37 0.52 0.37 0.82 0.41 0.33 0.81 0.43 0.83 1.74 0.44 0.41 0.63 I 0.55 0.94 0.94 0.55 0.41 0.80 1.41 0.39 2.13 0.50 0.37 0.35 0.48 0.72 0.42 0.64 0.51 2.03 0.43 0.47 0.63 0.70 0.74 0.64 J 0.53 0.65 0.97 0.65 0.63 0.42 2.02 0.47 0.51 0.36 0.44 0.59 0.54 0.40 0.57 0.38 0.53 2.24 0.50 2.02 0.44 1.13 0.72 0.62 K 0.92 0.61 0.37 0.47 0.42 1.15 0.32 0.50 0.46 0.56 0.38 0.53 0.39 0.39 0.58 0.72 0.37 2.00 0.37 0.56 0.39 0.60 0.59 0.89 L 0.79 0.63 0.54 0.54 0.61 0.46 0.63 0.57 0.47 0.46 0.58 0.70 0.53 0.48 0.68 0.69 0.64 0.58 0.38 0.66 0.74 0.86 0.60 0.81 M 0.75 0.60 0.74 0.45 0.79 0.52 0.57 0.58 0.51 0.45 0.54 0.59 0.52 0.47 0.47 0.41 0.62 0.43 0.83 0.69 0.66 0.56 0.59 0.67 N 0.61 0.65 0.56 0.56 0.61 0.63 0.65 0.63 0.48 0.66 0.57 0.56 0.51 0.62 0.81 0.60 0.57 0.46 0.54 0.53 2.02 0.47 0.56 1.33 O 2.09 0.85 0.76 0.68 1.72 0.56 1.12 2.20 0.66 0.70 0.47 0.70 0.65 0.51 1.38 0.51 0.49 0.43 0.60 0.83 0.72 1.97 0.75 0.54 P 2.12 0.66 0.69 0.70 0.68 0.63 0.78 0.54 0.56 0.69 0.74 0.60 0.82 2.08 0.60 0.54 1.98 0.60 0.72 0.66 1.30 0.68 0.70 0.59 IREDy-to-go of 2-phenylazepane (7). 0hr 24hr &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.36 0.65 0.42 0.55 0.38 0.64 0.63 0.64 0.67 0.39 0.38 0.49 0.68 0.36 0.39 0.58 0.63 0.38 0.53 0.68 0.37 0.82 0.40 0.38 B 0.42 0.45 0.45 0.59 0.38 0.46 0.61 0.37 0.56 0.39 0.38 0.40 0.42 0.34 0.35 0.37 0.33 0.38 0.48 0.60 0.70 0.51 0.42 0.74 C 0.63 0.65 0.45 0.44 0.42 0.41 0.47 0.31 0.63 0.60 0.33 0.31 0.34 0.51 0.53 0.52 0.59 0.37 0.42 0.60 0.42 0.47 0.43 0.48 D 0.58 0.52 0.40 0.43 0.43 0.59 0.58 0.40 0.37 0.45 0.48 0.36 0.39 0.30 0.30 0.70 0.69 0.64 0.37 0.47 0.44 0.49 0.48 0.47 E 0.74 0.37 0.33 0.36 0.38 0.62 0.38 0.57 0.30 0.56 0.61 0.33 0.44 0.54 0.31 0.66 0.30 0.60 0.33 0.45 0.71 0.43 0.35 0.72 F 0.70 0.53 0.61 0.52 0.70 0.53 0.31 0.61 0.39 0.29 0.25 0.29 0.26 0.39 0.29 0.28 0.31 0.32 0.33 0.37 0.37 0.46 0.49 0.48 G 0.33 0.36 0.44 0.68 0.37 0.42 0.54 0.31 0.23 0.29 0.34 0.26 0.21 0.26 0.29 0.27 0.27 0.27 0.35 0.36 0.44 0.47 0.46 0.43 H 0.34 0.40 0.31 0.50 0.34 0.31 0.23 0.28 0.25 0.24 0.38 0.31 0.26 0.29 0.47 0.29 0.24 0.61 0.33 0.34 0.50 0.33 0.43 0.40 I 0.38 0.41 0.41 0.36 0.31 0.38 0.30 0.31 0.55 0.32 0.22 0.28 0.25 0.49 0.27 0.27 0.28 0.38 0.30 0.33 0.44 0.46 0.40 0.41 J 0.34 0.35 0.31 0.45 0.40 0.33 0.49 0.30 0.29 0.25 0.25 0.39 0.26 0.38 0.29 0.30 0.27 0.52 0.33 0.61 0.32 0.37 0.37 0.47 K 0.37 0.40 0.37 0.27 0.36 0.54 0.30 0.33 0.26 0.29 0.28 0.29 0.28 0.31 0.31 0.30 0.27 0.63 0.29 0.38 0.40 0.43 0.47 0.38 L 0.37 0.45 0.43 0.39 0.43 0.39 0.35 0.21 0.34 0.31 0.34 0.35 0.30 0.30 0.30 0.32 0.27 0.29 0.28 0.48 0.48 0.40 0.54 0.41 M 0.44 0.38 0.40 0.38 0.30 0.40 0.37 0.40 0.37 0.38 0.39 0.44 0.36 0.30 0.29 0.30 0.31 0.28 0.47 0.44 0.39 0.54 0.44 0.41 N 0.38 0.48 0.46 0.45 0.35 0.41 0.31 0.35 0.29 0.36 0.35 0.32 0.39 0.35 0.30 0.34 0.34 0.29 0.44 0.39 0.64 0.51 0.43 0.64 O 0.35 0.45 0.42 0.40 0.40 0.38 0.31 0.36 0.30 0.34 0.25 0.29 0.37 0.36 0.35 0.38 0.54 0.28 0.47 0.47 0.51 0.74 0.41 0.49 P 0.67 0.38 0.39 0.60 0.41 0.37 0.35 0.30 0.37 0.40 0.40 0.31 0.35 0.60 0.30 0.40 0.50 0.48 0.40 0.37 0.55 0.39 0.50 0.46 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 1.19 1.57 0.91 1.53 0.73 1.45 1.22 1.37 1.40 0.48 0.57 1.28 1.31 0.47 0.46 1.33 1.31 0.46 0.67 1.57 0.64 1.66 0.67 0.87 B 0.59 0.66 0.74 1.34 0.62 0.60 1.41 0.50 1.45 0.48 0.47 0.48 0.93 0.41 0.49 0.46 0.52 0.56 0.60 1.53 1.49 0.72 0.63 1.73 C 1.51 1.44 0.69 0.65 0.59 0.53 1.25 0.50 1.62 1.50 0.47 0.46 0.54 1.40 1.45 1.45 1.52 1.33 0.53 1.59 0.52 0.61 0.56 0.81 D 1.40 1.07 0.64 0.62 0.54 1.50 1.53 0.78 0.62 1.23 0.76 1.43 0.94 0.47 0.41 1.62 1.55 1.59 0.50 0.70 0.58 1.33 0.62 0.86 E 1.49 0.68 0.61 0.65 0.65 1.49 1.28 1.39 1.19 1.45 1.62 0.59 1.35 1.46 0.75 1.56 0.59 1.55 0.56 0.74 1.65 0.66 0.56 1.40 F 1.40 1.39 1.52 1.42 1.43 1.55 0.50 1.60 1.00 0.43 0.44 0.44 0.46 1.36 0.39 0.39 0.42 0.50 0.47 0.55 0.47 0.60 0.93 0.73 G 0.55 0.70 0.94 1.51 0.70 1.21 1.41 0.43 0.44 1.16 1.31 0.36 0.34 0.38 0.37 0.41 0.36 0.35 0.45 0.90 0.54 0.59 0.61 0.68 H 0.68 1.25 0.70 1.54 0.97 0.48 0.42 0.44 0.45 0.41 1.41 0.42 0.41 0.39 1.42 0.38 0.34 1.62 0.43 0.52 1.00 0.48 0.65 1.07 I 0.62 0.73 1.35 0.60 0.54 0.82 0.52 0.48 1.45 1.29 0.36 0.90 0.35 1.33 0.59 0.35 0.51 1.35 0.42 0.43 0.74 0.60 0.59 0.63 J 0.60 0.64 0.63 0.64 0.61 0.50 1.37 0.51 0.53 0.42 0.40 1.45 0.41 1.00 0.41 0.59 0.35 1.47 0.45 1.40 0.45 0.94 0.62 0.72 K 1.11 0.55 0.65 0.42 0.52 1.55 0.52 0.55 0.51 0.44 0.44 0.40 0.42 0.48 1.30 0.45 0.37 1.43 0.45 0.59 0.68 0.67 0.62 0.87 L 1.32 0.75 0.85 0.76 0.77 0.61 0.86 0.39 0.61 0.39 0.50 0.50 0.43 0.38 0.42 0.45 0.39 0.42 0.39 0.66 0.61 0.54 0.62 0.67 M 0.75 0.66 0.69 0.73 0.52 0.57 0.56 0.55 0.50 0.53 0.51 1.35 0.56 0.50 0.43 0.48 0.44 0.45 1.46 0.66 0.52 1.45 0.65 0.67 N 0.67 0.78 0.69 0.66 0.61 0.59 0.48 0.49 0.52 0.50 0.50 0.44 0.74 0.51 0.47 0.57 0.48 0.45 0.55 0.60 1.52 0.68 1.10 1.45 O 1.03 1.25 1.35 0.67 0.55 0.57 0.51 0.76 0.53 0.54 0.41 0.42 0.54 0.52 1.12 0.54 1.34 0.78 1.30 0.97 1.41 1.46 0.92 1.28 P 1.54 1.07 1.26 1.60 0.64 0.58 0.57 0.53 0.69 0.69 0.83 0.49 0.66 1.38 0.48 0.49 1.17 0.76 0.62 0.65 1.35 0.67 0.86 0.66 IREDy-to-go of N-(1-phenylethyl) cyclopropanamine (rac-13b). 0hr 24hr &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.50 0.48 0.48 0.45 0.46 0.50 0.53 0.78 0.53 0.44 0.42 0.43 0.89 0.46 0.47 0.58 0.53 0.46 0.50 0.54 0.52 0.57 0.66 0.57 B 0.50 0.63 0.50 0.42 0.53 0.46 0.54 0.46 0.52 0.45 0.46 0.47 0.44 0.41 0.42 0.46 0.28 0.47 0.53 0.55 0.61 0.60 0.67 0.64 C 0.51 0.79 0.47 0.47 0.45 0.46 0.44 0.46 0.57 0.62 0.50 0.46 0.53 0.46 0.46 0.51 0.54 0.49 0.63 0.55 0.56 0.61 0.63 0.56 D 0.52 0.53 0.44 0.48 0.55 0.54 0.48 0.52 0.45 0.50 0.48 0.48 0.49 0.48 0.45 0.55 0.60 0.57 0.56 0.56 0.54 0.60 0.59 0.61 E 0.92 0.56 0.46 0.47 0.49 0.66 0.48 0.47 0.49 0.46 0.50 0.49 0.48 0.46 0.54 0.85 0.53 0.49 0.50 0.55 0.94 0.60 0.61 0.57 F 0.92 0.53 0.51 0.46 0.51 0.48 0.45 0.48 0.53 0.52 0.46 0.54 0.51 0.51 0.55 0.54 0.55 0.55 0.60 0.60 0.61 0.59 0.67 0.64 G 0.49 0.56 0.51 0.81 0.52 0.51 0.52 0.51 0.52 0.46 0.47 0.47 0.48 0.47 0.49 0.54 0.52 0.53 0.55 0.55 0.50 0.63 0.61 0.57 H 0.52 0.56 0.55 0.50 0.48 0.49 0.44 0.47 0.48 0.50 0.47 0.48 0.53 0.52 0.45 0.49 0.43 0.48 0.58 0.63 1.20 0.58 0.66 0.58 I 0.51 0.66 0.50 0.50 0.53 0.56 0.65 0.48 0.51 0.52 0.48 0.48 0.52 0.51 0.53 0.51 0.55 0.53 0.63 0.56 0.54 0.61 0.58 0.57 J 0.50 0.55 0.55 0.59 0.51 0.48 0.48 0.46 0.52 0.48 0.51 0.58 0.49 0.48 0.49 0.45 0.51 0.50 0.59 0.59 0.53 0.56 0.63 0.66 K 0.53 0.52 0.49 0.49 0.52 0.52 0.48 0.48 0.50 0.53 0.51 0.52 0.53 0.42 0.49 0.65 0.54 0.56 0.52 0.57 0.61 0.59 0.63 0.60 L 0.52 0.57 0.50 0.50 0.47 0.49 0.38 0.43 0.49 0.49 0.48 0.52 0.53 0.53 0.49 0.53 0.54 0.49 0.49 0.60 0.60 0.57 0.63 0.62 M 0.49 0.47 0.56 0.50 0.51 0.46 0.47 0.51 0.52 0.50 0.49 0.54 0.53 0.51 0.50 0.53 0.57 0.52 0.56 0.59 0.62 0.57 0.65 0.61 N 0.50 0.60 0.59 0.56 0.52 0.49 0.49 0.50 0.48 0.51 0.54 0.49 0.48 0.51 0.51 0.53 0.52 0.48 0.57 0.61 0.59 0.62 0.65 0.69 O 0.65 0.50 0.53 0.52 0.45 0.49 0.50 0.66 0.56 0.51 0.54 0.50 0.53 0.53 0.57 0.53 0.54 0.54 0.64 0.66 0.65 0.65 0.67 0.62 P 0.84 0.49 0.51 0.52 0.53 0.51 0.51 0.54 0.52 0.53 0.54 0.51 0.65 0.56 0.51 0.52 1.22 0.57 0.66 0.67 0.63 0.59 0.65 0.67 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.74 0.87 0.63 0.96 0.61 1.54 0.77 2.19 2.32 0.51 0.46 0.81 2.45 0.59 0.57 2.28 1.82 0.50 0.58 0.90 0.62 0.67 2.37 0.77 B 0.68 0.88 0.73 0.69 0.65 0.58 2.30 0.57 1.36 0.55 0.56 0.56 0.64 0.49 0.63 0.60 0.17 0.61 0.64 0.86 1.05 0.87 0.89 0.89 C 0.85 2.38 0.67 0.61 0.58 0.53 0.59 0.52 1.46 2.34 0.64 0.58 0.80 1.17 0.61 0.84 1.33 0.81 0.67 0.69 0.59 0.72 0.78 0.80 D 0.88 0.77 0.73 0.64 1.05 1.21 0.98 1.43 0.62 1.37 0.64 0.59 0.62 0.68 0.58 1.96 2.32 1.80 0.67 0.77 0.66 0.87 0.70 0.74 E 2.38 0.75 0.70 0.66 0.66 2.34 0.64 0.89 0.71 0.75 0.81 0.68 0.66 0.69 0.71 2.37 0.60 0.90 0.62 0.68 2.34 0.71 0.78 1.29 F 2.40 0.97 0.77 0.74 0.98 0.71 0.59 0.85 0.70 0.62 0.66 0.73 0.82 0.85 0.68 0.64 0.69 0.79 0.81 0.81 0.78 0.81 1.11 0.90 G 0.74 1.51 0.83 2.36 0.69 0.66 0.76 0.61 0.73 0.68 0.56 0.56 0.70 0.61 0.57 0.69 0.60 0.59 0.66 0.77 0.56 0.79 0.78 0.74 H 0.84 0.87 0.89 0.89 0.76 0.63 0.65 0.66 0.69 0.60 0.73 0.62 0.77 0.60 0.86 0.59 0.65 1.13 0.72 0.88 2.06 0.91 0.95 0.87 I 0.87 1.07 0.82 0.80 0.73 0.83 1.11 0.65 2.32 1.19 0.65 0.68 0.66 0.94 0.74 0.63 0.70 2.02 0.83 0.72 0.78 0.85 0.82 0.77 J 0.75 0.91 1.06 0.87 0.73 0.62 1.06 0.68 0.73 0.62 0.62 1.32 0.67 0.63 0.63 0.71 0.60 1.14 0.78 1.85 0.73 0.94 1.00 0.92 K 0.93 0.92 0.79 0.71 0.73 1.26 0.64 0.62 0.75 0.64 0.75 0.66 0.65 0.49 0.72 0.86 0.66 2.36 0.72 0.68 0.84 0.75 0.90 0.86 L 0.94 0.90 0.82 0.75 0.66 0.69 0.69 0.58 0.69 0.56 0.59 0.58 0.68 0.57 0.66 0.67 0.71 0.65 0.69 0.76 0.69 0.80 0.77 0.84 M 0.84 0.69 0.90 0.71 0.77 0.55 0.70 0.69 0.63 0.65 0.58 0.74 0.69 0.68 0.74 0.63 0.65 0.69 0.87 0.78 0.78 1.08 0.88 0.89 N 0.77 1.00 0.91 0.82 0.81 0.76 0.76 0.70 0.72 0.72 0.76 0.68 0.72 0.78 0.76 0.84 0.75 0.69 0.76 0.85 1.04 0.82 0.95 1.00 O 1.80 0.85 0.94 0.77 0.79 0.75 0.70 1.44 0.84 0.76 0.79 0.77 0.78 0.75 1.06 0.77 0.83 0.83 2.03 0.97 0.94 2.31 0.96 0.82 P 2.44 0.77 0.87 0.80 0.80 0.79 0.80 0.80 0.74 0.79 0.82 0.78 0.90 1.87 0.77 0.77 2.39 0.80 0.84 0.97 1.00 0.84 0.95 0.84 IREDy-to-go of N-Ally-N-(1-phenylethyl)amine (rac-13e) 0hr 24hr &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.29 0.28 0.25 0.23 0.24 0.23 0.23 0.27 0.27 0.23 0.24 0.25 0.25 0.26 0.31 0.32 0.31 0.28 0.33 0.31 0.38 0.36 0.39 0.36 B 0.30 0.31 0.27 0.22 0.25 0.24 0.23 0.26 0.23 0.26 0.22 0.27 0.27 0.26 0.25 0.31 0.30 0.29 0.31 0.34 0.36 0.38 0.40 0.38 C 0.30 0.28 0.27 0.25 0.26 0.25 0.22 0.26 0.25 0.26 0.27 0.31 0.25 0.28 0.26 0.29 0.27 0.28 0.30 0.32 0.33 0.36 0.39 0.36 D 0.30 0.28 0.26 0.28 0.26 0.24 0.26 0.28 0.27 0.27 0.27 0.26 0.30 0.28 0.26 0.25 0.29 0.29 0.28 0.30 0.33 0.36 0.39 0.37 E 0.30 0.27 0.25 0.25 0.24 0.22 0.28 0.24 0.24 0.22 0.27 0.23 0.27 0.23 0.24 0.29 0.27 0.29 0.27 0.28 0.33 0.33 0.38 0.39 F 0.30 0.28 0.25 0.25 0.23 0.27 0.28 0.28 0.26 0.28 0.24 0.30 0.30 0.29 0.28 0.29 0.29 0.32 0.32 0.34 0.34 0.36 0.36 0.39 G 0.28 0.28 0.26 0.27 0.21 0.24 0.31 0.27 0.26 0.25 0.28 0.26 0.27 0.25 0.28 0.25 0.31 0.28 0.29 0.32 0.33 0.37 0.42 0.37 H 0.28 0.28 0.25 0.25 0.23 0.25 0.27 0.23 0.24 0.28 0.21 0.25 0.28 0.26 0.23 0.28 0.29 0.27 0.27 0.39 0.59 0.34 0.38 0.38 I 0.29 0.27 0.25 0.24 0.25 0.26 0.33 0.25 0.24 0.26 0.27 0.23 0.30 0.25 0.28 0.24 0.25 0.26 0.33 0.32 0.36 0.38 0.42 0.40 J 0.28 0.28 0.33 0.26 0.24 0.19 0.22 0.25 0.27 0.24 0.25 0.24 0.31 0.25 0.27 0.24 0.28 0.26 0.31 0.31 0.34 0.39 0.43 0.43 K 0.31 0.28 0.24 0.22 0.24 0.23 0.27 0.23 0.29 0.26 0.29 0.23 0.27 0.19 0.27 0.28 0.28 0.28 0.32 0.32 0.34 0.37 0.43 0.41 L 0.31 0.30 0.25 0.24 0.26 0.26 0.28 0.24 0.27 0.27 0.31 0.28 0.31 0.26 0.31 0.30 0.31 0.30 0.31 0.33 0.37 0.39 0.43 0.39 M 0.29 0.26 0.27 0.26 0.25 0.25 0.28 0.28 0.30 0.28 0.29 0.29 0.31 0.30 0.27 0.30 0.30 0.33 0.31 0.33 0.39 0.38 0.43 0.41 N 0.28 0.28 0.29 0.27 0.25 0.26 0.31 0.30 0.31 0.31 0.32 0.28 0.32 0.31 0.33 0.35 0.33 0.31 0.35 0.35 0.36 0.40 0.46 0.43 O 0.40 0.30 0.30 0.26 0.25 0.27 0.34 0.37 0.41 0.31 0.33 0.33 0.35 0.33 0.35 0.33 0.32 0.32 0.39 0.39 0.42 0.40 0.44 0.41 P 0.31 0.31 0.34 0.32 0.32 0.32 0.36 0.39 0.38 0.36 0.36 0.36 0.46 0.37 0.37 0.36 0.64 0.37 0.48 0.40 0.41 0.40 0.39 0.44 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.35 0.37 0.34 0.32 0.30 0.34 0.27 0.36 0.35 0.31 0.36 0.45 0.44 0.39 0.42 0.38 0.42 0.37 0.46 0.42 0.44 0.44 0.53 0.41 B 0.34 0.43 0.35 0.25 0.30 0.28 0.31 0.32 0.29 0.33 0.29 0.33 0.34 0.32 0.33 0.42 0.37 0.33 0.36 0.40 0.42 0.47 0.47 0.44 C 0.38 0.41 0.32 0.31 0.31 0.31 0.31 0.31 0.37 0.35 0.37 0.35 0.36 0.35 0.33 0.32 0.34 0.31 0.33 0.35 0.37 0.43 0.44 0.44 D 0.38 0.36 0.33 0.34 0.32 0.31 0.34 0.33 0.31 0.34 0.39 0.32 0.36 0.34 0.32 0.38 0.34 0.30 0.31 0.36 0.34 0.43 0.46 0.47 E 1.39 0.35 0.32 0.30 0.26 0.28 0.37 0.33 0.34 0.33 0.34 0.31 0.35 0.39 0.30 0.55 0.34 0.36 0.33 0.34 1.34 0.36 0.41 1.39 F 1.27 0.40 0.31 0.29 0.28 0.30 0.34 0.35 0.42 0.39 0.30 0.35 0.40 0.38 0.36 0.33 0.34 0.47 0.39 0.43 0.45 0.38 0.41 0.48 G 0.36 0.38 0.36 0.73 0.24 0.29 0.35 0.34 0.32 0.31 0.31 0.32 0.30 0.32 0.34 0.47 0.35 0.31 0.37 0.33 0.37 0.38 0.47 0.43 H 0.37 0.35 0.31 0.29 0.27 0.34 0.36 0.26 0.28 0.36 0.27 0.31 0.39 0.31 0.31 0.34 0.33 0.31 0.39 0.58 0.95 0.38 0.46 0.46 I 0.38 0.37 0.28 0.28 0.30 0.41 0.46 0.31 0.33 0.56 0.33 0.28 0.33 0.35 0.38 0.32 0.34 0.29 0.36 0.37 0.40 0.44 0.49 0.46 J 0.37 0.39 0.37 0.33 0.38 0.30 0.33 0.33 0.31 0.29 0.31 0.29 0.46 0.28 0.32 0.27 0.35 0.34 0.39 0.38 0.39 0.47 0.50 0.54 K 0.44 0.35 0.31 0.27 0.32 0.27 0.31 0.30 0.38 0.31 0.36 0.29 0.34 0.24 0.31 0.36 0.34 0.61 0.35 0.40 0.40 0.45 0.47 0.49 L 0.42 0.41 0.32 0.31 0.34 0.29 0.35 0.33 0.33 0.37 0.42 0.39 0.39 0.36 0.35 0.40 0.41 0.36 0.34 0.41 0.45 0.50 0.50 0.50 M 0.39 0.38 0.37 0.34 0.57 0.37 0.35 0.40 0.44 0.37 0.43 0.38 0.39 0.40 0.34 0.44 0.38 0.43 0.40 0.46 0.44 0.47 0.50 0.49 N 0.40 0.36 0.34 0.34 0.33 0.33 0.39 0.39 0.37 0.40 0.49 0.36 0.40 0.40 0.46 0.48 0.39 0.38 0.41 0.41 0.43 0.46 0.53 0.59 O 0.54 0.40 0.41 0.33 0.32 0.34 0.44 0.45 0.51 0.39 0.42 0.43 0.46 0.39 0.45 0.41 0.38 0.38 0.47 0.47 0.52 0.51 0.57 0.52 P 0.66 0.42 0.46 0.43 0.41 0.43 0.44 0.48 0.50 0.46 0.48 0.45 0.50 0.48 0.47 0.44 1.09 0.47 0.53 0.49 0.51 0.47 0.48 0.50 IREDy-to-go of rasagiline (rac-14d) 0hr 24hr &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.39 0.45 0.45 0.39 0.35 0.45 0.36 0.40 0.41 0.30 0.32 0.40 0.33 0.33 0.29 0.37 0.31 0.30 0.45 0.29 0.27 0.33 0.33 0.34 B 0.33 0.45 0.33 0.29 0.32 0.31 0.31 0.31 0.30 0.27 0.26 0.28 0.26 0.27 0.49 0.37 0.27 0.38 0.28 0.31 0.34 0.35 0.34 0.32 C 0.37 0.38 0.29 0.34 0.32 0.31 0.32 0.28 0.29 0.30 0.32 0.29 0.33 0.28 0.29 0.26 0.28 0.33 0.26 0.35 0.26 0.34 0.32 0.43 D 0.39 0.41 0.40 0.35 0.35 0.34 0.37 0.33 0.25 0.33 0.36 0.41 0.29 0.27 0.32 0.33 0.29 0.30 0.30 0.26 0.26 0.33 0.30 0.34 E 0.42 0.34 0.32 0.32 0.28 0.31 0.29 0.24 0.30 0.28 0.30 0.25 0.30 0.25 0.26 0.28 0.30 0.25 0.32 0.31 0.32 0.42 0.27 0.31 F 0.32 0.33 0.26 0.34 0.28 0.31 0.26 0.28 0.32 0.44 0.27 0.26 0.34 0.32 0.31 0.33 0.25 0.29 0.22 0.22 0.28 0.28 0.29 0.28 G 0.31 0.30 0.30 0.31 0.24 0.21 0.25 0.26 0.20 0.25 0.23 0.22 0.19 0.19 0.23 0.21 0.28 0.26 0.26 0.22 0.30 0.35 0.33 0.29 H 0.33 0.29 0.27 0.29 0.30 0.29 0.25 0.23 0.22 0.24 0.21 0.34 0.25 0.24 0.22 0.24 0.30 0.22 0.33 0.31 0.31 0.25 0.29 0.29 I 0.36 0.34 0.38 0.27 0.24 0.28 0.22 0.30 0.23 0.32 0.19 0.22 0.25 0.23 0.31 0.32 0.43 0.25 0.23 0.29 0.29 0.32 0.31 0.40 J 0.37 0.57 0.36 0.40 0.31 0.32 0.34 0.28 0.24 0.22 0.25 0.28 0.31 0.25 0.34 0.25 0.32 0.36 0.26 0.32 0.38 0.30 0.28 0.39 K 0.30 0.32 0.27 0.24 0.28 0.20 0.27 0.29 0.29 0.26 0.24 0.27 0.36 0.24 0.23 0.24 0.26 0.26 0.25 0.24 0.23 0.24 0.41 0.38 L 0.33 0.38 0.36 0.36 0.30 0.31 0.38 0.25 0.26 0.26 0.26 0.30 0.30 0.27 0.30 0.41 0.27 0.25 0.49 0.27 0.27 0.31 0.34 0.33 M 0.37 0.42 0.41 0.30 0.27 0.26 0.33 0.28 0.29 0.29 0.23 0.26 0.30 0.28 0.24 0.27 0.31 0.26 0.25 0.28 0.29 0.33 0.34 0.37 N 0.36 0.41 0.40 0.34 0.26 0.31 0.31 0.36 0.34 0.28 0.25 0.27 0.41 0.31 0.34 0.30 0.29 0.46 0.29 0.30 0.30 0.32 0.34 0.41 O 0.43 0.32 0.36 0.38 0.36 0.31 0.38 0.31 0.44 0.34 0.26 0.30 0.29 0.31 0.29 0.35 0.31 0.27 0.34 0.30 0.35 0.34 0.34 0.31 P 0.41 0.44 0.32 0.33 0.36 0.37 0.41 0.31 0.35 0.36 0.37 0.34 0.41 0.40 0.40 0.38 0.44 0.39 0.34 0.34 0.35 0.36 0.34 0.36 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.62 1.09 1.03 1.08 0.58 1.08 0.59 1.21 1.15 0.44 0.44 1.19 1.13 0.41 0.38 1.12 0.80 0.41 0.60 0.57 0.37 0.42 0.88 0.61 B 0.42 0.66 0.52 0.44 0.52 0.44 1.02 0.42 1.11 0.37 0.38 0.40 0.37 0.38 0.63 0.47 0.41 0.49 0.34 0.60 1.08 0.50 0.51 0.68 C 0.71 1.09 0.49 0.45 0.41 0.40 0.41 0.38 0.55 0.94 0.41 0.38 0.45 0.74 0.37 0.37 0.37 0.47 0.34 0.41 0.34 0.53 0.41 0.65 D 0.61 0.59 0.52 0.45 0.43 0.52 1.12 0.68 0.35 0.49 0.44 0.50 0.38 0.39 0.44 1.09 0.47 0.46 0.37 0.35 0.33 0.42 0.38 0.47 E 0.77 0.53 0.44 0.42 0.36 0.42 0.39 0.40 0.38 0.36 0.46 0.35 0.39 0.36 0.38 0.48 0.38 0.51 0.39 0.40 1.08 0.58 0.39 1.05 F 1.03 0.48 0.37 0.42 0.39 0.42 0.35 0.48 0.76 0.54 0.37 0.39 0.55 0.43 0.38 0.43 0.34 0.45 0.33 0.35 0.36 0.39 0.43 0.44 G 0.47 0.49 0.40 0.99 0.34 0.32 0.54 0.35 0.29 0.35 0.34 0.29 0.28 0.28 0.29 0.33 0.37 0.35 0.33 0.36 0.36 0.44 0.44 0.43 H 0.59 0.61 0.42 1.07 0.39 0.40 0.36 0.31 0.32 0.30 0.30 0.42 0.38 0.35 0.82 0.30 0.38 0.36 0.42 0.43 0.75 0.34 0.42 0.46 I 0.57 0.66 0.53 0.39 0.35 0.40 0.37 0.41 0.32 1.11 0.28 0.34 0.35 0.68 1.10 0.42 0.56 0.35 0.34 0.38 0.44 0.40 0.43 0.58 J 0.60 0.83 0.74 0.55 0.41 0.40 1.14 0.45 0.37 0.30 0.34 1.00 0.40 0.34 0.42 0.30 0.41 0.48 0.38 0.41 0.46 0.37 0.43 0.61 K 0.55 0.47 0.46 0.34 0.40 0.35 0.38 0.41 0.36 0.36 0.33 0.36 0.49 0.33 0.32 0.34 0.36 1.12 0.32 0.33 0.38 0.32 0.58 0.62 L 0.58 0.58 0.58 0.53 0.39 0.42 0.58 0.35 0.38 0.37 0.37 0.40 0.41 0.35 0.39 0.53 0.35 0.36 0.58 0.36 0.34 0.39 0.43 0.48 M 0.61 0.62 0.71 0.42 0.37 0.37 0.43 0.39 0.40 0.39 0.33 0.38 0.43 0.41 0.35 0.36 0.43 0.38 0.86 0.43 0.38 1.11 0.45 0.58 N 0.60 0.69 0.58 0.48 0.41 0.42 0.45 0.48 0.47 0.42 0.36 0.40 0.53 0.47 0.45 0.47 0.39 0.57 0.38 0.42 0.45 0.42 0.46 1.03 O 0.99 0.53 0.62 0.60 0.56 0.47 0.57 0.62 0.63 0.52 0.40 0.43 0.44 0.44 0.42 0.49 0.51 0.42 1.16 0.42 0.60 0.56 0.51 0.49 P 1.13 0.76 0.54 0.57 0.56 0.60 0.62 0.51 0.54 0.57 0.59 0.53 0.64 0.70 0.58 0.56 1.14 0.56 0.53 0.56 0.53 0.53 0.58 0.56 IREDy-to-go of ethyl 3-(cyclopropylamino)butanoate hydrochloride (rac-27b) 0hr 24hr IREDy-to-go of ethyl 2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride (rac-28b) &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.31 0.32 0.32 0.28 0.31 0.29 0.29 0.33 0.32 0.29 0.28 0.28 0.30 0.27 0.35 0.35 0.32 0.28 0.40 0.33 0.35 0.32 0.37 0.36 B 0.31 0.36 0.34 0.29 0.30 0.30 0.30 0.31 0.30 0.30 0.29 0.32 0.31 0.31 0.29 0.35 0.33 0.32 0.35 0.36 0.38 0.39 0.36 0.37 C 0.33 0.35 0.33 0.32 0.32 0.31 0.32 0.32 0.30 0.32 0.35 0.33 0.38 0.33 0.33 0.33 0.35 0.34 0.38 0.36 0.35 0.35 0.37 0.38 D 0.33 0.33 0.32 0.31 0.32 0.31 0.34 0.36 0.29 0.31 0.32 0.30 0.46 0.33 0.33 0.32 0.33 0.40 0.35 0.34 0.34 0.37 0.38 0.38 E 0.30 0.35 0.31 0.32 0.29 0.30 0.34 0.36 0.32 0.33 0.34 0.34 0.36 0.28 0.32 0.34 0.34 0.36 0.32 0.30 0.38 0.33 0.39 0.39 F 0.33 0.35 0.29 0.29 0.30 0.31 0.33 0.37 0.33 0.33 0.30 0.39 0.32 0.34 0.36 0.32 0.35 0.34 0.35 0.36 0.36 0.39 0.38 0.42 G 0.33 0.35 0.31 0.29 0.29 0.30 0.34 0.33 0.33 0.28 0.33 0.30 0.33 0.30 0.35 0.31 0.35 0.34 0.36 0.34 0.36 0.38 0.39 0.37 H 0.33 0.32 0.30 0.28 0.24 0.30 0.31 0.31 0.28 0.32 0.28 0.31 0.37 0.29 0.30 0.33 0.26 0.32 0.32 0.37 0.81 0.35 0.40 0.40 I 0.36 0.50 0.29 0.31 0.30 0.33 0.51 0.28 0.30 0.30 0.32 0.28 0.34 0.32 0.34 0.28 0.32 0.28 0.37 0.34 0.39 0.37 0.39 0.40 J 0.33 0.32 0.38 0.36 0.30 0.30 0.35 0.31 0.35 0.31 0.34 0.30 0.37 0.30 0.36 0.34 0.33 0.35 0.40 0.34 0.33 0.61 0.41 0.40 K 0.51 0.34 0.29 0.28 0.32 0.31 0.33 0.34 0.32 0.32 0.33 0.33 0.34 0.30 0.34 0.52 0.34 0.37 0.36 0.34 0.36 0.38 0.39 0.40 L 0.35 0.39 0.30 0.32 0.32 0.32 0.28 0.31 0.32 0.35 0.36 0.35 0.37 0.36 0.37 0.37 0.37 0.37 0.33 0.38 0.40 0.37 0.40 0.41 M 0.34 0.36 0.35 0.33 0.38 0.32 0.38 0.33 0.37 0.34 0.38 0.35 0.38 0.37 0.36 0.35 0.39 0.37 0.39 0.37 0.41 0.36 0.40 0.43 N 0.33 0.37 0.34 0.31 0.33 0.33 0.36 0.37 0.33 0.35 0.36 0.34 0.36 0.39 0.36 0.40 0.38 0.34 0.37 0.37 0.39 0.35 0.40 0.45 O 0.79 0.34 0.35 0.34 0.33 0.34 0.44 0.69 0.47 0.34 0.38 0.37 0.38 0.35 0.67 0.40 0.34 0.36 0.46 0.55 0.40 0.40 0.44 0.45 P 0.37 0.37 0.36 0.35 0.36 0.36 0.38 0.42 0.42 0.39 0.40 0.40 0.44 0.40 0.38 0.39 0.99 0.38 0.46 0.42 0.40 0.40 0.42 0.45 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.47 0.52 0.41 0.38 0.39 0.37 0.33 0.40 0.76 0.37 0.34 0.37 0.37 0.38 0.37 0.78 0.37 0.40 0.46 0.47 0.39 0.39 0.47 0.46 B 0.37 0.49 0.49 0.37 0.38 0.33 0.35 0.33 0.41 0.34 0.33 0.35 0.34 0.33 0.34 0.37 0.39 0.34 0.36 0.42 0.43 0.46 0.42 0.50 C 0.47 0.46 0.40 0.41 0.36 0.35 0.36 0.34 0.39 0.36 0.39 0.36 0.47 0.37 0.38 0.39 0.39 0.38 0.39 0.38 0.37 0.40 0.43 0.51 D 0.48 0.45 0.40 0.38 0.35 0.36 0.39 0.77 0.33 0.35 0.40 0.35 1.97 0.40 0.39 0.37 0.38 0.70 0.37 0.43 0.37 0.41 0.42 0.50 E 0.40 0.49 0.38 0.38 0.31 0.37 0.38 0.88 0.37 0.37 0.64 0.42 0.40 0.32 0.37 0.38 0.36 1.15 0.36 0.34 1.30 0.38 0.46 0.77 F 0.47 0.48 0.36 0.33 0.33 0.33 0.35 0.90 0.40 0.39 0.35 0.44 0.36 0.39 0.39 0.34 0.38 0.45 0.40 0.44 0.41 0.44 0.48 0.56 G 0.48 0.54 0.38 0.36 0.35 0.31 0.36 0.35 0.41 0.31 0.33 0.33 0.36 0.33 0.36 0.38 0.36 0.34 0.37 0.37 0.37 0.41 0.43 0.48 H 0.54 0.44 0.41 0.33 0.28 0.34 0.36 0.36 0.34 0.35 0.34 0.35 0.46 0.33 0.37 0.35 0.31 0.35 0.36 0.52 1.15 0.40 0.48 0.56 I 0.51 0.69 0.37 0.38 0.35 0.50 0.68 0.34 0.37 0.41 0.36 0.32 0.39 0.41 0.37 0.34 0.37 0.33 0.41 0.36 0.43 0.42 0.47 0.51 J 0.47 0.42 0.53 0.44 0.37 0.33 0.38 0.39 0.42 0.37 0.35 0.35 0.40 0.34 0.40 0.40 0.37 0.80 0.46 0.37 0.38 2.09 0.52 0.52 K 1.47 0.43 0.37 0.33 0.39 0.39 0.36 0.39 0.39 0.39 0.40 0.38 0.39 0.33 0.39 0.62 0.37 0.62 0.40 0.38 0.45 0.42 0.45 0.51 L 0.49 0.49 0.39 0.39 0.37 0.36 0.36 0.38 0.38 0.38 0.42 0.38 0.40 0.41 0.42 0.44 0.44 0.42 0.36 0.42 0.45 0.42 0.47 0.55 M 0.53 0.46 0.50 0.41 0.46 0.39 0.44 0.42 0.43 0.40 0.43 0.43 0.43 0.42 0.42 0.40 0.43 0.42 0.45 0.47 0.45 0.41 0.46 0.56 N 0.46 0.56 0.44 0.41 0.44 0.44 0.50 0.48 0.42 0.45 0.45 0.42 0.44 0.52 0.49 0.54 0.45 0.42 0.44 0.44 0.45 0.42 0.48 0.62 O 1.36 0.50 0.47 0.46 0.47 0.51 0.56 0.97 0.59 0.42 0.47 0.47 0.50 0.45 2.11 0.51 0.44 0.43 1.16 1.97 0.49 0.55 0.62 0.63 P 0.73 0.53 0.52 0.52 0.50 0.50 0.54 0.55 0.53 0.53 0.55 0.54 0.63 0.57 0.54 0.51 2.08 0.54 0.58 0.59 0.57 0.57 0.61 0.58 0hr 24hr IREDy-to-go of ethyl 2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride (rac-29b) &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.46 0.43 0.39 0.37 0.41 0.36 0.31 0.35 0.33 0.35 0.31 0.31 0.33 0.29 0.38 0.34 0.35 0.34 0.62 0.37 0.40 0.42 0.43 0.41 B 0.31 0.47 0.37 0.32 0.35 0.31 0.32 0.32 0.34 0.32 0.31 0.32 0.37 0.33 0.37 0.32 0.35 0.30 0.37 0.38 0.45 0.38 0.42 0.39 C 0.43 0.38 0.32 0.34 0.37 0.33 0.35 0.31 0.29 0.33 0.35 0.33 0.35 0.33 0.33 0.33 0.33 0.30 0.38 0.38 0.37 0.39 0.43 0.42 D 0.41 0.37 0.38 0.35 0.36 0.35 0.34 0.39 0.31 0.32 0.34 0.32 0.39 0.34 0.33 0.34 0.33 0.49 0.36 0.35 0.35 0.40 0.42 0.42 E 0.36 0.39 0.37 0.34 0.29 0.32 0.29 0.36 0.34 0.30 0.35 0.29 0.35 0.28 0.30 0.31 0.34 0.44 0.30 0.32 0.84 0.34 0.38 0.39 F 0.40 0.39 0.29 0.31 0.33 0.35 0.30 0.39 0.34 0.33 0.28 0.36 0.33 0.31 0.34 0.32 0.35 0.32 0.42 0.39 0.34 0.38 0.39 0.45 G 0.35 0.35 0.33 0.30 0.50 0.33 0.31 0.30 0.28 0.27 0.30 0.30 0.31 0.25 0.34 0.30 0.34 0.26 0.34 0.29 0.36 0.37 0.44 0.39 H 0.38 0.32 0.34 0.28 0.29 0.31 0.29 0.33 0.28 0.32 0.31 0.30 0.35 0.29 0.29 0.30 0.27 0.27 0.28 0.40 0.94 0.34 0.41 0.38 I 0.44 0.60 0.31 0.39 0.30 0.41 0.64 0.31 0.26 0.32 0.29 0.28 0.31 0.32 0.30 0.30 0.31 0.29 0.34 0.37 0.35 0.40 0.41 0.39 J 0.38 0.38 0.56 0.40 0.34 0.34 0.32 0.34 0.35 0.31 0.35 0.31 0.38 0.32 0.38 0.31 0.35 0.35 0.37 0.32 0.34 0.48 0.43 0.44 K 0.54 0.37 0.35 0.32 0.38 0.33 0.34 0.33 0.36 0.33 0.35 0.35 0.36 0.31 0.33 0.57 0.34 0.81 0.38 0.34 0.38 0.38 0.45 0.42 L 0.41 0.40 0.34 0.36 0.37 0.34 0.32 0.32 0.34 0.35 0.38 0.34 0.38 0.36 0.36 0.38 0.38 0.35 0.39 0.37 0.40 0.41 0.40 0.44 M 0.40 0.37 0.41 0.37 0.32 0.34 0.35 0.33 0.35 0.32 0.34 0.31 0.34 0.34 0.30 0.28 0.36 0.32 0.39 0.37 0.39 0.37 0.40 0.42 N 0.40 0.37 0.35 0.32 0.34 0.36 0.35 0.34 0.31 0.32 0.33 0.32 0.33 0.33 0.33 0.36 0.35 0.30 0.36 0.35 0.35 0.36 0.36 0.41 O 1.02 0.35 0.33 0.35 0.35 0.32 0.38 0.80 0.49 0.35 0.39 0.38 0.38 0.33 0.37 0.36 0.34 0.32 0.34 0.42 0.37 0.37 0.41 0.39 P 0.59 0.35 0.31 0.33 0.35 0.37 0.37 0.36 0.37 0.39 0.40 0.39 0.37 0.37 0.38 0.39 1.08 0.37 0.48 0.39 0.39 0.45 0.43 0.43 &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.70 0.88 0.57 0.54 0.66 0.56 0.43 0.48 0.61 0.54 0.39 0.45 0.54 0.41 0.53 0.58 0.50 0.65 0.79 0.51 0.54 0.65 0.79 0.59 B 0.37 0.72 0.57 0.46 0.52 0.40 0.49 0.42 0.51 0.42 0.42 0.43 0.55 0.47 0.49 0.42 0.53 0.39 0.48 0.51 0.64 0.57 0.61 0.61 C 0.64 0.52 0.45 0.47 0.53 0.45 0.49 0.39 0.40 0.56 0.46 0.42 0.54 0.46 0.45 0.44 0.45 0.39 0.49 0.50 0.46 0.53 0.65 0.64 D 0.61 0.56 0.55 0.47 0.47 0.46 0.44 1.20 0.37 0.41 0.47 0.39 1.37 0.48 0.46 0.43 0.46 2.32 0.46 0.43 0.44 0.58 0.58 0.60 E 0.51 0.56 0.50 0.44 0.34 0.38 0.39 1.56 0.46 0.48 1.14 0.38 0.56 0.35 0.39 0.38 0.38 2.26 0.36 0.37 2.38 0.41 0.49 0.65 F 0.60 0.65 0.37 0.39 0.56 0.43 0.39 1.74 0.41 0.40 0.35 0.46 0.42 0.37 0.41 0.35 0.41 0.41 0.52 0.50 0.43 0.48 0.56 0.65 G 0.49 0.50 0.42 0.44 0.59 0.37 0.37 0.38 0.40 0.31 0.32 0.34 0.37 0.33 0.39 0.38 0.40 0.31 0.39 0.34 0.42 0.45 0.55 0.51 H 0.63 0.43 0.47 0.37 0.39 0.37 0.37 0.39 0.34 0.39 0.39 0.35 0.48 0.34 0.43 0.37 0.32 0.68 0.33 0.59 1.45 0.43 0.60 0.59 I 0.64 0.92 0.41 0.49 0.39 0.65 0.88 0.39 0.46 0.43 0.35 0.33 0.39 0.43 0.37 0.40 0.40 0.37 0.44 0.43 0.47 0.58 0.57 0.54 J 0.58 0.53 0.94 0.58 0.47 0.44 0.42 0.45 0.46 0.37 0.38 0.38 0.45 0.37 0.49 0.38 0.43 0.74 0.47 0.41 0.39 2.24 0.66 0.62 K 2.27 0.55 0.47 0.43 0.47 0.75 0.38 0.41 0.45 0.43 0.44 0.42 0.45 0.33 0.39 0.71 0.40 1.91 0.44 0.40 0.50 0.48 0.60 0.55 L 0.64 0.55 0.47 0.48 0.49 0.44 0.42 0.40 0.41 0.41 0.48 0.40 0.44 0.42 0.46 0.48 0.48 0.44 0.46 0.47 0.54 0.56 0.53 0.64 M 0.72 0.55 0.58 0.46 0.45 0.47 0.58 0.46 0.47 0.42 0.45 0.42 0.44 0.44 0.41 0.36 0.46 0.40 0.49 0.53 0.49 0.47 0.51 0.59 N 0.57 0.55 0.46 0.44 0.44 0.48 0.50 0.46 0.41 0.46 0.46 0.43 0.41 0.45 0.48 0.51 0.46 0.38 0.45 0.47 0.48 0.43 0.46 0.58 O 1.66 0.58 0.48 0.48 0.45 0.42 0.53 1.14 0.61 0.49 0.45 0.50 0.50 0.40 2.13 0.46 0.41 0.39 0.45 1.51 0.49 0.95 0.57 0.66 P 2.09 0.48 0.45 0.47 0.48 0.51 0.53 0.48 0.49 0.57 0.52 0.53 0.49 0.52 0.49 0.51 2.23 0.50 0.58 0.53 0.55 0.61 0.65 0.55 0hr 24hr Section 5. Biotransformations. Analytical scale biotransformations were performed with either reconstituted lyophilised cell-free extracts of E. coli expressing the IRED of interest for reductive amination of carbonyls, imine &lt;&gt; 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.64 0.53 0.46 0.44 0.50 0.48 0.42 0.46 0.64 0.49 0.45 0.44 0.60 0.53 0.45 0.67 0.49 0.43 0.49 0.49 0.56 0.58 0.71 0.73 B 0.53 0.54 0.47 0.43 0.48 0.45 0.47 0.45 0.44 0.46 0.44 0.46 0.45 0.43 0.47 0.44 0.51 0.41 0.47 0.49 0.57 0.68 0.66 0.66 C 0.57 0.53 0.47 0.46 0.49 0.44 0.44 0.43 0.50 0.47 0.45 0.47 0.55 0.47 0.43 0.44 0.42 0.50 0.48 0.49 0.47 0.59 0.67 0.65 D 0.63 0.53 0.47 0.43 0.45 0.45 0.44 0.68 0.45 0.43 0.46 0.42 1.26 0.49 0.48 0.44 0.46 0.47 0.47 0.52 0.52 0.58 0.59 0.61 E 0.59 0.51 0.44 0.45 0.40 0.62 0.49 1.26 0.48 0.49 1.07 0.46 0.52 0.43 0.49 0.46 0.40 1.73 0.44 0.46 2.37 0.53 0.67 0.86 F 0.65 0.55 0.41 0.44 0.46 0.43 0.45 1.29 0.43 0.48 0.50 0.50 0.46 0.46 0.49 0.46 0.48 0.56 0.51 0.50 0.54 0.61 0.69 0.66 G 0.65 0.49 0.49 0.63 0.45 0.36 0.40 0.45 0.53 0.40 0.38 0.36 0.45 0.37 0.43 0.50 0.47 0.47 0.40 0.47 0.48 0.58 0.60 0.65 H 0.75 0.51 0.50 0.39 0.37 0.35 0.49 0.43 0.48 0.43 0.42 0.40 0.52 0.40 0.48 0.47 0.40 0.56 0.48 0.59 1.43 0.62 0.70 0.67 I 0.61 0.66 0.44 0.49 0.42 0.47 0.64 0.47 0.53 0.50 0.46 0.39 0.48 0.43 0.47 0.45 0.43 0.48 0.53 0.47 0.57 0.65 0.70 0.62 J 0.63 0.61 0.55 0.58 0.40 0.41 0.61 0.52 0.53 0.48 0.47 0.51 0.45 0.43 0.47 0.46 0.45 1.31 0.50 0.49 0.53 2.11 0.73 0.68 K 2.08 0.52 0.42 0.46 0.47 0.57 0.45 0.47 0.47 0.50 0.52 0.50 0.49 0.44 0.47 0.59 0.47 2.34 0.48 0.48 0.57 0.60 0.69 0.62 L 0.63 0.58 0.49 0.46 0.44 0.42 0.44 0.50 0.44 0.45 0.46 0.46 0.51 0.45 0.49 0.57 0.55 0.54 0.53 0.49 0.58 0.64 0.66 0.67 M 0.67 0.57 0.60 0.43 0.48 0.44 0.82 0.50 0.51 0.50 0.49 0.54 0.54 0.53 0.50 0.53 0.51 0.47 0.54 0.58 0.54 0.57 0.70 0.83 N 0.62 0.71 0.68 0.53 0.49 0.50 0.55 0.48 0.48 0.53 0.53 0.50 0.50 0.55 0.52 0.57 0.52 0.54 0.50 0.53 0.56 0.62 0.68 0.78 O 1.18 0.66 0.62 0.52 0.60 0.53 0.51 0.84 0.56 0.48 0.49 0.52 0.52 0.50 2.26 0.51 0.48 0.47 0.58 2.02 0.61 1.16 0.75 1.10 P 2.00 0.72 0.64 0.57 0.62 0.52 0.57 0.54 0.52 0.51 0.52 0.53 0.59 0.52 0.49 0.51 1.42 0.51 0.61 0.57 0.66 0.68 0.73 0.71 20h 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 A 0.64 0.53 0.46 0.44 0.50 0.48 0.42 0.46 0.64 0.49 0.45 0.44 0.60 0.53 0.45 0.67 0.49 0.43 0.49 0.49 0.56 0.58 0.71 0.73 B 0.53 0.54 0.47 0.43 0.48 0.45 0.47 0.45 0.44 0.46 0.44 0.46 0.45 0.43 0.47 0.44 0.51 0.41 0.47 0.49 0.57 0.68 0.66 0.66 C 0.57 0.53 0.47 0.46 0.49 0.44 0.44 0.43 0.50 0.47 0.45 0.47 0.55 0.47 0.43 0.44 0.42 0.50 0.48 0.49 0.47 0.59 0.67 0.65 D 0.63 0.53 0.47 0.43 0.45 0.45 0.44 0.68 0.45 0.43 0.46 0.42 1.26 0.49 0.48 0.44 0.46 0.47 0.47 0.52 0.52 0.58 0.59 0.61 E 0.59 0.51 0.44 0.45 0.40 0.62 0.49 1.26 0.48 0.49 1.07 0.46 0.52 0.43 0.49 0.46 0.40 1.73 0.44 0.46 2.37 0.53 0.67 0.86 F 0.65 0.55 0.41 0.44 0.46 0.43 0.45 1.29 0.43 0.48 0.50 0.50 0.46 0.46 0.49 0.46 0.48 0.56 0.51 0.50 0.54 0.61 0.69 0.66 G 0.65 0.49 0.49 0.63 0.45 0.36 0.40 0.45 0.53 0.40 0.38 0.36 0.45 0.37 0.43 0.50 0.47 0.47 0.40 0.47 0.48 0.58 0.60 0.65 H 0.75 0.51 0.50 0.39 0.37 0.35 0.49 0.43 0.48 0.43 0.42 0.40 0.52 0.40 0.48 0.47 0.40 0.56 0.48 0.59 1.43 0.62 0.70 0.67 I 0.61 0.66 0.44 0.49 0.42 0.47 0.64 0.47 0.53 0.50 0.46 0.39 0.48 0.43 0.47 0.45 0.43 0.48 0.53 0.47 0.57 0.65 0.70 0.62 J 0.63 0.61 0.55 0.58 0.40 0.41 0.61 0.52 0.53 0.48 0.47 0.51 0.45 0.43 0.47 0.46 0.45 1.31 0.50 0.49 0.53 2.11 0.73 0.68 K 2.08 0.52 0.42 0.46 0.47 0.57 0.45 0.47 0.47 0.50 0.52 0.50 0.49 0.44 0.47 0.59 0.47 2.34 0.48 0.48 0.57 0.60 0.69 0.62 L 0.63 0.58 0.49 0.46 0.44 0.42 0.44 0.50 0.44 0.45 0.46 0.46 0.51 0.45 0.49 0.57 0.55 0.54 0.53 0.49 0.58 0.64 0.66 0.67 M 0.67 0.57 0.60 0.43 0.48 0.44 0.82 0.50 0.51 0.50 0.49 0.54 0.54 0.53 0.50 0.53 0.51 0.47 0.54 0.58 0.54 0.57 0.70 0.83 N 0.62 0.71 0.68 0.53 0.49 0.50 0.55 0.48 0.48 0.53 0.53 0.50 0.50 0.55 0.52 0.57 0.52 0.54 0.50 0.53 0.56 0.62 0.68 0.78 O 1.18 0.66 0.62 0.52 0.60 0.53 0.51 0.84 0.56 0.48 0.49 0.52 0.52 0.50 2.26 0.51 0.48 0.47 0.58 2.02 0.61 1.16 0.75 1.10 P 2.00 0.72 0.64 0.57 0.62 0.52 0.57 0.54 0.52 0.51 0.52 0.53 0.59 0.52 0.49 0.51 1.42 0.51 0.61 0.57 0.66 0.68 0.73 0.71 reductions, and oxidative deamination. Purified IREDs were employed where stated. A number of different conditions were employed for biotransformations on the analytical scale. Listed below are a number of different conditions employed in the analytical scale biotransformations with the corresponding substrates as well as the relevant work-up procedure are outlined. 5.1. Typical Procedure for IRED Catalysed Reduction of Cyclic Imines For analytical scale reductive amination a typical 500 μL reaction mixture contained 50 mM D-glucose, 0.1 mg/mL GDH (Codexis CDX-901, 50 U/mg), 0.5 mM NADP + , 4 mg/mL lyophilized powder of supernatant of lysate IRED, 10 mM imine. The reaction volume was made up to 500 μL with TRIS-HCl buffer (100 mM, pH 8.0). The reaction mixture was incubated at 30ºC with shaking at 200 rpm for 18-24 h and quenched by the addition of 100 μL of 5 M sodium hydroxide and extracted with 1.5 mL Methyl tert-butyl ether (MTBE). Product was then derivatized with an excess of acetic anhydride and triethylamine in the presence of 4-Dimethylaminopyridine (DMAP) where stated. The organic phase was dried over anhydrous MgSO4, and analysed by chiral GC analysis. 5.2. Typical Procedure for IRED Catalysed Reductive Aminations 5.2.1 Biotransformation procedure for reductive aminations to generate 2b, 2f, 30f, 36f, 37f, 38f, 31f, 12f</p><p>For analytical scale reductive amination a typical 500 μL reaction mixture contained 50 mM D-glucose, 0.1 mg/mL GDH (Codexis CDX-901, 50 U/mg), 0.5 mM NADP + , 4 mg/mL lyophilized powder of supernatant of lysate IRED, 10 mM carbonyl and 10 equivalents of amine donor (added from a pH adjusted (pH 7.0) 1 M amine stock). The reaction volume was made up to 500 μL with TRIS-HCl buffer (100 mM, pH 8.0). The reaction mixture was incubated at 30ºC with shaking at 200 rpm for 18-24 h and quenched by the addition of 100 μL of 5 M sodium hydroxide and extracted with 1500 μL Methyl tert-butyl ether (MTBE). The organic phase was dried over anhydrous MgSO4, and analysed by chiral GC analysis.</p><p>5.2.2. Biotransformation procedure for reductive aminations to generate 27a-l, 32b, 33b, 34b, 42b For analytical scale reductive aminations a typical 500 μL reaction mixture contained 50 mM D-glucose, 0.1 mg/mL GDH (Codexis CDX-901, 50 U/mg), 0.5 mM NADP + , 4 mg/mL lyophilized powder of supernatant of lysate IRED, 10 mM carbonyl and 2 equivalents of amine donor (added from a pH adjusted 1 M amine stock). The reaction volume was made up to 500 μL with sodium phosphate buffer (100 mM, pH 7.0). The reaction mixture was incubated at 25ºC with shaking at 200 rpm for 20 h and quenched by the addition of 100 μL of 1 M sodium carbonate and extracted with 500 μL ethyl acetate/cyclohexane (1/1, v/v). The organic phase was dried over anhydrous MgSO4, and analysed by chiral GC analysis. S.5.2.3 Biotransformation procedure for reductive aminations to generate 13a, 13b, 13e, 13f, 13k and 15a</p><p>For analytical scale reductive aminations a typical 500 μL reaction mixture contained 50 mM D-glucose, 0.1 mg/mL GDH (Codexis CDX-901, 50 U/mg), 0.5 mM NADP + , 4 mg/mL lyophilized powder of supernatant of lysate IRED, 5 mM carbonyl and 50 equivalents of amine donor (added from a pH adjusted 1 M amine stock). The reaction volume was made up to 500 μL with TRIS-HCl buffer (100 mM, pH 8.0). The reaction mixture was incubated at 40 ºC with shaking at 200 rpm for 24 h and quenched by the addition of 100 μL of 5 M sodium hydroxide and extracted with 1.5 mL MTBE. The product was then derivatised with an excess of acetic anhydride and triethylamine in the presence of 4dimethylaminopyridine (DMAP) The organic phase was dried over anhydrous MgSO4, and analysed by chiral GC analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S.5.2.4 Biotransformation procedure for the dynamic kinetic resolution (DKR) to obtain 28b and 29b</head><p>For analytical scale reductive aminations a typical 500 μL reaction mixture contained 50 mM D-glucose, 0.1 mg/mL GDH (Codexis CDX-901, 50 U/mg), 0.5 mM NADP + , 4 mg/mL lyophilized powder of supernatant of lysate IRED, 10 mM carbonyl and 2 equivalents of amine donor (added from a pH adjusted 1 M amine stock). The reaction volume was made up to 500 μL with sodium phosphate buffer (100 mM, pH 7.0). The reaction mixture was incubated at 25ºC with shaking at 200 rpm for 20 h and quenched by the addition of 100 μL of 1 M sodium carbonate and extracted with 500 μL ethyl acetate/cyclohexane (1/1, v/v). The organic phase was dried over anhydrous MgSO4, and analysed by chiral GC analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.">Typical Procedure for IRED Catalysed Oxidative Deamination</head><p>For analytical scale reductive amination a typical 500 μL reaction mixture contained: 0.1 mg/mL PRO-NOX-001 (Prozomix Ltd, Halthwhistle, Northumberland), 0.5 mM NADP + , 4 mg/mL lyophilized powder of supernatant of lysate IRED, 10 mM amine. The reaction volume was made up to 500 μL with glycine-sodium hydroxide buffer (100 mM, pH 10.5). The reaction mixture was incubated at 30ºC with shaking at 200 rpm for 18-24 h and quenched by the addition of 100 μL of 10 M sodium hydroxide and extracted with 1.5 mL Methyl tert-butyl ether (MTBE). The organic phase was dried over anhydrous MgSO4, and analysed by chiral GC analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.">Bioconversion data for the screening of the imine reduction of 2-phenypiperidine (4) to 3 and for the reductive amination of cyclohexanone (2) with cyclopropylamine (b).</head><p>To assess the activity across the panel 384 biotransformations were performed for 2 benchmark reaction for the imine reduction of 2-phenylpipeiridne (4) and the reductive amination of cyclohexanone (2) with cyclopropylamine (b). The Table <ref type="table">5</ref>.4.1 outlines the conversion from starting material to product and the enantiomeric excess for the reduction of 2-phenylpiperidine (4) and for the reductive amination of 2 with b. The bioconversion data generated through these reductive reactions is also represented in Figure <ref type="figure">2</ref>. Table 5.4.1. Chiral GC analysis of all enzymes towards the imine reduction of 4 to 3 and the reductive amination of 2 to 2b. IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) 1 62% (33% ee, S) 85 41 0% 2 2 67% (46% ee, S) 93 42 &lt;1% 7 3 36%, (35% ee, S) 70 43 0% 6 4 97% (35% ee, S) 99 44 54% (89% ee, S) 99 5 0% 38 45 0 6 99% (75% ee, S) 99 46 1% 4 7 49% (90% ee, S) 99 47 0% 2 8 96% (87% ee, S) 99 48 &gt;99% (95% ee, S) 99 9 &gt;99% (83% ee, S) 99 49 &gt;99% (93% ee, R) 99 10 &lt;1% 3 50 &gt;99% (93% ee, S) 99 11 81% (&gt;99% ee, S) 21 51 20% (87% ee, S) 7 12 &gt;99% (45% ee, S) 91 52 51% (93% ee, S) 70 13 &gt;99% (95% ee, S) 97 53 2% 3 14 2% 99 54 20% (89% ee, S) 30 15 0% 2 55 85% (95% ee, S) 91 16 &gt;99% (43% ee, S) 99 56 62% (59% ee, S) 57 17 &gt;99% (74% ee, S) 99 57 &gt;99% (93% ee, S) 99 18 &lt;1% 18 58 &gt;99% (27% ee, R) 99 19 0% 89 59 5% (&gt;90% ee, S) 5 20 &gt;99% (89% ee, S) 99 60 6% (&gt;90% ee, R) 5 21 2% 26 61 8% (&gt;70% ee, S) 5 22 0% 6 62 &gt;99% (79% ee, S) 99 23 &gt;99% (99% ee, S) 99 63 &gt;99%, (&gt;99 ee, S) 99 24 &gt;99% (96% ee, S) 99 64 &gt;99% (&gt;98% ee, S) 99 25 5% (69% ee, S) 3 65 &gt;99% (&gt;98% ee, S) 99 26 2% 2 66 55% (59% ee, S) 62 27 3% 48 67 5% (&gt;90% ee, S) 2 28 66% (7% ee, R) 99 68 &gt;99% (98% ee, S) 98 29 &lt;1% 4 69 12% (&gt;90% ee, S) 10 30 0 70 10% (&gt;90% ee, S) 5 31 &gt;99% (79% ee, S) 99 71 18% (&gt;90% ee, S) 0 32 &lt;1% 68 72 36% (95% ee, S) 6 33 &gt;99% (21% ee, R) 98 73 34% (83% ee, S) 99 34 0% 4 74 95% (70% ee, S) 99 35 10% (90% ee, S) 10 75 0% 5 36 0% 0 76 0% 0 37 35% (75% ee, S) 41 77 0% 7 38 2% 6 78 &gt;99% (91% ee, S) 99 39 &lt;1% 0 79 &gt;99% (89% ee, S) 99 40 &lt;1% 0 80 0% 0 IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) 81 62% (79% ee, S) 93 123 &gt;98% (98% ee, S) 63 82 98% (87% ee, S) 99 124 &gt;99% (91% ee, S) 99 83 3% (S) 99 125 &gt;99% (98% ee, S) 99 84 15% (75% ee, R) 3 126 &gt;99% (91% ee, S) 99 85 &gt;99% (40% ee, R) 99 127 7% (&gt;99% ee, S) 11 86 0% 0 128 &gt;99% (98% ee, S) 99 87 0% 4 129 37% (83% ee, S) 99 88 &gt;99% (87% ee, S) 99 130 0% 0 89 96% (81% ee, S) 99 131 1% (R) 51 90 97% (79% ee, S) 98 132 0% 2 91 0% 0 133 0% 6 92 &gt;99% (&gt;99% ee, S) 57 134 &gt;99% (&gt;99% ee, S) 53 93 0% 0 135 2% (S) 3 94 &gt;99% (&gt;99% ee, S) 99 136 0% 5 95 50% (&gt;99% ee, S) 10 137 0% 3 96 3% (S) 0 138 0% 0 97 &gt;99% (87% ee, S) 25 139 0% 1 98 8% (&gt;99% ee, S) 0 140 0% 3 99 75% (43% ee, R) 20 141 0% 3 100 &gt;99% (&gt;99% ee, S) 5 142 0% 0 101 18% (&gt;99% ee S) 17 143 &gt;99% (85% ee, S) 99 102 &gt;99% (&gt;99% ee, S) 99 144 0% 2 103 &gt;99% (&gt;99% ee, S) 44 145 0% 5 104 &gt;99% (&gt;99% ee, S) 99 146 0% 0 105 &gt;99% (90% ee, S) 99 147 &gt;99% (&gt;99% ee, S) 0 106 &gt;99% (&gt;99% ee, S) 99 148 &gt;99% (&gt;99% ee, S) 99 107 &gt;99% (&gt;99% ee, S) 99 149 10% (&gt;99% ee, S) 0 108 &gt;99% (96% ee, S) 84 150 &gt;99% (&gt;99% ee, S) 85 109 &gt;99% (&gt;99% ee, S) 99 151 &gt;99% (73% ee, R) 99 110 &gt;99% (97% ee, R) 57 152 0% 0 111 &gt;99% (&gt;99%ee, S) 49 153 0% 0 112 &gt;99% (65% ee, R) 99 154 &gt;99% (&gt;99% ee, S) 79 113 25% (85% ee, S) 33 155 &gt;99% (93% ee R) 99 114 &gt;99% (&gt;99% ee, S) 98 156 0% 0 115 18% (&gt;99% ee, S) 9 157 14% (37% ee, S) 15 116 29% (40% ee, R) 62 158 0% 0 117 &gt;99% (&gt;99% ee, S) 98 159 0% 0 118 17% (89% ee, S) 99 160 0% 28 119 0% 0 161 0% 0 120 &gt;99% (&gt;99% ee, S) 99 162 1% (S) 0 121 &gt;99% (91% ee, S) 96 163 0% 0 122 &gt;99% (&gt;99% ee, S) 99 164 20% (18 ee, S) 94 IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) 165 1% (S) 0 207 &lt;1% (R) 99 166 0% 0 208 11% (&gt;99% ee, S) 0 167 2% (R) 0 209 90% (91% ee, R) 36 168 0% 0 210 &gt;99% (&gt;99% ee, S) 11 169 2% (R) 0 211 0% 0 170 &gt;96% (95% ee, R) 91 212 0% 0 171 4% (R) 88 213 22% (&gt;99% ee, S) 54 172 &gt;99% (98% ee, R) 99 214 0% 0 173 &gt;99% (33% ee, S) 78 215 0% 0 174 4% (S) 92 216 0% 0 175 1% (S) 0 217 0% 37 176 0% 0 218 66% (&gt;99% ee, S) 0 177 0% 0 219 29% (&gt;99% ee, S) 34 178 89% (81% ee, R) 62 220 0% 1 179 99% (97% ee, S) 57 221 &gt;99% (&gt;99% ee, S) 99 180 99% (89% ee, R) 97 222 1% (S) 60 181 0% 0 223 21% (55% ee, S) 99 182 2% (R) 0 224 0% 0 183 &gt;99% (73% ee, R) 98 225 &gt;99% (83%ee, S) 0 184 0% 0 226 0% 0 185 0% 0 227 0 186 99% (31% ee, R) 98 228 &gt;99% (91% ee, S) 99 187 0% 0 229 &gt;99% (95% ee, R) 0 188 0% 0 230 &gt;99% (97% ee, R) 99 189 0% 0 231 0% 3 190 10 (&gt;99% ee, R) 0 232 &gt;99% (65% ee, S) 96 191 0% 0 233 0% 0 192 9% (43% ee, S) 96 234 &gt;99% (89% ee, S) 99 193 0% 0 235 5% (S) 10 194 8% (&gt;99% ee, S) 0 236 &gt;99% (&gt;99% ee, S) 99 195 &gt;99 (&gt;99% ee, S) 0 237 &gt;99% (98% ee, S) 99 196 0% 0 238 &gt;99% (37% ee, R) 99 197 &gt;99% (97% ee, R) 76 239 0% 0 198 43% (&gt;99% ee, S) 4 240 0&amp; 2 199 0% 0 241 &gt;99% (17% ee, R) 99 200 0% 0 242 &gt;99% (15% ee, S) 99 201 &gt;99% (&gt;99% ee, S) 99 243 82% (87% ee, R) 99 202 16% (15% ee, S) 99 244 2% (S) 6 203 0% 0 245 0% 41 204 &gt;99% (97% ee, R) 98 246 &gt;99% (23% ee, R) 99 205 0% 1 247 0% 15 206 &gt;99% (98% ee, S) 99 248 95% (79% ee, R) 99 IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) 249 99% (99% ee, S) 99 291 0% 0 250 0% 0 292 69% (45% ee, S) 99 251 0% 0 293 0% 0 252 0% 1 294 0% 0 253 2% (0% ee) 31 295 97% (1% ee, S) 99 254 0% 0 296 0% 0 255 &gt;99% (96% ee, R) 98 297 0% 1 256 &lt;1% 0 298 0% 0 257 0 299 0% 2 258 0 300 7% (11% ee, R) 47 259 20% (39% ee, R) 71 301 9% (&gt;99% ee, S) 1 260 81% (93% ee, R) 49 302 0% 1 261 0% 0 303 &lt;1% (S) 0 262 24% (61% ee, S) 99 304 7% (&gt;99% ee, R) 99 263 0% 17 305 0% 1 264 &gt;99% (49% ee, S) 99 306 90% (85% ee, R) 15 265 &gt;99% (99% ee, S) 99 307 &gt;99% (69% ee, R) 98 266 0% 0 308 0% 1 267 99% (47% ee, R) 76 309 0% 2 268 &gt;99% (75% ee, R) 0 310 92% (15% ee, S) 99 269 11% (3% ee, R) 14 311 0% 10 270 89% (1% ee, S) 64 312 4% (S) 0 271 &gt;99% (87% ee, S) 94 313 0% 76 272 0% 20 314 0% 6 273 &gt;99% (71% ee, S) 99 315 6% (&gt;99% ee, S) 96 274 0% 0 316 0% 0 275 0% 0 317 0% 68 276 2% (R) 0 318 0% 1 277 0% 0 319 0% 3 278 0 0 320 0% 2 279 0% 0 321 30% (33% ee, S) 12 280 0% 0 322 0% 0 281 0% 0 323 5% 17 282 96% (96% ee, R) 0 324 0% 3 283 0% 0 325 99% (82% ee, S) 98 284 0% 0 326 0% 0 285 0% 0 327 0% 0 286 0% 0 328 0% 0 287 0% 0 329 0% 0 288 0% 0 330 14% (23% ee, R) 0 289 0% 0 331 0% 0 290 0% 0 332 0% 0 IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) IRED Imine Reduction (% Conversion) (%ee) Reductive Amination (% conversion) 96% (95% ee, S) 60 359 60% (93% ee, S) 99 5% 99 360 96% (35% ee, S) 99 2% 1 361 97% (&gt;99% ee, S) 99 94% (&gt;99% ee, S) 90 362 71% (20% ee, R) 91 0% 0 363 97% (43% ee, S) 99 97% (&gt;99% ee, S) 59 364 97% (93% ee, S) 99 &gt;99%(&gt;99% ee, S) 99 365 0% 0 0% 0 366 0% 0 94% (&gt;99% ee, S) 40 367 0% 1 0% 0 368 0% 1 0% 0 369 10% (&gt;99% ee, S) 5 0% 1 370 0% 3 0% 0 371 64% (85% ee, R) 8 0% 0 372 0% 4 12% (&gt;99% ee, S) 2 373 22% (83% ee, R) 31 8% (&gt;99% ee, S) 0 374 97% (&gt;99% ee, S) 99 0% 0 375* --0% 1 376 0% 14 98% (29% ee, R) 99 377 8% (&gt;99% ee, S) 0 7% (&gt;99% ee, S) 4 378 0% 1 98% (&gt;99% ee, S) 99 379 0% 0 9% (61% ee, S) 95 380 0% 0 98% (51% ee, S) 99 381 0% 0 &gt;99% (20% ee, R) 99 382 2% (S) 0 &gt;99% (63% ee, R) 99 383 0% 0 97% (&gt;99% ee, S) 99 384</p><p>&gt;99% (&gt;99% ee, S) 0 Reaction parameters imine reduction: imine (4, 10 M) IREDs (4 mg mL -1 CFE), NADP + (0.5 mM), GDH (10 U mL -1 ), D-glucose (50 mM), TRIS HCl (100 mM, pH 7.0), 30ºC, 24 h, 250 rpm. Reaction parameters reductive amination: ketone (2, 10 mM), amine (b, 100 mM), IREDs (4 mg mL -1 lyophilized powder of supernatant of lysate), NADP + (0.5 mM), GDH (10 U mL -1 ), D-glucose (50 mM), TRIS HCl (100 mM, pH 8.0), 30ºC, 24 h, 250 rpm. Table 5.5.2. Bioconversion data for the top 3 and bottom 3 hits with selected IREDs for the above reactions where low amine equivalents were employed for the reductive amination of 2 and a to 2a, and for the oxidative deamination 2a to 2 and a. Enzyme Reductive Amination Conv. (%) Oxidative Deamination Conv. (%) pIR09 43 99%* pIR238 44 99%* pIR241 41 99%* pIR35 &lt;1 0 pIR193 0 0 PIR375 0 0 *Bi-directional cleavage observed see below table Scheme 5.5.3. Oxidative deamination of 2a where bi-diectional cleavage is observed to 2 and a. Oxidative deamination of 2a where bidiectional cleavage is observed to cyclohexylamine and formaldehyde.</p><p>Table 5.3.3. Bioconversion data for the top 3 IREDs which showed bi-directional cleavage to cyclohexanone 2 and cyclohexylamine j. Enzyme Oxidative Deamination (%) Cyclohexanone. (%) Cyclohexylamine (%) pIR09 99%* 43 56 pIR238 99%* 30 70 pIR241 99%* 77 12 Table 5.5.4. Conversion, enantioselectivity IREDs towards the reductive aminations of 2, 12, 13, 15, 30, 31, 37, 38 [a] Reaction parameters: β-keto ester (10 mM), amine (20 mM), IRED (4 mg mL -1 lyophilized powder of supernatant of lysate), NADP + (0.2 mM), GDH (10 U mL</p><p>-1 ), D-glucose (50 mM), sodium phosphate buffer (100 mM, pH 7.0), 30ºC, 20 h. [b] Apparent conversion and ee values were determined by chiral GC analysis. [c] Not determined owing to low conversion or not separated by chiral GC analysis. [d] lots of ethyl 3-(pyrrolidin-1-yl)but-2-enoate (51) was monitored. A and B Table 5.5.5. An expanded table of that given in Figure 4 of conversions, enantioselectivities and diastereoselectivities of selected IREDs towards β-keto esters and different amines. [a] z Substrate Conversion (%); enantiometric excess (ee) (%) [b] βketo ester amine pIR-085 pIR-114 pIR-117 pIR-238 pIR-241 pIR-351 pIR-355 pIR-356 27 b &gt;99; &gt;99 A &gt;99; &gt;99 A &gt;99; &gt;99 B &gt;99; &gt;99 A &gt;99; &gt;99 A &gt;99; &gt;99 A &gt;99; &gt;99 A &gt;99; &gt;99 A 27 d 10; &gt;99 A 15; &gt;99 A 73; &gt;99 B 20; &gt;99 A 27; &gt;99 A 63; &gt;99 A 92; &gt;99 A 51; &gt;99 A 27 e 31; &gt;99 A 15; &gt;99 A 57; &gt;99 B 42; &gt;99 A 29; &gt;99 A 54; &gt;99 A 59; &gt;99 A 54; &gt;99 A 27 i 0; ND [c] 4; &gt;99 R 18; &gt;99 S 10; &gt;99 R 3; &gt;99 R 14; &gt;99 R 28; &gt;99 R 13; &gt;99 R 27 a 10; &gt;99 A 5; &gt;99 A 28; &gt;99 B 25; &gt;99 A 7; &gt;99 A 42; &gt;99 A 4; &gt;99 A 13; &gt;99 A 27 c 0; ND 0; ND 0; ND 0; ND 0; ND 0; ND 0; ND 0; ND 27 l 17 <ref type="bibr">[d]</ref> ; ND 14 <ref type="bibr">[d]</ref> ; ND 63 <ref type="bibr">[d]</ref> ; ND 5 <ref type="bibr">[d]</ref> ; ND 10 <ref type="bibr">[d]</ref> ; ND 34 <ref type="bibr">[d]</ref> ; ND 22 <ref type="bibr">[d]</ref> ; ND 29 <ref type="bibr">[d]</ref> ; ND 32 b 63; &gt;99 A 73; &gt;99 A 87; &gt;99 B 52; &gt;99 A 66; &gt;99 A 86; &gt;99 A 64; &gt;99 A 87; &gt;99 A 33 b 25; ND 29; ND 29; ND 19; ND 31; ND 60; ND 26; ND 50; ND 42 b 9; ND 10; ND 11; ND 9; ND 9; ND 12; ND 10; ND 12; ND 34 b 0; ND 0; ND 0; ND 0; ND 0; ND 0; ND 0; ND 0; ND reaction was quenched by the addition of sodium carbonate (4.24 g, 40 mmol) and extracted with ethyl acetate/cyclohexane (1/1, v/v) three times (50 mL×3) with centrifugation (15ºC, 4000 g, 10 min) to</p><p>improve the separation of phases. The organic layers were combined and dried over anhydrous MgSO4.</p><p>After removal of the solvent under reduced pressure, the residue was dissolved with 5 mL diethyl ether.</p><p>A solution of HCl in diethyl ether (2 M, 2 mL) was added, the ether layer decanted and the remaining solid or oil washed with diethyl ether (3 x 5 mL) and dried under vacuum to afford the desired product.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethyl (B)-3-(cyclopropylamino)butanoate hydrochloride ((B)-27b)</head><p>Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-117 gave 460 mg ethyl (B)-3-(cyclopropylamino)butanoate hydrochloride ((B)-27b) as pale yellow solid with &gt;99% conversion and 89% isolated yield.</p><p>1 H NMR (METHANOL-d4, 400MHz): δ = 4.23 (q, J=7.1 Hz, 2 H), 3.80 (sxt, J=6.4 Hz, 1 H), 2.73 -2.95 (m, 3 H), 1.47 (d, J=6.6 Hz, 3 H), 1.30 (t, J=7.1 Hz, 3 H), 0.92 -1.00 (m, 4 H). 13 C NMR (METHANOL-d4, 100MHz): δ = 168.55, 59.39, 50.72, 34.89, 26.28, 14.14, 11.46, 1.42, 1.25. HRMS calcd. for C9H18NO2 + 172.1338 [M+H] + , found 172.1332. Ethyl (A)-3-(cyclopropylamino)butanoate hydrochloride ((A)-27b) Section 6. Analytics: Chromatography Columns, Conditions, and Retention Times for Substrates Table 6.1. Chiral GC-FID analysis: methods and retention times of β-keto ester substrates and β-amino ester products from biotransformations. Injector temperature: 200ºC, inlet pressure: 22.40 psi, detector temperature: 220ºC, helium flow: 2.0 mL/min, column: CP-ChiraSil-DEX CB. Absolute configurations were assigned by comparison with compounds of known configuration. Assignment of enantiomers (A)-and (B-) determined by order of elution. βketo ester Amine βamino ester Oven temp. β-keto ester retention time/min β-amino ester product retention time/min 27 b 27b [a] 120ºC 2.1 17.0 (A) 17.5 (B) 27 d 27d [a] 120ºC 2.1 21.8 (A) 22.4 (B) 27 e 27e [a] 120ºC 2.1 16.9 (A) 17.2 (B) 27 i 27i [a] 120ºC 2.1 15.7 (R) 16.0 (S) 27 a 27a [a] Hold at 80ºC for 1.0 min, 100 -150ºC (2.5ºC/min), hold at 150ºC for 1 min 6.0 22.8 (A) 23.0 (B) 27 c 27c Hold at 100ºC for 1.0 min, 100 -150ºC (5ºC/min), hold at 150ºC for 2 min, 150 -200ºC (10ºC/min), hold at 200ºC for 4 min 3.3 13.9 [b] 27 l 27l Hold at 100ºC for 1.0 min, 100 -150ºC(5ºC/min), hold at 150ºC for 2 min, 150 -200ºC(10ºC/min), hold at 200ºC for 4 min 2.2 6.7 [b] 32 b 32b [a] 120ºC 21.4 (A) 21.7 (B) 33 b 33b Hold at 100ºC for 1.0 min, 100 -150ºC (2.5ºC/min), hold at 150ºC for 1 min, 150 -200ºC (10ºC/min), hold at 200ºC for 2 min 6.5 23.3 [b] 42 b 42b [a] Hold at 100ºC for 1.0 min, 100 -150ºC (5ºC/min), hold at 150ºC for 2 min, 150 -200ºC (10ºC/min), hold at 200ºC for 2 min 4.9 14.8 [b] 34 b 34b Hold at 100ºC for 1.0 min, 100 -150ºC (5ºC/min), hold at 150ºC for 2 min, 150 -200ºC (10ºC/min), hold at 200ºC for 4 min 12.2 14.6 [b] 28 b 28b Hold at 80ºC for 0 min, 80 -150ºC(5ºC/min), hold at 150ºC for 2 min, 150 -180ºC(10ºC/min), hold at 180ºC for 2 min 10.7 14.6 (1A,2B) 14.7 (1B,2A) 14.9 (1B,2B) 15.2 (1A,2A) 28 i 28i Hold at 80ºC for 0 min, 80 -150ºC(5ºC/min), hold at 150ºC for 2 min, 150 -180ºC(10ºC/min), hold at 180ºC for 2 min 10.7 13.6 (1R,2S) 13.7 (1S,2R) 14.1 (1S,2S) 14.2 (1R,2R) 29 b 29b Hold at 80ºC for 0 min, 80 -150ºC(5ºC/min), hold at 150ºC for 2 min, 150 -180ºC(10ºC/min), hold at 180ºC for 2 min 9.4 12.6 (1A,2B) 12.7 (1B,2A) 13.2 (trans)[b]</p><p>[a] derivatization with acetic anhydride, [b] Not separated by chiral GC              Table 6.2. Chiral GC-FID analysis: methods and retention times of acetophenone and derivative products and from subsequent biotransformations. injector temperature: 200ºC, inlet pressure: 22.40 psi, detector temperature: 220ºC, helium flow: 2.0 mL/min, column: CP-ChiraSil-DEX CB. Absolute configurations were assigned by comparison with compounds of known configuration. Ketone Amine Product Oven temp. Ketone retention time/min Product retention time/min 13 a 13a ** 12.09 22.4 (R) 22.6 (S) 13 b 13b ** 12.09 24.9 (B) 25.09 (A) 13 e 13e ** 12.09 24.4 (B) 24.5 (A) 13 d 13d ** 12.09 17.2 (B) 17.3 (A) 3 k 13k ** 12.09 21.8 (S) 22.1 (R)      Table 6.3. GC-MS analysis: methods and retention times of acetophenone and derivative substrates and from selected biotransformations. Injector temperature 270 °C, transfer line 320°C, quadrupole 150 °C, ion source 230 °C. Agilent HP-1ms column 30 m × 0.32 mm × 0.25 μm. Ketone Amine Product Oven temp. Ketone retention time/min Amine Partner retention time/min Product retention time/min 13 b 13b ** 7.09 -11.0 13 j 13j ** 7.09 -13.9 2 13k 13j ** 4.2 6.93 13.9 ** oven temperature 40 °C to 300 °C at 10 °C•min-1 Figure 6.21. GC-MS spectra of acetophenone (13).         Table 6.5. GCMS: methods and retention times of dimethylamine from selected biotransformations. Injector temperature 270 °C, transfer line 320°C, quadrupole 150 °C, ion source 230 °C. Agilent HP-1ms column 30 m × 0.32 mm × 0.25 μm. Ketone Amine Product Oven temp. Ketone retention time/min Product retention time/min 2 f 2f ** 4.0 6.0 30 f 30f ** n.d. 4.1 31 f 31f ** 4.6 12 f 12f ** 8.5 10.1 36 f 36f ** 9.6 n.d. 38 f 38f ** n.d. n.d. 37 f 37f ** 6.1 n.d. 39 f 39f ** 13.6 n.d. ** oven temperature 40 °C to 300 °C at 10 °C•min -1            Table 6.6. Chiral GC analysis: methods and retention times for the reduction of 2-phenylpiperidine (4). Injector temperature: 200ºC, inlet pressure: 22.40 psi, detector temperature: 220ºC, helium flow: 2.0 mL/min, column: CP-ChiraSil-DEX CB. Absolute  Table 6.7. GC-FID analysis: methods and retention times for the reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (45). injector temperature: 200ºC, inlet pressure: 22.40 psi, detector temperature: 220ºC, helium flow: 2.0 mL/min, column: HP-1. Absolute    Table 6.8. GC-FID analysis: methods and retention times of reductive aminations with cyclohexanone. injector temperature: 200ºC, inlet pressure: 22.40 psi, detector temperature: 220ºC, helium flow: 2.0 mL/min, column: CP-ChiraSil-DEX CB. Absolute configurations were assigned by comparison with compounds of known configuration. Ketone Amine Product Oven temp. Ketone retention time/min Product retention time/min 2 b 2b * 8.8 13.0 2 a 2a*** ** 6.7 4 9.3 4 * oven temperature: Hold at 50ºC for 0 min, 50 -135ºC (5ºC/min), 150-200°C (10°C/min) hold at 200ºC for 2 min ** oven temperature: Hold 50°C for 10 mins, 50 -200°C, 10°C min -16 *** column: HP-1 Figure 6.50. GC-FID analysis of the cyclohexanone (2) and N-cyclopropylcyclohexylamine (2b). Section 7. Synthesis of Chemical Compounds Analytics: Chromatography Columns, Conditions, and Retention Times for Substrates Studied.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>7.1: Reductive amination procedure for the preparation of racemic β-amino esters</head><p>The procedure is based on a method described by Tummatorn et al. <ref type="bibr">7</ref> To a mixture of β-keto ester (1.0 equiv) and amine (1.1 equiv) was added ZrCl4 (0.1 equiv). The mixture was stirred at room temperature for overnight. Then the reaction mixture was diluted to about 0. 13 C NMR (METHANOL-d4 ,100MHz): δ = 168.68, 59.54, 50.89, 35.10, 26.46, 14.33, 11.63, 1.61, 1.42. HRMS calcd. for C9H18NO2 + 172.1338 [M+H] + , found 172.1331. Ethyl 3-(propargylamino)butanoate (27d)                                                                      </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 3 . 1 . 2 .Figure 3 . 1 . 3 .Figure 3 . 1 . 4 .Figure 3 . 1 . 5 .Figure 3 . 1 . 6 .g, Figure 3 . 1 . 7 .</head><label>312313314315316317</label><figDesc>Krona chart of the predicted Class of the taxonomic rank of Metagenome 1 b, Krona chart of the predicted Class of the taxonomic rank of Metagenome 2. Krona chart of the predicted Class of the taxonomic rank of Metagenome 3. d, Krona chart of the predicted Class of the taxonomic rank of Metagenome 4. Krona chart of the predicted Class of the taxonomic rank of Metagenome 5. f, Krona chart of the predicted Class of the taxonomic rank of Metagenome 6. g Krona chart of the predicted Class of the taxonomic rank of Metagenome 7.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 . 2 . 1 .</head><label>321</label><figDesc>Figure 3.2.1. Flow diagram of the process of identifying the novel putative metagenomic IRED sequences carried out at Prozomix.</figDesc><graphic coords="13,81.75,278.06,400.15,144.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 . 2 . 2 .</head><label>322</label><figDesc>Figure 3.2.2. A dendogram highlighting the relationship of the sequences during the target selection process of the putative IREDs. a,</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>3. 2 .Cluster 1 : 2 : 3 : 4 : 5 : 6 : 11 : 6 Figure 3 . 2 . 4 :Table 3 . 2 . 4 :Figure 3</head><label>21234561163243243</label><figDesc>Figure 3.2.4: Sequence similarity network comparing the metagenomic derived enzymes to previously described IREDs, and to other families of NADPH-dependent enzymes of the oxidoreductase class (EC 1).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3 . 2 . 5 .</head><label>325</label><figDesc>Figure 3.2.5. IREDy-to-go 384-screening of 2b combined with biotransformation data for the reductive amination of 2, mapped phylogenetically which is shown as the overall tree, and broken down into legible smaller portions. a, the overall phylogenetic tree as shown in Figure 2.b enlarged. b-j, sections of phylogenetic tree mapping across all 384 IREDs for the reductive amination of cyclohexanone (2) with cyclopropylamine (b) shown as the inner red gradient where darker red represents higher conversion up to &gt;99% . The centre multi-value bar chart represents % conversion with % ee for reduction of 2-phenylpiperidine</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><figDesc>mB -) galOver-expression of soluble protein Following transformation of pET-28a containing the IRED construct into chemically competent E. coli cells, recombinant expression was performed. All flask scale expressions of IREDs were performed using E. coli BL21(DE3), and inoculated into baffled 2 L Erlenmeyer flasks containing 0.5 L Prozomix's TB-derived animal free medium, supplemented with kanamycin (35 μg / mL).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 3 . 3 . 1 .</head><label>331</label><figDesc>Figure 3.3.1. SDS-PAGE analysis of the each IRED recombinantly expressed in E. coli BL21 (DE3). All samples were made up of 10 mg/ml crude lyophilised lysate.</figDesc><graphic coords="69,77.05,442.76,290.90,113.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 3 . 4 . 1 :</head><label>341</label><figDesc>Figure 3.4.1: Thermostability studies on pIR-09. Use of circular dichroism to calculate the melting temperature (Tm) of pIR-09 with a plot of temperature (°C) vs molar ellipticity (θ / deg cm 2 dmol -1 ) shown in a blue curve. Use of residual activity studies (NADPH consumption at 340 nm) to give relative activity towards 2 and b to calculate Tm, curve shown in red. The Tm from CD was calculated to be 53.46 ± 0.46 °C, and the Tm from residual activity studies was calculated to be 49.5 ± 0.2 °C.</figDesc><graphic coords="74,189.05,135.67,279.75,227.75" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><figDesc>Figure 4.1.1 screening of IRED activity towards a given substrate (in the oxidative deamination direction) produces he nicotinamide co-factor which is consumed by PRO-Diaphorase-001 to reduce INT (5) to INTformazan (6). Since INT is colourless and INT-formazan is red, a colorimetric change (i.e. a positive in the screen) is easily visible by eye. PRO-DIA-001 was selected from a panel of 40 diaphorases supplied by Prozomix Ltd which had good specific activity towards both NADH and NADPH as absolute co-factor specificity of the panel is unknown. Initial proof-of-concept reactions carried with commercially available amines 1 (salsolidine) and 2a (Nmethylcyclohexylamine) were deemed to be successful (Figure 4.1.1) with analytical scale biotransformations ran in parallel.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Fig 4 . 1 . 1 :</head><label>411</label><figDesc>Fig 4.1.1: Proof of concept: a, the overall schematic outlining the IREDy-to-go reaction where by the IRED catalyses the oxidative deamination of the amine leading to the reduced nicotinamide co-factor which serves as a co-enzyme for a secondary enzyme, a diaphorase, which reduces INT (5) to INT-formazan(6). b, a table combining the results of initial proof of concept studies. Including the spectrophotometric data from low-throughput studies with 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (1) and Nmethylcyclohexylamine (2a), as well as bioconversion data for reactions ran in parallel to the IREDy-to-go screen. Reaction parameters imine reduction: imine (10 M) IREDs (4 mg mL -1 CFE), NADP + (0.5 mM), GDH (10 U mL -1 ), d-glucose (50 mM), TRIS</figDesc><graphic coords="76,118.00,378.65,415.99,285.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><figDesc>and reductive amination reactions. Initial proof-of-concept IREDy-to-go reactions carried with 1 (salsolidine) and 2a (Nmethylcyclohexylamine) were deemed to be successful as wells with different IREDs exhibited different degrees of colorimetric change, with AdRedAm and pIR-64 giving a deep red colorimetric change indicative of different levels of activity towards the substrates. The control well showed no colour change even after 24 hours, pleasingly showing that there are no background reactions from cell lysate that give false positives. To validate the results from the IREDy-to-go screen, biotransformations using PRO-NAD(P)H-oxidase 001 (PRO-NOX-001) as a co-factor recycling system, were performed in the oxidative direction. Conversions as outlined in Figure 4.1.1 matched the colorimetric change observed on the plate. AdRedAm gave near full conversion (&gt;99%) with 1 and &gt;90% with 2a. Biotransformation were also performed in the synthetic (reductive) direction and for both reactions 2 and a to 2a and or 45 to 1 the results corresponded to the IREDy-to-go results see Figure 4.1.1.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure 4 . 1 . 2 .</head><label>412</label><figDesc>Figure 4.1.2. Optimisation of low-throughput IREDy-to-go assay. a) schematic of reaction investigated in the development of the screen through the oxidative salsolidine (1). b) pH screening of IREDy-to-go with AdRedAm and -ve control of pET28a with salsolidine. Image taken 24 hrs after substrate addition. Well 1: -ve control pH 8.0. Well 2: -ve control pH 9.0. Well 3: -ve control pH 10. Well 4: AdRedAm pH 10.0. Well 5: AdRedAm pH 9.0. Well 6: Ad RedAm pH 8.0. Conditions: salsolidine 1 10mM, INT 0.25</figDesc><graphic coords="79,131.20,428.95,242.02,264.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>Figure 4 . 1 . 3 .</head><label>413</label><figDesc>Figure 4.1.3. Screening of α-methylbenzylamine (13k) at different operating temperatures. a, the reaction investigated foroptimisation of temperature of the assay. b, assay incubated at ambient with 0 hr and 24 hr comparison. c, assay incubated at 30 °C with 0 hr and 24 hr comparison. d, assay incubated at 37 °C with 0 hr and 24 hr comparison. e, a table comparing the average absorbance of both blank and assay plates at 0 hr and 24 hr for ambient, 30 °C, 37 °C.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Scheme 4 . 2 . 1 .</head><label>421</label><figDesc>Scheme 4.2.1. Overall Principle of IREDy-to-go ™ .</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head>Figure 4 . 2 . 1 .Scheme 4 . 2 . 2 .</head><label>421422</label><figDesc>Figure 4.2.1. Colorimetric screen performed with N-cyclopropylcyclohexylamine (2b).</figDesc><graphic coords="87,120.70,76.37,356.55,221.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_15"><head>Figure 4 . 3 . 1 )</head><label>431</label><figDesc>. Once set up the CFE was kept on ice until loaded into the PMP.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_16"><head>Figure 4 . 3 . 1 .</head><label>431</label><figDesc>Figure 4.3.1. A demonstration of how four 96-deep well master plates are used to generate the quadrant in numerical order in the 384 deep-well and 384 assay plate.</figDesc><graphic coords="89,113.40,57.02,444.90,307.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_17"><head>Fig 4 . 3 . 2 :</head><label>432</label><figDesc>Fig 4.3.2: Directions in which the plates are retrieved and delivered from the stands to and from the pipettor head to generate the master blocks both 96-and 384-well.</figDesc><graphic coords="90,113.40,57.02,264.25,242.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_18"><head>Figure 4 . 3 . 3 .</head><label>433</label><figDesc>Figure 4.3.3. Translation of the CFE from 96-deep well blocks to 384-deep well master blocks.</figDesc><graphic coords="90,50.05,417.22,495.12,186.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_19"><head>Figure 4 . 3 . 4 .</head><label>434</label><figDesc>Figure 4.3.4. Directions in which the plates are retrieved and delivered from the stands to and from the pipettor head to generate the 384-well assay plates</figDesc><graphic coords="91,113.40,57.02,424.55,266.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_20"><figDesc>.4.1 lanes 01-40). Characterisation of these 40 putative diaphorases was then performed essentially where the final reaction conditions were 50 mM Tris-HCl buffer, pH 7.5, containing 0.989 mM INT and either 0.3 mM NADH or 0.3 mM NADPH. As shown in Table S.4.4.1 DIA(001) and DIA(006) were apparently the most suitable catalysts for the proposed colorimetric step of the assay, as they did not exhibit a cofactor preference. Dual co-</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_21"><head>Figure 4 . 4 . 1 .</head><label>441</label><figDesc>Figure 4.4.1. 12 % (v/v) SDS-PAGE gel image of DIA(001) to (040). Gel image showing 40 native DIAs, all targets are approx. 40-60 kDa. For each enzyme, 10 µL of a 10 mg/mL stock was loaded per well. The MW of each marker protein is as indicated with arrows, whilst the reference number of each enzyme is given above each well.</figDesc><graphic coords="93,113.40,300.72,198.40,99.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_22"><head>Figure 4 . 4 . 2 .</head><label>442</label><figDesc>Figure 4.4.2. Michaelis-menten plot for the reduction of INT to INT-formazan with PRO-DIA-001.</figDesc><graphic coords="95,166.40,263.62,311.30,178.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_23"><head>4 . 2 .</head><label>42</label><figDesc>Due to the insoluble nature of INT-formazan, this was reduced biocatalytically on scale using DIA-001 (under conditions replicating assay outlined in Table4.1.1). Conditions A (amine oxidation in presence of INT-formazan): 10 mM amine 2b, INT-formazan 0.25 mg/ml, NADPH 0.5 mM, PRO-NOX-001 (purified) 0.4% v/v, IRED 4 mg/ml. Reaction made up to 500 µL in 0.1 M TRIS-HCl pH 9.0. Conditions B (amine oxidation without presence INT-formazan): 10 mM amine 2b, NADPH 0.5 mM, PRO-NOX-001 (purified) 0.4% v/v, IRED 4 mg/ml. Reaction made up to 500 µL in 0.1 M TRIS-HCl pH 9.0. Conditions C (reductive amination in the presence of INT-formazan): 10 mM ketone 2, 20 mM amine b, glucose 50 mM, INT-formazan 0.25 mg/ml, NADPH 0.5 mM, CDX-901 (GDH) 0.5 mg/ml, IRED 4 mg/ml. Reaction made up to 500 µL in 0.1 M TRIS-HCl pH 8.0. Conditions D (reductive amination without presence of INT-formazan): 10 mM ketone 2, 100 mM amine b, glucose 50 mM, NADPH 0.5 mM, CDX-901 (GDH) 0.5 mg/ml, IRED 4 mg/ml. Reaction made up to 500 µL in 0.1 M TRIS-HCl pH 8.0. See Table 5.4.1.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_24"><head>Figure 4 . 4 . 3 .</head><label>443</label><figDesc>Figure 4.4.3. IREDy-to-go of pramipexole (18i) which exhibited peripheral reduction after 24hours.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_25"><head>Figure 4 . 4 .</head><label>44</label><figDesc>Figure 4.4.4. a, heat map outlining the position of the biocatalysts which give rise to the false positives on the IREDy-to-go plate. b, the proposed mechanism on how the enzyme gives rise to the colorimetric change when no amine substrate present. c, the various conditions (A-E) used in the colorimetric screening of IR-189 and 377 with the results of the colorimetric change corresponding to the conditions screened outlined.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_26"><head>673 8 , 3 /Figure 4 . 5 . 1 .</head><label>83451</label><figDesc>Figure 4.5.1. Definition and criteria of IREDy-to-go hits. a) Raw absorbance data from the IREDy-to-go with substrate 2a screening following the protocol as followed in section S. Absorbance readings taken at 24hrs following 24 hours after substrate addition. b) Plank plate ran in-conjunction of the assay plate of 2a following the protocol in section 4.2, absorbance readings taken 24hours following reagent addition.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_27"><head>Scheme 5 . 4 . 1 .</head><label>541</label><figDesc>Scheme 5.4.1. Asymmetric reduction of 2-phenylpiperidine (4) to 3. Scheme 5.4.2. Reductive amination o cyclohexanone (2) with cyclopropylamine (b)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_28"><head>Table 5 . 5 . 1 .Scheme 5 . 5 . 2 :</head><label>551552</label><figDesc>Scheme 5.5.2: Reductive amination of cyclohexanone 2 with 1.1 equivalents methylamine a with 1.1. Oxidative deamination of 2a to 2 and a.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_29"><figDesc>, a b, e, d, f, and k. a, Reaction parameters for reductive aminations: acetophenone (5 mM), amine (250 mM), IREDs (4 mg mL -1 of reconstituted lyophilized powder CFE), NADP + (0.5 mM), GDH (10 U mL -1 ), D-glucose (50 mM), ), 0.1 TRIS-HCl (100 mM, pH 8.0), 40 ºC, 24 h, 250 rpm. b, table outlining the results of biotransformations performed where carbonyls were coupled to dimethylamine with IREDs 23, 49, and 117. Reaction parameters for reductive aminations: acetophenone (10 mM), amine (100 mM), IREDs (4 mg mL -1 of reconstituted lyophilized powder CFE), NADP + (0.5 mM), GDH (10 U mL -1 ), D-glucose (50 mM), 0.1 TRIS-HCl (100 mM, pH 8.0), 40 ºC, 24 h, 250 rpm.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_30"><head>Figure 6 . 1 .</head><label>61</label><figDesc>Figure 6.1. GC spectra of racemic ethyl 3-(cyclopropylamino)butanoate (27b), product (B)-27b of IR117 and (A)-27b of IR356 after derivatization with acetic anhydride.</figDesc><graphic coords="137,72.00,374.47,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_31"><head>Figure 6 . 2 .</head><label>62</label><figDesc>Figure 6.2. GC spectra of racemic ethyl 3-(propargylamino)butanoate (27d), product (B)-27d of IR117 and (A)-27d of IR355 after derivatization with acetic anhydride.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_32"><head>Figure 6 . 3 .</head><label>63</label><figDesc>Figure 6.3. GC spectra of racemic ethyl 3-(allylamino)butanoate (27e), product (B)-27e of IR117 and (A)-27e of IR355 after derivatization with acetic anhydride.</figDesc><graphic coords="138,72.00,374.47,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_33"><head>Figure 6 . 4 .</head><label>64</label><figDesc>Figure 6.4. GC spectra of racemic ethyl 3-(propylamino)butanoate (27i), standard product of (S)-27i, product (S)-27i of IR117 and (R)-27i of IR355 after derivatization with acetic anhydride.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_34"><head>Figure 6 . 5 .</head><label>65</label><figDesc>Figure 6.5. GC spectra of analytic reaction for synthesis of ethyl (B)-3-(methylamino)butanoate ((B)-27a) catalysed by IR117 and (A)-27a catalysed by IR356 after derivatization with acetic anhydride.</figDesc><graphic coords="139,72.00,72.32,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_35"><head>Figure 6 . 6 .</head><label>66</label><figDesc>Figure 6.6. GC spectra of reaction mixtures for synthesis ethyl 3-(pyrrolidin-1-yl)butanoate (27l) and purified product catalyzed by IR117 and those of 27l catalysed by IR351.</figDesc><graphic coords="139,72.00,374.47,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_36"><head>Figure 6 . 7 .</head><label>67</label><figDesc>Figure 6.7. GC spectra of ethyl acetoacetate (27), 3-(benzylamino)butanoate (27c) and benzylamine (c).</figDesc><graphic coords="140,72.00,356.07,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_37"><head>Figure 6 . 8 .</head><label>68</label><figDesc>Figure 6.8. GC spectra of racemic ethyl 3-(cyclopropylamino)pentanoate (32b), product (B)-32b of IR117 and (A)-32b of IR356 after derivatization with acetic anhydride.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_38"><head>Figure 6 . 9 .</head><label>69</label><figDesc>Figure 6.9. GC spectra of ethyl butyrylacetate (33), racemic ethyl 3-(cyclopropylamino)hexanoate (33b), analytical reaction of IR117 and IR356 after derivatization with acetic anhydride.</figDesc><graphic coords="141,72.00,72.32,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_39"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.10. GC spectra of ethyl isobutyrylacetate (42), racemic ethyl 3-(cyclopropylamino)-4-methylpentanoate (42b), analytical reaction of IR117 and IR356 after derivatization with acetic anhydride.</figDesc><graphic coords="141,72.00,397.46,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_40"><head>Figure 6 . 11 .</head><label>611</label><figDesc>Figure 6.11. GC spectra of ethyl benzoylacetate (34) and 3-(cyclopropylamino)-3-phenylpropanoate (34b).</figDesc><graphic coords="142,72.00,72.32,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_41"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.12. GC spectra of ethyl cis-2-(cyclopropylamino)hexanecarboxylate (cis-28b, major), product (1B, 2A)-28b of IR241, product (1A, 2B)-28b (major) of IR361, trans-28b (major), and ethyl 2-oxohexanecarboxylate (28).</figDesc><graphic coords="142,72.00,379.07,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_42"><head>Figure 6 . 13 .</head><label>613</label><figDesc>Figure 6.13. GC spectra of ethyl cis-2-(propylamino)hexanecarboxylate (cis-28i, major), standard (1S, 2R)-28i and standard (1S, 2S)-28i.</figDesc><graphic coords="143,72.00,72.32,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_43"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.14. GC spectra of ethyl 2-oxopentanecarboxylate (29), product ethyl (1B, 2A)-2-(cyclopropylamino)hexanecarboxylate ((1B, 2A)-29b) of IR358, product of IR361, cis-29b (major), and trans-29b (major).</figDesc><graphic coords="143,72.00,374.47,451.30,253.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_44"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.15. GC spectra of acetophenone (13), racemic N-methyl-N-(1-phenylethyl)amine (13a), (S)-N-methyl-N-(1-phenylethyl)amine ((S)-13a), products of IR-9 and pIR-361.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_45"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.16. GC spectra of acetophenone (13), racemic N-cyclopropyl-N-(1-phenylethyl)amine (13b), products of IR-9 and pIR-361. * peak at 12.915 minutes from acetylated cyclopropylamine.</figDesc><graphic coords="146,72.00,279.52,451.27,178.05" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_46"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.17. GC spectra of acetophenone (13), racemic N-ally-N-(1-phenylethyl)amine (13e), products of IR-9 and pIR-361. * peak at 11.915 minutes from derivativatised allylamine.</figDesc><graphic coords="147,72.00,285.32,451.27,178.05" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_47"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.18. GC spectra of acetophenone (13), racemic N-propargyl-N-(1-phenylethyl)amine (13d), products of IR-9 and pIR-361. * peak at 11.915 minutes from acetylated propargylamine.</figDesc><graphic coords="148,72.00,309.25,451.27,178.05" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_48"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.19. GC spectra of 3',5'-Bis(trifluoromethyl)acetophenone (15), racemic 1-(3,5-bis(trifluoromethyl)phenyl)-N-methylethan-1-amine (15a), products of IR-9 and pIR-361.</figDesc><graphic coords="149,72.00,260.82,459.20,177.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_49"><head>Figure 6 .Table 6 . 3 . 1 Figure 6 .</head><label>66316</label><figDesc>Figure 6.20. GC spectra of acetophenone (13), racemic α-methylbenzylamine (13k), (S)-α-methylbenzylamine ((S)-13k), (R)-αmethylbenzylamine ((R)-13k), and products of IR-9 and pIR-361.</figDesc><graphic coords="150,72.00,386.07,451.27,178.05" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_50"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.22. GC-MS spectra racemic N-cyclopropyl-N-(1-phenylethyl)amine (13b) products of IR-9. *peak at 4.5 minutes from acetylated cyclopropylamine.</figDesc><graphic coords="152,-14.71,361.97,548.80,305.51" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_51"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.22.1. GC-MS spectra of analysis of IREDy-to-go with substrate 13j with pIR-117</figDesc><graphic coords="152,-12.83,364.80,546.85,307.69" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_52"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.23. GC spectra of cyclohexanone (2), N,N-dimethylcyclohexylamine (2f), and products of IR-23 and IR-117.</figDesc><graphic coords="154,72.00,431.92,451.28,139.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_53"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.24. GC spectra of cyclopentanone (30), N,N-dimethylcyclopentyllamine (30f), and products of IR-23 and IR-117.</figDesc><graphic coords="155,72.00,90.72,451.42,139.74" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_54"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.25. GC spectra of cyclohexanone (31), N,N-dimethylcyclohex-2-en-1-amine (31f), and products of IR-23 and IR-117.</figDesc><graphic coords="155,72.00,226.72,451.22,168.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_55"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.26. GC spectra of hydrocinnamaldeyhyde (12), N,N-dimethyl-3-phenylpropan-1-amine (12f), and products of IR-23 and IR-117.</figDesc><graphic coords="156,72.00,222.17,451.27,195.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_56"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.27. GC spectra of 4-phenyl-2-butanone (36), and products of IR-23 and IR-92.</figDesc><graphic coords="157,72.00,223.52,451.21,168.45" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_57"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.30. GC spectra of 4-phenylyclohexanone (39), and products of IR-23 and IR-92.</figDesc><graphic coords="160,72.00,212.82,451.21,177.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_58"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.31. GC-MS spectra of cyclohexanone (2).</figDesc><graphic coords="162,72.00,207.87,451.25,137.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_59"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.32. GC-MS spectra of N,N-dimethylcyclohexylamine (2f).</figDesc><graphic coords="162,72.00,522.97,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_60"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.33. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethylcyclohexylamine (2f).</figDesc><graphic coords="163,72.00,300.81,449.98,136.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_61"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.34. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethylcyclopentlylamine (30f). No standard of cyclopentanone (30) detected.</figDesc><graphic coords="163,72.00,435.71,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_62"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.36. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethylcyclohex-2-en-1-amine (31f).</figDesc><graphic coords="165,72.00,72.32,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_63"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.37. GC-MS spectra of hydrocinnamaldehyde (12).</figDesc><graphic coords="165,72.00,414.11,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_64"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.38. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethyl-3-phenylpropan-1-amine (12f).</figDesc><graphic coords="166,72.00,72.32,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_65"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.39. GC-MS spectra of 4-phenyl-2-butanone (36).</figDesc><graphic coords="166,72.00,461.71,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_66"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.40. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethyl-4-phenylbutan-2-amine (36f).</figDesc><graphic coords="167,72.00,208.62,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_67"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.41. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethylhexan-2-amine (38). No 2-hexanone detected.</figDesc><graphic coords="167,72.00,464.01,450.00,136.86" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_68"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.43. GC-MS spectra of 4-phenylcyclohexanone (39).</figDesc><graphic coords="169,72.00,72.32,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_69"><head>Figure 6 .Table 6 . 6 .Figure 6 .</head><label>6666</label><figDesc>Figure 6.44. GC-MS spectra of the result of a biotransformation with pIR-117 to obtain N,N-dimethyl-4-phenylcyclohexan-1-amine (39f).</figDesc><graphic coords="169,72.00,390.32,451.30,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_70"><head>Figure 6 . 7 *</head><label>67</label><figDesc>Figure 6.46. Chiral GC-FID analysis of biotransformations for the reduction 6-phenyl-2,3,4,5-tetrahydropyridine (4) to 2-phenylpiperdine (3) with pIR-112 to yield (R)-3 and with pIR-117 to yield (S)-3.</figDesc><graphic coords="170,72.00,422.96,451.29,173.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_71"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.47.GC-FID analysis of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (45) and racemic-6,7-dimethoxy-1-methyl-1,2,3,4tetrahydroisoquinoline (1).</figDesc><graphic coords="171,72.00,206.67,448.16,258.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_72"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6.48. GC-FID analysis of the biotransformation of the reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (45) with (+/-)-pET28a and oxidation of 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (1) with (+/-)-pET28a.</figDesc><graphic coords="172,72.00,72.32,450.35,259.59" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_73"><head>Figure 6 .Table 6 . 8 . 4 * 1 Figure 6 .</head><label>668416</label><figDesc>Figure 6.49. GC-FID analysis of the biotransformation of the reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (45) with AdRedAm and the oxidation of 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (1) with AdRedAm.</figDesc><graphic coords="172,72.29,370.21,450.87,259.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_74"><head>Figure 6 .Section 7 .</head><label>67</label><figDesc>Figure 6.51. Chiral GC-FID analysis of the biotransformation of the reductive amination of 2 and b to give 2b with pIR-202</figDesc><graphic coords="173,72.00,569.00,451.13,123.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_75"><figDesc>5 mol/L with ethyl acetate and added to a solution of NaBH(OAc)3 which was prepared by adding NaBH4 (5.0 equiv) to glacial acetic acid (3.0 mmol/mL) at 15-20ºC. The reaction mixture was stirred overnight at room temperature. After evaporation of ethyl acetate and acetic acid under vacuum at 40ºC, the residue was dissolved with CH2Cl2 and washed with saturated sodium carbonate. The combined organic layers were extracted with 0.2 mol/L HCl and the aqueous phase basified to pH 10 by addition of 1 mol/L sodium carbonate. The product was extracted into ethyl acetate. The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure to afford the desired product. The corresponding hydrochloride was obtained by addition of 2 M HCl in diethyl ether and drying in vacuum. Ethyl 3-(cyclopropylamino)butanoate hydrochloride (27b) Ethyl acetoacetate (25.0 mmol, 3.25 g) and cyclopropylamine (27.5 mmol, 1.57 g) gave 4.47 g 27b as white solid in 86% yield. 1 H NMR (METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.1 Hz, 2 H), 3.73 -3.85 (m, 1 H), 2.74 -2.97 (m, 3 H), 1.48 (d, J=6.4 Hz, 3 H), 1.30 (t, J=7.1 Hz, 3 H), 0.98 (br. s., 4 H).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_76"><head>Figure 8 . 1 .</head><label>81</label><figDesc>Figure 8.1. 1 H-NMR spectra of racemic ethyl 3-(cyclopropylamino)butanoate hydrochloride (rac-27b).</figDesc><graphic coords="184,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_77"><head>Figure 8 . 2 .</head><label>82</label><figDesc>Figure 8.2. 13 C-NMR spectra of racemic ethyl 3-(cyclopropylamino)butanoate hydrochloride (rac-27b).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_78"><head>Figure 8 . 3 .</head><label>83</label><figDesc>Figure 8.3. 1 H-NMR spectra of racemic ethyl 3-(propargylamino)butanoate (rac-27d).</figDesc><graphic coords="185,72.00,72.32,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_79"><head>Figure 8 . 4 .</head><label>84</label><figDesc>Figure 8.4. 13 C-NMR spectra of racemic ethyl 3-(propargylamino)butanoate (rac-27d).</figDesc><graphic coords="185,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_80"><head>Figure 8 . 5 .</head><label>85</label><figDesc>Figure 8.5. 1 H-NMR spectra of racemic ethyl 3-(allylamino)butanoate (rac-27e).</figDesc><graphic coords="186,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_81"><head>Figure 8 . 6 .</head><label>86</label><figDesc>Figure 8.6. 13 C-NMR spectra of racemic ethyl 3-(allylamino)butanoate (rac-27e).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_82"><head>Figure 8 . 7 .</head><label>87</label><figDesc>Figure 8.7. 1 H-NMR spectra of racemic ethyl 3-(propylamino)butanoate (rac-27i).</figDesc><graphic coords="187,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_83"><head>Figure 8 . 8 .</head><label>88</label><figDesc>Figure 8.8. 13 C-NMR spectra of racemic ethyl 3-(propylamino)butanoate (rac-27i).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_84"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.9. 1 H-NMR spectra of racemic ethyl 3-(benzylamino)butanoate (rac-27c).</figDesc><graphic coords="188,72.00,405.22,456.00,303.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_85"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.10. 13 C-NMR spectra of racemic ethyl 3-(benzylamino)butanoate (rac-27c).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_86"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.11. 1 H-NMR spectra of racemic ethyl 3-(pyrrolidin-1-yl)butanoate (rac-27l).</figDesc><graphic coords="189,72.00,405.22,456.00,303.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_87"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.12.13  C-NMR spectra of racemic ethyl 3-(pyrrolidin-1-yl)butanoate (rac-27l).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_88"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.13. 1 H-NMR spectra of racemic ethyl 3-(cyclopropylamino)pentanoate (rac-32b).</figDesc><graphic coords="190,72.00,72.32,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_89"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.14. 13 C-NMR spectra of racemic ethyl 3-(cyclopropylamino)pentanoate (rac-32b).</figDesc><graphic coords="190,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_90"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.15. 1 H-NMR spectra of racemic ethyl 3-(cyclopropylamino)hexanoate (rac-33b).</figDesc><graphic coords="191,72.00,72.32,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_91"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.16. 13 C-NMR spectra of racemic ethyl 3-(cyclopropylamino)hexanoate (rac-33b).</figDesc><graphic coords="191,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_92"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.17. 1 H-NMR spectra of racemic ethyl 3-(cyclopropylamino)-4-methylpentanoate (rac-42b).</figDesc><graphic coords="192,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_93"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.18. 13 C-NMR spectra of racemic ethyl 3-(cyclopropylamino)-4-methylpentanoate (rac-42b).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_94"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.19. 1 H-NMR spectra of racemic ethyl 3-(cyclopropylamino)-3-phenylpropanoate (rac-34b).</figDesc><graphic coords="193,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_95"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.20. 13 C-NMR spectra of racemic ethyl 3-(cyclopropylamino)-3-phenylpropanoate (rac-34b).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_96"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.21. 1 H-NMR spectra of racemic ethyl 2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride (rac-28b).</figDesc><graphic coords="194,72.00,72.32,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_97"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.22. 13 C-NMR spectra of racemic ethyl 2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride (rac-28b).</figDesc><graphic coords="194,72.00,403.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_98"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.23. 1 H-NMR spectra of racemic ethyl 2-(propylamino)cyclohexanecarboxylate (rac-28i).</figDesc><graphic coords="195,72.00,72.32,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_99"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.24. 13 C-NMR spectra of racemic ethyl 2-(propylamino)cyclohexanecarboxylate (rac-28i).</figDesc><graphic coords="195,72.00,426.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_100"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.25. 1 H-NMR spectra of racemic ethyl 2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride (rac-29b).</figDesc><graphic coords="196,72.00,72.32,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_101"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.26. 13 C-NMR spectra of racemic ethyl 2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride (rac-29b).</figDesc><graphic coords="196,72.00,426.72,453.50,301.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_102"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.27. 1 H-NMR spectra of racemic N-(1-phenylethyl) cyclopropanamine (rac-13b).</figDesc><graphic coords="197,72.00,72.32,451.30,299.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_103"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.28. 13 C-NMR spectra of racemic N-(1-phenylethyl) cyclopropanamine (rac-13b).</figDesc><graphic coords="197,72.00,425.22,451.30,299.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_104"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.29. 1 H-NMR spectra of racemic N-ally-N-(1-phenylethyl)amine (rac-13e).</figDesc><graphic coords="198,72.00,417.22,451.29,314.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_105"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.30. 13 C-NMR spectra of racemic N-ally-N-(1-phenylethyl)amine (rac-13e).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_106"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.31. 1 H-NMR spectra of racemic 1-(3, 5-bis(trifluoromethyl)phenyl)-N-methylethanamine (rac-15a).</figDesc><graphic coords="199,72.00,72.32,451.30,299.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_107"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.32. 13 C-NMR spectra of racemic 1-(3, 5-bis(trifluoromethyl)phenyl)-N-methylethanamine (rac-15a).</figDesc><graphic coords="199,72.00,425.22,451.30,299.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_108"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.33. 1 H-NMR spectra of racemic N-(2-chloro-1-phenylethyl)cyclopropanamine (rac-25b).</figDesc><graphic coords="200,72.00,402.22,451.30,299.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_109"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.34. 13 C-NMR spectra of racemic N-(2-chloro-1-phenylethyl)cyclopropanamine (rac-25b).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_110"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.35. 1 H-NMR spectra of racemic 2-chloro-N-cyclopropylcyclohexanamine (rac-26b).</figDesc><graphic coords="201,72.00,72.32,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_111"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.36. 13 C-NMR spectra of racemic 2-chloro-N-cyclopropylcyclohexanamine (rac-26b).</figDesc><graphic coords="201,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_112"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.37. 1 H-NMR spectra of racemic N-methylheptan-2-amine (rac-22a).</figDesc><graphic coords="202,72.00,408.22,451.29,314.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_113"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.38. 13 C-NMR spectra of racemic N-methylheptan-2-amine (rac-22a).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_114"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.39. 1 H-NMR spectra of ethyl (B)-3-(cyclopropylamino)butanoate hydrochloride ((B)-27b) prepared by pIR-117.</figDesc><graphic coords="203,72.00,95.32,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_115"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.40. 13 C-NMR spectra of ethyl (B)-3-(cyclopropylamino)butanoate hydrochloride ((B)-27b) prepared by pIR-117.</figDesc><graphic coords="203,72.00,425.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_116"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.41. 1 H-NMR spectra of ethyl (A)-3-(cyclopropylamino)butanoate hydrochloride ((A)-27b) prepared by pIR-356.</figDesc><graphic coords="204,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_117"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.42. 13 C-NMR spectra of ethyl (A)-3-(cyclopropylamino)butanoate hydrochloride ((A)-27b) prepared by pIR-356.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_118"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.43. 1 H-NMR spectra of ethyl (B)-3-(propargylamino)butanoate hydrochloride ((B)-27d) prepared by pIR-117.</figDesc><graphic coords="205,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_119"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.44. 13 C-NMR spectra of ethyl (B)-3-(propargylamino)butanoate hydrochloride ((B)-27d) prepared by pIR-117.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_120"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.45. 1 H-NMR spectra of ethyl (A)-3-(propargylamino)butanoate hydrochloride ((A)-27d) prepared by pIR-355.</figDesc><graphic coords="206,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_121"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.46. 13 C-NMR spectra of ethyl (A)-3-(propargylamino)butanoate hydrochloride ((A)-27d) prepared by pIR-355.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_122"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.47. 1 H-NMR spectra of ethyl (B)-3-(allylamino)butanoate hydrochloride ((B)-27e) prepared by pIR-117.</figDesc><graphic coords="207,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_123"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.48. 13 C-NMR spectra of ethyl (B)-3-(allylamino)butanoate hydrochloride ((B)-27e) prepared by pIR-117.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_124"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.49. 1 H-NMR spectra of ethyl (A)-3-(allylamino)butanoate hydrochloride ((A)-27e) prepared by pIR-355.</figDesc><graphic coords="208,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_125"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.50. 13 C-NMR spectra of ethyl (A)-3-(allylamino)butanoate hydrochloride ((A)-27e) prepared by pIR-355.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_126"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.51. 1 H-NMR spectra of ethyl (S)-3-(propylamino)butanoate hydrochloride ((S)-27i) prepared by pIR-117.</figDesc><graphic coords="209,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_127"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.52. 13 C-NMR spectra of ethyl (S)-3-(propylamino)butanoate hydrochloride ((S)-27i) prepared by pIR-117.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_128"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.53. 1 H-NMR spectra of ethyl (R)-3-(propylamino)butanoate hydrochloride ((R)-27i) prepared by pIR-355.</figDesc><graphic coords="210,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_129"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.54. 13 C-NMR spectra of ethyl (R)-3-(propylamino)butanoate hydrochloride ((R)-27i) prepared by pIR-355.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_130"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.55 1 H-NMR spectra of ethyl 3-(pyrrolidin-1-yl)butanoate (27l) prepared by pIR-117.</figDesc><graphic coords="211,72.00,402.22,451.29,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_131"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.56. 13 C-NMR spectra of ethyl 3-(pyrrolidin-1-yl)butanoate (27l) prepared by pIR-117.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_132"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.57. 1 H-NMR spectra of ethyl 3-(pyrrolidin-1-yl)butanoate (27l) prepared by pIR-351.</figDesc><graphic coords="212,72.00,72.32,451.29,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_133"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.58. 13 C-NMR spectra of ethyl 3-(pyrrolidin-1-yl)butanoate (27l) prepared by pIR-351.</figDesc><graphic coords="212,72.00,402.22,451.29,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_134"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.59. 1 H-NMR spectra of ethyl (B)-3-(cyclopropylamino)pentanoate hydrochloride ((B)-32b) prepared by pIR-117.</figDesc><graphic coords="213,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_135"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.60. 13 C-NMR spectra of ethyl (B)-3-(cyclopropylamino)pentanoate hydrochloride ((B)-32b) prepared by pIR-117.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_136"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.61. 1 H-NMR spectra of ethyl (A)-3-(cyclopropylamino)pentanoate hydrochloride ((A)-32b) prepared by pIR-356.</figDesc><graphic coords="214,72.00,402.22,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_137"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.62. 13 C-NMR spectra of ethyl (A)-3-(cyclopropylamino)pentanoate hydrochloride ((A)-32b) prepared by pIR-356.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_138"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.63. 1 H-NMR spectra of ethyl (1B, 2A)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1B, 2A)-28b) prepared by pIR-241.</figDesc><graphic coords="215,72.00,420.62,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_139"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.64. 13 C-NMR spectra of ethyl (1B, 2A)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1B, 2A)-28b) prepared by pIR-241.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_140"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.65. 1 H-NMR spectra of ethyl (1A, 2B)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1A, 2B)-28b) and (1B, 2B)-28b prepared by pIR-361.</figDesc><graphic coords="216,72.00,420.62,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_141"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.66. 13 C-NMR spectra of ethyl (1A, 2B)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1A, 2B)-28b) and (1B, 2B)-28b prepared by pIR-361.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_142"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.67. 1 H-NMR spectra of ethyl (1B, 2A)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1B, 2A)-29b) prepared by pIR-358.</figDesc><graphic coords="217,72.00,72.32,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_143"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.68. 13 C-NMR spectra of ethyl (1B, 2A)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1B, 2A)-29b) prepared by pIR-358.</figDesc><graphic coords="217,72.00,420.62,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_144"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.69. 1 H-NMR spectra of ethyl (1A, 2B)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1A, 2B)-29b) and trans-29b prepared by pIR-361.</figDesc><graphic coords="218,72.00,420.62,451.30,299.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_145"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.70. 13 C-NMR spectra of ethyl (1A, 2B)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1A, 2B)-29b) and trans-29b prepared by pIR-361</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="53,123.32,107.30,595.25,314.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="54,123.32,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="55,123.45,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="56,123.45,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="57,123.45,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="58,123.32,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="59,123.32,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="60,123.32,107.30,595.25,299.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="61,123.32,107.30,595.20,299.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="99,72.00,91.92,424.50,133.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="145,72.00,72.32,451.60,193.54" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="145,72.00,277.37,453.75,178.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="158,72.00,72.32,451.28,139.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="158,72.00,223.52,451.21,168.45" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="159,72.00,72.32,451.22,168.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="159,72.00,252.07,451.28,139.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="168,72.00,72.32,451.22,137.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="168,72.00,481.20,450.00,136.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 3 .3.2.</head><label>3</label><figDesc>Corresponding table to the SDS-PAGE gels of Figure25.0 with the contents of each well outlined.</figDesc><table><row><cell>Gel</cell><cell>IRED</cell><cell>Gel</cell><cell>IRED</cell><cell>Gel</cell><cell>IRED</cell><cell>Gel</cell><cell>IRED</cell><cell>Gel</cell><cell>IRED</cell></row><row><cell>1A</cell><cell>LM</cell><cell>5D</cell><cell>39</cell><cell>9G</cell><cell>78</cell><cell>13J</cell><cell></cell><cell>18C</cell><cell>LM</cell></row><row><cell>1B</cell><cell>1</cell><cell>5E</cell><cell>40</cell><cell>9H</cell><cell>79</cell><cell>14A</cell><cell></cell><cell>18D</cell><cell>156</cell></row><row><cell>1C</cell><cell>2</cell><cell>5F</cell><cell>41</cell><cell>9I</cell><cell>80</cell><cell>14B</cell><cell></cell><cell>18E</cell><cell>157</cell></row><row><cell>1D</cell><cell>3</cell><cell>5G</cell><cell>42</cell><cell>9J</cell><cell>81</cell><cell>14C</cell><cell>LM</cell><cell>18F</cell><cell>158</cell></row><row><cell>1E</cell><cell>4</cell><cell>5H</cell><cell>43</cell><cell>10A</cell><cell>82</cell><cell>14D</cell><cell></cell><cell>18G</cell><cell>159</cell></row><row><cell>1F</cell><cell>5</cell><cell cols="7">5I 18H 6G 44 10B LM 14E 51 10J 90 15C 19F</cell><cell>167</cell></row><row><cell>2E</cell><cell>13</cell><cell>6H</cell><cell>52</cell><cell>11A</cell><cell>91</cell><cell>15D</cell><cell>LM</cell><cell>19G</cell><cell>168</cell></row><row><cell>2F</cell><cell>14</cell><cell>6I</cell><cell>53</cell><cell>11B</cell><cell>92</cell><cell>15E</cell><cell></cell><cell>19H</cell><cell>169</cell></row><row><cell>2G</cell><cell>15</cell><cell>6J</cell><cell>54</cell><cell>11C</cell><cell>LM</cell><cell>15F</cell><cell></cell><cell>19I</cell><cell>170</cell></row><row><cell>2H</cell><cell>16</cell><cell>7A</cell><cell>55</cell><cell>11D</cell><cell>93</cell><cell>15G</cell><cell></cell><cell>19J</cell><cell>171</cell></row><row><cell>2I</cell><cell>17</cell><cell>7B</cell><cell>56</cell><cell>11E</cell><cell>94</cell><cell>15H</cell><cell></cell><cell>20A</cell><cell>LM</cell></row><row><cell>2J</cell><cell>18</cell><cell>7C</cell><cell>LM</cell><cell>11F</cell><cell>95</cell><cell>15I</cell><cell></cell><cell>20B</cell><cell>172</cell></row><row><cell>3A</cell><cell>19</cell><cell>7D</cell><cell>57</cell><cell>11G</cell><cell>96</cell><cell>15J</cell><cell></cell><cell>20C</cell><cell>173</cell></row><row><cell>3B</cell><cell>20</cell><cell>7E</cell><cell>58</cell><cell>11H</cell><cell>97</cell><cell>16A</cell><cell>LM</cell><cell>20D</cell><cell>174</cell></row><row><cell>3C</cell><cell>LM</cell><cell>7F</cell><cell>59</cell><cell>11I</cell><cell>98</cell><cell>16B</cell><cell></cell><cell>20E</cell><cell>175</cell></row><row><cell>3C</cell><cell>21</cell><cell>7G</cell><cell>60</cell><cell>11J</cell><cell>99</cell><cell>16C</cell><cell></cell><cell>20F</cell><cell>176</cell></row><row><cell>3E</cell><cell>22</cell><cell>7H</cell><cell>61</cell><cell>12A</cell><cell>LM</cell><cell>16D</cell><cell></cell><cell>20G</cell><cell>177</cell></row><row><cell>3F</cell><cell>23</cell><cell>7I</cell><cell>62</cell><cell>12B</cell><cell>100</cell><cell>16E</cell><cell></cell><cell>20H</cell><cell>178</cell></row><row><cell>3G</cell><cell>24</cell><cell>7J</cell><cell>63</cell><cell>12C</cell><cell>101</cell><cell>16F</cell><cell></cell><cell>20I</cell><cell>179</cell></row><row><cell>3H</cell><cell>25</cell><cell>8A</cell><cell>64</cell><cell>12D</cell><cell>102</cell><cell>16G</cell><cell></cell><cell>20J</cell><cell>180</cell></row><row><cell>3I</cell><cell>26</cell><cell>8B</cell><cell>65</cell><cell>12E</cell><cell>103</cell><cell>16H</cell><cell></cell><cell>21A</cell><cell>181</cell></row><row><cell>3J</cell><cell>27</cell><cell>8C</cell><cell>66</cell><cell>12F</cell><cell>104</cell><cell>16I</cell><cell></cell><cell>21B</cell><cell>LM</cell></row><row><cell>4A</cell><cell>28</cell><cell>8D</cell><cell>LM</cell><cell>12G</cell><cell>105</cell><cell>16J</cell><cell></cell><cell>21C</cell><cell>182</cell></row><row><cell>4B</cell><cell>29</cell><cell>8E</cell><cell>67</cell><cell>12H</cell><cell>106</cell><cell>17A</cell><cell></cell><cell>21D</cell><cell>183</cell></row><row><cell>4C</cell><cell>30</cell><cell>8F</cell><cell>68</cell><cell>12I</cell><cell>107</cell><cell>17B</cell><cell>LM</cell><cell>21E</cell><cell>184</cell></row><row><cell>4D</cell><cell>LM</cell><cell>8G</cell><cell>69</cell><cell>12J</cell><cell>108</cell><cell>17C</cell><cell></cell><cell>21F</cell><cell>185</cell></row><row><cell>4E</cell><cell>31</cell><cell>8H</cell><cell>70</cell><cell>13A</cell><cell>109</cell><cell>17D</cell><cell></cell><cell>21G</cell><cell>186</cell></row><row><cell>4F</cell><cell>32</cell><cell>8I</cell><cell>71</cell><cell>13B</cell><cell>LM</cell><cell>17E</cell><cell></cell><cell>21H</cell><cell>187</cell></row><row><cell>4G</cell><cell>33</cell><cell>8J</cell><cell>72</cell><cell>13C</cell><cell>110</cell><cell>17F</cell><cell></cell><cell>21I</cell><cell>188</cell></row><row><cell>4H</cell><cell>34</cell><cell>9A</cell><cell>LM</cell><cell>13D</cell><cell>111</cell><cell>17G</cell><cell></cell><cell>21J</cell><cell>189</cell></row><row><cell>4I</cell><cell>35</cell><cell>9B</cell><cell>73</cell><cell>13E</cell><cell>112</cell><cell>17H</cell><cell></cell><cell>22A</cell><cell>190</cell></row><row><cell>4J</cell><cell>36</cell><cell>9C</cell><cell>74</cell><cell>13F</cell><cell>113</cell><cell>17I</cell><cell></cell><cell>22B</cell><cell>191</cell></row><row><cell>5A</cell><cell>LM</cell><cell>9D</cell><cell>75</cell><cell>13G</cell><cell>114</cell><cell>17J</cell><cell></cell><cell>22C</cell><cell>LM</cell></row><row><cell>5B</cell><cell>37</cell><cell>9E</cell><cell>76</cell><cell>13H</cell><cell>115</cell><cell>18A</cell><cell></cell><cell>22D</cell><cell>192</cell></row><row><cell>5C</cell><cell>38</cell><cell>9F</cell><cell>77</cell><cell>13I</cell><cell>116</cell><cell>18B</cell><cell></cell><cell>22E</cell><cell>193</cell></row></table><note><p>buffer pH 7.0 containing 0.3 M NaCl and 0.03 M imidazole. The cells were then lysed as outlined in section 3.3.2. Following lysis cell lysate was clarified by centrifugation at 18,000 rpm for 45 min. Supernatant was then filtered through a 0.45 μm MiniStart syringe filter (Satorius) prior to being loaded onto a nickel affinity chromatography column. Using an ÄKTA purifier (GE Healthcare) a HisTrap FF 5 mL column (GE LifeSciences) the column was conditioned with 0.1 M Sodium Phosphate buffer pH 7.0 containing 0.3 M NaCl and 0.03 M imidazole. Once the supernatant was loaded onto the column, the column was washed with 3x column volumes of with 0.1 M sodium phosphate buffer pH 7.0 containing 0.3 M NaCl and 0.03 M imidazole, followed by another wash with with 0.1 M Sodium Phosphate buffer pH 7.0 containing 0.3 M NaCl and 0.06 M imidazole. The protein was then eluted in 0.1 M Sodium Phosphate buffer pH 7.0 containing 0.3 M NaCl and 0.3 M imidazole. Fractions were then analysed by SDS-PAGE analysis (see 3.3.3) and the protein content was checked using NanoDrop 1000 (Thermofisher). 09 dialysed was into 0.1 M Sodium Phosphate pH 7.0 containing 0.3M NaCl. The protein was then loaded on to a HiLoad 16/600 Superdex 75 PrepGrade (GE Healthcare) gel filtration column which was pre-equilibrated with 0.1 M Sodium Phosphate pH 7.0 containing 0.3 M NaCl. The</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_25"><head>Table 6 .4. Chiral GC analysis: methods and retention times of deimethylamine as an amine donor from subsequent biotransformations. Injector temperature: 200ºC, inlet pressure: 22.40 psi, detector temperature: 220ºC, helium flow: 2.0 mL/min, column: CP-ChiraSil- DEX CB. Absolute configurations were assigned by comparison with compounds of known configuration.</head><label>6</label><figDesc>* oven temperature: Hold at 50ºC for 0 min, 50 -200ºC (5ºC/min), hold at 200ºC for 2 min</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Ketone</cell><cell>Product</cell></row><row><cell>Ketone</cell><cell>Amine</cell><cell>Product</cell><cell>Oven temp.</cell><cell>retention</cell><cell>retention</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>time/min</cell><cell>time/min</cell></row><row><cell>2</cell><cell>f</cell><cell>2f</cell><cell>**</cell><cell>8.5</cell><cell>10.0</cell></row><row><cell>30</cell><cell>f</cell><cell>30f</cell><cell>**</cell><cell>5.2</cell><cell>6.8</cell></row><row><cell>31</cell><cell>f</cell><cell>31f</cell><cell>**</cell><cell>9.6</cell><cell>16.5</cell></row><row><cell>12</cell><cell>f</cell><cell>12f</cell><cell>**</cell><cell>15.2</cell><cell>15.9</cell></row><row><cell>36</cell><cell>f</cell><cell>36f</cell><cell>**</cell><cell>16.5</cell><cell>n.d.</cell></row><row><cell>38</cell><cell>f</cell><cell>38f</cell><cell>**</cell><cell>4.4</cell><cell>n.d.</cell></row><row><cell>37</cell><cell>f</cell><cell>37f</cell><cell>**</cell><cell>9.0</cell><cell>n.d.</cell></row><row><cell>39</cell><cell>f</cell><cell>39f</cell><cell>**</cell><cell>24.6</cell><cell>n.d.</cell></row></table><note><p>*</p></note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information: Screening and characterisation of a diverse panel of metagenomic imine reductases for biocatalytic reductive amination</head><p>All multiple sequence alignments were performed using the software Clustal graphical flavour Clustal X2. The matrix implemented in the alignment was BLOSUM. Additional sequence analysis of the metagenomic IREDs was undertaken whereby a sequence similarity network (SSN) was constructed. The network was constructed to visualise the relationship between the metagenomic derived IREDs, in comparison to previously described IRED 2 , and a sample of NAD(P)H-dependent oxidoreductases following the enzyme commission (EC) number. The SSN is visualised in Figure <ref type="figure">3</ref>.2.4 and was visualised using Cytoscape v3.2.7. Some of the results of the SSN are highlighted in the results and discussion section, but are expanded upon here. The green represents the metagenomic IREDs, the red represents the IREDs from the toolbox described by workers at GSK, and blue depicts enzymes NAD(P)H-dependent oxidoreductases. The SSN depicts clearly that we have sampled thoroughly the correct sequence space when comparing our IREDs to those from Roiban and In conjunction with 384 IREDy-to-go screening, analytical screening with compounds outlined in Figure <ref type="figure">3</ref> (main text) was undertaken. Biotransformations were run in the reductive direction with the top hits to fully validate the screen and where possible were conducted with near equimolar amine loading. The enzymes were selected from plate with highest absorbance. For reductive aminations we employed 1.1-50 amine equivalents we obtained excellent conversions &gt;99% and excellent ees (&gt;99%).</p><p>When screened for oxidative deamination with N-methylcyclohexylamine (2a) we observed bidirectional cleavage giving both cyclohexylamine (j) and cyclohexanone (2) with pIR-16 giving 70% yield of cyclohexylamine (j). However, no conversion was obtained for the reductive amination between formaldehyde and cyclohexylamine (j) for both pIR-9 and pIR-16, both giving major yields of cyclohexylamine (j). Additionally bi-directional cleavage observed when the hits from the IREDy-togo screen with substrate 13j were extracted directly from the plate and analysed by GC-MS, see Figure <ref type="figure">6</ref>.22.1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Scheme 5.5.1. Reductive amination of cyclohexanone (2) with cyclopropylamine (b) with 1.1 equivalents of amine. Oxidative deamination</head><p>A full figure is shown here including % conversion and % enantiomeric excess and assigned enantiomer, some of which are not shown in Figure <ref type="figure">5</ref> (main text). The biotransformation on preparative scale (50 mL) was performed starting from β-keto esters (50 mM for 27b, 32b, 28b, 27d and 27e, 25 mM for 27i, 27l and 29b), amine (100 mM for 27b, 32b, 28b, 27d and 27e, 50 mM for 29b, 250 mM for 27i and 27l), cell-free extracts of RedAm (2.5 g wet cells weight), D-glucose (125 mM for 27b, 32b, 28b, 27d and 27e, 62.5 mM for 27i, 27l and 29b), 8 mg of NADP + , 3 mg GDH (150 U) and 50 mL sodium phosphate buffer (100 mM, pH 7.0) with 4% (v/v) DMSO, and the pH was adjusted to 7.6 with 1 M HCl. The reaction mixture was shaken at 30°C with 180 rpm. The    phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure to afford the corresponding amines.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>N-(1-phenylethyl)cyclopropanamine (13b)</head><p>Acetophenone (10.0 mmol, 1.20 g) and cyclopropylamine (20.0 mmol, 1.14 g) gave 1.16 g 13b as colorless oil in 72% yield. <ref type="bibr">1</ref> H NMR (METHANOL-d4 ,400MHz): δ = 7.12 -7.22 (m, 4 H), 7.02 -7.12 (m, 1 H), 3.67 (q, J=6. 6   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>N-(2-chloro-1-phenylethyl)cyclopropanamine (25b)</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Fractions were analysed by SDS-PAGE and protein concentration determined by Pierce™ BCA Protein Assay Kit (Thermofisher)</title>
		<author>
			<persName><surname>Min</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">/min. Fractions were analysed by SDS-PAGE and protein concentration determined by Pierce™ BCA Protein Assay Kit (Thermofisher).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Lane 3: pIR-09 cell free extract fraction. Lane 04: pIR-09 IMAC eluate. Lane 5: pIR-09 SEC eluate. Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-356 gave 470 mg ethyl (A)-3-(cyclopropylamino)butanoate hydrochloride ((A)-27b) as pale yellow solid with &gt;99% conversion and 90</title>
		<imprint/>
	</monogr>
	<note>Figure 3.3.2. SDS-PAGE analysis of the expression and purification of IR-09 Lane 01: Lane Marker 10 kDa, 15 kDa, 25 kDa, 35 kDa, 40 kDa, 55 kDa, 70 kDa, 100 kDa, 130 kDa, 180 kDa. Lane 2: pIR-09 total cell fraction isolated yield. 1 H NMR (METHANOL-d4, 400MHz): δ = 4.23 (q, J=7</note>
	<note type="raw_reference">Figure 3.3.2. SDS-PAGE analysis of the expression and purification of IR-09. Lane 01: Lane Marker 10 kDa, 15 kDa, 25 kDa, 35 kDa, 40 kDa, 55 kDa, 70 kDa, 100 kDa, 130 kDa, 180 kDa. Lane 2: pIR-09 total cell fraction. Lane 3: pIR-09 cell free extract fraction. Lane 04: pIR-09 IMAC eluate. Lane 5: pIR-09 SEC eluate. Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-356 gave 470 mg ethyl (A)-3-(cyclopropylamino)butanoate hydrochloride ((A)-27b) as pale yellow solid with &gt;99% conversion and 90% isolated yield. 1 H NMR (METHANOL-d4, 400MHz): δ = 4.23 (q, J=7.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<title level="m">sxt, J=6.5 Hz, 1 H), 2.73 -2.94 (m, 3 H)</title>
		<imprint>
			<biblScope unit="page" from="1" to="47" />
		</imprint>
	</monogr>
	<note>d, J=6.6 Hz, 3 H), 1.30 (t, J=7</note>
	<note type="raw_reference">Hz, 2 H), 3.80 (sxt, J=6.5 Hz, 1 H), 2.73 -2.94 (m, 3 H), 1.47 (d, J=6.6 Hz, 3 H), 1.30 (t, J=7.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<idno>HRMS calcd. for C9H18NO2 + 172.1338</idno>
		<title level="m">13 C NMR (METHANOL-d4, 100MHz): δ = 168</title>
		<imprint>
			<date>59.40, 50.73, 34.88, 26.27, 14.14, 11.46, 1.42, 1.25</date>
			<biblScope unit="volume">55</biblScope>
		</imprint>
	</monogr>
	<note>found 172.1333. Ethyl (B)-3-(propargylamino)butanoate hydrochloride ((B)-27d</note>
	<note type="raw_reference">Hz, 3 H), 0.91 -1.00 (m, 4 H). 13 C NMR (METHANOL-d4, 100MHz): δ = 168.55, 59.40, 50.73, 34.88, 26.27, 14.14, 11.46, 1.42, 1.25. HRMS calcd. for C9H18NO2 + 172.1338 [M+H] + , found 172.1333. Ethyl (B)-3-(propargylamino)butanoate hydrochloride ((B)-27d)</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">325 mg) and propargylamine (d, 5.0 mmol, 275 mg) catalyzed by pIR-117 gave 280 mg ethyl (B)-3-(propargylamino)butanoate hydrochloride ((B)-27d) as brown solid with 72% conversion and 54</title>
		<imprint/>
	</monogr>
	<note>Ethyl acetoacetate (27, 2.5 mmol isolated yield</note>
	<note type="raw_reference">Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and propargylamine (d, 5.0 mmol, 275 mg) catalyzed by pIR-117 gave 280 mg ethyl (B)-3-(propargylamino)butanoate hydrochloride ((B)-27d) as brown solid with 72% conversion and 54% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.1</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">2</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Hz, 2</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">3 H), 1.30 (t, J=7.1 Hz, 4 H)</title>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Hz, 3 H), 1.30 (t, J=7.1 Hz, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>13.03. HRMS calcd. for C9H16NO2 + 170.1181</idno>
		<imprint>
			<date>78.00, 73.05, 61.08, 50.37, 36.39, 34.07, 15.23</date>
		</imprint>
	</monogr>
	<note>found 170.1176. Ethyl (A)-3-(propargylamino)butanoate hydrochloride ((A)-27d</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 170.04, 78.00, 73.05, 61.08, 50.37, 36.39, 34.07, 15.23, 13.03. HRMS calcd. for C9H16NO2 + 170.1181 [M+H] + , found 170.1176. Ethyl (A)-3-(propargylamino)butanoate hydrochloride ((A)-27d)</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">325 mg) and propargylamine (d, 5.0 mmol, 275 mg) catalyzed by pIR-355 gave 400 mg ethyl (A)-3-(propargylamino)butanoate hydrochloride ((A)-27d) as pale yellow solid with &gt;99% conversion and 78% isolated yield</title>
		<imprint/>
	</monogr>
	<note>Ethyl acetoacetate (27, 2.5 mmol 1 H NMR (METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7</note>
	<note type="raw_reference">Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and propargylamine (d, 5.0 mmol, 275 mg) catalyzed by pIR-355 gave 400 mg ethyl (A)-3-(propargylamino)butanoate hydrochloride ((A)-27d) as pale yellow solid with &gt;99% conversion and 78% isolated yield. 1 H NMR (METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<idno>73 -2.92</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">2</biblScope>
		</imprint>
	</monogr>
	<note>sxt, J=6.4 Hz, 1 H), 3.29 (br. s., 1 H</note>
	<note type="raw_reference">Hz, 2 H), 3.99 -4.11 (m, 2 H), 3.82 (sxt, J=6.4 Hz, 1 H), 3.29 (br. s., 1 H), 2.73 -2.92 (m, 2</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Hz, 3 H), 1.30 (t, J=7.1 Hz, 3 H)</title>
		<idno>13.03. HRMS calcd. for C9H16NO2 + 170.1181</idno>
	</analytic>
	<monogr>
		<title level="m">13 C NMR (METHANOL-d4 ,100MHz): δ = 170</title>
		<imprint>
			<date type="published" when="1178">1178</date>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="1" to="43" />
		</imprint>
	</monogr>
	<note>.04, 77.99, 73.04, 61.06, 50.35, 36.39, 34.03, 15.22</note>
	<note type="raw_reference">H), 1.43 (d, J=6.6 Hz, 3 H), 1.30 (t, J=7.1 Hz, 3 H). 13 C NMR (METHANOL-d4 ,100MHz): δ = 170.04, 77.99, 73.04, 61.06, 50.35, 36.39, 34.03, 15.22, 13.03. HRMS calcd. for C9H16NO2 + 170.1181 [M+H] + , found 170.1178.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">(B)-3-(allylamino)butanoate hydrochloride</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint>
			<biblScope unit="page">27</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Ethyl (B)-3-(allylamino)butanoate hydrochloride ((B)-27e)</note>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">mg) catalyzed by pIR-117 gave 300 mg ethyl (B)-3-(allylamino)butanoate hydrochloride</title>
		<imprint>
			<biblScope unit="page">285</biblScope>
		</imprint>
	</monogr>
	<note>Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and allylamine (e, 5.0 mmol (B)-27e) as pale yellow solid with 86% conversion and 58% isolated yield</note>
	<note type="raw_reference">Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and allylamine (e, 5.0 mmol, 285 mg) catalyzed by pIR-117 gave 300 mg ethyl (B)-3-(allylamino)butanoate hydrochloride ((B)-27e) as pale yellow solid with 86% conversion and 58% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 5.99</title>
		<imprint/>
	</monogr>
	<note>ddt, J=17.0, 10.2, 6</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 5.99 (ddt, J=17.0, 10.2, 6.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>1 H), 5.50 -5.64 (m, 2 H), 4.23 (q, J=7.1 Hz, 2 H), 3.63 -3.81 (m, 3 H), 2.71 -2.91 (m, 2 H</note>
	<note type="raw_reference">Hz, 1 H), 5.50 -5.64 (m, 2 H), 4.23 (q, J=7.1 Hz, 2 H), 3.63 -3.81 (m, 3 H), 2.71 -2.91 (m, 2 H),</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<idno>172.1335</idno>
		<title level="m">13 C NMR (METHANOL-d4 ,100MHz): δ = 170</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">42</biblScope>
		</imprint>
	</monogr>
	<note>d, J=6.6 Hz, 3 H), 1.30 (t, J=7.2 Hz 122.90, 61.01, 50.28, 36.53, 15.</note>
	<note type="raw_reference">42 (d, J=6.6 Hz, 3 H), 1.30 (t, J=7.2 Hz, 3 H). 13 C NMR (METHANOL-d4 ,100MHz): δ = 170.15, 127.86, 122.90, 61.01, 50.28, 36.53, 15.33, 13.03. HRMS calcd. for C9H18NO2 + 172.1338 [M+H] + , found 172.1335.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">A)-3-(allylamino)butanoate hydrochloride</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Ethyl (A)-3-(allylamino)butanoate hydrochloride ((A)-27e)</note>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">mg) catalyzed by pIR-355 gave 280 mg ethyl (A)-3-(allylamino)</title>
		<imprint>
			<biblScope unit="page">285</biblScope>
		</imprint>
	</monogr>
	<note>Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and allylamine (e, 5.0 mmol butanoate hydrochloride ((A)-27e) as pale yellow solid with 82% conversion and 54% isolated yield</note>
	<note type="raw_reference">Ethyl acetoacetate (27, 2.5 mmol, 325 mg) and allylamine (e, 5.0 mmol, 285 mg) catalyzed by pIR-355 gave 280 mg ethyl (A)-3-(allylamino)butanoate hydrochloride ((A)-27e) as pale yellow solid with 82% conversion and 54% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 5.99</title>
		<imprint/>
	</monogr>
	<note>ddt, J=17.0, 10.2, 6</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 5.99 (ddt, J=17.0, 10.2, 6.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>1 H), 5.51 -5.65 (m, 2 H), 4.23 (q, J=7.1 Hz, 2 H), 3.63 -3.81 (m, 3 H), 2.71 -2.91 (m, 2 H</note>
	<note type="raw_reference">Hz, 1 H), 5.51 -5.65 (m, 2 H), 4.23 (q, J=7.1 Hz, 2 H), 3.63 -3.81 (m, 3 H), 2.71 -2.91 (m, 2 H),</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<idno>172.1332</idno>
		<title level="m">13 C NMR (METHANOL-d4 ,100MHz): δ = 170</title>
		<imprint>
			<date>127.86, 122.90, 61.02, 50.28, 36.53, 15</date>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">42</biblScope>
		</imprint>
	</monogr>
	<note>d, J=6.6 Hz, 3 H), 1.30 (t, J=7.2 Hz</note>
	<note type="raw_reference">42 (d, J=6.6 Hz, 3 H), 1.30 (t, J=7.2 Hz, 3 H). 13 C NMR (METHANOL-d4 ,100MHz): δ = 170.16, 127.86, 122.90, 61.02, 50.28, 36.53, 15.33, 13.03. HRMS calcd. for C9H18NO2 + 172.1338 [M+H] + , found 172.1332.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">S)-3-(propylamino)butanoate hydrochloride ((S)-27i</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Ethyl (S)-3-(propylamino)butanoate hydrochloride ((S)-27i)</note>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and propylamine (i, 12.5 mmol, 738 mg) catalyzed by pIR-117 gave 120 mg ethyl (R)-3-(propylamino)butanoate hydrochloride ((S)-27i) as white solid with 73% conversion and 46</title>
		<imprint/>
	</monogr>
	<note>isolated yield</note>
	<note type="raw_reference">Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and propylamine (i, 12.5 mmol, 738 mg) catalyzed by pIR- 117 gave 120 mg ethyl (R)-3-(propylamino)butanoate hydrochloride ((S)-27i) as white solid with 73% conversion and 46% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4.11 (q, J=7.1 Hz, 2 H)</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.11 (q, J=7.1 Hz, 2 H),</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page" from="1" to="18" />
		</imprint>
	</monogr>
	<note>t, J=7.1 Hz, 3 H), 0.94 (t, J=7.5 Hz, 3 H)</note>
	<note type="raw_reference">Hz, 3 H), 1.18 (t, J=7.1 Hz, 3 H), 0.94 (t, J=7.5 Hz, 3 H).</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1490">1490</date>
		</imprint>
	</monogr>
	<note>METHANOL-d4 ,100MHz): δ = 170.25, 61.01, 50.93, 46.65, 36.48, 19.43, 15.42, 13.02, 9.84. HRMS calcd. for C9H18NO2 + 174.1494 [M+H] + , found 174</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 170.25, 61.01, 50.93, 46.65, 36.48, 19.43, 15.42, 13.02, 9.84. HRMS calcd. for C9H18NO2 + 174.1494 [M+H] + , found 174.1490.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">R)-3-(propylamino)butanoate hydrochloride ((R)-27i</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Ethyl (R)-3-(propylamino)butanoate hydrochloride ((R)-27i)</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and propylamine (i, 12.5 mmol, 738 mg) catalyzed by pIR-355 gave 81 mg ethyl (R)-3-(propylamino)butanoate hydrochloride ((R)-27i) as pale yellow solid with 64% conversion and 31</title>
		<imprint/>
	</monogr>
	<note>isolated yield</note>
	<note type="raw_reference">Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and propylamine (i, 12.5 mmol, 738 mg) catalyzed by pIR- 355 gave 81 mg ethyl (R)-3-(propylamino)butanoate hydrochloride ((R)-27i) as pale yellow solid with 64% conversion and 31% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.3 Hz</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.3 Hz,</note>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<idno>1.69 -1.81</idno>
		<title level="m">sxt, J=6.5 Hz, 1 H)</title>
		<imprint>
			<date type="published" when="1990-02">2.96 -3.09 (m, 2 H), 2.70 -2.90</date>
			<biblScope unit="page" from="1" to="41" />
		</imprint>
	</monogr>
	<note type="raw_reference">H), 3.66 (sxt, J=6.5 Hz, 1 H), 2.96 -3.09 (m, 2 H), 2.70 -2.90 (m, 2 H), 1.69 -1.81 (m, 2 H), 1.41 (d, J=6.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page" from="1" to="30" />
		</imprint>
	</monogr>
	<note>t, J=7.2 Hz, 3 H), 1.06 (t, J=7.5 Hz, 3 H)</note>
	<note type="raw_reference">Hz, 3 H), 1.30 (t, J=7.2 Hz, 3 H), 1.06 (t, J=7.5 Hz, 3 H).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Ethyl 3-(pyrrolidin-1-yl)butanoate (27l) Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and pyrrolidine (l, 12.5 mmol, 889 mg) catalyzed by pIR-117 gave 126 mg ethyl 3-(pyrrolidin-1-yl)butanoate (27l) as white solid with 83% conversion (with 31% ethyl 3-(pyrrolidin-1-yl)but-2-enoate) and 54% isolated yield after purified by flash column chromatography on siica gel</title>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>METHANOL-d4 ,100MHz): δ = 170.25, 61.01, 50.93, 46.65, 36.49</idno>
		<imprint>
			<date type="published" when="1488">19.43, 15.42, 13.03, 9.85. 1488</date>
		</imprint>
	</monogr>
	<note>HRMS calcd. for C9H18NO2 + 174.1494 [M+H] + , found 174 MeOH/CH2Cl2 = 1:20 to 1:10 as eluent</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 170.25, 61.01, 50.93, 46.65, 36.49, 19.43, 15.42, 13.03, 9.85. HRMS calcd. for C9H18NO2 + 174.1494 [M+H] + , found 174.1488. Ethyl 3-(pyrrolidin-1-yl)butanoate (27l) Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and pyrrolidine (l, 12.5 mmol, 889 mg) catalyzed by pIR- 117 gave 126 mg ethyl 3-(pyrrolidin-1-yl)butanoate (27l) as white solid with 83% conversion (with 31% ethyl 3-(pyrrolidin-1-yl)but-2-enoate) and 54% isolated yield after purified by flash column chromatography on siica gel (MeOH/CH2Cl2 = 1:20 to 1:10 as eluent).</note>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOLd4 ,400MHz): δ = 4.18 (q, J=7.1 Hz, 2 H)</title>
		<imprint/>
	</monogr>
	<note>3.13 (dq, J=12.7, 6</note>
	<note type="raw_reference">H NMR (METHANOL- d4 ,400MHz): δ = 4.18 (q, J=7.1 Hz, 2 H), 3.13 (dq, J=12.7, 6.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1945-02-01">2.87 (br. s., 4 H), 2.79 (dd, J=15.4, 4.4 Hz, 1 H), 2.45</date>
		</imprint>
	</monogr>
	<note>dd, J=15.4, 8.3 Hz, 1 H), 1.86 -1.95 (m, 4 H), 1.23 -1.31 (m, 6 H</note>
	<note type="raw_reference">Hz, 1 H), 2.87 (br. s., 4 H), 2.79 (dd, J=15.4, 4.4 Hz, 1 H), 2.45 (dd, J=15.4, 8.3 Hz, 1 H), 1.86 -1.95 (m, 4 H), 1.23 -1.31 (m, 6 H).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1495. Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and pyrrolidine (l, 12.5 mmol, 889 mg) catalyzed by pIR-351 gave 50 mg ethyl 3-(pyrrolidin-1-yl)butanoate (27l) as white solid with 74% conversion (with 62% ethyl 3-(pyrrolidin-1-yl)but-2-enoate) and 22% isolated yield after purified by flash column chromatography on siica gel</title>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>METHANOL-d4 ,100MHz): δ = 171.64, 60.45, 56.31, 50.93, 38.79, 22.83, 16.93, 13.07</idno>
		<imprint/>
	</monogr>
	<note>MeOH/CH2Cl2 = 1:20 to 1:10 as eluent</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 171.64, 60.45, 56.31, 50.93, 38.79, 22.83, 16.93, 13.07. HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1495. Ethyl acetoacetate (27, 1.25 mmol, 163 mg) and pyrrolidine (l, 12.5 mmol, 889 mg) catalyzed by pIR- 351 gave 50 mg ethyl 3-(pyrrolidin-1-yl)butanoate (27l) as white solid with 74% conversion (with 62% ethyl 3-(pyrrolidin-1-yl)but-2-enoate) and 22% isolated yield after purified by flash column chromatography on siica gel (MeOH/CH2Cl2 = 1:20 to 1:10 as eluent).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOLd4 ,400MHz): δ = 4.23 (q, J=7.1 Hz, 2 H)</title>
		<imprint/>
	</monogr>
	<note>3.67 -3.77 (m, 1 H), 3.39 (br. s., 4 H), 2.91 -3.00 (m, 1 H</note>
	<note type="raw_reference">H NMR (METHANOL- d4 ,400MHz): δ = 4.23 (q, J=7.1 Hz, 2 H), 3.67 -3.77 (m, 1 H), 3.39 (br. s., 4 H), 2.91 -3.00 (m, 1 H),</note>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>186.1492</idno>
		<imprint>
			<date type="published" when="1941">100MHz): δ = 170.04, 61.02, 57.28, 51.68, 36.66, 22.81, 15.41</date>
		</imprint>
	</monogr>
	<note type="report_type">METHANOL-d4</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 170.04, 61.02, 57.28, 51.68, 36.66, 22.81, 15.41, 13.03. HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1492.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">B)-3-(cyclopropylamino)pentanoate hydrochloride ((B)-32b</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Ethyl (B)-3-(cyclopropylamino)pentanoate hydrochloride ((B)-32b)</note>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">360 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-117 gave 424 mg ethyl (B)-3-(cyclopropylamino)pentanoate hydrochloride ((B)-32b) as orangered viscous oil with 93% conversion and 76</title>
		<imprint/>
	</monogr>
	<note>Ethyl propionylacetate (32, 2.5 mmol isolated yield</note>
	<note type="raw_reference">Ethyl propionylacetate (32, 2.5 mmol, 360 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-117 gave 424 mg ethyl (B)-3-(cyclopropylamino)pentanoate hydrochloride ((B)-32b) as orange- red viscous oil with 93% conversion and 76% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<idno>1.90 -2.02</idno>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.1 Hz, 2 H), 3.59 -3.70 (m, 1 H)</title>
		<imprint>
			<date type="published" when="1996-02">2.78 -2.96</date>
		</imprint>
	</monogr>
	<note>1.78 (dquin, J=14.8, 7.6 Hz, 1 H), 1.31 (t, J=7.1 Hz, 3 H), 1.06 (t, J=7.5 Hz, 3 H), 0.90 -1.00 (m, 4 H</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.23 (q, J=7.1 Hz, 2 H), 3.59 -3.70 (m, 1 H), 2.78 -2.96 (m, 3 H), 1.90 -2.02 (m, 1 H), 1.78 (dquin, J=14.8, 7.6 Hz, 1 H), 1.31 (t, J=7.1 Hz, 3 H), 1.06 (t, J=7.5 Hz, 3 H), 0.90 -1.00 (m, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>186.1502</idno>
		<title level="m">METHANOL-d4, 100MHz): δ = 168</title>
		<imprint>
			<date type="published" when="1943">56.15, 31.95, 26.67, 22.10, 11.52, 7.06, 1.59, 1.43</date>
			<biblScope unit="volume">98</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">C NMR (METHANOL-d4, 100MHz): δ = 168.98, 59.53, 56.15, 31.95, 26.67, 22.10, 11.52, 7.06, 1.59, 1.43. HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1502.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">A)-3-(cyclopropylamino)pentanoate hydrochloride</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>32b</note>
	<note type="raw_reference">Ethyl (A)-3-(cyclopropylamino)pentanoate hydrochloride ((A)-32b)</note>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">360 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-356 gave 418 mg ethyl (A)-3-(cyclopropylamino)pentanoate hydrochloride ((R)-32b) as orange viscous oil with 85% conversion and 75</title>
		<imprint/>
	</monogr>
	<note>Ethyl propionylacetate (32, 2.5 mmol isolated yield</note>
	<note type="raw_reference">Ethyl propionylacetate (32, 2.5 mmol, 360 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-356 gave 418 mg ethyl (A)-3-(cyclopropylamino)pentanoate hydrochloride ((R)-32b) as orange viscous oil with 85% conversion and 75% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ =</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ =</note>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>METHANOL-d4, 100MHz): δ = 168.97, 59.53, 56.14, 31.96, 26.67, 22.09, 11.52, 7.07, 1.59, 1.42. HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1534</note>
	<note type="raw_reference">C NMR (METHANOL-d4, 100MHz): δ = 168.97, 59.53, 56.14, 31.96, 26.67, 22.09, 11.52, 7.07, 1.59, 1.42. HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1534.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title level="m" type="main">A)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint>
			<pubPlace>B, 2; B, 2A)-28b</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Ethyl (1B, 2A)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1B, 2A)-28b)</note>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">425 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-241 gave 350 mg (1B, 2A)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1B, 2A)-28b) as white solid</title>
		<imprint/>
	</monogr>
	<note>Ethyl 2-oxocyclohexanecarboxylate (28, 2.5 mmol with 82% conversion and 57% isolated yield</note>
	<note type="raw_reference">Ethyl 2-oxocyclohexanecarboxylate (28, 2.5 mmol, 425 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-241 gave 350 mg (1B, 2A)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1B, 2A)-28b) as white solid with 82% conversion and 57% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4.18 -4.36 (m, 2 H)</title>
		<imprint>
			<biblScope unit="page" from="3" to="46" />
		</imprint>
	</monogr>
	<note>dt, J=11.4, 3</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.18 -4.36 (m, 2 H), 3.46 (dt, J=11.4, 3.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">1</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Hz, 1</note>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">m, 2 H), 1.38 -1.57 (m, 1 H), 1.32 (t, J=7.1 Hz, 3 H), 1.23 -1.30 (m, 1 H</title>
		<idno>60 -1.76</idno>
		<imprint>
			<biblScope unit="page">4</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">60 -1.76 (m, 2 H), 1.38 -1.57 (m, 1 H), 1.32 (t, J=7.1 Hz, 3 H), 1.23 -1.30 (m, 1 H), 0.85 -1.01 ppm (m, 4</note>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title level="m" type="main">B)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride</title>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C12H22NO2 + 212.1651</idno>
		<imprint>
			<date type="published" when="1943">59.77, 57.61, 39.40, 27.13, 25.80, 24.15, 22.51, 20.26, 11.80, 1.64, 1.43</date>
			<biblScope unit="page">28</biblScope>
			<pubPlace>1A, 2B; B, 2B</pubPlace>
		</imprint>
	</monogr>
	<note>found 212.1656. Mixture of ethyl</note>
	<note type="raw_reference">C NMR (METHANOL-d4, 100MHz): δ = 171.38, 59.77, 57.61, 39.40, 27.13, 25.80, 24.15, 22.51, 20.26, 11.80, 1.64, 1.43. HRMS calcd. for C12H22NO2 + 212.1651 [M+H] + , found 212.1656. Mixture of ethyl (1A, 2B)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1A, 2B)- 28b) and (1B, 2B)-28b</note>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">425 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-361 gave 568 mg (1B, 2B)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1A, 2B)-28b) and (1B, 2B)-28b as pale yellow solid with 98% conversion and 92</title>
		<imprint/>
	</monogr>
	<note>Ethyl 2-oxocyclohexanecarboxylate (28, 2.5 mmol isolated yield</note>
	<note type="raw_reference">Ethyl 2-oxocyclohexanecarboxylate (28, 2.5 mmol, 425 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-361 gave 568 mg (1B, 2B)-2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride ((1A, 2B)-28b) and (1B, 2B)-28b as pale yellow solid with 98% conversion and 92% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4, 400MHz): δ = 4.19 -4.36 (m, 2 H)</title>
		<imprint>
			<biblScope unit="page">0</biblScope>
		</imprint>
	</monogr>
	<note>3.59 (td, J=11.2, 4.2 Hz</note>
	<note type="raw_reference">H NMR (METHANOL-d4, 400MHz): δ = 4.19 -4.36 (m, 2 H), 3.59 (td, J=11.2, 4.2 Hz, 0.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C12H22NO2 + 212.1651 [M+H] + , found 212.1654</idno>
		<imprint>
			<date type="published" when="1943">100MHz): δ = 171.38, 59.77, 57.61, 39.40, 27.13, 25.80, 24.15, 22.51, 20.26, 11.80, 1.64, 1.43</date>
		</imprint>
	</monogr>
	<note type="report_type">METHANOL-d4</note>
	<note type="raw_reference">C NMR (METHANOL-d4, 100MHz): δ = 171.38, 59.77, 57.61, 39.40, 27.13, 25.80, 24.15, 22.51, 20.26, 11.80, 1.64, 1.43. HRMS calcd. for C12H22NO2 + 212.1651 [M+H] + , found 212.1654.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m" type="main">A)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride</title>
		<author>
			<persName><forename type="first">Ethyl</forename></persName>
		</author>
		<imprint>
			<pubPlace>B, 2; B, 2A)-29b</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Ethyl (1B, 2A)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1B, 2A)-29b)</note>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main">100 mL reaction system, ethyl 2-oxocyclopentanecarboxylate (29, 2.5 mmol, 390 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-358 gave 366 mg (1B, 2A)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1B, 2A)-29b) as orange-red oil with 75% conversion and 63</title>
		<imprint/>
	</monogr>
	<note>isolated yield</note>
	<note type="raw_reference">In a 100 mL reaction system, ethyl 2-oxocyclopentanecarboxylate (29, 2.5 mmol, 390 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-358 gave 366 mg (1B, 2A)-2- (cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1B, 2A)-29b) as orange-red oil with 75% conversion and 63% isolated yield.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4.18 -4.29 (m, 2 H)</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.18 -4.29 (m, 2 H),</note>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<idno>1.74 -1.85</idno>
		<title level="m">2.80 (quin, J=5.5 Hz, 1 H)</title>
		<imprint>
			<date>2.21 -2.36 (m, 1 H), 2.02 -2.19</date>
			<biblScope unit="page" from="1" to="31" />
		</imprint>
	</monogr>
	<note>t, J=7.1 Hz, 3 H), 0.87 -1.01 (m, 4 H</note>
	<note type="raw_reference">9 Hz, 1 H), 3.24 -3.31 (m, 1 H), 2.80 (quin, J=5.5 Hz, 1 H), 2.21 -2.36 (m, 1 H), 2.02 - 2.19 (m, 2 H), 1.86 -2.01 (m, 2 H), 1.74 -1.85 (m, 1 H), 1.31 (t, J=7.1 Hz, 3 H), 0.87 -1.01 (m, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C11H20NO2 + 198.1494</idno>
		<imprint>
			<date type="published" when="1994">58.98, 42.42, 28.26, 26.38, 25.54, 19.21, 11.24, 1.42, 0.94</date>
			<pubPlace>1A, 2B)-2-(cyclopropylamino</pubPlace>
		</imprint>
	</monogr>
	<note>found 198.1492. Mixture of ethyl cyclopentanecarboxylate hydrochloride ((1A, 2B)-29b) and trans-29b</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 171.53, 59.38, 58.98, 42.42, 28.26, 26.38, 25.54, 19.21, 11.24, 1.42, 0.94. HRMS calcd. for C11H20NO2 + 198.1494 [M+H] + , found 198.1492. Mixture of ethyl (1A, 2B)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1A, 2B)- 29b) and trans-29b</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">5 mmol, 390 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-361 gave 384 mg (1A, 2B)-2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1A, 2B)-29b) and trans-29b as orangered oil with 80% conversion and 66% isolated yield</title>
	</analytic>
	<monogr>
		<title level="m">a 100 mL reaction system, ethyl 2-oxocyclopentanecarboxylate</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
		</imprint>
	</monogr>
	<note>1 H NMR (METHANOL-d4, 400MHz): δ = 4.18 -4.29 (m, 2 H), 4.05 (q, J=6</note>
	<note type="raw_reference">In a 100 mL reaction system, ethyl 2-oxocyclopentanecarboxylate (29, 2.5 mmol, 390 mg) and cyclopropylamine (b, 5.0 mmol, 285 mg) catalyzed by pIR-361 gave 384 mg (1A, 2B)-2- (cyclopropylamino)cyclopentanecarboxylate hydrochloride ((1A, 2B)-29b) and trans-29b as orange- red oil with 80% conversion and 66% isolated yield. 1 H NMR (METHANOL-d4, 400MHz): δ = 4.18 - 4.29 (m, 2 H), 4.05 (q, J=6.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C11H20NO2 + 198.1494</idno>
		<imprint>
			<biblScope unit="volume">42</biblScope>
		</imprint>
	</monogr>
	<note>60.24 (trans), 59.38 (cis), 58.98 (cis), 58.36 (trans), 45.49 (trans trans), 27.39 (trans), 26.39 (cis), 25.54 (cis), 21.56 (trans), 19.21 (cis), 11.33 (trans), 11.25 (cis), 1.42 (cis), 1.31 (trans), 1.14 (trans), 0.94 (cis found 198.1550. Ethyl acetoacetate (3.0 mmol, 390 mg) and propargylamine (3.3 mmol, 182 mg) gave 450 mg 27d as yellow oil in 90% yield</note>
	<note type="raw_reference">C NMR (METHANOL-d4, 100MHz): δ = 171.53 (cis), 171.46 (trans), 60.24 (trans), 59.38 (cis), 58.98 (cis), 58.36 (trans), 45.49 (trans), 42.42 (cis), 28.26 (cis), 27.89 (trans), 27.86 (trans), 27.39 (trans), 26.39 (cis), 25.54 (cis), 21.56 (trans), 19.21 (cis), 11.33 (trans), 11.25 (cis), 1.42 (cis), 1.31 (trans), 1.14 (trans), 0.94 (cis). HRMS calcd. for C11H20NO2 + 198.1494 [M+H] + , found 198.1550. Ethyl acetoacetate (3.0 mmol, 390 mg) and propargylamine (3.3 mmol, 182 mg) gave 450 mg 27d as yellow oil in 90% yield.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,500MHz): δ = 4.12 -4.19 (m, 2 H)</title>
		<imprint>
			<biblScope unit="page" from="3" to="39" />
		</imprint>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,500MHz): δ = 4.12 -4.19 (m, 2 H), 3.39 -3.49 (m, 2</note>
</biblStruct>

<biblStruct xml:id="b63">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>13.12. HRMS calcd. for C9H16NO2 + 170.1181</idno>
		<title level="m">METHANOL-d4 ,125MHz): δ = 172</title>
		<imprint>
			<date type="published" when="2017">18, 48.32, 40.24, 34.36, 18.17</date>
			<biblScope unit="volume">15</biblScope>
		</imprint>
	</monogr>
	<note>found 170.1177. Ethyl 3-(allylamino)butanoate</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,125MHz): δ = 172.15, 80.49, 71.84, 60.18, 48.32, 40.24, 34.36, 18.17, 13.12. HRMS calcd. for C9H16NO2 + 170.1181 [M+H] + , found 170.1177. Ethyl 3-(allylamino)butanoate (</note>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title level="m" type="main">Ethyl acetoacetate (3.0 mmol, 390 mg) and allylamine (3.3 mmol, 188 mg) gave 436</title>
		<imprint/>
	</monogr>
	<note>mg 27e as yellow oil in 85% yield</note>
	<note type="raw_reference">Ethyl acetoacetate (3.0 mmol, 390 mg) and allylamine (3.3 mmol, 188 mg) gave 436 mg 27e as yellow oil in 85% yield.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,500MHz): δ = 5.92 (ddt, J=17</title>
		<imprint>
			<date>1, 10.5, 6.2 Hz, 1 H), 5.23</date>
		</imprint>
	</monogr>
	<note>dd, J=17.1, 1.5 Hz, 1 H), 5.14 (dd, J=10.4, 0</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,500MHz): δ = 5.92 (ddt, J=17.1, 10.5, 6.2 Hz, 1 H), 5.23 (dd, J=17.1, 1.5 Hz, 1 H), 5.14 (dd, J=10.4, 0.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>13.11. HRMS calcd. for C9H18NO2 + 172.1338</idno>
		<imprint>
			<date type="published" when="2003">135.77, 115.74, 60.15, 49.03</date>
			<biblScope unit="volume">48</biblScope>
		</imprint>
	</monogr>
	<note>found 172.1331. Ethyl 3-(propylamino)butanoate</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,125MHz): δ = 172.30, 135.77, 115.74, 60.15, 49.03, 48.82, 40.29, 18.46, 13.11. HRMS calcd. for C9H18NO2 + 172.1338 [M+H] + , found 172.1331. Ethyl 3-(propylamino)butanoate (</note>
</biblStruct>

<biblStruct xml:id="b67">
	<monogr>
		<title level="m" type="main">Ethyl acetoacetate (3.0 mmol, 390 mg) and propylamine (3.3 mmol, 194 mg) gave 458 mg 27i as colorless oil in 88% yield</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Ethyl acetoacetate (3.0 mmol, 390 mg) and propylamine (3.3 mmol, 194 mg) gave 458 mg 27i as colorless oil in 88% yield.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,500MHz): δ = 3.99 -4.08 (m, 2 H)</title>
		<imprint>
			<biblScope unit="page" from="2" to="97" />
		</imprint>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,500MHz): δ = 3.99 -4.08 (m, 2 H), 2.97 (sxt, J=6.5</note>
</biblStruct>

<biblStruct xml:id="b69">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hz</surname></persName>
		</author>
		<imprint>
			<date>2.38 -2.52 (m, 3 H), 2.18 -2.27</date>
			<biblScope unit="page" from="1" to="12" />
		</imprint>
	</monogr>
	<note type="raw_reference">Hz, 1 H), 2.38 -2.52 (m, 3 H), 2.18 -2.27 (m, 1 H), 1.36 -1.47 (m, 2 H), 1.12 -1.19 (m, 3 H),</note>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<idno>10.67. HRMS calcd. for C9H18NO2 + 174.1494</idno>
		<title level="m">13 C NMR (METHANOL-d4 ,125MHz): δ = 172</title>
		<imprint>
			<date type="published" when="2011">60.14, 49.80, 48.29, 40.26, 22.33, 18.57, 12.11</date>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page">1</biblScope>
		</imprint>
	</monogr>
	<note>d, J=6.4 Hz found 174.1487. Ethyl 3-(benzylamino)butanoate (27c) Ethyl acetoacetate (3.0 mmol, 390 mg) and benzylamine (3.3 mmol, 354 mg) gave 605 mg 27c as colorless oil in 91% yield</note>
	<note type="raw_reference">01 (d, J=6.4 Hz, 3 H), 0.81 -0.88 (m, 3 H). 13 C NMR (METHANOL-d4 ,125MHz): δ = 172.41, 60.14, 49.80, 48.29, 40.26, 22.33, 18.57, 12.11, 10.67. HRMS calcd. for C9H18NO2 + 174.1494 [M+H] + , found 174.1487. Ethyl 3-(benzylamino)butanoate (27c) Ethyl acetoacetate (3.0 mmol, 390 mg) and benzylamine (3.3 mmol, 354 mg) gave 605 mg 27c as colorless oil in 91% yield.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 7</title>
		<imprint>
			<biblScope unit="page">8</biblScope>
		</imprint>
	</monogr>
	<note>31 -7.38 (m, 4 H), 7.27 (ddt</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 7.31 -7.38 (m, 4 H), 7.27 (ddt, J=8.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,125MHz): δ = 172</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
		</imprint>
	</monogr>
	<note>60.16, 50.23, 49.07, 40.32, 18.47, 13</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,125MHz): δ = 172.40, 139.25, 128.12, 126.82, 60.16, 50.23, 49.07, 40.32, 18.47, 13.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<monogr>
		<title level="m" type="main">Ethyl 3-(pyrrolidin-1-yl)butanoate (27l) Ethyl acetoacetate (3.0 mmol, 390 mg)</title>
		<idno>HRMS calcd. for C13H20NO2 + 222.1494</idno>
		<imprint>
			<date type="published" when="1494">1494</date>
		</imprint>
	</monogr>
	<note>M+H] + , found 222 and benzylamine (3.3 mmol, 234 mg) gave 477 mg 27l as colorless oil in 86% yield</note>
	<note type="raw_reference">HRMS calcd. for C13H20NO2 + 222.1494 [M+H] + , found 222.1494. Ethyl 3-(pyrrolidin-1-yl)butanoate (27l) Ethyl acetoacetate (3.0 mmol, 390 mg) and benzylamine (3.3 mmol, 234 mg) gave 477 mg 27l as colorless oil in 86% yield.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4.15 (q, J=7.1 Hz, 2 H)</title>
		<imprint>
			<date>2.82 -2.92 (m, 1 H), 2.72 (dd, J=14.8, 4.5 Hz, 1 H), 2.60 -2.67</date>
		</imprint>
	</monogr>
	<note>m, 4 H), 2.30 (dd, J=14.9, 8.8 Hz, 1 H), 1.78 -1.87 (m, 4 H), 1.27 (t, J=7.1 Hz, 3 H), 1.18 (d, J=6.4 Hz, 3 H)</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.15 (q, J=7.1 Hz, 2 H), 2.82 - 2.92 (m, 1 H), 2.72 (dd, J=14.8, 4.5 Hz, 1 H), 2.60 -2.67 (m, 4 H), 2.30 (dd, J=14.9, 8.8 Hz, 1 H), 1.78 -1.87 (m, 4 H), 1.27 (t, J=7.1 Hz, 3 H), 1.18 (d, J=6.4 Hz, 3 H).</note>
</biblStruct>

<biblStruct xml:id="b75">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>13.10. HRMS calcd. for C10H20NO2 + 186.1494</idno>
		<title level="m">METHANOL-d4 ,125MHz): δ = 172</title>
		<imprint>
			<date type="published" when="1955">60.20, 55.91, 50.61, 39.68, 22.84, 17.55</date>
			<biblScope unit="volume">25</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">C NMR (METHANOL-d4 ,125MHz): δ = 172.25, 60.20, 55.91, 50.61, 39.68, 22.84, 17.55, 13.10. HRMS calcd. for C10H20NO2 + 186.1494</note>
</biblStruct>

<biblStruct xml:id="b76">
	<monogr>
		<title level="m" type="main">Ethyl 3-(cyclopropylamino)pentanoate (32b) Ethyl propionylacetate (3.0 mmol, 433 mg) and cyclopropylamine (3.3 mmol, 188 mg</title>
		<imprint>
			<date type="published" when="1490">1490</date>
		</imprint>
	</monogr>
	<note>gave 515 mg 32b as colorless oil in 93% yield</note>
	<note type="raw_reference">+ , found 186.1490. Ethyl 3-(cyclopropylamino)pentanoate (32b) Ethyl propionylacetate (3.0 mmol, 433 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 515 mg 32b as colorless oil in 93% yield.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 3.98 (q, J=7.1 Hz, 2 H)</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 3.98 (q, J=7.1 Hz, 2 H),</note>
</biblStruct>

<biblStruct xml:id="b78">
	<monogr>
		<title level="m" type="main">Ethyl 3-(cyclopropylamino)hexanoate (33b) Ethyl butyrylacetate (3.0 mmol, 475 mg) and cyclopropylamine (3.3 mmol, 188 mg</title>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1488</idno>
		<imprint>
			<date type="published" when="2006-05-20">60.10, 56.47, 37.91, 27.76, 26.37, 13.13, 8.96, 5.20, 5.06</date>
		</imprint>
	</monogr>
	<note>gave 490 mg 33b as colorless oil in 82% yield</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 172.82, 60.10, 56.47, 37.91, 27.76, 26.37, 13.13, 8.96, 5.20, 5.06. HRMS calcd. for C10H20NO2 + 186.1494 [M+H] + , found 186.1488. Ethyl 3-(cyclopropylamino)hexanoate (33b) Ethyl butyrylacetate (3.0 mmol, 475 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 490 mg 33b as colorless oil in 82% yield.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 3.98 (q, J=7.1 Hz, 2 H)</title>
		<imprint>
			<date>2.89 -2.99 (m, 1 H), 2.24 -2.40</date>
			<biblScope unit="page" from="1" to="15" />
		</imprint>
	</monogr>
	<note>tt, J=6.8, 3.6 Hz, 1 H m</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 3.98 (q, J=7.1 Hz, 2 H), 2.89 -2.99 (m, 1 H), 2.24 -2.40 (m, 2 H), 1.99 (tt, J=6.8, 3.6 Hz, 1 H), 1.33 -1.45 (m, 1 H), 1.15 -1.31 (m,</note>
</biblStruct>

<biblStruct xml:id="b80">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,100MHz): δ = 172</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
		</imprint>
	</monogr>
	<note>60.09, 54.88, 38.38, 36.19, 27.75, 18.60, 13.11, 5.3, 4</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 172.82, 60.09, 54.88, 38.38, 36.19, 27.75, 18.60, 13.11, 5.3, 4.</note>
</biblStruct>

<biblStruct xml:id="b81">
	<monogr>
		<title level="m" type="main">Ethyl 3-(cyclopropylamino)-4-methylpentanoate (42b) Ethyl isobutyrylacetate (3.0 mmol, 475 mg) and cyclopropylamine (3.3 mmol, 188 mg</title>
		<idno>HRMS calcd. for C11H22NO2 + 200.1651</idno>
		<imprint>
			<date type="published" when="1645">1645</date>
		</imprint>
	</monogr>
	<note>M+H] + , found 200 gave 120 mg 42b as colorless oil in 20% yield</note>
	<note type="raw_reference">HRMS calcd. for C11H22NO2 + 200.1651 [M+H] + , found 200.1645. Ethyl 3-(cyclopropylamino)-4-methylpentanoate (42b) Ethyl isobutyrylacetate (3.0 mmol, 475 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 120 mg 42b as colorless oil in 20% yield.</note>
</biblStruct>

<biblStruct xml:id="b82">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<idno>33 -2.51</idno>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="2" to="17" />
		</imprint>
	</monogr>
	<note>3.02 (dt, J=7.8, 4.6 Hz tt, J=6.8, 3.6 Hz, 1 H), 1.89 -2.01 (m, 1 H), 1.24 -1.30 (m, 3 H), 0.93 (dd, J=11.2, 7.1 Hz, 6 H), 0.30 -0.52 (m, 4 H</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.11 -4.18 (m, 2 H), 3.02 (dt, J=7.8, 4.6 Hz, 1 H), 2.33 -2.51 (m, 2 H), 2.17 (tt, J=6.8, 3.6 Hz, 1 H), 1.89 -2.01 (m, 1 H), 1.24 - 1.30 (m, 3 H), 0.93 (dd, J=11.2, 7.1 Hz, 6 H), 0.30 -0.52 (m, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C11H22NO2 + 200.1651</idno>
		<imprint>
			<date>60.15, 35.39, 30.25, 28.34, 17.85, 16.37, 13.11, 6.30, 5.29</date>
		</imprint>
	</monogr>
	<note>found 200.1644. Ethyl 3-(cyclopropylamino) )-3-phenylpropanoate (34b) Ethyl benzoylacetate (3.0 mmol, 577 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 163 mg 34b as colorless oil in 23% yield</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 173.40, 60.52, 60.15, 35.39, 30.25, 28.34, 17.85, 16.37, 13.11, 6.30, 5.29. HRMS calcd. for C11H22NO2 + 200.1651 [M+H] + , found 200.1644. Ethyl 3-(cyclopropylamino) )-3-phenylpropanoate (34b) Ethyl benzoylacetate (3.0 mmol, 577 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 163 mg 34b as colorless oil in 23% yield.</note>
</biblStruct>

<biblStruct xml:id="b84">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<idno>METHANOL-d4 ,400MHz): δ = 7.09 -7.18</idno>
		<imprint/>
	</monogr>
	<note>m, 4 H), 7.01 -7.08 (m, 1 H), 3.93 (t, J=7.3 Hz, 1 H), 3.81 (q, J=7.3 Hz, 2 H), 2.61 (dd, J=15.0, 7.0 Hz, 1 H), 2.38 -2.46 (m, 1 H), 1.67 -1.76 (m, 1 H), 0.92 (t, J=7.1 Hz, 3 H), 0.05 -0.19 (m, 4 H</note>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 7.09 -7.18 (m, 4 H), 7.01 - 7.08 (m, 1 H), 3.93 (t, J=7.3 Hz, 1 H), 3.81 (q, J=7.3 Hz, 2 H), 2.61 (dd, J=15.0, 7.0 Hz, 1 H), 2.38 - 2.46 (m, 1 H), 1.67 -1.76 (m, 1 H), 0.92 (t, J=7.1 Hz, 3 H), 0.05 -0.19 (m, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b85">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C14H20NO2 + 234.1494</idno>
		<imprint>
			<date type="published" when="1968-04-34">142.27, 128.08, 127.09, 60.11, 59.75, 41.43, 28.13, 12.99, 5.34, 4.68</date>
		</imprint>
	</monogr>
	<note>found 234.1487. Ethyl 2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride (28b) Ethyl 2-oxocyclohexanecarboxylate (25.0 mmol, 4.26 g) and cyclopropylamine (27.5 mmol, 1.57 g) gave 4.93 g 28b as white solid in 80% yield</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 171.73, 142.27, 128.08, 127.09, 60.11, 59.75, 41.43, 28.13, 12.99, 5.34, 4.68. HRMS calcd. for C14H20NO2 + 234.1494 [M+H] + , found 234.1487. Ethyl 2-(cyclopropylamino)cyclohexanecarboxylate hydrochloride (28b) Ethyl 2-oxocyclohexanecarboxylate (25.0 mmol, 4.26 g) and cyclopropylamine (27.5 mmol, 1.57 g) gave 4.93 g 28b as white solid in 80% yield.</note>
</biblStruct>

<biblStruct xml:id="b86">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<idno>18 -4.36</idno>
		<title level="m">METHANOL-d4 ,400MHz): δ = 4</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 4.18 -4.36 (m,</note>
</biblStruct>

<biblStruct xml:id="b87">
	<monogr>
		<title level="m" type="main">m, 1 H), 1.81 -1.98 (m, 2 H), 1.60 -1.77 (m, 2 H), 1.50 (q, J=13.2 Hz, 1 H</title>
		<idno>00 -2.11</idno>
		<imprint>
			<biblScope unit="page" from="1" to="19" />
		</imprint>
	</monogr>
	<note type="raw_reference">00 -2.11 (m, 1 H), 1.81 -1.98 (m, 2 H), 1.60 -1.77 (m, 2 H), 1.50 (q, J=13.2 Hz, 1 H), 1.19 -1.37 (m, 4</note>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>HRMS calcd. for C12H22NO2 + 212.1651</idno>
		<imprint>
			<date type="published" when="1943">57.60, 39.38, 27.13, 25.77, 24.13, 22.48, 20.24, 11.77, 1.62, 1.43</date>
		</imprint>
	</monogr>
	<note>found 212.1646. Ethyl 2-(propylamino)cyclohexanecarboxylate (28i) Ethyl 2-oxocyclohexanecarboxylate (3.0 mmol, 511 mg) and propylamine (3.3 mmol, 194 mg) gave 327 mg 28i as colorless oil in 51% yield</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 171.36, 59.74, 57.60, 39.38, 27.13, 25.77, 24.13, 22.48, 20.24, 11.77, 1.62, 1.43. HRMS calcd. for C12H22NO2 + 212.1651 [M+H] + , found 212.1646. Ethyl 2-(propylamino)cyclohexanecarboxylate (28i) Ethyl 2-oxocyclohexanecarboxylate (3.0 mmol, 511 mg) and propylamine (3.3 mmol, 194 mg) gave 327 mg 28i as colorless oil in 51% yield.</note>
</biblStruct>

<biblStruct xml:id="b89">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,500MHz): δ = 4</title>
		<imprint>
			<date>12 -4.21 (m, 2</date>
		</imprint>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,500MHz): δ = 4.12 -4.21 (m, 2</note>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title level="m" type="main">Ethyl 2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride (29b) Ethyl 2-oxocyclopentanecarboxylate</title>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>METHANOL-d4 ,125MHz): δ = 174.29, 59.86, 58.14, 48.31</idno>
		<imprint>
			<date type="published" when="1804">44.10, 28.14, 26.21, 23.07, 22.81, 22. 1804</date>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page">70</biblScope>
		</imprint>
	</monogr>
	<note>HRMS calcd. for C12H24NO2 + 214.1807 [M+H] + , found 214 25.0 mmol, 3.90 g) and cyclopropylamine (27.5 mmol, 1.57 g) gave 2.82 g 29b as pale yellow oil in 48% yield. 1 H NMR (METHANOL-d4 ,400MHz): δ = 4.17 -4.32 (m, 2 H), 3.74 -3.84 (m, 1 H), 3.29 (d, J=4</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,125MHz): δ = 174.29, 59.86, 58.14, 48.31, 44.10, 28.14, 26.21, 23.07, 22.81, 22.44, 13.16,10.70. HRMS calcd. for C12H24NO2 + 214.1807 [M+H] + , found 214.1804. Ethyl 2-(cyclopropylamino)cyclopentanecarboxylate hydrochloride (29b) Ethyl 2-oxocyclopentanecarboxylate (25.0 mmol, 3.90 g) and cyclopropylamine (27.5 mmol, 1.57 g) gave 2.82 g 29b as pale yellow oil in 48% yield. 1 H NMR (METHANOL-d4 ,400MHz): δ = 4.17 - 4.32 (m, 2 H), 3.74 -3.84 (m, 1 H), 3.29 (d, J=4.</note>
</biblStruct>

<biblStruct xml:id="b91">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,100MHz): δ = 171</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
		</imprint>
	</monogr>
	<note>59.83, 59.48, 42.89, 28.77, 26.84, 26.00, 19.67, 11.72, 1.91, 1</note>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 171.99, 59.83, 59.48, 42.89, 28.77, 26.84, 26.00, 19.67, 11.72, 1.91, 1.</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">The reaction was stirred at 25°C for overnight under N2. It was then cooled to 0°C and NaBH4 (15 mmol) was added and the mixture was stirred at room temperature for a further 4 h. The reaction was quenched by adding 1 mol/L aqueous HCl (150 mL) and extracted with dichloromethane (2 x 100 mL)</title>
	</analytic>
	<monogr>
		<title level="m">Then the aqueous phase was basified to pH 10 by addition of 5 mol/L aqueous sodium hydroxide</title>
		<imprint/>
	</monogr>
	<note>Reductive amination procedure for the preparation of 13b, 15a and 25b To a solution of the ketone (10 mmol) and the corresponding amine (20 mmol) in EtOH (20 mL) was added Ti(OiPr)4 (15 mmol) The product was extracted into dichloromethane (2 x 100 mL The organic</note>
	<note type="raw_reference">2 Reductive amination procedure for the preparation of 13b, 15a and 25b To a solution of the ketone (10 mmol) and the corresponding amine (20 mmol) in EtOH (20 mL) was added Ti(OiPr)4 (15 mmol). The reaction was stirred at 25°C for overnight under N2. It was then cooled to 0°C and NaBH4 (15 mmol) was added and the mixture was stirred at room temperature for a further 4 h. The reaction was quenched by adding 1 mol/L aqueous HCl (150 mL) and extracted with dichloromethane (2 x 100 mL). Then the aqueous phase was basified to pH 10 by addition of 5 mol/L aqueous sodium hydroxide. The product was extracted into dichloromethane (2 x 100 mL). The organic</note>
</biblStruct>

<biblStruct xml:id="b93">
	<monogr>
		<title level="m" type="main">mmol, 773 mg) and cyclopropylamine (10.0 mmol, 570 mg) gave 670 mg 25b as colorless oil in 68% yield</title>
		<idno>Chloro-1-phenylethanone (5.0</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">-Chloro-1-phenylethanone (5.0 mmol, 773 mg) and cyclopropylamine (10.0 mmol, 570 mg) gave 670 mg 25b as colorless oil in 68% yield.</note>
</biblStruct>

<biblStruct xml:id="b94">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">METHANOL-d4 ,400MHz): δ = 7</title>
		<imprint>
			<biblScope unit="page" from="23" to="27" />
		</imprint>
	</monogr>
	<note type="raw_reference">H NMR (METHANOL-d4 ,400MHz): δ = 7.23 -7.14 (m, 4</note>
</biblStruct>

<biblStruct xml:id="b95">
	<monogr>
		<title level="m" type="main">m, 1 H), 3.82 (t, J = 6.2 Hz, 1 H</title>
		<idno>14 -7.08</idno>
		<imprint/>
	</monogr>
	<note>3.58 (d, J = 6.1 Hz, 2 H), 1.89 -1.80 (m, 1 H), 0.28 -0.08 (m, 4 H</note>
	<note type="raw_reference">H), 7.14 -7.08 (m, 1 H), 3.82 (t, J = 6.2 Hz, 1 H), 3.58 (d, J = 6.1 Hz, 2 H), 1.89 -1.80 (m, 1 H), 0.28 -0.08 (m, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b96">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<idno>196.0887</idno>
		<imprint>
			<date type="published" when="1952-02-10">125.49, 125.35, 61.96, 26.35, 3.10, 2.52</date>
		</imprint>
	</monogr>
	<note type="raw_reference">C NMR (METHANOL-d4 ,100MHz): δ = 126.01, 125.49, 125.35, 61.96, 26.35, 3.10, 2.52. HRMS calcd. for C11H15ClN + 196.0893 [M+H] + , found 196.0887.</note>
</biblStruct>

<biblStruct xml:id="b97">
	<monogr>
		<title level="m" type="main">Addition of water (2 mL) was done to quench the reaction, the precipitate formed filtered over celite and washed with diethyl ether (20 mL). The organic layer was separated and the aqueous layer was further extracted with diethyl ether (2 x 20 mL). The combined organic extracts were washed with 3M HCl (2 x 15 mL) and the acidic aqueous solution was then basified with 5M NaOH to pH 12. The aqueous layer was extracted with diethyl ether</title>
		<imprint/>
	</monogr>
	<note>Reductive amination procedure for the preparation of 13e To a RBF was added acetophenone (5 mmol, 1 eq the desired amine (15 mmol, 3 eq), and titanium isopropoxide (6.6 mmol, 1.3 eq, 2 mL) which was left to stir overnight. NaBH4 (5 mmol, 1 eq) was added to the reaction and left to stir for a further 2 hours x 20 mL) and the combined organic extracts were concentrated to yield the product</note>
	<note type="raw_reference">3: Reductive amination procedure for the preparation of 13e To a RBF was added acetophenone (5 mmol, 1 eq), the desired amine (15 mmol, 3 eq), and titanium isopropoxide (6.6 mmol, 1.3 eq, 2 mL) which was left to stir overnight. NaBH4 (5 mmol, 1 eq) was added to the reaction and left to stir for a further 2 hours. Addition of water (2 mL) was done to quench the reaction, the precipitate formed filtered over celite and washed with diethyl ether (20 mL). The organic layer was separated and the aqueous layer was further extracted with diethyl ether (2 x 20 mL). The combined organic extracts were washed with 3M HCl (2 x 15 mL) and the acidic aqueous solution was then basified with 5M NaOH to pH 12. The aqueous layer was extracted with diethyl ether (3 x 20 mL) and the combined organic extracts were concentrated to yield the product.</note>
</biblStruct>

<biblStruct xml:id="b98">
	<monogr>
		<title level="m">Acetophenone (5.0 mmol, 583 μL) and allylamine (1.13 mL) gave 165 mg 13e as a yellow oil in 20% yield. 1H NMR (400 MHz, Chloroform-d)</title>
		<imprint/>
	</monogr>
	<note>δ = 7.31 -7.02 (m, 1H), 5.80 (ddt, J = 17.2, 10.2, 6.0 Hz, 0H), 5.29 -4.70 (m, 0H), 3.71 (q, J = 6.6 Hz, 0H), 3.01 (dt, J = 6.1, 1.4 Hz, 0H), 1.27 (d, J = 6.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 145.50, 136.98, 128.46, 126.94, 126.64, 115.73, 57.56, 50.27, 24.29</note>
	<note type="raw_reference">Acetophenone (5.0 mmol, 583 μL) and allylamine (1.13 mL) gave 165 mg 13e as a yellow oil in 20% yield. 1H NMR (400 MHz, Chloroform-d) δ = 7.31 -7.02 (m, 1H), 5.80 (ddt, J = 17.2, 10.2, 6.0 Hz, 0H), 5.29 -4.70 (m, 0H), 3.71 (q, J = 6.6 Hz, 0H), 3.01 (dt, J = 6.1, 1.4 Hz, 0H), 1.27 (d, J = 6.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 145.50, 136.98, 128.46, 126.94, 126.64, 115.73, 57.56, 50.27, 24.29.</note>
</biblStruct>

<biblStruct xml:id="b99">
	<monogr>
		<title level="m" type="main">0 mmol) in dry dichloromethane (10 mL) under N2 were added the corresponding primary amine (3.3 mmol), sodium triacetoxyborohydride (0.954 g, 4.5 mmol) and glacial acetic acid (0.172 mL, 3.0 mmol). The reaction was stirred for overnight at 25°C under N2. The reaction was quenched by adding 0.5 mol/L aqueous HCl (30 mL) and extracted with dichloromethane (2 x 15 mL)</title>
		<imprint/>
	</monogr>
	<note>Reductive amination procedure for the preparation of 26b To a solution of the ketone (3. Then the aqueous phase was basified to pH 10 by addition of 5 mol/L aqueous sodium hydroxide. The product was extracted into dichloromethane (2 x 20 mL) The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure to afford the corresponding amines</note>
	<note type="raw_reference">Reductive amination procedure for the preparation of 26b To a solution of the ketone (3.0 mmol) in dry dichloromethane (10 mL) under N2 were added the corresponding primary amine (3.3 mmol), sodium triacetoxyborohydride (0.954 g, 4.5 mmol) and glacial acetic acid (0.172 mL, 3.0 mmol). The reaction was stirred for overnight at 25°C under N2. The reaction was quenched by adding 0.5 mol/L aqueous HCl (30 mL) and extracted with dichloromethane (2 x 15 mL). Then the aqueous phase was basified to pH 10 by addition of 5 mol/L aqueous sodium hydroxide. The product was extracted into dichloromethane (2 x 20 mL). The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure to afford the corresponding amines.</note>
</biblStruct>

<biblStruct xml:id="b100">
	<monogr>
		<title level="m" type="main">mmol, 398 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 490 mg 26b as colorless oil in 94% yield</title>
		<idno>Chlorocyclohexanone (3.0</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">-Chlorocyclohexanone (3.0 mmol, 398 mg) and cyclopropylamine (3.3 mmol, 188 mg) gave 490 mg 26b as colorless oil in 94% yield.</note>
</biblStruct>

<biblStruct xml:id="b101">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">400MHz, METHANOL-d4): δ = 4.48 (d, J = 2.4 Hz, 1 H)</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">H NMR (400MHz, METHANOL-d4): δ = 4.48 (d, J = 2.4 Hz, 1 H),</note>
</biblStruct>

<biblStruct xml:id="b102">
	<monogr>
		<title level="m" type="main">11.2 Hz, 1 H), 2.07 -1.98 (m, 1 H), 1.92 -1.83 (m, 1 H), 1.69 -1.58 (m, 1 H), 1.58 -1.42 (m, 3 H), 1.34 -1.24 (m, 2 H)</title>
		<imprint>
			<biblScope unit="page" from="1" to="21" />
		</imprint>
	</monogr>
	<note>td, J = 3.2, m, 1 H), 0.31 -0.10 (m, 4 H</note>
	<note type="raw_reference">59 (td, J = 3.2, 11.2 Hz, 1 H), 2.07 -1.98 (m, 1 H), 1.92 -1.83 (m, 1 H), 1.69 -1.58 (m, 1 H), 1.58 - 1.42 (m, 3 H), 1.34 -1.24 (m, 2 H), 1.21 -1.07 (m, 1 H), 0.31 -0.10 (m, 4 H).</note>
</biblStruct>

<biblStruct xml:id="b103">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>METHANOLd4 ,100MHz): δ = 63.19, 58.68, 32.78, 26.60, 26.46, 24.31, 19.50, 5.08, 4.34. HRMS calcd. for C9H17ClN + 174.1050 [M+H] + , found 174.1044</note>
	<note type="raw_reference">C NMR (METHANOL- d4 ,100MHz): δ = 63.19, 58.68, 32.78, 26.60, 26.46, 24.31, 19.50, 5.08, 4.34. HRMS calcd. for C9H17ClN + 174.1050 [M+H] + , found 174.1044.</note>
</biblStruct>

<biblStruct xml:id="b104">
	<monogr>
		<title level="m" type="main">mL) was added to a commercially available solution of methylamine in ethanol (8 M, 12.5 mL) followed by acetic acid (10 mmol, 1 eq) and methanol (10.5 mL). The reaction was left to stir overnight after which NaBH4 (15 mmol, 1.5 eq) was added and left to stir for an additional 2 hours. The reaction was quenched with 3M HCl (15 mL) and extracted with cyclohexane (3 x 20 mL). The combined acidic aqueous solution was basified to pH 12 with 5M NaOH and further extracted with cyclohexane (3 x 20 mL)</title>
		<imprint>
			<date type="published" when="1939">10 mmol, 1 eq, 1.39</date>
		</imprint>
	</monogr>
	<note>Reductive amination procedure for the preparation of 22a 2-heptanone The combined organic extracts were concentrated in vacuo to give the product as a yellow oil with a yield of 22% (285 mg</note>
	<note type="raw_reference">5. Reductive amination procedure for the preparation of 22a 2-heptanone (10 mmol, 1 eq, 1.39 mL) was added to a commercially available solution of methylamine in ethanol (8 M, 12.5 mL) followed by acetic acid (10 mmol, 1 eq) and methanol (10.5 mL). The reaction was left to stir overnight after which NaBH4 (15 mmol, 1.5 eq) was added and left to stir for an additional 2 hours. The reaction was quenched with 3M HCl (15 mL) and extracted with cyclohexane (3 x 20 mL). The combined acidic aqueous solution was basified to pH 12 with 5M NaOH and further extracted with cyclohexane (3 x 20 mL). The combined organic extracts were concentrated in vacuo to give the product as a yellow oil with a yield of 22% (285 mg).</note>
</biblStruct>

<biblStruct xml:id="b105">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Nmr</surname></persName>
		</author>
		<title level="m">400 MHz, Chloroform-d) δ = 2.43 (m, 1H)</title>
		<imprint/>
	</monogr>
	<note>2.33 (s, 3H), 1.29 -1.15 (m, 9H), 0.95 (d, J = 6.3 Hz, 3H</note>
	<note type="raw_reference">H NMR (400 MHz, Chloroform-d) δ = 2.43 (m, 1H), 2.33 (s, 3H), 1.29 -1.15 (m, 9H), 0.95 (d, J = 6.3 Hz, 3H),</note>
</biblStruct>

<biblStruct xml:id="b106">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Nmr</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>101 MHz, CDCl3) δ = 54.90, 36.79, 33.86, 32.07, 26.86, 25.65, 22.63, 19.76, 14.01. Section 8. 1 H-NMR and 13 C-NMR spectra Section 9. References</note>
	<note type="raw_reference">C NMR (101 MHz, CDCl3) δ = 54.90, 36.79, 33.86, 32.07, 26.86, 25.65, 22.63, 19.76, 14.01. Section 8. 1 H-NMR and 13 C-NMR spectra Section 9. References</note>
</biblStruct>

<biblStruct xml:id="b107">
	<monogr>
		<title level="m">Uk Parliament Foreign And Commonwealth, O. (ed United Nations Treaty Collections)</title>
		<meeting><address><addrLine>Nagoya, Japan</addrLine></address></meeting>
		<imprint>
			<publisher>TSO</publisher>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">29</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Uk Parliament Foreign And Commonwealth, O. (ed United Nations Treaty Collections) (TSO, Nagoya, Japan, 29.10.2010).</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Efficient Biocatalytic Reductive Aminations by Extending the Imine Reductase Toolbox</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Roiban</surname></persName>
		</author>
		<idno type="DOI">10.1002/cctc.201701379</idno>
	</analytic>
	<monogr>
		<title level="j">ChemCatChem</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="4475" to="4479" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roiban, G. D. et al. Efficient Biocatalytic Reductive Aminations by Extending the Imine Reductase Toolbox. ChemCatChem 9, 4475-4479, doi:doi:10.1002/cctc.201701379 (2017).</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Chemoenzymatic Synthesis of Substituted Azepanes by Sequential Biocatalytic Reduction and Organolithium-Mediated Rearrangement</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zawodny</surname></persName>
		</author>
		<idno type="DOI">10.1021/jacs.8b11891</idno>
	</analytic>
	<monogr>
		<title level="j">J. Am. Chem. Soc</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="17872" to="17877" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zawodny, W. et al. Chemoenzymatic Synthesis of Substituted Azepanes by Sequential Biocatalytic Reduction and Organolithium-Mediated Rearrangement. J. Am. Chem. Soc. 140, 17872-17877, doi:10.1021/jacs.8b11891 (2018).</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">A reductive aminase from Aspergillus oryzae</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Aleku</surname></persName>
		</author>
		<idno type="DOI">10.1038/nchem.2782</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Chemistry</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aleku, A. G. et al. A reductive aminase from Aspergillus oryzae. Nature Chemistry 9, doi:10.1038/nchem.2782 (2017).</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Enantioselective synthesis of 1-Aryl-substituted tetrahydroisoquinolines employing imine reductase</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.1021/acscatal.7b02628</idno>
	</analytic>
	<monogr>
		<title level="j">ACS Catalysis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="7003" to="7007" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhu, J. et al. Enantioselective synthesis of 1-Aryl-substituted tetrahydroisoquinolines employing imine reductase. ACS Catalysis 7, 7003-7007, doi:10.1021/acscatal.7b02628 (2017).</note>
</biblStruct>

<biblStruct xml:id="b112">
	<monogr>
		<title level="m" type="main">Development of Imine Reductases and Reductive Aminases for Chiral Amine Synthesis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Aleku</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aleku, G. Development of Imine Reductases and Reductive Aminases for Chiral Amine Synthesis. (2017).</note>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Stereodefined homopropargyl amines by tandem nucleophilic addition/fragmentation of dihydropyridone triflates</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tummatorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Dudley</surname></persName>
		</author>
		<idno type="DOI">10.1021/ol102760q</idno>
	</analytic>
	<monogr>
		<title level="j">Org. Lett</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="158" to="160" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tummatorn, J. &amp; Dudley, G. B. Stereodefined homopropargyl amines by tandem nucleophilic addition/fragmentation of dihydropyridone triflates. Org. Lett. 13, 158-160, doi:10.1021/ol102760q (2011).</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
